High protein concentration pharmaceutical compositions and uses thereof
A pharmaceutical composition with high protein concentrations, balanced by sodium chloride and trehalose, addresses viscosity and osmolality issues, enhancing the manufacturability and administration of high protein drug products.
Patent Information
- Application Number
- PCT/US2026/027159
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Formulating high protein concentration drug products is challenging due to increased viscosity, stability issues, and administration difficulties, particularly in low volume subcutaneous drug products, which are exacerbated by protein interactions and the need to maintain suitable osmolality.
A pharmaceutical composition comprising high protein concentrations with a salt and sugar, achieving osmolality below 600 mOsmol/kg and viscosity below 15 cP, using sodium chloride and trehalose to balance viscosity and osmolality.
The composition provides reduced viscosity and maintains suitable osmolality, improving manufacturing, storage, and administration of high protein concentration drug products.
Smart Images

Figure IMGF000005_0001 
Figure IMGF000124_0001_TABLE 
Figure IMGF000216_0001_TABLE
Abstract
Description
HIGH PROTEIN CONCENTRATION PHARMACEUTICAL COMPOSITIONS AND USES THEREOF CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This PCT application claims the priority benefit of U. S. Provisional Application No. 63 / 801,637, filed May 7, 2025, which is incorporated herein by reference in its entirety.REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY
[0002] The content of the electronically submitted sequence listing (Name: 3338_344PC01_SequenceListing_ST26; Size: 491, 170 Bytes; and Date of Creation: May 5, 2026), filed with the application, is herein incorporated by reference in its entirety.FIELD OF THE INVENTION
[0003] The present disclosure provides pharmaceutical compositions comprising high concentrations of proteins and methods of making and using the same.BACKGROUND OF THE INVENTION
[0004] The formulation of drug products with high concentrations of proteins is challenging. Increasing the protein concentration in a formulation generally leads to an increase in viscosity, which in turn can lead to difficulties in manufacturing the formulation (e.g., during filtration of the formulation, during mixing of the formulation to achieve the uniform distribution of components, and at other stages of the manufacturing process), difficulties in storing the formulation (e.g., lower stability due to protein interactions such as aggregation), and difficulties in administering the formulation to patients (e.g., increased pull and push forces associated with drawing the formulation into a syringe and injecting the formulation into a patient, respectively). These difficulties are increased when formulating a drug product with two or more highly concentrated proteins (e.g., antibodies) due, for example, to the complexity of interactions among ingredients in the formulation and their effects on viscosity. Additionally, these difficulties are particularly problematic in the development of high protein concentration drug products that are administered in lower volumes, such as subcutaneous drug products. Moreover, decreasing theviscosity of a drug product should be balanced with the need to maintain the drug product at a suitable osmolality in order to avoid causing, for example, injection pain and / or cell swelling and potential cell lysis.
[0005] There is a need for high protein concentration drug products with reduced viscosities and methods of making the same.SUMMARY OF THE DISCLOSURE
[0006] The present disclosure is directed to a pharmaceutical composition comprising about 100 mg / mL or more of a protein, a salt, and a sugar, wherein the pharmaceutical composition comprises an osmolality of less than about 600 mOsmol / kg, and wherein the pharmaceutical composition comprises a lower viscosity than a corresponding composition that lacks the salt and / or that comprises a higher concentration of the sugar.
[0007] In some aspects, the osmolality is about 200 mOsmol / kg to less than about 600 mOsmol / kg, about 210 mOsmol / kg to less than about 600 mOsmol / kg, about 220 mOsmol / kg to less than about 600 mOsmol / kg, about 230 mOsmol / kg to less than about 600 mOsmol / kg, about 240 mOsmol / kg to less than about 600 mOsmol / kg, about 250 mOsmol / kg to less than about 600 mOsmol / kg, about 260 mOsmol / kg to less than about 600 mOsmol / kg, about 270 mOsmol / kg to less than about 600 mOsmol / kg, about 280 mOsmol / kg to less than about 600 mOsmol / kg, about 290 mOsmol / kg to less than about 600 mOsmol / kg, about 300 mOsmol / kg to less than about 600 mOsmol / kg, about 350 mOsmol / kg to less than about 600 mOsmol / kg, about 400 mOsmol / kg to less than about 600 mOsmol / kg, about 450 mOsmol / kg to less than about 600 mOsmol / kg, about 500 mOsmol / kg to less than about 600 mOsmol / kg, about 550 mOsmol / kg to less than about 600 mOsmol / kg, about 500 mOsmol / kg to about 550 mOsmol / kg, about 450 mOsmol / kg to about 550 mOsmol / kg, about 400 mOsmol / kg to about 550 mOsmol / kg, about 350 mOsmol / kg to about 550 mOsmol / kg, about 300 mOsmol / kg to about 550 mOsmol / kg, about 250 mOsmol / kg to about 550 mOsmol / kg, about 200 mOsmol / kg to about 550 mOsmol / kg, about 200 mOsmol / kg to about 500 mOsmol / kg, about 250 mOsmol / kg to about 500 mOsmol / kg, about 300 mOsmol / kg to about 500 mOsmol / kg, about 350 mOsmol / kg to about 500 mOsmol / kg, about 400 mOsmol / kg to about 500 mOsmol / kg, about 450 mOsmol / kg to about 500 mOsmol / kg, about 400 mOsmol / kg to about 450 mOsmol / kg, about 350 mOsmol / kg to about 450 mOsmol / kg, about 300 mOsmol / kg to about 450 mOsmol / kg, about 250 mOsmol / kg to about 450 mOsmol / kg, about 200 mOsmol / kg to about 450 mOsmol / kg, about 200 mOsmol / kg to about 400 mOsmol / kg, about 250 mOsmol / kg to about 400mOsmol / kg, about 300 mOsmol / kg to about 400 mOsmol / kg, about 350 mOsmol / kg to about 400 mOsmol / kg, about 300 mOsmol / kg to about 350 mOsmol / kg, about 250 mOsmol / kg to about 350 mOsmol / kg, about 200 mOsmol / kg to about 350 mOsmol / kg, about 200 mOsmol / kg to about 300 mOsmol / kg, or about 250 mOsmol / kg to about 300 mOsmol / kg. In some aspects, the osmolality is about 280 mOsmol / kg to less than about 600 mOsmol / kg.
[0008] The present disclosure is directed to a pharmaceutical composition comprising about 100 mg / mL or more of a protein, a salt, and a sugar, wherein the pharmaceutical composition comprises a lower viscosity than a corresponding composition that lacks the salt and that comprises a higher concentration of the sugar. In some aspects, the pharmaceutical composition comprises an osmolality of about 200 mOsmol / kg to about 600 mOsmol / kg, about 210 mOsmol / kg to about 600 mOsmol / kg, about 220 mOsmol / kg to about 600 mOsmol / kg, about 230 mOsmol / kg to about 600 mOsmol / kg, about 240 mOsmol / kg to about 600 mOsmol / kg, about 250 mOsmol / kg to about 600 mOsmol / kg, about 260 mOsmol / kg to about 600 mOsmol / kg, about 270 mOsmol / kg to about 600 mOsmol / kg, about 280 mOsmol / kg to about 600 mOsmol / kg, about 290 mOsmol / kg to about 600 mOsmol / kg, about 300 mOsmol / kg to about 600 mOsmol / kg, about 350 mOsmol / kg to about 600 mOsmol / kg, about 400 mOsmol / kg to about 600 mOsmol / kg, about 450 mOsmol / kg to about 600 mOsmol / kg, about 500 mOsmol / kg to about 600 mOsmol / kg, about 550 mOsmol / kg to about 600 mOsmol / kg, about 500 mOsmol / kg to about 550 mOsmol / kg, about 450 mOsmol / kg to about 550 mOsmol / kg, about 400 mOsmol / kg to about 550 mOsmol / kg, about 350 mOsmol / kg to about 550 mOsmol / kg, about 300 mOsmol / kg to about 550 mOsmol / kg, about 250 mOsmol / kg to about 550 mOsmol / kg, about 200 mOsmol / kg to about 550 mOsmol / kg, about 200 mOsmol / kg to about 500 mOsmol / kg, about 250 mOsmol / kg to about 500 mOsmol / kg, about 300 mOsmol / kg to about 500 mOsmol / kg, about 350 mOsmol / kg to about 500 mOsmol / kg, about 400 mOsmol / kg to about 500 mOsmol / kg, about 450 mOsmol / kg to about 500 mOsmol / kg, about 400 mOsmol / kg to about 450 mOsmol / kg, about 350 mOsmol / kg to about 450 mOsmol / kg, about 300 mOsmol / kg to about 450 mOsmol / kg, about 250 mOsmol / kg to about 450 mOsmol / kg, about 200 mOsmol / kg to about 450 mOsmol / kg, about 200 mOsmol / kg to about 400 mOsmol / kg, about 250 mOsmol / kg to about 400 mOsmol / kg, about 300 mOsmol / kg to about 400 mOsmol / kg, about 350 mOsmol / kg to about 400 mOsmol / kg, about 300 mOsmol / kg to about 350 mOsmol / kg, about 250 mOsmol / kg to about 350 mOsmol / kg, about 200 mOsmol / kg to about 350 mOsmol / kg, about 200 mOsmol / kg to about 300 mOsmol / kg, or about 250 mOsmol / kg to about 300 mOsmol / kg. In some aspects, the osmolality is about 280 mOsmol / kg to about 600 mOsmol / kg.
[0009] In some aspects, the osmolality is about 200 mOsmol / kg, about 205 mOsmol / kg, about 210 mOsmol / kg, about 215 mOsmol / kg, about 220 mOsmol / kg, about 225 mOsmol / kg, about 230 mOsmol / kg, about 235 mOsmol / kg, about 240 mOsmol / kg, about 245 mOsmol / kg, about 250 mOsmol / kg, about 255 mOsmol / kg, about 260 mOsmol / kg, about 265 mOsmol / kg, about 270 mOsmol / kg, about 275 mOsmol / kg, about 280 mOsmol / kg, about 285 mOsmol / kg, about 290 mOsmol / kg, about 295 mOsmol / kg, about 300 mOsmol / kg, about 305 mOsmol / kg, about 310 mOsmol / kg, about 315 mOsmol / kg, about 320 mOsmol / kg, about 325 mOsmol / kg, about 330 mOsmol / kg, about 335 mOsmol / kg, about 340 mOsmol / kg, about 345 mOsmol / kg, about 350 mOsmol / kg, about 355 mOsmol / kg, about 360 mOsmol / kg, about 365 mOsmol / kg, about 370 mOsmol / kg, about 375 mOsmol / kg, about 380 mOsmol / kg, about 385 mOsmol / kg, about 390 mOsmol / kg, about 395 mOsmol / kg, about 400 mOsmol / kg, about 405 mOsmol / kg, about 410 mOsmol / kg, about 415 mOsmol / kg, about 420 mOsmol / kg, about 425 mOsmol / kg, about 430 mOsmol / kg, about 435 mOsmol / kg, about 440 mOsmol / kg, about 445 mOsmol / kg, about 450 mOsmol / kg, about 455 mOsmol / kg, about 460 mOsmol / kg, about 465 mOsmol / kg, about 470 mOsmol / kg, about 475 mOsmol / kg, about 480 mOsmol / kg, about 485 mOsmol / kg, about 490 mOsmol / kg, about 495 mOsmol / kg, about 500 mOsmol / kg, about 505 mOsmol / kg, about 510 mOsmol / kg, about 515 mOsmol / kg, about 520 mOsmol / kg, about 525 mOsmol / kg, about 530 mOsmol / kg, about 535 mOsmol / kg, about 540 mOsmol / kg, about 545 mOsmol / kg, about 550 mOsmol / kg, about 555 mOsmol / kg, about 560 mOsmol / kg, about 565 mOsmol / kg, about 570 mOsmol / kg, about 575 mOsmol / kg, about 580 mOsmol / kg, about 585 mOsmol / kg, about 590 mOsmol / kg, or about 595 mOsmol / kg.
[0010] In some aspects, the osmolality is determined by vapor-pressure osmometry.
[0011] In some aspects, the osmolality is determined with a vapor pressure osmometer.
[0012] In some aspects, the viscosity is about 15 centipoise (cP) or less.
[0013] In some aspects, the viscosity is about 1 cP to about 15 cP, about 1 cP to about 14 cP, about 1 cP to about 13 cP, about 1 cP to about 12 cP, about 1 cP to about 11 cP, about 1 cP to about 10 cP, about 1 cP to about 9 cP, about 1 cP to about 8 cP, about 1 cP to about 7 cP, about 1 cP to about 6 cP, about 1 cP to about 5 cP, about 1 cP to about 4 cP, about 1 cP to about 3 cP, about 2 cP to about 15 cP, about 2 cP to about 14 cP, about 2 cP to about 13 cP, about 2 cP to about 12 cP, about 2 cP to about 11 cP, about 2 cP to about 10 cP, about 2 cP to about 9 cP, about 2 cP to about 8 cP, about 2 cP to about 7 cP, about 2 cP to about 6 cP, about 2 cP to about 5 cP, about 2 cP to about 4 cP, about 3 cP to about 15 cP, about 3 cP to about 14 cP, about 3 cP to about 13 cP, about 3 cP to about 12 cP, about 3 cP to about 11 cP, about 3 cP to about 10 cP, about 3 cP to about9 cP, about 3 cP to about 8 cP, about 3 cP to about 7 cP, about 3 cP to about 6 cP, about 3 cP to about 5 cP, about 4 cP to about 15 cP, about 4 cP to about 14 cP, about 4 cP to about 13 cP, about 4 cP to about 12 cP, about 4 cP to about 11 cP, about 4 cP to about 10 cP, about 4 cP to about 9 cP, about 4 cP to about 8 cP, about 4 cP to about 7 cP, about 4 cP to about 6 cP, about 5 cP to about 15 cP, about 5 cP to about 14 cP, about 5 cP to about 13 cP, about 5 cP to about 12 cP, about 5 cP to about 11 cP, about 5 cP to about 10 cP, about 5 cP to about 9 cP, about 5 cP to about 8 cP, about 5 cP to about 7 cP, about 6 cP to about 15 cP, about 6 cP to about 14 cP, about 6 cP to about 13 cP, about 6 cP to about 12 cP, about 6 cP to about 11 cP, about 6 cP to about 10 cP, about 6 cP to about 9 cP, about 6 cP to about 8 cP, about 7 cP to about 15 cP, about 7 cP to about 14 cP, about 7 cP to about 13 cP, about 7 cP to about 12 cP, about 7 cP to about 11 cP, about 7 cP to about 10 cP, about 7 cP to about 9 cP, about 8 cP to about 15 cP, about 8 cP to about 14 cP, about 8 cP to about 13 cP, about 8 cP to about 12 cP, about 8 cP to about 11 cP, about 8 cP to about 10 cP, about 9 cP to about 15 cP, about 9 cP to about 14 cP, about 9 cP to about 13 cP, about 9 cP to about 12 cP, about 9 cP to about 11 cP, about 10 cP to about 15 cP, about 10 cP to about 14 cP, about 10 cP to about 13 cP, about 10 cP to about 12 cP, about 11 cP to about 15 cP, about 11 cP to about 14 cP, about 11 cP to about 13 cP, about 12 cP to about 15 cP, about 12 cP to about 14 cP, or about 13 cP to about 15 cP.
[0014] In some aspects, the viscosity is determined with a microfluidic viscometer.
[0015] In some aspects, the viscosity is determined at 20 °C.
[0016] In some aspects, the pharmaceutical composition comprises about 10 mM to about 400 mM, about 10 mM to about 350 mM, about 10 mM to about 300 mM, about 10 mM to about 250 mM, about 10 mM to about 200 mM, about 10 mM to about 150 mM, about 10 mM to about 100 mM, about 10 mM to about 90 mM, about 10 mM to about 80 mM, about 10 mM to about 70 mM, about 10 mM to about 60 mM, about 10 mM to about 50 mM, about 30 mM to about 400 mM, about 30 mM to about 350 mM, about 30 mM to about 300 mM, about 30 mM to about 250 mM, about 30 mM to about 200 mM, about 30 mM to about 150 mM, about 30 mM to about 100 mM, about 30 mM to about 90 mM, about 30 mM to about 80 mM, about 30 mM to about 70 mM, about 30 mM to about 60 mM, about 30 mM to about 50 mM, about 50 mM to about 400 mM, about 50 mM to about 350 mM, about 50 mM to about 300 mM, about 50 mM to about 250 mM, about 50 mM to about 200 mM, about 50 mM to about 150 mM, about 50 mM to about 100 mM, about 100 mM to about 400 mM, about 100 mM to about 350 mM, about 100 mM to about 300 mM, about 100 mM to about 250 mM, about 100 mM to about 200 mM, or about 100 mM to about
[0017] In some aspects, the pharmaceutical composition comprises about 10 mM, about 15 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM, about 55 mM, about 60 mM, about 65 mM, about 70 mM, about 75 mM, about 80 mM, about 85 mM, about 90 mM, about 95 mM, about 100 mM, about 110 mM, about 120 mM, about 130 mM, about 140 mM, about 150 mM, about 160 mM, about 170 mM, about 180 mM, about 190 mM, about 200 mM, about 210 mM, about 220 mM, about 230 mM, about 240 mM, about 250 mM, about 260 mM, about 270 mM, about 280 mM, about 290 mM, about 300 mM, about 310 mM, about 320 mM, about 330 mM, about 340 mM, about 350 mM, about 360 mM, about 370 mM, about 380 mM, about 390 mM, or about 400 mM of the salt.
[0018] In some aspects, the salt comprises sodium chloride, arginine hydrochloride, histidine hydrochloride, lysine hydrochloride, magnesium chloride, potassium chloride, ammonium chloride, calcium chloride, sodium acetate, zinc chloride, ammonium thiocyanate, sodium thiocyanate, sodium sulfate, ammonium sulfate, sodium phosphate, sodium biphosphate, potassium phosphate, dipotassium hydrogen phosphate, monobasic potassium phosphate, calcium phosphate, tris(hydroxymethyl)aminomethane, or a combination thereof. In some aspects, the salt comprises sodium chloride. In some aspects, the salt comprises arginine hydrochloride. In some aspects, the salt comprises sodium chloride and arginine hydrochloride.
[0019] In some aspects, the pharmaceutical composition comprises about 500 mM or less, about 475 mM or less, about 450 mM or less, about 425 mM or less, about 400 mM or less, about 375 mM or less, about 350 mM or less, about 325 mM or less, about 300 mM or less, about 275 mM or less, about 250 mM or less, about 225 mM or less, about 200 mM or less, about 175 mM or less, about 150 mM or less, about 125 mM or less, about 100 mM or less, or about 75 mM or less of the sugar.
[0020] In some aspects, the pharmaceutical composition comprises about 1 mM to about 500 mM, about 1 mM to about 475 mM, about 1 mM to about 450 mM, about 1 mM to about 425 mM, about 1 mM to about 400 mM, about 1 mM to about 375 mM, about 1 mM to about 350 mM, about 1 mM to about 325 mM, about 1 mM to about 300 mM, about 1 mM to about 275 mM, about 1 mM to about 250 mM, about 1 mM to about 225 mM, about 1 mM to about 200 mM, about 1 mM to about 175 mM, about 1 mM to about 150 mM, about 1 mM to about 125 mM, about 1 mM to about 100 mM, or about 1 mM to about 75 mM of the sugar.
[0021] In some aspects, the sugar comprises a monosaccharide, a disaccharide, a polysaccharide, a polyol, or a combination thereof.
[0022] In some aspects, the sugar comprises glucose, xylose, erythritol, sucrose, trehalose, maltose, galactose, dextrose, raffinose, stachyose, lactose, mannitol, sorbitol, xylitol, lactitol, maltitol, glycerol, or a combination thereof. In some aspects, wherein the sugar comprises sucrose. In some aspects, the sugar comprises trehalose.
[0023] In some aspects, the pharmaceutical composition comprises a volume of about 0.001 mL to about 20 mL.
[0024] In some aspects, the pharmaceutical composition comprises a volume of about 0.001 mL, about 0.005 mL, about 0.010 mL, about 0.015 mL, about 0.020 mL, about 0.025 mL, about 0.030 mL, about 0.035 mL, about 0.040 mL, about 0.045 mL, about 0.050 mL, about 0.055 mL, about 0.060 mL, about 0.065 mL, about 0.070 mL, about 0.075 mL, about 0.080 mL, about 0.085 mL, about 0.090 mL, about 0.095 mL, about 0.100 mL, about 0.150 mL, about 0.200 mL, about 0.250 mL, about 0.300 mL, about 0.350 mL, about 0.400 mL, about 0.450 mL, about 0.500 mL, about 0.550 mL, about 0.600 mL, about 0.650 mL, about 0.700 mL, about 0.750 mL, about 0.800 mL, about 0.850 mL, about 0.900 mL, about 0.950 mL, about 1 mL, about 1.1 mL, about 1.2 mL, about 1.3 mL, about 1.4 mL, about 1.5 mL, about 1.6 mL, about 1.7 mL, about 1.8 mL, about 1.9 mL, about 2 mL, about 2.1 mL, about 2.2 mL, about 2.3 mL, about 2.4 mL, about 2.5 mL, about 2.6 mL, about 2.7 mL, about 2.8 mL, about 2.9 mL, about 3 mL, about 3.1 mL, about 3.2 mL, about 3.3 mL, about 3.4 mL, about 3.5 mL, about 3.6 mL, about 3.7 mL, about 3.8 mL, about 3.9 mL, about 4 mL, about 4.1 mL, about 4.2 mL, about 4.3 mL, about 4.4 mL, about 4.5 mL, about 4.6 mL, about 4.7 mL, about 4.8 mL, about 4.9 mL, about 5 mL, about 5.1 mL, about 5.2 mL, about 5.3 mL, about 5.4 mL, about 5.5 mL, about 5.6 mL, about 5.7 mL, about 5.8 mL, about 5.9 mL, about 6 mL, about 6.1 mL, about 6.2 mL, about 6.3 mL, about 6.4 mL, about 6.5 mL, about 6.6 mL, about 6.7 mL, about 6.8 mL, about 6.9 mL, about 7 mL, about 7.1 mL, about 7.2 mL, about 7.3 mL, about 7.4 mL, about 7.5 mL, about 7.6 mL, about 7.7 mL, about 7.8 mL, about 7.9 mL, about 8 mL, about 8.1 mL, about 8.2 mL, about 8.3 mL, about 8.4 mL, about 8.5 mL, about 8.6 mL, about 8.7 mL, about 8.8 mL, about 8.9 mL, about 9 mL, about 9.1 mL, about 9.2 mL, about 9.3 mL, about 9.4 mL, about 9.5 mL, about 9.6 mL, about 9.7 mL, about 9.8 mL, about 9.9 mL, about 10 mL, about 10.1 mL, about 10.2 mL, about 10.3 mL, about 10.4 mL, about 10.5 mL, about 10.6 mL, about 10.7 mL, about 10.8 mL, about 10.9 mL, about 11 mL, about 11.1 mL, about 11.2 mL, about 11.3 mL, about 11.4 mL, about 11.5 mL, about 11.6 mL, about 11.7 mL, about 11.8 mL, about 11.9 mL, about 12 mL, about 12.1 mL, about 12.2 mL, about 12.3 mL, about 12.4 mL, about 12.5 mL, about 12.6 mL, about 12.7 mL, about 12.8 mL, about 12.9 mL, about 13 mL, about 13.1 mL, about 13.2 mL, about 13.3 mL, about 13.4 mL, about 13.5 mL, about13.6 mL, about 13.7 mL, about 13.8 mL, about 13.9 mL, about 14 mL, about 14.1 mL, about 14.2 mL, about 14.3 mL, about 14.4 mL, about 14.5 mL, about 14.6 mL, about 14.7 mL, about 14.8 mL, about 14.9 mL, about 15 mL, about 15.1 mL, about 15.2 mL, about 15.3 mL, about 15.4 mL, about 15.5 mL, about 15.6 mL, about 15.7 mL, about 15.8 mL, about 15.9 mL, about 16 mL, about 16.1 mL, about 16.2 mL, about 16.3 mL, about 16.4 mL, about 16.5 mL, about 16.6 mL, about 16.7 mL, about 16.8 mL, about 16.9 mL, about 17 mL, about 17.1 mL, about 17.2 mL, about 17.3 mL, about 17.4 mL, about 17.5 mL, about 17.6 mL, about 17.7 mL, about 17.8 mL, about 17.9 mL, about 18 mL, about 18.1 mL, about 18.2 mL, about 18.3 mL, about 18.4 mL, about 18.5 mL, about 18.6 mL, about 18.7 mL, about 18.8 mL, about 18.9 mL, about 19 mL, about 19.1 mL, about 19.2 mL, about 19.3 mL, about 19.4 mL, about 19.5 mL, about 19.6 mL, about 19.7 mL, about 19.8 mL, about 19.9 mL, or about 20 mL.
[0025] In some aspects, the pharmaceutical composition comprises a volume of about 8.4 mL, about 9 mL, about 9.6 mL, about 10 mL, about 12 mL, about 12.8 mL, about 15 mL, or about 16 mL.
[0026] In some aspects, the pharmaceutical composition comprises about 100 mg / mL to about 500 mg / mL, about 100 mg / mL to about 450 mg / mL, about 100 mg / mL to about 400 mg / mL, about 100 mg / mL to about 350 mg / mL, about 100 mg / mL to about 300 mg / mL, about 100 mg / mL to about 250 mg / mL, about 100 mg / mL to about 200 mg / mL, about 100 mg / mL to about 150 mg / mL, about 100 mg / mL to about 140 mg / mL, about 100 mg / mL to about 130 mg / mL, about 100 mg / mL to about 120 mg / mL, about 100 mg / mL to about 115 mg / mL, about 100 mg / mL to about 110 mg / mL, about 100 mg / mL to about 105 mg / mL, about 110 mg / mL to about 500 mg / mL, about 110 mg / mL to about 450 mg / mL, about 110 mg / mL to about 400 mg / mL, about 110 mg / mL to about 350 mg / mL, about 110 mg / mL to about 300 mg / mL, about 110 mg / mL to about 250 mg / mL, about 110 mg / mL to about 200 mg / mL, about 110 mg / mL to about 150 mg / mL, about 110 mg / mL to about 140 mg / mL, about 110 mg / mL to about 130 mg / mL, about 110 mg / mL to about 120 mg / mL, about 110 mg / mL to about 115 mg / mL, about 115 mg / mL to about 500 mg / mL, about 115 mg / mL to about 450 mg / mL, about 115 mg / mL to about 400 mg / mL, about 115 mg / mL to about 350 mg / mL, about 115 mg / mL to about 300 mg / mL, about 115 mg / mL to about 250 mg / mL, about 115 mg / mL to about 200 mg / mL, about 115 mg / mL to about 150 mg / mL, about 115 mg / mL to about 140 mg / mL, about 115 mg / mL to about 130 mg / mL, about 115 mg / mL to about 120 mg / mL, about 120 mg / mL to about 450 mg / mL, about 120 mg / mL to about 400 mg / mL, about 120 mg / mL to about 350 mg / mL, about 120 mg / mL to about 300 mg / mL, about 120 mg / mL to about 250 mg / mL, about 120 mg / mL to about 200 mg / mL, about 120 mg / mL to about 150 mg / mL, about 120mg / mL to about 140 mg / mL, about 120 mg / mL to about 130 mg / mL, about 150 mg / mL to about 500 mg / mL, about 150 mg / mL to about 450 mg / mL, about 150 mg / mL to about 400 mg / mL, about 150 mg / mL to about 350 mg / mL, about 150 mg / mL to about 300 mg / mL, about 150 mg / mL to about 250 mg / mL, or about 150 mg / mL to about 200 mg / mL of the protein.
[0027] In some aspects, the pharmaceutical composition comprises about 100 mg / mL, about 101 mg / mL, about 102 mg / mL, about 103 mg / mL, about 104 mg / mL, about 105 mg / mL, about 106 mg / mL, about 107 mg / mL, about 108 mg / mL, about 109 mg / mL, about 110 mg / mL, about 111 mg / mL, about 112 mg / mL, about 113 mg / mL, about 114 mg / mL, about 115 mg / mL, about 116 mg / mL, about 117 mg / mL, about 118 mg / mL, about 119 mg / mL, about 120 mg / mL, about 121 mg / mL, about 122 mg / mL, about 123 mg / mL, about 124 mg / mL, about 125 mg / mL, about 126 mg / mL, about 127 mg / mL, about 128 mg / mL, about 129 mg / mL, about 130 mg / mL, about 131 mg / mL, about 132 mg / mL, about 133 mg / mL, about 134 mg / mL, about 135 mg / mL, about 136 mg / mL, about 137 mg / mL, about 138 mg / mL, about 139 mg / mL, about 140 mg / mL, about 141 mg / mL, about 142 mg / mL, about 143 mg / mL, about 144 mg / mL, about 145 mg / mL, about 146 mg / mL, about 147 mg / mL, about 148 mg / mL, about 149 mg / mL, about 150 mg / mL, about 155 mg / mL, about 160 mg / mL, about 165 mg / mL, about 170 mg / mL, about 175 mg / mL, about 180 mg / mL, about 185 mg / mL, about 190 mg / mL, about 195 mg / mL, about 200 mg / mL, about 205 mg / mL, about 210 mg / mL, about 215 mg / mL, about 220 mg / mL, about 225 mg / mL, about 230 mg / mL, about 235 mg / mL, about 240 mg / mL, about 245 mg / mL, about 250 mg / mL, about 255 mg / mL, about 260 mg / mL, about 265 mg / mL, about 270 mg / mL, about 275 mg / mL, about 280 mg / mL, about 285 mg / mL, about 290 mg / mL, about 295 mg / mL, about 300 mg / mL, about 305 mg / mL, about 310 mg / mL, about 315 mg / mL, about 320 mg / mL, about 325 mg / mL, about 330 mg / mL, about 335 mg / mL, about 340 mg / mL, about 345 mg / mL, about 350 mg / mL, about 355 mg / mL, about 360 mg / mL, about 365 mg / mL, about 370 mg / mL, about 375 mg / mL, about 380 mg / mL, about 385 mg / mL, about 390 mg / mL, about 395 mg / mL, about 400 mg / mL, about 405 mg / mL, about 410 mg / mL, about 415 mg / mL, about 420 mg / mL, about 425 mg / mL, about 430 mg / mL, about 435 mg / mL, about 440 mg / mL, about 445 mg / mL, about 450 mg / mL, about 455 mg / mL, about 460 mg / mL, about 465 mg / mL, about 470 mg / mL, about 475 mg / mL, about 480 mg / mL, about 485 mg / mL, about 490 mg / mL, about 495 mg / mL, or about 500 mg / mL of the protein.
[0028] In some aspects, the pharmaceutical composition comprises about 105 mg / mL, about 120 mg / mL, about 126 mg / mL, about 128 mg / mL, about 140 mg / mL, about 144 mg / mL, about 150 mg / mL, or about 160 mg / mL of the protein.
[0029] In some aspects, the pharmaceutical composition comprises about 0.25 mg to about 4000 mg, about 0.25 mg to about 3600 mg, about 0.25 mg to about 3200 mg, about 0.25 mg to about 3000 mg, about 0.25 mg to about 2600 mg, about 0.25 mg to about 2200 mg, about 0.25 mg to about 2000 mg, about 0.25 mg to about 1600 mg, about 0.25 mg to about 1200 mg, about 0.25 mg to about 1000 mg, about 0.25 mg to about 800 mg, about 0.25 mg to about 600 mg, about 0.25 mg to about 400 mg, about 0.25 mg to about 200 mg, about 0.25 mg to about 100 mg, about 0.25 mg to about 50 mg, about 0.25 mg to about 40 mg, about 0.25 mg to about 30 mg, about 0.25 mg to about 20 mg, about 20 mg to about 4000 mg, about 20 mg to about 3600 mg, about 20 mg to about 3200 mg, about 20 mg to about 3000 mg, about 20 mg to about 2600 mg, about 20 mg to about 2200 mg, about 20 mg to about 2000 mg, about 20 mg to about 1600 mg, about 20 mg to about 1200 mg, about 20 mg to about 1000 mg, about 20 mg to about 800 mg, about 20 mg to about 600 mg, about 20 mg to about 400 mg, about 20 mg to about 200 mg, about 20 mg to about 100 mg, about 100 mg to about 4000 mg, about 100 mg to about 3600 mg, about 100 mg to about 3200 mg, about 100 mg to about 3000 mg, about 100 mg to about 2600 mg, about 100 mg to about 2200 mg, about 100 mg to about 2000 mg, about 100 mg to about 1800 mg, about 100 mg to about 1600 mg, about 100 mg to about 1400 mg, about 100 mg to about 1200 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, about 400 mg to about 4000 mg, about 400 mg to about 3600 mg, about 400 mg to about 3200 mg, about 400 mg to about 3000 mg, about 400 mg to about 2600 mg, about 400 mg to about 2200 mg, about 400 mg to about 2000 mg, about 400 mg to about 1800 mg, about 400 mg to about 1600 mg, about 400 mg to about 1400 mg, about 400 mg to about 1200 mg, or about 400 mg to about 1000 mg of the protein.
[0030] In some aspects, the pharmaceutical composition comprises about 0.25 mg, about 0.5 mg, about 0.75 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3 mg, about 3.25 mg, about 3.5 mg, about 3.75 mg, about 4 mg, about 4.25 mg, about 4.5 mg, about 4.75 mg, about 5 mg, about 5.25 mg, about 5.5 mg, about 5.75 mg, about 6 mg, about 6.25 mg, about 6.5 mg, about 6.75 mg, about 7 mg, about 7.25 mg, about 7.5 mg, about 7.75 mg, about 8 mg, about 8.25 mg, about 8.5 mg, about 8.75 mg, about 9 mg, about 9.25 mg, about 9.5 mg, about 9.75 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, about 710 mg, about 720 mg, about 730 mg, about 740 mg, about 750 mg, about 760 mg, about 770 mg, about 780 mg, about 790 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 980 mg, about 990 mg, about 1000 mg, about 1020 mg, about 1040 mg, about 1060 mg, about 1080 mg, about 1100 mg, about 1120 mg, about 1140 mg, about 1160 mg, about 1180 mg, about 1200 mg, about 1220 mg, about 1240 mg, about 1260 mg, about 1280 mg, about 1300 mg, about 1320 mg, about 1340 mg, about 1360 mg, about 1380 mg, about 1400 mg, about 1420 mg, about 1440 mg, about 1460 mg, about 1480 mg, about 1500 mg, about 1520 mg, about 1540 mg, about 1560 mg, about 1580 mg, about 1600 mg, about 1620 mg, about 1640 mg, about 1660 mg, about 1680 mg, about 1700 mg, about 1720 mg, about 1740 mg, about 1760 mg, about 1780 mg, about 1800 mg, about 1820 mg, about 1840 mg, about 1860 mg, about 1880 mg, about 1900 mg, about 1920 mg, about 1940 mg, about 1960 mg, about 1980 mg, about 2000 mg, about 2020 mg, about 2040 mg, about 2060 mg, about 2080 mg, about 2100 mg, about 2120 mg, about 2140 mg, about 2160 mg, about 2180 mg, about 2200 mg, about 2220 mg, about 2240 mg, about 2260 mg, about 2280 mg, about 2300 mg, about 2320 mg, about 2340 mg, about 2360 mg, about 2380 mg, about 2400 mg, about 2420 mg, about 2440 mg, about 2460 mg, about 2480 mg, about 2500 mg, about 2520 mg, about 2540 mg, about 2560 mg, about 2580 mg, about 2600 mg, about 2620 mg, about 2640 mg, about 2660 mg, about 2680 mg, about 2700 mg, about 2720 mg, about 2740 mg, about 2760 mg, about 2780 mg, about 2800 mg, about 2820 mg, about 2840 mg, about 2860 mg, about 2880 mg, about 2900 mg, about 2920 mg, about 2940 mg, about 2960 mg, about 2980 mg, about 3000 mg, about 3020 mg, about 3040 mg, about 3060 mg, about 3080 mg, about 3100 mg, about 3120 mg, about 3140 mg, about 3160 mg, about 3180 mg, about 3200 mg, about 3220 mg, about 3240 mg, about 3260 mg, about 3280 mg, about 3300 mg, about 3320 mg, about 3340 mg, about 3360 mg, about 3380 mg, about 3400 mg, about 3420 mg, about 3440 mg, about 3460 mg, about 3480 mg, about 3500 mg, about 3520 mg, about 3540 mg, about 3560 mg, about 3580 mg,about 3600 mg, about 3620 mg, about 3640 mg, about 3660 mg, about 3680 mg, about 3700 mg, about 3720 mg, about 3740 mg, about 3760 mg, about 3780 mg, about 3800 mg, about 3820 mg, about 3840 mg, about 3860 mg, about 3880 mg, about 3900 mg, about 3920 mg, about 3940 mg, about 3960 mg, about 3980 mg, or about 4000 mg of the protein.
[0031] In some aspects, the pharmaceutical composition comprises about 1260 mg, about 1440 mg, or about 1920 mg of the protein.
[0032] In some aspects, the pharmaceutical composition comprises about 100 mg / mL to about 150 mg / mL of the protein, about 200 mM or less of the salt, and about 250 mM or less of the sugar.
[0033] In some aspects, the sugar is sucrose and the salt is sodium chloride.
[0034] In some aspects, the protein comprises an antibody, a checkpoint inhibitor, a fusion protein, a growth factor, a hormone, an enzyme, a cytokine, a coagulation factor, a plasma protein, or a combination thereof. In some aspects, the protein comprises an antibody. In some aspects, the antibody comprises a full-length antibody. In some aspects, the antibody comprises a monoclonal, human, humanized, chimeric, or multispecific antibody. In some aspects, the multispecific antibody comprises a dual-affinity re-targeting antibody, a dual variable domain immunoglobulin, or a bispecific antibody. In some aspects, the antibody comprises a F(ab')2 fragment, a Fab' fragment, a Fab fragment, a Fv fragment, a scFv fragment, a dsFv fragment, a dAb fragment, or a single chain binding polypeptide. In some aspects, the antibody comprises an anti-LAG-3 antibody, an anti-PD-1 antibody, an anti-PD-Ll antibody, an anti-CTLA-4 antibody, an anti-TIM-3 antibody, an anti-TIGIT antibody, an anti-NKG2a antibody, an anti-OX40 antibody, an anti-ICOS antibody, an anti-MICA antibody, an anti-CD137 antibody, an anti-KIR antibody, an anti-TGFp antibody, an anti-IL-10 antibody, an anti-IL-8 antibody, an anti-B7-H4 antibody, an anti-Fas ligand antibody, an anti-CXCR4 antibody, an anti-mesothelin antibody, an anti-CD27 antibody, an anti-GITR antibody, an anti-CCR8 antibody, an anti-ILT4 antibody, or a combination thereof. In some aspects, the anti-LAG-3 antibody comprises BMS-986016 (relatlimab), IMP731 (H5L7BW), MK4280 (28G-10, favezelimab), REGN3767 (fianlimab), GSK2831781, humanized BAP050, IMP-701 (LAG525, ieramilimab), aLAG3(0414), aLAG3(0416), Sym022, TSR-033, TSR-075, XmAb841 (XmAb22841), MGD013 (tebotelimab), BI754111, FS118, P 13B02-30, AVA-017, 25F7, AGEN1746, RO7247669, INCAGN02385, IBI-110, EMB-02, IBL323, LBL-007, ABL501, or an antigen-binding portion thereof. In some aspects, the anti-LAG-3 antibody comprises relatlimab, or an antigen-binding portion thereof. In some aspects, the anti-LAG-3 antibody comprises: (a) CDR1, CDR2 and CDR3 domains of the heavy chain variable region having theamino acid sequence set forth in SEQ ID NO:3, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO:4; (b) a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10, respectively; (c) heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:3 and 4, respectively; (d) heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:l and 2, respectively; or (e) heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:21 and 2, respectively. In some aspects, the anti-PD-1 antibody comprises nivolumab, pembrolizumab, PDR001 (spartalizumab), MEDI-0680, TSR-042, cemiplimab, JS001, PF-06801591, BGB-A317, BI 754091, INCSHR1210, GLS-010, AM-001, STI-1110, AGEN2034, MGA012, BCD-100, IBI308, SSI-361, or an antigen-binding portion thereof. In some aspects, the anti-PD-1 antibody comprises nivolumab, or an antigen-binding portion thereof. In some aspects, the anti-PD-1 antibody comprises: (a) CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 13, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO: 14; (b) a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO:20, respectively; (c) heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:13 and 14, respectively; or (d) heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:11 and 12, respectively. In some aspects, the anti-PD-Ll antibody comprises BMS-936559, atezolizumab, durvalumab, avelumab, STI-1014, CX-072, KN035, LY3300054, BGB-A333, ICO 36, FAZ053, CK-301, or an antigenbinding portion thereof. In some aspects, the anti-CTLA-4 antibody comprises ipilimumab, tremelimumab, MK-1308, AGEN-1884, or an antigen-binding portion thereof. In some aspects, the antibody comprises two antibodies. In some aspects, the antibody comprises an anti-PD-1 or anti-PD-Ll antibody and an anti -LAG-3 antibody. In some aspects, the mg:mg or mg / mL:mg / mL ratio of the anti-PD-1 or anti-PD-Ll antibody to the anti-LAG-3 antibody is about 1:1, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, about 1:15, about 1:20, about 1:30, about 1:40, about 1:50, about 1:60, about 1:70, about 1:80, about 1:90, about 1:100, about 1:120, about 1:140, about 1:160, about 1:180, about 1:200, about 200:1, about180:1, about 160:1, about 140:1, about 120:1, about 100:1, about 90:1, about 80:1, about 70:1, about 60:1, about 50:1, about 40:1, about 30:1, about 20:1, about 15:1, about 10:1, about 9:1, about 8:1, about 7:1, about 6:1, about 5:1, about 4:1, about 3:1, about 2:1, about 3:4, about 3:2, about 2:3, or about 4:3. In some aspects, the mg:mg or mg / mL:mg / mL ratio of the anti-PD-1 or anti-PD-Ll antibody to the anti-LAG-3 antibody is about 1:1, about 2:1, or about 3:4. In some aspects, the concentration of the anti-PD-1 or anti-PD-Ll antibody is about 10 mg / mL, about 15 mg / mL, about 20 mg / mL, about 25 mg / mL, about 30 mg / mL, about 35 mg / mL, about 40 mg / mL, about 45 mg / mL, about 50 mg / mL, about 52.5 mg / mL, about 55 mg / mL, about 60 mg / mL, about 64 mg / mL, about 65 mg / mL, about 70 mg / mL, about 72 mg / mL, about 75 mg / mL, about 78.8 mg / mL, about 80 mg / mL, about 85 mg / mL, about 90 mg / mL, about 94.5 mg / mL, about 95 mg / mL, about 100 mg / mL, about 105 mg / mL, about 108 mg / mL, about 110 mg / mL, about 120 mg / mL, about 130 mg / mL, about 132 mg / mL, about 135 mg / mL, about 137.5 mg / mL, about 140 mg / mL, about 150 mg / mL, about 160 mg / mL, about 170 mg / mL, about 175 mg / mL, about 180 mg / mL, about 190 mg / mL, about 200 mg / mL, about 210 mg / mL, about 220 mg / mL, about 230 mg / mL, about 240 mg / mL, about 250 mg / mL, about 260 mg / mL, about 270 mg / mL, about 280 mg / mL, about 290 mg / mL, about 300 mg / mL, about 310 mg / mL, about 320 mg / mL, about 330 mg / mL, about 340 mg / mL, about 350 mg / mL, about 360 mg / mL, about 370 mg / mL, about 380 mg / mL, about 390 mg / mL, about 400 mg / mL, about 410 mg / mL, about 420 mg / mL, about 430 mg / mL, about 440 mg / mL, about 450 mg / mL, about 460 mg / mL, about 470 mg / mL, about 480 mg / mL, about 490 mg / mL, or about 500 mg / mL. In some aspects, the pharmaceutical composition comprises about 0.25 mg to about 2000 mg, about 0.25 mg to about 1600 mg, about 0.25 mg to about 1200 mg, about 0.25 mg to about 800 mg, about 0.25 mg to about 400 mg, about 0.25 mg to about 100 mg, about 0.25 mg to about 50 mg, about 0.25 mg to about 40 mg, about 0.25 mg to about 30 mg, about 0.25 mg to about 20 mg, about 20 mg to about 2000 mg, about 20 mg to about 1600 mg, about 20 mg to about 1200 mg, about 20 mg to about 800 mg, about 20 mg to about 400 mg, about 20 mg to about 100 mg, about 100 mg to about 2000 mg, about 100 mg to about 1800 mg, about 100 mg to about 1600 mg, about 100 mg to about 1400 mg, about 100 mg to about 1200 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, about 400 mg to about 2000 mg, about 400 mg to about 1800 mg, about 400 mg to about 1600 mg, about 400 mg to about 1400 mg, about 400 mg to about 1200 mg, or about 400 mg to about 1000 mg of the anti-PD-1 or anti-PD-Ll antibody. In some aspects, the pharmaceutical composition comprises about 0.25 mg, about 0.5 mg, about 0.75 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3 mg, about 3.25 mg, about 3.5mg, about 3.75 mg, about 4 mg, about 4.25 mg, about 4.5 mg, about 4.75 mg, about 5 mg, about 5.25 mg, about 5.5 mg, about 5.75 mg, about 6 mg, about 6.25 mg, about 6.5 mg, about 6.75 mg, about 7 mg, about 7.25 mg, about 7.5 mg, about 7.75 mg, about 8 mg, about 8.25 mg, about 8.5 mg, about 8.75 mg, about 9 mg, about 9.25 mg, about 9.5 mg, about 9.75 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, about 710 mg, about 720 mg, about 730 mg, about 740 mg, about 750 mg, about 760 mg, about 770 mg, about 780 mg, about 790 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 980 mg, about 990 mg, about 1000 mg, about 1040 mg, about 1080 mg, about 1100 mg, about 1140 mg, about 1180 mg, about 1200 mg, about 1240 mg, about 1280 mg, about 1300 mg, about 1340 mg, about 1380 mg, about 1400 mg, about 1440 mg, about 1480 mg, about 1500 mg, about 1540 mg, about 1580 mg, about 1600 mg, about 1640 mg, about 1680 mg, about 1700 mg, about 1740 mg, about 1780 mg, about 1800 mg, about 1840 mg, about 1880 mg, about 1900 mg, about 1940 mg, about 1980 mg, or about 2000 mg of the anti-PD-1 or anti-PD-Ll antibody. In some aspects, the concentration of the anti-LAG-3 antibody is about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 3.3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 6 mg / mL, about 7 mg / mL, about 8 mg / mL, about 9 mg / mL, about 10 mg / mL, about 13 mg / mL, about 13.35 mg / mL, about 15 mg / mL, about 18 mg / mL, about 20 mg / mL, about 23 mg / mL, about 25 mg / mL, about 26 mg / mL, about 26.2 mg / mL, about 26.7 mg / mL, about 27 mg / mL, about 28 mg / mL, about 29 mg / mL, about 30 mg / mL, about 31.5 mg / mL, about 35 mg / mL, about 37.5 mg / mL, about 40 mg / mL, about 45 mg / mL, about 50 mg / mL, about 52.5 mg / mL, about 55 mg / mL, about 60 mg / mL, about 64 mg / mL, about 65 mg / mL, about 70 mg / mL, about 72 mg / mL, about 75 mg / mL, about 80mg / mL, about 85 mg / mL, about 90 mg / mL, about 95 mg / mL, about 100 mg / mL, about 108 mg / mL, about 110 mg / mL, about 120 mg / mL, about 130 mg / mL, about 132 mg / mL, about 135 mg / mL, about 140 mg / mL, about 150 mg / mL, about 160 mg / mL, about 170 mg / mL, about 175 mg / mL, about 180 mg / mL, about 190 mg / mL, about 200 mg / mL, about 210 mg / mL, about 220 mg / mL, about 230 mg / mL, about 240 mg / mL, about 250 mg / mL, about 260 mg / mL, about 270 mg / mL, about 280 mg / mL, about 290 mg / mL, about 300 mg / mL, about 310 mg / mL, about 320 mg / mL, about 330 mg / mL, about 340 mg / mL, about 350 mg / mL, about 360 mg / mL, about 370 mg / mL, about 380 mg / mL, about 390 mg / mL, about 400 mg / mL, about 410 mg / mL, about 420 mg / mL, about 430 mg / mL, about 440 mg / mL, about 450 mg / mL, about 460 mg / mL, about 470 mg / mL, about 480 mg / mL, about 490 mg / mL, or about 500 mg / mL. In some aspects, the pharmaceutical composition comprises about 0.25 mg to about 2000 mg, about 0.25 mg to about 1600 mg, about 0.25 mg to about 1200 mg, about 0.25 mg to about 800 mg, about 0.25 mg to about 400 mg, about 0.25 mg to about 100 mg, about 0.25 mg to about 50 mg, about 0.25 mg to about 40 mg, about 0.25 mg to about 30 mg, about 0.25 mg to about 20 mg, about 20 mg to about 2000 mg, about 20 mg to about 1600 mg, about 20 mg to about 1200 mg, about 20 mg to about 800 mg, about 20 mg to about 400 mg, about 20 mg to about 100 mg, about 100 mg to about 2000 mg, about 100 mg to about 1800 mg, about 100 mg to about 1600 mg, about 100 mg to about 1400 mg, about 100 mg to about 1200 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, about 400 mg to about 2000 mg, about 400 mg to about 1800 mg, about 400 mg to about 1600 mg, about 400 mg to about 1400 mg, about 400 mg to about 1200 mg, or about 400 mg to about 1000 mg of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises about 0.25 mg, about 0.5 mg, about 0.75 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3 mg, about 3.25 mg, about 3.5 mg, about 3.75 mg, about 4 mg, about 4.25 mg, about 4.5 mg, about 4.75 mg, about 5 mg, about 5.25 mg, about 5.5 mg, about 5.75 mg, about 6 mg, about 6.25 mg, about 6.5 mg, about 6.75 mg, about 7 mg, about 7.25 mg, about 7.5 mg, about 7.75 mg, about 8 mg, about 8.25 mg, about 8.5 mg, about 8.75 mg, about 9 mg, about 9.25 mg, about 9.5 mg, about 9.75 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg,about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, about 710 mg, about 720 mg, about 730 mg, about 740 mg, about 750 mg, about 760 mg, about 770 mg, about 780 mg, about 790 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 980 mg, about 990 mg, about 1000 mg, about 1040 mg, about 1080 mg, about 1100 mg, about 1140 mg, about 1180 mg, about 1200 mg, about 1240 mg, about 1280 mg, about 1300 mg, about 1340 mg, about 1380 mg, about 1400 mg, about 1440 mg, about 1480 mg, about 1500 mg, about 1540 mg, about 1580 mg, about 1600 mg, about 1640 mg, about 1680 mg, about 1700 mg, about 1740 mg, about 1780 mg, about 1800 mg, about 1840 mg, about 1880 mg, about 1900 mg, about 1940 mg, about 1980 mg, or about 2000 mg of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises about 80 mg / mL of the anti-PD-1 antibody and about 80 mg / mL of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises a volume of about 12 mL. In some aspects, the pharmaceutical composition comprises a volume of about 9 mL. In some aspects, the pharmaceutical composition comprises about 75 mg / mL of the anti-PD-1 antibody and about 75 mg / mL of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises a volume of about 12.8 mL. In some aspects, the pharmaceutical composition comprises a volume of about 9.6 mL. In some aspects, the pharmaceutical composition comprises about 72 mg / mL of the anti-PD-1 antibody and about 72 mg / mL of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises a volume of about 10 mL. In some aspects, the pharmaceutical composition comprises about 64 mg / mL of the anti-PD-1 antibody and about 64 mg / mL of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises a volume of about 15 mL. In some aspects, the pharmaceutical composition comprises about 60 mg / mL of the anti-PD-1 antibody and about 60 mg / mL of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises comprising a volume of about 16 mL. In some aspects, the pharmaceutical composition comprises a volume of about 12 mL. In some aspects, the pharmaceutical composition comprises about 52.5 mg / mL of the anti-PD-1 antibody and about 52.5 mg / mL of the anti-LAG-3 antibody. In some aspects, the pharmaceutical compositioncomprises a volume of about 18.3 mL. In some aspects, the pharmaceutical composition comprises about 64.3 mg / mL of the anti-PD-1 antibody and about 85.7 mg / mL of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises a volume of about 8.4 mL. In some aspects, the pharmaceutical composition comprises about 60 mg / mL of the anti-PD-1 antibody and about 80 mg / mL of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises a volume of about 9 mL. In some aspects, the pharmaceutical composition comprises about 54 mg / mL of the anti-PD-1 antibody and about 72 mg / mL of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises a volume of about 10 mL. In some aspects, the pharmaceutical composition comprises about 45 mg / mL of the anti-PD-1 antibody and about 60 mg / mL of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises a volume of about 12 mL. In some aspects, the pharmaceutical composition comprises about 960 mg of the anti-PD-1 antibody and about 960 mg of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises about 720 mg of the anti-PD-1 antibody and about 720 mg of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises about 540 mg of the anti-PD-1 antibody and about 720 mg of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises about 75 mg / mL of the anti-PD-1 antibody and about 75 mg / mL of an anti-LAG-3 antibody, wherein the salt comprises about 100 mM of sodium chloride, and the sugar comprises about 210 mM of sucrose. In some aspects, the pharmaceutical composition comprises about 60 mg / mL of the anti-PD-1 antibody and about 60 mg / mL of the anti-LAG-3 antibody, wherein the salt comprises about 40 mM of sodium chloride, and the sugar comprises about 170 mM of sucrose. In some aspects, the pharmaceutical composition comprises about 52.5 mg / mL of the anti-PD-1 antibody and about 52.5 mg / mL of the anti-LAG-3 antibody, wherein the salt comprises about 50 mM of sodium chloride, and the sugar comprises about 150 mM of sucrose. In some aspects, the anti-PD-1 antibody comprises nivolumab, or an antigen-binding portion thereof, and the anti-LAG-3 antibody comprises relatlimab, or an antigen-binding portion thereof. In some aspects: (a) the anti-LAG-3 antibody comprises CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:3, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO:4, and the anti-PD-1 antibody comprises CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 13, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO: 14; (b) the anti-LAG-3 antibody comprises a heavy chain variable region CDR1, CDR2, and CDR3 comprisingthe amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO: 10, respectively, and the anti-PD-1 antibody comprises a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO:20, respectively; (c) the anti-LAG-3 antibody comprises heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:3 and 4, respectively, and the anti-PD-1 antibody comprises heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:13 and 14, respectively; (d) the anti-LAG-3 antibody comprises heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:1 and 2, respectively, and the anti-PD-1 antibody comprises heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs: 11 and 12, respectively; or (e) the anti-LAG-3 antibody comprises heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:21 and 2, respectively, and the anti-PD-1 antibody comprises heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs: 11 and 12, respectively. In some aspects, percent high molecular weight species (% HMW) in the pharmaceutical composition as measured by size exclusion chromatography are less than about 1.5% following: agitation at 250 rpm for 1 week at 30 °C, agitation at 250 rpm for 2 weeks at 30 °C, storage at room temperature and room light conditions for 2 weeks, storage at 40 °C for 2 weeks, and / or storage at 50 °C for 2 weeks. In some aspects, the %HMW species are about 1% or less. In some aspects, the %HMW species are less than about 1%. In some aspects, percent monomer (% monomer) in the pharmaceutical composition as measured by size exclusion chromatography is greater than about 97% following: agitation at 250 rpm for 1 week at 30 °C, agitation at 250 rpm for 2 weeks at 30 °C, storage at room temperature and room light conditions for 2 weeks, storage at 40 °C for 2 weeks, and / or storage at 50 °C for 2 weeks. In some aspects, the % monomer in the pharmaceutical composition as measured by size exclusion chromatography is about 98% or more following: agitation at 250 rpm for 1 week at 30 °C, agitation at 250 rpm for 2 weeks at 30 °C, storage at room temperature and room light conditions for 2 weeks, and / or storage at 40 °C for 2 weeks.
[0035] In some aspects, the pharmaceutical composition further comprises an antioxidant. In some aspects, the antioxidant comprises a sacrificial antioxidant, a metal ion chelator, or both. In some aspects, the antioxidant comprises methionine, tryptophan, histidine, cysteine, ascorbicacid, glycine, pentetic acid (" DTPA"), ethylenediaminetetraacetic acid (" EDTA"), or a combination thereof. In some aspects, the pharmaceutical composition comprises at least two antioxidants. In some aspects, the at least two antioxidants are (i) methionine and DTPA or (ii) methionine and EDTA. In some aspects, the pharmaceutical composition comprises at least about 1 mM, at least about 1.5 mM, at least about 2 mM, at least about 2.5 mM, at least about 3 mM, at least about 3.5 mM, at least about 4 mM, at least about 4.5 mM, at least about 5 mM, at least about 5.5 mM, at least about 6 mM, at least about 6.5 mM, at least about 7 mM, at least about 7.5 mM, at least about 8 mM, at least about 8.5 mM, at least about 9 mM, at least about 9.5 mM, at least about 10 mM, at least about 11 mM, at least about 12 mM, at least about 13 mM, at least about 14 mM, at least about 15 mM, at least about 16 mM, at least about 17 mM, at least about 18 mM, at least about 19 mM, or at least about 20 mM of methionine. In some aspects, the pharmaceutical composition comprises about 0.1 mM to about 100 mM, about 0.1 mM to about 90 mM, about 0.1 mM to about 80 mM, about 0.1 mM to about 70 mM, about 0.1 mM to about 60 mM, about 0.1 mM to about 50 mM, about 0.1 mM to about 40 mM, about 0.1 mM to about 30 mM, about 0.1 mM to about 20 mM, about 0.1 mM to about 10 mM, about 1 mM to about 20 mM, about 1 mM to about 15 mM, about 1 mM to about 10 mM, about 1 mM to about 9 mM, about 1 mM to about 8 mM, about 1 mM to about 7 mM, about 1 mM to about 6 mM, about 1 mM to about 5 mM, about 2 mM to about 9 mM, about 3 mM to about 8 mM, about 4 mM to about 7 mM, about 4 mM to about 6 mM, about 4 mM to about 5 mM, about 5 mM to about 20 mM, about 5 mM to about 15 mM, about 5 mM to about 10 mM, about 5 mM to about 9 mM, about 5 mM to about 8 mM, about 5 mM to about 7 mM, or about 5 mM to about 6 mM of methionine. In some aspects, the pharmaceutical composition comprises about 1 mM, about 1.5 mM, about 2 mM, about 2.5 mM, about 3 mM, about 3.5 mM, about 4 mM, about 4.5 mM, about 5 mM, about 5.5 mM, about 6 mM, about 6.5 mM, about 7 mM, about 7.5 mM, about 8 mM, about 8.5 mM, about 9 mM, about 9.5 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM, about 55 mM, about 60 mM, about 65 mM, about 70 mM, about 75 mM, about 80 mM, about 85 mM, about 90 mM, about 95 mM, or about 100 mM of methionine. In some aspects, the pharmaceutical composition comprises about 5 mM of methionine. In some aspects, the pharmaceutical composition comprises about 1 pM to about 250 pM, about 10 pM to about 200 pM, about 10 pM to about 175 pM, about 10 pM to about 150 pM, about 10 pM to about 125 pM, about 10 pM to about 100 pM, about 10 pM to about 75 pM, about 10 pM to about 70 pM, about 10 pM to about 60 pM, about 10 pM to about50 pM, about 20 pM to about 100 pM, about 20 pM to about 75 pM, about 20 pM to about 70 pM, about 20 pM to about 60 pM, about 20 pM to about 50 pM, about 25 pM to about 100 pM, about 25 pM to about 75 pM, about 25 pM to about 50 pM, about 30 pM to about 100 pM, about 30 pM to about 75 pM, about 30 pM to about 70 pM, about 30 pM to about 60 pM, about 30 pM to about 50 pM, about 40 pM to about 100 pM, about 40 pM to about 75 pM, about 40 pM to about 70 pM, about 40 pM to about 60 pM, about 40 pM to about 50 pM, about 41 pM to about 59 pM, about 42 pM to about 58 pM, about 43 pM to about 57 pM, about 44 pM to about 56 pM, about 45 pM to about 55 pM, about 46 pM to about 54 pM, about 47 pM to about 53 pM, about 48 pM to about 52 pM, about 49 pM to about 51 pM, about 50 pM to about 100 pM, about 50 pM to about 75 pM, about 50 pM to about 70 pM, about 50 pM to about 60 pM of DTPA. In some aspects, the pharmaceutical composition comprises about 1 pM, about 5 pM, about 10 pM, about 15 pM, about 20 pM, about 25 pM, about 30 pM, about 35 pM, about 40 pM, about 45 pM, about 50 pM, about 55 pM, about 60 pM, about 65 pM, about 70 pM, about 75 pM, about 80 pM, about 85 pM, about 90 pM, about 95 pM, about 100 pM, about 110 pM, about 120 pM, about 130 pM, about 140 pM, about 150 pM, about 160 pM, about 170 pM, about 180 pM, about 190 pM, about 200 pM, about 210 pM, about 220 pM, about 230 pM, about 240 pM, or about 250 pM of DTPA. In some aspects, the pharmaceutical composition comprises about 50 pM of DTPA.
[0036] In some aspects, the pharmaceutical composition further comprises a buffering agent. In some aspects, the pharmaceutical composition comprises a higher concentration of the buffering agent as compared to the corresponding composition. In some aspects, the buffering agent comprises histidine, succinate, Tris, sodium phosphate, sodium acetate, sodium citrate, or a combination thereof. In some aspects, the buffering agent comprises histidine. In some aspects, the buffering agent comprises at least about 5 mM, at least about 10 mM, at least about 15 mM, at least about 20 mM, at least about 25 mM, at least about 30 mM, at least about 35 mM, at least about 40 mM, at least about 45 mM, at least about 50 mM, at least about 60 mM, at least about 70 mM, at least about 80 mM, at least about 90 mM, or at least about 100 mM of histidine. In some aspects, the buffering agent comprises about 1 mM to about 100 mM, about 1 mM to about 90 mM, about 1 mM to about 80 mM, about 1 mM to about 75 mM, about 1 mM to about 70 mM, about 1 mM to about 65 mM, about 1 mM to about 60 mM, about 1 mM to about 55 mM, about 1 mM to about 50 mM, about 1 mM to about 45 mM, about 1 mM to about 40 mM, about 1 mM to about 35 mM, about 1 mM to about 30 mM, about 1 mM to about 25 mM, about 1 mM to about 20 mM, about 1 mM to about 15 mM, about 1 mM to about 10 mM, about 1 mM to about 5 mM, about 5 mM to about 100 mM, about 5 mM to about 90 mM, about 5 mM to about 80 mM, about 5 mM to about75 mM, about 5 mM to about 70 mM, about 5 mM to about 65 mM, about 5 mM to about 60 mM, about 5 mM to about 55 mM, about 5 mM to about 50 mM, about 5 mM to about 45 mM, about 5 mM to about 40 mM, about 5 mM to about 35 mM, about 5 mM to about 30 mM, about 5 mM to about 25 mM, about 5 mM to about 20 mM, about 5 mM to about 15 mM, about 5 mM to about 10 mM, about 10 mM to about 100 mM, about 10 mM to about 90 mM, about 10 mM to about 80 mM, about 10 mM to about 75 mM, about 10 mM to about 70 mM, about 10 mM to about 65 mM, about 10 mM to about 60 mM, about 10 mM to about 55 mM, about 10 mM to about 50 mM, about 10 mM to about 45 mM, about 10 mM to about 40 mM, about 10 mM to about 35 mM, about 10 mM to about 30 mM, about 10 mM to about 25 mM, about 10 mM to about 20 mM, about 10 mM to about 15 mM, about 15 mM to about 100 mM, about 15 mM to about 90 mM, about 15 mM to about 80 mM, about 15 mM to about 75 mM, about 15 mM to about 70 mM, about 15 mM to about 65 mM, about 15 mM to about 60 mM, about 15 mM to about 55 mM, about 15 mM to about 50 mM, about 15 mM to about 45 mM, about 15 mM to about 40 mM, about 15 mM to about 35 mM, about 15 mM to about 30 mM, about 15 mM to about 25 mM, about 15 mM to about 20 mM, about 16 mM to about 24 mM, about 17 mM to about 23 mM, about 18 mM to about 22 mM, about 19 mM to about 21 mM, about 20 mM to about 100 mM, about 20 mM to about 90 mM, about 20 mM to about 80 mM, about 20 mM to about 75 mM, about 20 mM to about 70 mM, about 20 mM to about 65 mM, about 20 mM to about 60 mM, about 20 mM to about 55 mM, about 20 mM to about 50 mM, about 20 mM to about 45 mM, about 20 mM to about 40 mM, about 20 mM to about 35 mM, about 20 mM to about 30 mM, about 20 mM to about 25 mM, about 25 mM to about 100 mM, about 30 mM to about 100 mM, about 35 mM to about 100 mM, about 40 mM to about 100 mM, about 45 mM to about 100 mM, or about 50 mM to about 100 mM of histidine. In some aspects, the buffering agent comprises about 1 mM, about 5 mM, about 10 mM, about 15 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM, about 55 mM, about 60 mM, about 65 mM, about 70 mM, about 75 mM, about 80 mM, about 90 mM, or about 100 mM of histidine. In some aspects, the buffering agent comprises about 20 mM of histidine.
[0037] In some aspects, the pharmaceutical composition further comprises a surfactant. In some aspects, the surfactant comprises polysorbate 20, polysorbate 80, or poloxamer 188. In some aspects, the surfactant comprises polysorbate 80. In some aspects, the pharmaceutical composition comprises at least about 0.01% w / v, at least about 0.02% w / v, at least about 0.03% w / v, at least about 0.04% w / v, at least about 0.05% w / v, at least about 0.06% w / v, at least about 0.07% w / v, at least about 0.08% w / v, at least about 0.09% w / v, or at least about 0.1% w / v of polysorbate 80. Insome aspects, the pharmaceutical composition comprises about 0.001% to about 1% w / v, about 0.001% w / v to about 0.9% w / v, about 0.001% w / v to about 0.8% w / v, about 0.001% w / v to about 0.7% w / v, about 0.001% w / v to about 0.6% w / v, about 0.001% w / v to about 0.5% w / v, about 0.001% w / v to about 0.4% w / v, about 0.001% w / v to about 0.3% w / v, about 0.001% w / v to about 0.2% w / v, about 0.001% w / v to about 0.1% w / v, about 0.001% w / v to about 0.09% w / v, about 0.001% w / v to about 0.08% w / v, about 0.001% w / v to about 0.07% w / v, about 0.001% w / v to about 0.06% w / v, about 0.001% w / v to about 0.05% w / v, about 0.01% w / v to about 0.9% w / v, about 0.01% w / v to about 0.8% w / v, about 0.01% w / v to about 0.7% w / v, about 0.01% w / v to about 0.6% w / v, about 0.01% w / v to about 0.5% w / v, about 0.01% w / v to about 0.4% w / v, about 0.01% w / v to about 0.3% w / v, about 0.01% w / v to about 0.2% w / v, about 0.01% w / v to about 0.1% w / v, about 0.01% w / v to about 0.09% w / v, about 0.01% w / v to about 0.08% w / v, about 0.01% w / v to about 0.07% w / v, about 0.01% w / v to about 0.06% w / v, about 0.01% w / v to about 0.05% w / v, about 0.02% w / v to about 0.1% w / v, about 0.02% w / v to about 0.09% w / v, about 0.02% w / v to about 0.08% w / v, about 0.02% w / v to about 0.07% w / v, about 0.02% w / v to about 0.06% w / v, about 0.02% w / v to about 0.05% w / v, about 0.03% w / v to about 0.1% w / v, about 0.03% w / v to about 0.09% w / v, about 0.03% w / v to about 0.08% w / v, about 0.03% w / v to about 0.07% w / v, about 0.03% w / v to about 0.06% w / v, about 0.03% w / v to about 0.05% w / v, about 0.04% w / v to about 0.1% w / v, about 0.04% w / v to about 0.09% w / v, about 0.04% w / v to about 0.08% w / v, about 0.04% w / v to about 0.07% w / v, about 0.04% w / v to about 0.06% w / v, about 0.04% w / v to about 0.05%, about 0.05% w / v to about 0.1% w / v, about 0.05% w / v to about 0.09% w / v, about 0.05% w / v to about 0.08% w / v, about 0.05% w / v to about 0.07% w / v, or about 0.05% w / v to about 0.06% w / v of polysorbate 80. In some aspects, the pharmaceutical composition comprises about 0.001% w / v, about 0.002% w / v, about 0.003% w / v, about 0.004% w / v, about 0.005% w / v, about 0.006% w / v, about 0.007% w / v, about 0.008% w / v, about 0.009% w / v, about 0.01% w / v, about 0.02% w / v, about 0.03% w / v, about 0.04% w / v, about 0.05% w / v, about 0.06% w / v, about 0.07% w / v, about 0.08% w / v, about 0.09% w / v, about 0.1% w / v, about 0.2% w / v, about 0.3% w / v, about 0.4% w / v, about 0.5% w / v, about 0.6% w / v, about 0.7% w / v, about 0.8% w / v, about 0.9% w / v, or about 1% w / v of polysorbate 80. In some aspects, the pharmaceutical composition comprises about 0.05% w / v of polysorbate 80.
[0038] In some aspects, the pharmaceutical composition further comprises an endoglycosidase hydrolase enzyme. In some aspects, the endoglycosidase hydrolase enzyme cleaves hyaluronic acid at a hexosaminidic P (1-4) or (1-3) linkage. In some aspects, the endoglycosidase hydrolase enzyme comprises a catalytic domain of hyaluronidase PH-20(HuPH20), HYAL1, HYAL2, HYAL3, HYAL4, or HYALPS1. In some aspects, the endoglycosidase hydrolase enzyme comprises a hyaluronidase. In some aspects, the hyaluronidase comprises HuPH20, HYAL1, HYAL2, HYAL3, HYAL4, or a variant or isoform thereof. In some aspects, the endoglycosidase hydrolase enzyme comprises rHuPH20 or a fragment thereof. In some aspects, the endoglycosidase hydrolase enzyme comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity to amino acids 36-490 of SEQ ID NO:87. In some aspects, the endoglycosidase hydrolase enzyme comprises a modified hyaluronidase comprising one or more amino acid substitutions relative to a wild-type hyaluronidase that is HuPH20, HYAL1, HYAL2, HYAL3, HYAL4, HYALPS1, or a fragment thereof. In some aspects, the endoglycosidase hydrolase enzyme comprises a modified hyaluronidase comprising (i) one or more amino acid substitution in an alpha-helix region, (ii) one or more amino acid substitution in a linker region, (iii) deletion of one or more N-terminal and / or C-terminal amino acids, or (iv) any combination of (i)-(iii), relative to a wild-type hyaluronidase that is HuPH20, HYAL1, HYAL2, HYAL3, HYAL4, HYALPS1, or a fragment thereof. In some aspects, the endoglycosidase hydrolase enzyme comprises a modified rHuPH20, wherein the modified rHuPH20 comprises: (a) one or more amino acid substitution in an alpha-helix region, a linker region, or both an alpha-helix region and a linker region relative to wild-type rHuPH20; (b) deletion of one or more N-terminal amino acid, one or more C-terminal amino acid, or one or more N-terminal amino acid and one or more C-terminal amino acid relative to wild-type rHuPH20; or (c) both (a) and (b). In some aspects, the pharmaceutical composition comprises at least about 50 IU / mL, at least about 100 IU / mL, at least about 150 IU / mL, at least about 200 IU / mL, at least about 250 IU / mL, at least about 300 IU / mL, at least about 350 IU / mL, at least about 400 IU / mL, at least about 450 IU / mL, at least about 500 IU / mL, at least about 550 IU / mL, at least about 600 IU / mL, at least about 650 IU / mL, at least about 700 IU / mL, at least about 750 IU / mL, at least about 800 IU / mL, at least about 850 IU / mL, at least about 900 IU / mL, at least about 950 IU / mL, at least about 1000 IU / mL, at least about 1100 IU / mL, at least about 1200 IU / mL, at least about 1300 IU / mL, at least about 1400 IU / mL, at least about 1500 IU / mL, at least about 1600 IU / mL, at least about 1700 IU / mL, at least about 1800 IU / mL, at least about 1900 IU / mL, at least about 2000 IU / mL, at least about 2100 IU / mL, at least about 2200 IU / mL, at least about 2300 IU / mL, at least about 2400 IU / mL, at least about 2500 IU / mL, at least about 3000 IU / mL, at least about 3500 IU / mL, at least about 4000 IU / mL, at least about 4500 IU / mL, or at least about 5000 IU / mL of the endoglycosidase hydrolase enzyme. Insome aspects, the pharmaceutical composition comprises about 50 IU / mL to about 10,000 IU / mL, about 100 IU / mL to about 9500 IU / mL, about 150 IU / mL to about 9000 IU / mL, about 200 IU / mL to about 8500 IU / mL, about 250 IU / mL to about 8000 IU / mL, about 300 IU / mL to about 7500 IU / mL, about 350 IU / mL to about 7000 IU / mL, about 400 IU / mL to about 6500 IU / mL, about 450 IU / mL to about 6000 IU / mL, about 500 IU / mL to about 5500 IU / mL, about 550 IU / mL to about 5000 IU / mL, about 600 IU / mL to about 4500 IU / mL, about 650 IU / mL to about 4000 IU / mL, about 700 IU / mL to about 3500 IU / mL, about 750 IU / mL to about 3000 IU / mL, about 800 IU / mL to about 2500 IU / mL, about 900 IU / mL to about 2500 IU / mL, about 1000 IU / mL to about 2500 IU / mL, about 1500 IU / mL to about 2500 IU / mL, about 1600 IU / mL to about 2500 IU / mL, about 1700 IU / mL to about 2500 IU / mL, about 1800 IU / mL to about 2500 IU / mL, about 1900 IU / mL to about 2500 IU / mL, about 2000 IU / mL to about 2500 IU / mL, about 2100 IU / mL to about 2500 IU / mL, about 2200 IU / mL to about 2500 IU / mL, about 2300 IU / mL to about 2500 IU / mL, about 1500 IU / mL to about 2500 IU / mL, about 1600 IU / mL to about 2400 IU / mL, about 1700 IU / mL to about 2300 IU / mL, about 1800 IU / mL to about 2200 IU / mL, or about 1900 IU / mL to about 2100 IU / mL of the endoglycosidase hydrolase enzyme. In some aspects, the pharmaceutical composition comprises about 50 IU / mL, about 100 IU / mL, about 150 IU / mL, about 200 IU / mL, about 250 IU / mL, about 300 IU / mL, about 350 IU / mL, about 400 IU / mL, about 450 IU / mL, about 500 IU / mL, about 550 IU / mL, about 600 IU / mL, about 650 IU / mL, about 700 IU / mL, about 750 IU / mL, about 800 IU / mL, about 850 IU / mL, about 900 IU / mL, about 950 IU / mL, about 1000 IU / mL, about 1100 IU / mL, about 1200 IU / mL, about 1300 IU / mL, about 1400 IU / mL, about 1500 IU / mL, about 1600 IU / mL, about 1700 IU / mL, about 1800 IU / mL, about 1900 IU / mL, about 2000 IU / mL, about 2100 IU / mL, about 2200 IU / mL, about 2300 IU / mL, about 2400 IU / mL, about 2500 IU / mL, about 3000 IU / mL, about 3500 IU / mL, about 4000 IU / mL, about 4500 IU / mL, about 5000 IU / mL, about 5500 IU / mL, about 6000 IU / mL, about 6500 IU / mL, about 7000 IU / mL, about 7500 IU / mL, about 8000 IU / mL, about 8500 IU / mL, about 9000 IU / mL, about 9500 IU / mL, or about 10,000 IU / mL of the endoglycosidase hydrolase enzyme. In some aspects, the pharmaceutical composition comprises about 2000 IU / mL of the endoglycosidase hydrolase enzyme.
[0039] In some aspects, the pharmaceutical composition comprises a pH of about 4.0 to about 12.0.
[0040] In some aspects, the pharmaceutical composition comprises a pH of about 5.2 to about 6.8.
[0041] In some aspects, the pharmaceutical composition comprises a pH of about 5.2, about 5.3, about 5.4, about 5.5, about 5.6, about 5.7, about 5.8, about 5.9, about 6.0, about 6.1, about 6.2, about 6.3, about 6.4, about 6.5, about 6.6, about 6.7, or about 6.8.
[0042] In some aspects, the pharmaceutical composition comprises a pH of about 5.8.
[0043] The present disclosure is directed to a pharmaceutical composition comprising: (a) about 80 mg / mL of relatlimab; (b) about 80 mg / mL of nivolumab; (c) about 100 mM of sodium chloride; (d) about 222 mM of sucrose; (e) about 20 mM of histidine; (f) about 0.05% w / v of polysorbate 80; (g) about 50 pM of DTP A; (h) about 5 mM of methionine; (i) about 2000 IU / mL of rHuPH20; and (j) a pH of about 5.8. In some aspects, the pharmaceutical composition comprises a volume of about 12 mL. In some aspects, the pharmaceutical composition comprises a volume of about 9 mL.
[0044] The present disclosure is directed to a pharmaceutical composition comprising: (a) about 75 mg / mL of relatlimab; (b) about 75 mg / mL of nivolumab; (c) about 100 mM of sodium chloride; (d) about 209 mM of sucrose; (e) about 20 mM of histidine; (f) about 0.05% w / v of polysorbate 80; (g) about 50 pM of DTP A; (h) about 5 mM of methionine; (i) about 2000 IU / mL of rHuPH20; and (j) a pH of about 5.8. In some aspects, the pharmaceutical composition comprises a volume of about 12.8 mL. In some aspects, the pharmaceutical composition comprises a volume of about 9.6 mL.
[0045] The present disclosure is directed to a pharmaceutical composition comprising: (a) about 60 mg / mL of relatlimab; (b) about 60 mg / mL of nivolumab; (c) about 40 mM of sodium chloride; (d) about 167 mM of sucrose; (e) about 20 mM of histidine; (f) about 0.05% w / v of polysorbate 80; (g) about 50 pM of DTP A; (h) about 5 mM of methionine; (i) about 2000 IU / mL of rHuPH20; and (j) a pH of about 5.8. In some aspects, the pharmaceutical composition comprises a volume of about 16 mL.
[0046] The present disclosure is directed to a pharmaceutical composition comprising: (a) about 52.5 mg / mL of relatlimab; (b) about 52.5 mg / mL of nivolumab; (c) about 50 mM of sodium chloride; (d) about 146 mM of sucrose; (e) about 20 mM of histidine; (f) about 0.05% w / v of polysorbate 80; (g) about 50 pM of DTP A; (h) about 5 mM of methionine; (i) about 2000 IU / mL of rHuPH20; and (j) a pH of about 5.8. In some aspects, the pharmaceutical composition comprises a volume of about 18.3 mL.
[0047] The present disclosure is directed to a pharmaceutical composition comprising: (a) about 960 mg of relatlimab; (b) about 960 mg of nivolumab; (c) about 100 mM of sodium chloride; (d) about 222 mM of sucrose; (e) about 20 mM of histidine; (f) about 0.05% w / v of polysorbate80; (g) about 50 pM of DTP A; (h) about 5 mM of methionine; (i) about 2000 IU / mL of rHuPH20; and (j) a pH of about 5.8.
[0048] The present disclosure is directed to a pharmaceutical composition comprising: (a) about 720 mg of relatlimab; (b) about 720 mg of nivolumab; (c) about 100 mM of sodium chloride; (d) about 222 mM of sucrose; (e) about 20 mM of histidine; (f) about 0.05% w / v of polysorbate 80; (g) about 50 pM of DTP A; (h) about 5 mM of methionine; (i) about 2000 IU / mL of rHuPH20; and (j) a pH of about 5.8.
[0049] The present disclosure is directed to a pharmaceutical composition comprising: (a) about 960 mg of relatlimab; (b) about 960 mg of nivolumab; (c) about 100 mM of sodium chloride; (d) about 209 mM of sucrose; (e) about 20 mM of histidine; (f) about 0.05% w / v of polysorbate 80; (g) about 50 pM of DTP A; (h) about 5 mM of methionine; (i) about 2000 IU / mL of rHuPH20; and (j) a pH of about 5.8.
[0050] The present disclosure is directed to a pharmaceutical composition comprising: (a) about 720 mg of relatlimab; (b) about 720 mg of nivolumab; (c) about 100 mM of sodium chloride; (d) about 209 mM of sucrose; (e) about 20 mM of histidine; (f) about 0.05% w / v of polysorbate 80; (g) about 50 pM of DTP A; (h) about 5 mM of methionine; (i) about 2000 IU / mL of rHuPH20; and (j) a pH of about 5.8.
[0051] The present disclosure is directed to a pharmaceutical composition comprising: (a) about 960 mg of relatlimab; (b) about 960 mg of nivolumab; (c) about 40 mM of sodium chloride; (d) about 167 mM of sucrose; (e) about 20 mM of histidine; (f) about 0.05% w / v of polysorbate 80; (g) about 50 pM of DTP A; (h) about 5 mM of methionine; (i) about 2000 IU / mL of rHuPH20; and (j) a pH of about 5.8.
[0052] The present disclosure is directed to a pharmaceutical composition comprising: (a) about 720 mg of relatlimab; (b) about 720 mg of nivolumab; (c) about 40 mM of sodium chloride; (d) about 167 mM of sucrose; (e) about 20 mM of histidine; (f) about 0.05% w / v of polysorbate 80; (g) about 50 pM of DTP A; (h) about 5 mM of methionine; (i) about 2000 IU / mL of rHuPH20; and (j) a pH of about 5.8.
[0053] The present disclosure is directed to a pharmaceutical composition comprising: (a) about 960 mg of relatlimab; (b) about 960 mg of nivolumab; (c) about 50 mM of sodium chloride; (d) about 146 mM of sucrose; (e) about 20 mM of histidine; (f) about 0.05% w / v of polysorbate 80; (g) about 50 pM of DTP A; (h) about 5 mM of methionine; (i) about 2000 IU / mL of rHuPH20; and (j) a pH of about 5.8.
[0054] In some aspects, the pharmaceutical composition is suitable for intravitreal, intravenous, intramuscular, and / or subcutaneous administration.
[0055] In some aspects, the pharmaceutical composition is suitable for subcutaneous administration.
[0056] In some aspects, the pharmaceutical composition is capable of being injected within about 10 minutes or less. In some aspects, the pharmaceutical composition is capable of being injected within about 5 minutes to about 7 minutes. In some aspects, the pharmaceutical composition is capable of being injected within about 3 minutes to about 5 minutes.
[0057] The present disclosure is directed to a vial comprising any of the above pharmaceutical compositions.
[0058] The present disclosure is directed to a syringe comprising any of the above pharmaceutical compositions. In some aspects, the syringe is a pre-filled syringe and / or further comprises a plunger.
[0059] The present disclosure is directed to an auto-injector comprising any of the above pharmaceutical compositions.
[0060] The present disclosure is directed to a wearable pump or a wearable device comprising any of the above pharmaceutical compositions.
[0061] The present disclosure is directed to a pen injector comprising any of the above pharmaceutical compositions.
[0062] The present disclosure is directed to a needle-free injector comprising any of the above pharmaceutical compositions.
[0063] The present disclosure is directed to a method of treating a disease or disorder in a subject in need thereof comprising administering to the subject a pharmaceutically effective amount of any of the above pharmaceutical compositions.
[0064] In some aspects, the pharmaceutical composition is administered intravitreally, intravenously, intramuscularly, and / or subcutaneously.
[0065] In some aspects, the pharmaceutical composition is administered subcutaneously.
[0066] In some aspects, the disease or disorder comprises a tumor. In some aspects, the tumor comprises a hepatocellular carcinoma, colorectal cancer, gastric cancer, small-cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), squamous NSCLC, nonsquamous NSCLC, solid cancer with liver metastatic disease, cervical cancer, breast cancer, triple-negative breast cancer, pancreatic cancer, urothelial cancer, prostate cancer, hormone refractory prostate adenocarcinoma, hematological cancer, squamous cell carcinoma, glioma, gastrointestinal cancer,renal cancer, clear cell carcinoma, ovarian cancer, liver cancer, endometrial cancer, kidney cancer, renal cell carcinoma (RCC), thyroid cancer, neuroblastoma, glioblastoma, glioblastoma multiforme, stomach cancer, bladder cancer, hepatoma, colon cancer, head and neck cancer, gastroesophageal cancer, germ cell tumor, pediatric sarcoma, sinonasal natural killer T-cell lymphoma, melanoma, bone cancer, skin cancer, uterine cancer, cancer of the anal region, testicular cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, rectal cancer, solid tumor of childhood, cancer of the ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, spinal axis tumor, brain cancer, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, environmentally-induced cancer, virus-related cancer or cancer of viral origin, or a combination thereof. In some aspects, the tumor is recurrent or refractory. In some aspects, the tumor is unresectable, advanced, and / or metastatic. In some aspects, the tumor is a malignant tumor. In some aspects, the method further comprises administering an additional anti-cancer therapy. In some aspects, the additional anti-cancer therapy comprises a surgery, a radiation therapy, a chemotherapy, an immunotherapy, or any combination thereof. In some aspects, the additional anti-cancer therapy comprises a chemotherapy.
[0067] The present disclosure is directed to a method of reducing the viscosity of a pharmaceutical composition, comprising: (a) preparing a pharmaceutical composition comprising about 100 mg / mL or more of a protein and a lower concentration of a sugar as compared to a corresponding composition that comprises the sugar and the same concentration of the protein, and (b) adding a salt to the pharmaceutical composition, wherein the viscosity of the pharmaceutical composition is reduced as compared to the corresponding composition.
[0068] In some aspects, the pharmaceutical composition comprises about 100 mg / mL to about 500 mg / mL, about 100 mg / mL to about 450 mg / mL, about 100 mg / mL to about 400 mg / mL, about 100 mg / mL to about 350 mg / mL, about 100 mg / mL to about 300 mg / mL, about 100 mg / mL to about 250 mg / mL, about 100 mg / mL to about 200 mg / mL, about 100 mg / mL to about 150 mg / mL, about 100 mg / mL to about 140 mg / mL, about 100 mg / mL to about 130 mg / mL, about 100 mg / mL to about 120 mg / mL, about 100 mg / mL to about 115 mg / mL, about 100 mg / mL to about 110 mg / mL, about 100 mg / mL to about 105 mg / mL, about 110 mg / mL to about 500 mg / mL, about 110 mg / mL to about 450 mg / mL, about 110 mg / mL to about 400 mg / mL, about 110 mg / mL toabout 350 mg / mL, about 110 mg / mL to about 300 mg / mL, about 110 mg / mL to about 250 mg / mL, about 110 mg / mL to about 200 mg / mL, about 110 mg / mL to about 150 mg / mL, about 110 mg / mL to about 140 mg / mL, about 110 mg / mL to about 130 mg / mL, about 110 mg / mL to about 120 mg / mL, about 110 mg / mL to about 115 mg / mL, about 115 mg / mL to about 500 mg / mL, about 115 mg / mL to about 450 mg / mL, about 115 mg / mL to about 400 mg / mL, about 115 mg / mL to about 350 mg / mL, about 115 mg / mL to about 300 mg / mL, about 115 mg / mL to about 250 mg / mL, about 115 mg / mL to about 200 mg / mL, about 115 mg / mL to about 150 mg / mL, about 115 mg / mL to about 140 mg / mL, about 115 mg / mL to about 130 mg / mL, about 115 mg / mL to about 120 mg / mL, about 120 mg / mL to about 450 mg / mL, about 120 mg / mL to about 400 mg / mL, about 120 mg / mL to about 350 mg / mL, about 120 mg / mL to about 300 mg / mL, about 120 mg / mL to about 250 mg / mL, about 120 mg / mL to about 200 mg / mL, about 120 mg / mL to about 150 mg / mL, about 120 mg / mL to about 140 mg / mL, about 120 mg / mL to about 130 mg / mL, about 150 mg / mL to about 500 mg / mL, about 150 mg / mL to about 450 mg / mL, about 150 mg / mL to about 400 mg / mL, about 150 mg / mL to about 350 mg / mL, about 150 mg / mL to about 300 mg / mL, about 150 mg / mL to about 250 mg / mL, or about 150 mg / mL to about 200 mg / mL of the protein.
[0069] In some aspects, the pharmaceutical composition comprises about 100 mg / mL, about 101 mg / mL, about 102 mg / mL, about 103 mg / mL, about 104 mg / mL, about 105 mg / mL, about 106 mg / mL, about 107 mg / mL, about 108 mg / mL, about 109 mg / mL, about 110 mg / mL, about 111 mg / mL, about 112 mg / mL, about 113 mg / mL, about 114 mg / mL, about 115 mg / mL, about 116 mg / mL, about 117 mg / mL, about 118 mg / mL, about 119 mg / mL, about 120 mg / mL, about 121 mg / mL, about 122 mg / mL, about 123 mg / mL, about 124 mg / mL, about 125 mg / mL, about 126 mg / mL, about 127 mg / mL, about 128 mg / mL, about 129 mg / mL, about 130 mg / mL, about 131 mg / mL, about 132 mg / mL, about 133 mg / mL, about 134 mg / mL, about 135 mg / mL, about 136 mg / mL, about 137 mg / mL, about 138 mg / mL, about 139 mg / mL, about 140 mg / mL, about 141 mg / mL, about 142 mg / mL, about 143 mg / mL, about 144 mg / mL, about 145 mg / mL, about 146 mg / mL, about 147 mg / mL, about 148 mg / mL, about 149 mg / mL, about 150 mg / mL, about 155 mg / mL, about 160 mg / mL, about 165 mg / mL, about 170 mg / mL, about 175 mg / mL, about 180 mg / mL, about 185 mg / mL, about 190 mg / mL, about 195 mg / mL, about 200 mg / mL, about 205 mg / mL, about 210 mg / mL, about 215 mg / mL, about 220 mg / mL, about 225 mg / mL, about 230 mg / mL, about 235 mg / mL, about 240 mg / mL, about 245 mg / mL, about 250 mg / mL, about 255 mg / mL, about 260 mg / mL, about 265 mg / mL, about 270 mg / mL, about 275 mg / mL, about 280 mg / mL, about 285 mg / mL, about 290 mg / mL, about 295 mg / mL, about 300 mg / mL, about 305 mg / mL, about 310 mg / mL, about 315 mg / mL, about 320 mg / mL, about 325 mg / mL,about 330 mg / mL, about 335 mg / mL, about 340 mg / mL, about 345 mg / mL, about 350 mg / mL, about 355 mg / mL, about 360 mg / mL, about 365 mg / mL, about 370 mg / mL, about 375 mg / mL, about 380 mg / mL, about 385 mg / mL, about 390 mg / mL, about 395 mg / mL, about 400 mg / mL, about 405 mg / mL, about 410 mg / mL, about 415 mg / mL, about 420 mg / mL, about 425 mg / mL, about 430 mg / mL, about 435 mg / mL, about 440 mg / mL, about 445 mg / mL, about 450 mg / mL, about 455 mg / mL, about 460 mg / mL, about 465 mg / mL, about 470 mg / mL, about 475 mg / mL, about 480 mg / mL, about 485 mg / mL, about 490 mg / mL, about 495 mg / mL, or about 500 mg / mL of the protein.
[0070] In some aspects, the pharmaceutical composition comprises a volume of about 0.001 mL to about 20 mL.
[0071] In some aspects, the pharmaceutical composition comprises a volume of about 0.001 mL, about 0.005 mL, about 0.010 mL, about 0.015 mL, about 0.020 mL, about 0.025 mL, about 0.030 mL, about 0.035 mL, about 0.040 mL, about 0.045 mL, about 0.050 mL, about 0.055 mL, about 0.060 mL, about 0.065 mL, about 0.070 mL, about 0.075 mL, about 0.080 mL, about 0.085 mL, about 0.090 mL, about 0.095 mL, about 0.100 mL, about 0.150 mL, about 0.200 mL, about 0.250 mL, about 0.300 mL, about 0.350 mL, about 0.400 mL, about 0.450 mL, about 0.500 mL, about 0.550 mL, about 0.600 mL, about 0.650 mL, about 0.700 mL, about 0.750 mL, about 0.800 mL, about 0.850 mL, about 0.900 mL, about 0.950 mL, about 1 mL, about 1.1 mL, about 1.2 mL, about 1.3 mL, about 1.4 mL, about 1.5 mL, about 1.6 mL, about 1.7 mL, about 1.8 mL, about 1.9 mL, about 2 mL, about 2.1 mL, about 2.2 mL, about 2.3 mL, about 2.4 mL, about 2.5 mL, about 2.6 mL, about 2.7 mL, about 2.8 mL, about 2.9 mL, about 3 mL, about 3.1 mL, about 3.2 mL, about 3.3 mL, about 3.4 mL, about 3.5 mL, about 3.6 mL, about 3.7 mL, about 3.8 mL, about 3.9 mL, about 4 mL, about 4.1 mL, about 4.2 mL, about 4.3 mL, about 4.4 mL, about 4.5 mL, about 4.6 mL, about 4.7 mL, about 4.8 mL, about 4.9 mL, about 5 mL, about 5.1 mL, about 5.2 mL, about 5.3 mL, about 5.4 mL, about 5.5 mL, about 5.6 mL, about 5.7 mL, about 5.8 mL, about 5.9 mL, about 6 mL, about 6.1 mL, about 6.2 mL, about 6.3 mL, about 6.4 mL, about 6.5 mL, about 6.6 mL, about 6.7 mL, about 6.8 mL, about 6.9 mL, about 7 mL, about 7.1 mL, about 7.2 mL, about 7.3 mL, about 7.4 mL, about 7.5 mL, about 7.6 mL, about 7.7 mL, about 7.8 mL, about 7.9 mL, about 8 mL, about 8.1 mL, about 8.2 mL, about 8.3 mL, about 8.4 mL, about 8.5 mL, about 8.6 mL, about 8.7 mL, about 8.8 mL, about 8.9 mL, about 9 mL, about 9.1 mL, about 9.2 mL, about 9.3 mL, about 9.4 mL, about 9.5 mL, about 9.6 mL, about 9.7 mL, about 9.8 mL, about 9.9 mL, about 10 mL, about 10.1 mL, about 10.2 mL, about 10.3 mL, about 10.4 mL, about 10.5 mL, about 10.6 mL, about 10.7 mL, about 10.8 mL, about 10.9 mL, about 11 mL, about 11.1mL, about 11.2 mL, about 11.3 mL, about 11.4 mL, about 11.5 mL, about 11.6 mL, about 11.7 mL, about 11.8 mL, about 11.9 mL, about 12 mL, about 12.1 mL, about 12.2 mL, about 12.3 mL, about 12.4 mL, about 12.5 mL, about 12.6 mL, about 12.7 mL, about 12.8 mL, about 12.9 mL, about 13 mL, about 13.1 mL, about 13.2 mL, about 13.3 mL, about 13.4 mL, about 13.5 mL, about 13.6 mL, about 13.7 mL, about 13.8 mL, about 13.9 mL, about 14 mL, about 14.1 mL, about 14.2 mL, about 14.3 mL, about 14.4 mL, about 14.5 mL, about 14.6 mL, about 14.7 mL, about 14.8 mL, about 14.9 mL, about 15 mL, about 15.1 mL, about 15.2 mL, about 15.3 mL, about 15.4 mL, about 15.5 mL, about 15.6 mL, about 15.7 mL, about 15.8 mL, about 15.9 mL, about 16 mL, about 16.1 mL, about 16.2 mL, about 16.3 mL, about 16.4 mL, about 16.5 mL, about 16.6 mL, about 16.7 mL, about 16.8 mL, about 16.9 mL, about 17 mL, about 17.1 mL, about 17.2 mL, about 17.3 mL, about 17.4 mL, about 17.5 mL, about 17.6 mL, about 17.7 mL, about 17.8 mL, about 17.9 mL, about 18 mL, about 18.1 mL, about 18.2 mL, about 18.3 mL, about 18.4 mL, about 18.5 mL, about 18.6 mL, about 18.7 mL, about 18.8 mL, about 18.9 mL, about 19 mL, about 19.1 mL, about 19.2 mL, about 19.3 mL, about 19.4 mL, about 19.5 mL, about 19.6 mL, about 19.7 mL, about 19.8 mL, about 19.9 mL, or about 20 mL.
[0072] In some aspects, the pharmaceutical composition comprises about 0.25 mg to about 4000 mg, about 0.25 mg to about 3600 mg, about 0.25 mg to about 3200 mg, about 0.25 mg to about 3000 mg, about 0.25 mg to about 2600 mg, about 0.25 mg to about 2200 mg, about 0.25 mg to about 2000 mg, about 0.25 mg to about 1600 mg, about 0.25 mg to about 1200 mg, about 0.25 mg to about 1000 mg, about 0.25 mg to about 800 mg, about 0.25 mg to about 600 mg, about 0.25 mg to about 400 mg, about 0.25 mg to about 200 mg, about 0.25 mg to about 100 mg, about 0.25 mg to about 50 mg, about 0.25 mg to about 40 mg, about 0.25 mg to about 30 mg, about 0.25 mg to about 20 mg, about 20 mg to about 4000 mg, about 20 mg to about 3600 mg, about 20 mg to about 3200 mg, about 20 mg to about 3000 mg, about 20 mg to about 2600 mg, about 20 mg to about 2200 mg, about 20 mg to about 2000 mg, about 20 mg to about 1600 mg, about 20 mg to about 1200 mg, about 20 mg to about 1000 mg, about 20 mg to about 800 mg, about 20 mg to about 600 mg, about 20 mg to about 400 mg, about 20 mg to about 200 mg, about 20 mg to about 100 mg, about 100 mg to about 4000 mg, about 100 mg to about 3600 mg, about 100 mg to about 3200 mg, about 100 mg to about 3000 mg, about 100 mg to about 2600 mg, about 100 mg to about 2200 mg, about 100 mg to about 2000 mg, about 100 mg to about 1800 mg, about 100 mg to about 1600 mg, about 100 mg to about 1400 mg, about 100 mg to about 1200 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, about 400 mg to about 4000 mg, about 400 mg to about 3600 mg, about 400 mg to about3200 mg, about 400 mg to about 3000 mg, about 400 mg to about 2600 mg, about 400 mg to about 2200 mg, about 400 mg to about 2000 mg, about 400 mg to about 1800 mg, about 400 mg to about 1600 mg, about 400 mg to about 1400 mg, about 400 mg to about 1200 mg, or about 400 mg to about 1000 mg of the protein.
[0073] In some aspects, the pharmaceutical composition comprises about 0.25 mg, about 0.5 mg, about 0.75 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3 mg, about 3.25 mg, about 3.5 mg, about 3.75 mg, about 4 mg, about 4.25 mg, about 4.5 mg, about 4.75 mg, about 5 mg, about 5.25 mg, about 5.5 mg, about 5.75 mg, about 6 mg, about 6.25 mg, about 6.5 mg, about 6.75 mg, about 7 mg, about 7.25 mg, about 7.5 mg, about 7.75 mg, about 8 mg, about 8.25 mg, about 8.5 mg, about 8.75 mg, about 9 mg, about 9.25 mg, about 9.5 mg, about 9.75 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, about 710 mg, about 720 mg, about 730 mg, about 740 mg, about 750 mg, about 760 mg, about 770 mg, about 780 mg, about 790 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 980 mg, about 990 mg, about 1000 mg, about 1020 mg, about 1040 mg, about 1060 mg, about 1080 mg, about 1100 mg, about 1120 mg, about 1140 mg, about 1160 mg, about 1180 mg, about 1200 mg, about 1220 mg, about 1240 mg, about 1260 mg, about 1280 mg, about 1300 mg, about 1320 mg, about 1340 mg, about 1360 mg, about 1380 mg, about 1400 mg, about 1420 mg, about 1440 mg, about 1460 mg, about 1480 mg, about 1500 mg, about 1520 mg, about 1540 mg, about 1560 mg, about 1580 mg, about 1600 mg, about 1620 mg, about 1640 mg, about 1660 mg, about 1680 mg, about 1700 mg, about 1720 mg, about 1740 mg, about 1760 mg, about 1780 mg,about 1800 mg, about 1820 mg, about 1840 mg, about 1860 mg, about 1880 mg, about 1900 mg, about 1920 mg, about 1940 mg, about 1960 mg, about 1980 mg, about 2000 mg, about 2020 mg, about 2040 mg, about 2060 mg, about 2080 mg, about 2100 mg, about 2120 mg, about 2140 mg, about 2160 mg, about 2180 mg, about 2200 mg, about 2220 mg, about 2240 mg, about 2260 mg, about 2280 mg, about 2300 mg, about 2320 mg, about 2340 mg, about 2360 mg, about 2380 mg, about 2400 mg, about 2420 mg, about 2440 mg, about 2460 mg, about 2480 mg, about 2500 mg, about 2520 mg, about 2540 mg, about 2560 mg, about 2580 mg, about 2600 mg, about 2620 mg, about 2640 mg, about 2660 mg, about 2680 mg, about 2700 mg, about 2720 mg, about 2740 mg, about 2760 mg, about 2780 mg, about 2800 mg, about 2820 mg, about 2840 mg, about 2860 mg, about 2880 mg, about 2900 mg, about 2920 mg, about 2940 mg, about 2960 mg, about 2980 mg, about 3000 mg, about 3020 mg, about 3040 mg, about 3060 mg, about 3080 mg, about 3100 mg, about 3120 mg, about 3140 mg, about 3160 mg, about 3180 mg, about 3200 mg, about 3220 mg, about 3240 mg, about 3260 mg, about 3280 mg, about 3300 mg, about 3320 mg, about 3340 mg, about 3360 mg, about 3380 mg, about 3400 mg, about 3420 mg, about 3440 mg, about 3460 mg, about 3480 mg, about 3500 mg, about 3520 mg, about 3540 mg, about 3560 mg, about 3580 mg, about 3600 mg, about 3620 mg, about 3640 mg, about 3660 mg, about 3680 mg, about 3700 mg, about 3720 mg, about 3740 mg, about 3760 mg, about 3780 mg, about 3800 mg, about 3820 mg, about 3840 mg, about 3860 mg, about 3880 mg, about 3900 mg, about 3920 mg, about 3940 mg, about 3960 mg, about 3980 mg, or about 4000 mg of the protein.
[0074] In some aspects, the concentration of the sugar in the pharmaceutical composition is less than about 500 mM, less than about 475 mM, less than about 450 mM, less than about 425 mM, less than about 400 mM, less than about 375 mM, less than about 350 mM, less than about 325 mM, less than about 300 mM, less than about 275 mM, less than about 250 mM, less than about 225 mM, less than about 200 mM, less than about 175 mM, less than about 150 mM, less than about 125 mM, less than about 100 mM, or less than about 75 mM.
[0075] In some aspects, the sugar comprises a monosaccharide, a disaccharide, a polysaccharide, a polyol, or a combination thereof.
[0076] In some aspects, the sugar comprises glucose, xylose, erythritol, sucrose, trehalose, maltose, galactose, dextrose, raffinose, stachyose, lactose, mannitol, sorbitol, xylitol, lactitol, maltitol, glycerol or a combination thereof. In some aspects, the sugar comprises sucrose. In some aspects, the sugar comprises trehalose.
[0077] In some aspects, about 10 mM to about 400 mM, about 10 mM to about 350 mM, about 10 mM to about 300 mM, about 10 mM to about 250 mM, about 10 mM to about 200 mM,about 10 mM to about 150 mM, about 10 mM to about 100 mM, about 10 mM to about 90 mM, about 10 mM to about 80 mM, about 10 mM to about 70 mM, about 10 mM to about 60 mM, about 10 mM to about 50 mM, about 30 mM to about 400 mM, about 30 mM to about 350 mM, about 30 mM to about 300 mM, about 30 mM to about 250 mM, about 30 mM to about 200 mM, about 30 mM to about 150 mM, about 30 mM to about 100 mM, about 30 mM to about 90 mM, about 30 mM to about 80 mM, about 30 mM to about 70 mM, about 30 mM to about 60 mM, about 30 mM to about 50 mM, about 50 mM to about 400 mM, about 50 mM to about 350 mM, about 50 mM to about 300 mM, about 50 mM to about 250 mM, about 50 mM to about 200 mM, about 50 mM to about 150 mM, about 50 mM to about 100 mM, about 100 mM to about 400 mM, about 100 mM to about 350 mM, about 100 mM to about 300 mM, about 100 mM to about 250 mM, about 100 mM to about 200 mM, or about 100 mM to about 150 mM of the salt is added.
[0078] In some aspects, about 10 mM, about 15 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM, about 55 mM, about 60 mM, about 65 mM, about 70 mM, about 75 mM, about 80 mM, about 85 mM, about 90 mM, about 95 mM, about 100 mM, about 110 mM, about 120 mM, about 130 mM, about 140 mM, about 150 mM, about 160 mM, about 170 mM, about 180 mM, about 190 mM, about 200 mM, about 210 mM, about 220 mM, about 230 mM, about 240 mM, about 250 mM, about 260 mM, about 270 mM, about 280 mM, about 290 mM, about 300 mM, about 310 mM, about 320 mM, about 330 mM, about 340 mM, about 350 mM, about 360 mM, about 370 mM, about 380 mM, about 390 mM, or about 400 mM of the salt is added.
[0079] In some aspects, the salt comprises sodium chloride, arginine hydrochloride, histidine hydrochloride, lysine hydrochloride, magnesium chloride, potassium chloride, ammonium chloride, calcium chloride, sodium acetate, zinc chloride, ammonium thiocyanate, sodium thiocyanate, sodium sulfate, ammonium sulfate, sodium phosphate, sodium biphosphate, potassium phosphate, dipotassium hydrogen phosphate, monobasic potassium phosphate, calcium phosphate, tris(hydroxymethyl)aminomethane, or a combination thereof. In some aspects, the salt comprises sodium chloride. In some aspects, the salt comprises arginine hydrochloride. In some aspects, the salt comprises sodium chloride and arginine hydrochloride.
[0080] In some aspects, after the viscosity of the pharmaceutical composition is reduced, the pharmaceutical composition comprises an osmolality of about 600 mOsmol / kg or less.
[0081] In some aspects, the pharmaceutical composition comprises an osmolality of about 200 mOsmol / kg to about 600 mOsmol / kg, about 210 mOsmol / kg to about 600 mOsmol / kg, about 220 mOsmol / kg to about 600 mOsmol / kg, about 230 mOsmol / kg to about 600 mOsmol / kg, about240 mOsmol / kg to about 600 mOsmol / kg, about 250 mOsmol / kg to about 600 mOsmol / kg, about 260 mOsmol / kg to about 600 mOsmol / kg, about 270 mOsmol / kg to about 600 mOsmol / kg, about 280 mOsmol / kg to about 600 mOsmol / kg, about 290 mOsmol / kg to about 600 mOsmol / kg, about 300 mOsmol / kg to about 600 mOsmol / kg, about 350 mOsmol / kg to about 600 mOsmol / kg, about 400 mOsmol / kg to about 600 mOsmol / kg, about 450 mOsmol / kg to about 600 mOsmol / kg, about 500 mOsmol / kg to about 600 mOsmol / kg, about 550 mOsmol / kg to about 600 mOsmol / kg, about 500 mOsmol / kg to about 550 mOsmol / kg, about 450 mOsmol / kg to about 550 mOsmol / kg, about 400 mOsmol / kg to about 550 mOsmol / kg, about 350 mOsmol / kg to about 550 mOsmol / kg, about 300 mOsmol / kg to about 550 mOsmol / kg, about 250 mOsmol / kg to about 550 mOsmol / kg, about 200 mOsmol / kg to about 550 mOsmol / kg, about 200 mOsmol / kg to about 500 mOsmol / kg, about 250 mOsmol / kg to about 500 mOsmol / kg, about 300 mOsmol / kg to about 500 mOsmol / kg, about 350 mOsmol / kg to about 500 mOsmol / kg, about 400 mOsmol / kg to about 500 mOsmol / kg, about 450 mOsmol / kg to about 500 mOsmol / kg, about 400 mOsmol / kg to about 450 mOsmol / kg, about 350 mOsmol / kg to about 450 mOsmol / kg, about 300 mOsmol / kg to about 450 mOsmol / kg, about 250 mOsmol / kg to about 450 mOsmol / kg, about 200 mOsmol / kg to about 450 mOsmol / kg, about 200 mOsmol / kg to about 400 mOsmol / kg, about 250 mOsmol / kg to about 400 mOsmol / kg, about 300 mOsmol / kg to about 400 mOsmol / kg, about 350 mOsmol / kg to about 400 mOsmol / kg, about 300 mOsmol / kg to about 350 mOsmol / kg, about 250 mOsmol / kg to about 350 mOsmol / kg, about 200 mOsmol / kg to about 350 mOsmol / kg, about 200 mOsmol / kg to about 300 mOsmol / kg, or about 250 mOsmol / kg to about 300 mOsmol / kg.
[0082] In some aspects, the pharmaceutical composition comprises an osmolality of about 280 mOsmol / kg to about 600 mOsmol / kg.
[0083] In some aspects, the osmolality is determined by vapor-pressure osmometry.
[0084] In some aspects, the osmolality is determined with a vapor pressure osmometer.
[0085] In some aspects, the viscosity is determined with a microfluidic viscometer.
[0086] In some aspects, the viscosity is determined at 20 °C.
[0087] In some aspects, the sugar is sucrose and the salt is sodium chloride.
[0088] In some aspects, the pharmaceutical composition comprises about 100 mg / mL to about 150 mg / mL of the protein, wherein the concentration of the sugar is less than about 250 mM, and wherein about 200 mM or less of the salt is added.
[0089] In some aspects, the protein comprises an antibody, a checkpoint inhibitor, a fusion protein, a growth factor, a hormone, an enzyme, a cytokine, a coagulation factor, a plasma protein, or a combination thereof. In some aspects, the protein comprises an antibody. In some aspects, theantibody comprises a full-length antibody. In some aspects, the antibody comprises a monoclonal, human, humanized, chimeric, or multispecific antibody. In some aspects, the multispecific antibody comprises a dual-affinity re-targeting antibody, a dual variable domain immunoglobulin, or a bispecific antibody. In some aspects, the antibody comprises a F(ab')2 fragment, a Fab' fragment, a Fab fragment, a Fv fragment, a scFv fragment, a dsFv fragment, a dAb fragment, or a single chain binding polypeptide. In some aspects, the antibody comprises an anti-LAG-3 antibody, an anti-PD-1 antibody, an anti-PD-Ll antibody, an anti-CTLA-4 antibody, an anti-TIM-3 antibody, an anti-TIGIT antibody, an anti-NKG2a antibody, an anti-OX40 antibody, an anti-ICOS antibody, an anti-MICA antibody, an anti-CD137 antibody, an anti-KIR antibody, an anti-TGFp antibody, an anti-IL-10 antibody, an anti-IL-8 antibody, an anti-B7-H4 antibody, an anti-Fas ligand antibody, an anti-CXCR4 antibody, an anti-mesothelin antibody, an anti-CD27 antibody, an anti-GITR antibody, an anti-CCR8 antibody, an anti-ILT4 antibody, or a combination thereof. In some aspects, the anti-LAG-3 antibody comprises BMS-986016 (relatlimab), IMP731 (H5L7BW), MK4280 (28G-10, favezelimab), REGN3767 (fianlimab), GSK2831781, humanized BAP050, IMP-701 (LAG525, ieramilimab), aLAG3(0414), aLAG3(0416), Sym022, TSR-033, TSR-075, XmAb841 (XmAb22841), MGD013 (tebotelimab), BI754111, FS118, P 13B02-30, AVA-017, 25F7, AGEN1746, RO7247669, INCAGN02385, IBI-110, EMB-02, IBL323, LBL-007, ABL501, or an antigen-binding portion thereof. In some aspects, the anti-LAG-3 antibody comprises relatlimab, or an antigen-binding portion thereof. In some aspects, the anti-LAG-3 antibody comprises: (a) CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:3, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO:4; (b) a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10, respectively; (c) heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:3 and 4, respectively; (d) heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:l and 2, respectively; or (e) heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:21 and 2, respectively. In some aspects, the anti-PD-1 antibody comprises nivolumab, pembrolizumab, PDR001 (spartalizumab), MEDI-0680, TSR-042, cemiplimab, JS001, PF-06801591, BGB-A317, BI 754091, INCSHR1210, GLS-010, AM-001, STI-1110, AGEN2034, MGA012, BCD-100, IBI308, SSI-361, or an antigen-binding portion thereof. In some aspects, the anti-PD-1 antibody comprisesnivolumab, or an antigen-binding portion thereof. In some aspects, the anti-PD-1 antibody comprises: (a) CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 13, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO: 14; (b) a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO:20, respectively; (c) heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:13 and 14, respectively; or (d) heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:11 and 12, respectively. In some aspects, the anti-PD-Ll antibody comprises BMS-936559, atezolizumab, durvalumab, avelumab, STI-1014, CX-072, KN035, LY3300054, BGB-A333, ICO 36, FAZ053, CK-301, or an antigenbinding portion thereof. In some aspects, the anti-CTLA-4 antibody comprises ipilimumab, tremelimumab, MK-1308, AGEN-1884, or an antigen-binding portion thereof. In some aspects, the antibody comprises two antibodies. In some aspects, the antibody comprises an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-Ll antibody. In some aspects, the mg:mg or mg / mL:mg / mL ratio of the anti-PD-1 or anti-PD-Ll antibody to the anti-LAG-3 antibody is about 1:1, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, about 1:15, about 1:20, about 1:30, about 1:40, about 1:50, about 1:60, about 1:70, about 1:80, about 1:90, about 1:100, about 1:120, about 1:140, about 1:160, about 1:180, about 1:200, about 200:1, about 180:1, about 160:1, about 140:1, about 120:1, about 100:1, about 90:1, about 80:1, about 70:1, about 60:1, about 50:1, about 40:1, about 30:1, about 20:1, about 15:1, about 10:1, about 9:1, about 8:1, about 7:1, about 6:1, about 5:1, about 4:1, about 3:1, about 2:1, about 3:4, about 3:2, about 2:3, or about 4:3. In some aspects, the mg:mg or mg / mL:mg / mL ratio of the anti-PD-1 or anti-PD-Ll antibody to the anti-LAG-3 antibody is about 1:1, about 2:1, or about 3:4. In some aspects, the concentration of the anti-PD-1 or anti-PD-Ll antibody is about 10 mg / mL, about 15 mg / mL, about 20 mg / mL, about 25 mg / mL, about 30 mg / mL, about 35 mg / mL, about 40 mg / mL, about 45 mg / mL, about 50 mg / mL, about 52.5 mg / mL, about 55 mg / mL, about 60 mg / mL, about 64 mg / mL, about 65 mg / mL, about 70 mg / mL, about 72 mg / mL, about 75 mg / mL, about 78.8 mg / mL, about 80 mg / mL, about 85 mg / mL, about 90 mg / mL, about 94.5 mg / mL, about 95 mg / mL, about 100 mg / mL, about 105 mg / mL, about 108 mg / mL, about 110 mg / mL, about 120 mg / mL, about 130 mg / mL, about 132 mg / mL, about 135 mg / mL, about 137.5 mg / mL, about 140 mg / mL, about 150 mg / mL, about 160 mg / mL, about 170 mg / mL, about 175 mg / mL, about 180 mg / mL, about 190 mg / mL, about 200 mg / mL, about210 mg / mL, about 220 mg / mL, about 230 mg / mL, about 240 mg / mL, about 250 mg / mL, about 260 mg / mL, about 270 mg / mL, about 280 mg / mL, about 290 mg / mL, about 300 mg / mL, about 310 mg / mL, about 320 mg / mL, about 330 mg / mL, about 340 mg / mL, about 350 mg / mL, about 360 mg / mL, about 370 mg / mL, about 380 mg / mL, about 390 mg / mL, about 400 mg / mL, about 410 mg / mL, about 420 mg / mL, about 430 mg / mL, about 440 mg / mL, about 450 mg / mL, about 460 mg / mL, about 470 mg / mL, about 480 mg / mL, about 490 mg / mL, or about 500 mg / mL. In some aspects, the pharmaceutical composition comprises about 0.25 mg to about 2000 mg, about 0.25 mg to about 1600 mg, about 0.25 mg to about 1200 mg, about 0.25 mg to about 800 mg, about 0.25 mg to about 400 mg, about 0.25 mg to about 100 mg, about 0.25 mg to about 50 mg, about 0.25 mg to about 40 mg, about 0.25 mg to about 30 mg, about 0.25 mg to about 20 mg, about 20 mg to about 2000 mg, about 20 mg to about 1600 mg, about 20 mg to about 1200 mg, about 20 mg to about 800 mg, about 20 mg to about 400 mg, about 20 mg to about 100 mg, about 100 mg to about 2000 mg, about 100 mg to about 1800 mg, about 100 mg to about 1600 mg, about 100 mg to about 1400 mg, about 100 mg to about 1200 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, about 400 mg to about 2000 mg, about 400 mg to about 1800 mg, about 400 mg to about 1600 mg, about 400 mg to about 1400 mg, about 400 mg to about 1200 mg, or about 400 mg to about 1000 mg of the anti-PD-1 or anti-PD-Ll antibody. In some aspects, the pharmaceutical composition comprises about 0.25 mg, about 0.5 mg, about 0.75 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3 mg, about 3.25 mg, about 3.5 mg, about 3.75 mg, about 4 mg, about 4.25 mg, about 4.5 mg, about 4.75 mg, about 5 mg, about 5.25 mg, about 5.5 mg, about 5.75 mg, about 6 mg, about 6.25 mg, about 6.5 mg, about 6.75 mg, about 7 mg, about 7.25 mg, about 7.5 mg, about 7.75 mg, about 8 mg, about 8.25 mg, about 8.5 mg, about 8.75 mg, about 9 mg, about 9.25 mg, about 9.5 mg, about 9.75 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg,about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, about 710 mg, about 720 mg, about 730 mg, about 740 mg, about 750 mg, about 760 mg, about 770 mg, about 780 mg, about 790 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 980 mg, about 990 mg, about 1000 mg, about 1040 mg, about 1080 mg, about 1100 mg, about 1140 mg, about 1180 mg, about 1200 mg, about 1240 mg, about 1280 mg, about 1300 mg, about 1340 mg, about 1380 mg, about 1400 mg, about 1440 mg, about 1480 mg, about 1500 mg, about 1540 mg, about 1580 mg, about 1600 mg, about 1640 mg, about 1680 mg, about 1700 mg, about 1740 mg, about 1780 mg, about 1800 mg, about 1840 mg, about 1880 mg, about 1900 mg, about 1940 mg, about 1980 mg, or about 2000 mg of the anti-PD-1 or anti-PD-Ll antibody. In some aspects, the concentration of the anti-LAG-3 antibody is about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 3.3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 6 mg / mL, about 7 mg / mL, about 8 mg / mL, about 9 mg / mL, about 10 mg / mL, about 13 mg / mL, about 13.35 mg / mL, about 15 mg / mL, about 18 mg / mL, about 20 mg / mL, about 23 mg / mL, about 25 mg / mL, about 26 mg / mL, about 26.2 mg / mL, about 26.7 mg / mL, about 27 mg / mL, about 28 mg / mL, about 29 mg / mL, about 30 mg / mL, about 31.5 mg / mL, about 35 mg / mL, about 37.5 mg / mL, about 40 mg / mL, about 45 mg / mL, about 50 mg / mL, about 52.5 mg / mL, about 55 mg / mL, about 60 mg / mL, about 64 mg / mL, about 65 mg / mL, about 70 mg / mL, about 72 mg / mL, about 75 mg / mL, about 80 mg / mL, about 85 mg / mL, about 90 mg / mL, about 95 mg / mL, about 100 mg / mL, about 108 mg / mL, about 110 mg / mL, about 120 mg / mL, about 130 mg / mL, about 132 mg / mL, about 135 mg / mL, about 140 mg / mL, about 150 mg / mL, about 160 mg / mL, about 170 mg / mL, about 175 mg / mL, about 180 mg / mL, about 190 mg / mL, about 200 mg / mL, about 210 mg / mL, about 220 mg / mL, about 230 mg / mL, about 240 mg / mL, about 250 mg / mL, about 260 mg / mL, about 270 mg / mL, about 280 mg / mL, about 290 mg / mL, about 300 mg / mL, about 310 mg / mL, about 320 mg / mL, about 330 mg / mL, about 340 mg / mL, about 350 mg / mL, about 360 mg / mL, about 370 mg / mL, about 380 mg / mL, about 390 mg / mL, about 400 mg / mL, about 410 mg / mL, about 420 mg / mL, about 430 mg / mL, about 440 mg / mL, about 450 mg / mL, about 460 mg / mL, about 470 mg / mL, about 480 mg / mL, about 490 mg / mL, or about 500 mg / mL. In some aspects, the pharmaceutical composition comprises about 0.25 mg to about 2000 mg, about 0.25 mg to about 1600 mg, about 0.25 mg to about 1200 mg, about 0.25 mg to about 800 mg, about 0.25 mg to about 400 mg, about 0.25 mg to about 100 mg, about 0.25 mg to about 50 mg, about 0.25 mg to about 40 mg, about0.25 mg to about 30 mg, about 0.25 mg to about 20 mg, about 20 mg to about 2000 mg, about 20 mg to about 1600 mg, about 20 mg to about 1200 mg, about 20 mg to about 800 mg, about 20 mg to about 400 mg, about 20 mg to about 100 mg, about 100 mg to about 2000 mg, about 100 mg to about 1800 mg, about 100 mg to about 1600 mg, about 100 mg to about 1400 mg, about 100 mg to about 1200 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, about 400 mg to about 2000 mg, about 400 mg to about 1800 mg, about 400 mg to about 1600 mg, about 400 mg to about 1400 mg, about 400 mg to about 1200 mg, or about 400 mg to about 1000 mg of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises about 0.25 mg, about 0.5 mg, about 0.75 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3 mg, about 3.25 mg, about 3.5 mg, about 3.75 mg, about 4 mg, about 4.25 mg, about 4.5 mg, about 4.75 mg, about 5 mg, about 5.25 mg, about 5.5 mg, about 5.75 mg, about 6 mg, about 6.25 mg, about 6.5 mg, about 6.75 mg, about 7 mg, about 7.25 mg, about 7.5 mg, about 7.75 mg, about 8 mg, about 8.25 mg, about 8.5 mg, about 8.75 mg, about 9 mg, about 9.25 mg, about 9.5 mg, about 9.75 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, about 710 mg, about 720 mg, about 730 mg, about 740 mg, about 750 mg, about 760 mg, about 770 mg, about 780 mg, about 790 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 980 mg, about 990 mg, about 1000 mg, about 1040 mg, about 1080 mg, about 1100 mg, about 1140 mg, about 1180 mg, about 1200 mg, about 1240 mg, about 1280 mg, about 1300 mg, about 1340 mg, about 1380 mg, about 1400 mg, about 1440 mg, about 1480 mg, about 1500 mg, about 1540 mg, about 1580 mg,about 1600 mg, about 1640 mg, about 1680 mg, about 1700 mg, about 1740 mg, about 1780 mg, about 1800 mg, about 1840 mg, about 1880 mg, about 1900 mg, about 1940 mg, about 1980 mg, or about 2000 mg of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises about 80 mg / mL of the anti-PD-1 antibody and about 80 mg / mL of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises a volume of about 12 mL. In some aspects, the pharmaceutical composition comprises a volume of about 9 mL. In some aspects, the pharmaceutical composition comprises about 75 mg / mL of the anti-PD-1 antibody and about 75 mg / mL of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises a volume of about 12.8 mL. In some aspects, the pharmaceutical composition comprises a volume of about 9.6 mL. In some aspects, the pharmaceutical composition comprises about 72 mg / mL of the anti-PD-1 antibody and about 72 mg / mL of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises a volume of about 10 mL. In some aspects, the pharmaceutical composition comprises about 64 mg / mL of the anti-PD-1 antibody and about 64 mg / mL of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises a volume of about 15 mL. In some aspects, the pharmaceutical composition comprises about 60 mg / mL of the anti-PD-1 antibody and about 60 mg / mL of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises a volume of about 16 mL. In some aspects, the pharmaceutical composition comprises a volume of about 12 mL. In some aspects, the pharmaceutical composition comprises about 52.5 mg / mL of the anti-PD-1 antibody and about 52.5 mg / mL of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises a volume of about 18.3 mL. In some aspects, the pharmaceutical composition comprises about 64.3 mg / mL of the anti-PD-1 antibody and about 85.7 mg / mL of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises a volume of about 8.4 mL. In some aspects, the pharmaceutical composition comprises about 60 mg / mL of the anti-PD-1 antibody and about 80 mg / mL of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises a volume of about 9 mL. In some aspects, the pharmaceutical composition comprises about 54 mg / mL of the anti-PD-1 antibody and about 72 mg / mL of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises a volume of about 10 mL. In some aspects, the pharmaceutical composition comprises about 45 mg / mL of the anti-PD-1 antibody and about 60 mg / mL of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises a volume of about 12 mL. In some aspects, the pharmaceutical composition comprises about 960 mg of the anti-PD-1 antibody and about 960 mg of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises about 720 mg of the anti-PD-1 antibody andabout 720 mg of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises about 540 mg of the anti-PD-1 antibody and about 720 mg of the anti-LAG-3 antibody. In some aspects, the anti-PD-1 antibody comprises nivolumab, or an antigen-binding portion thereof, and the anti-LAG-3 antibody comprises relatlimab, or an antigen-binding portion thereof. In some aspects: (a) the anti-LAG-3 antibody comprises CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:3, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO:4, and the anti-PD-1 antibody comprises CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 13, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO: 14; (b) the anti-LAG-3 antibody comprises a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10, respectively, and the anti-PD-1 antibody comprises a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO:20, respectively; (c) the anti-LAG-3 antibody comprises heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:3 and 4, respectively, and the anti-PD-1 antibody comprises heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs: 13 and 14, respectively; (d) the anti-LAG-3 antibody comprises heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:1 and 2, respectively, and the anti-PD-1 antibody comprises heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs: 11 and 12, respectively; or (e) the anti-LAG-3 antibody comprises heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:21 and 2, respectively, and the anti-PD-1 antibody comprises heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs: 11 and 12, respectively. In some aspects, percent high molecular weight species (% HMW) in the pharmaceutical composition are about 1.5% or less as measured by size exclusion chromatography following: agitation at 250 rpm for 1 week at 30 °C, agitation at 250 rpm for 2 weeks at 30 °C, storage at room temperature and room light conditions for 2 weeks, storage at 40 °C for 2 weeks, and / or storage at 50 °C for 2 weeks. In some aspects, the % HMW species are about 1% or less. In some aspects, the % HMW species are lessthan about 1%. In some aspects, percent monomer (% monomer) in the pharmaceutical composition as measured by size exclusion chromatography is greater than about 97% following: agitation at 250 rpm for 1 week at 30 °C, agitation at 250 rpm for 2 weeks at 30 °C, storage at room temperature and room light conditions for 2 weeks, storage at 40 °C for 2 weeks, and / or storage at 50 °C for 2 weeks. In some aspects, the % monomer in the pharmaceutical composition as measured by size exclusion chromatography is about 98% or more following: agitation at 250 rpm for 1 week at 30 °C, agitation at 250 rpm for 2 weeks at 30 °C, storage at room temperature and room light conditions for 2 weeks, and / or storage at 40 °C for 2 weeks.
[0090] In some aspects, the pharmaceutical composition further comprises an increased concentration of a buffering agent as compared to the corresponding composition. In some aspects, the buffering agent comprises histidine, succinate, Tris, sodium phosphate, sodium acetate, sodium citrate, or a combination thereof. In some aspects, the buffering agent comprises histidine.
[0091] In some aspects, the pharmaceutical composition further comprises an antioxidant. In some aspects, the antioxidant comprises a sacrificial antioxidant, a metal ion chelator, or both. In some aspects, the antioxidant comprises methionine, tryptophan, histidine, cysteine, ascorbic acid, glycine, pentetic acid (" DTPA"), ethylenediaminetetraacetic acid (" EDTA"), or a combination thereof. In some aspects, the pharmaceutical composition comprises at least two antioxidants. In some aspects, the at least two antioxidants are (i) methionine and DTPA or (ii) methionine and EDTA. In some aspects, the pharmaceutical composition comprises at least about 1 mM, at least about 1.5 mM, at least about 2 mM, at least about 2.5 mM, at least about 3 mM, at least about 3.5 mM, at least about 4 mM, at least about 4.5 mM, at least about 5 mM, at least about 5.5 mM, at least about 6 mM, at least about 6.5 mM, at least about 7 mM, at least about 7.5 mM, at least about 8 mM, at least about 8.5 mM, at least about 9 mM, at least about 9.5 mM, at least about 10 mM, at least about 11 mM, at least about 12 mM, at least about 13 mM, at least about 14 mM, at least about 15 mM, at least about 16 mM, at least about 17 mM, at least about 18 mM, at least about 19 mM, or at least about 20 mM of methionine. In some aspects, the pharmaceutical composition comprises about 0.1 mM to about 100 mM, about 0.1 mM to about 90 mM, about 0.1 mM to about 80 mM, about 0.1 mM to about 70 mM, about 0.1 mM to about 60 mM, about 0.1 mM to about 50 mM, about 0.1 mM to about 40 mM, about 0.1 mM to about 30 mM, about 0.1 mM to about 20 mM, about 0.1 mM to about 10 mM, about 1 mM to about 20 mM, about 1 mM to about 15 mM, about 1 mM to about 10 mM, about 1 mM to about 9 mM, about 1 mM to about 8 mM, about 1 mM to about 7 mM, about 1 mM to about 6 mM, about 1 mM to about 5 mM, about 2 mM to about 9 mM, about 3 mM to about 8 mM, about 4 mM to about 7 mM, about 4 mM toabout 6 mM, about 4 mM to about 5 mM, about 5 mM to about 20 mM, about 5 mM to about 15 mM, about 5 mM to about 10 mM, about 5 mM to about 9 mM, about 5 mM to about 8 mM, about 5 mM to about 7 mM, or about 5 mM to about 6 mM of methionine. In some aspects, the pharmaceutical composition comprises about 1 mM, about 1.5 mM, about 2 mM, about 2.5 mM, about 3 mM, about 3.5 mM, about 4 mM, about 4.5 mM, about 5 mM, about 5.5 mM, about 6 mM, about 6.5 mM, about 7 mM, about 7.5 mM, about 8 mM, about 8.5 mM, about 9 mM, about 9.5 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM, about 55 mM, about 60 mM, about 65 mM, about 70 mM, about 75 mM, about 80 mM, about 85 mM, about 90 mM, about 95 mM, or about 100 mM of methionine. In some aspects, the pharmaceutical composition comprises about 5 mM of methionine. In some aspects, the pharmaceutical composition comprises about 1 pM to about 250 pM, about 10 pM to about 200 pM, about 10 pM to about 175 pM, about 10 pM to about 150 pM, about 10 pM to about 125 pM, about 10 pM to about 100 pM, about 10 pM to about 75 pM, about 10 pM to about 70 pM, about 10 pM to about 60 pM, about 10 pM to about 50 pM, about 20 pM to about 100 pM, about 20 pM to about 75 pM, about 20 pM to about 70 pM, about 20 pM to about 60 pM, about 20 pM to about 50 pM, about 25 pM to about 100 pM, about 25 pM to about 75 pM, about 25 pM to about 50 pM, about 30 pM to about 100 pM, about 30 pM to about 75 pM, about 30 pM to about 70 pM, about 30 pM to about 60 pM, about 30 pM to about 50 pM, about 40 pM to about 100 pM, about 40 pM to about 75 pM, about 40 pM to about 70 pM, about 40 pM to about 60 pM, about 40 pM to about 50 pM, about 41 pM to about 59 pM, about 42 pM to about 58 pM, about 43 pM to about 57 pM, about 44 pM to about 56 pM, about 45 pM to about 55 pM, about 46 pM to about 54 pM, about 47 pM to about 53 pM, about 48 pM to about 52 pM, about 49 pM to about 51 pM, about 50 pM to about 100 pM, about 50 pM to about 75 pM, about 50 pM to about 70 pM, about 50 pM to about 60 pM of DTPA. In some aspects, the pharmaceutical composition comprises about 1 pM, about 5 pM, about 10 pM, about 15 pM, about 20 pM, about 25 pM, about 30 pM, about 35 pM, about 40 pM, about 45 pM, about 50 pM, about 55 pM, about 60 pM, about 65 pM, about 70 pM, about 75 pM, about 80 pM, about 85 pM, about 90 pM, about 95 pM, about 100 pM, about 110 pM, about 120 pM, about 130 pM, about 140 pM, about 150 pM, about 160 pM, about 170 pM, about 180 pM, about 190 pM, about 200 pM, about 210 pM, about 220 pM, about 230 pM, about 240 pM, or about 250 pM of DTPA. In some aspects, the pharmaceutical composition comprises about 50 pM of DTPA.
[0092] In some aspects, the pharmaceutical composition further comprises a surfactant. In some aspects, the surfactant comprises polysorbate 20, polysorbate 80, or poloxamer 188. In some aspects, the surfactant comprises polysorbate 80. In some aspects, the pharmaceutical composition comprises at least about 0.01% w / v, at least about 0.02% w / v, at least about 0.03% w / v, at least about 0.04% w / v, at least about 0.05% w / v, at least about 0.06% w / v, at least about 0.07% w / v, at least about 0.08% w / v, at least about 0.09% w / v, or at least about 0.1% w / v of polysorbate 80. In some aspects, the pharmaceutical composition comprises about 0.001% to about 1% w / v, about 0.001% w / v to about 0.9% w / v, about 0.001% w / v to about 0.8% w / v, about 0.001% w / v to about 0.7% w / v, about 0.001% w / v to about 0.6% w / v, about 0.001% w / v to about 0.5% w / v, about 0.001% w / v to about 0.4% w / v, about 0.001% w / v to about 0.3% w / v, about 0.001% w / v to about 0.2% w / v, about 0.001% w / v to about 0.1% w / v, about 0.001% w / v to about 0.09% w / v, about 0.001% w / v to about 0.08% w / v, about 0.001% w / v to about 0.07% w / v, about 0.001% w / v to about 0.06% w / v, about 0.001% w / v to about 0.05% w / v, about 0.01% w / v to about 0.9% w / v, about 0.01% w / v to about 0.8% w / v, about 0.01% w / v to about 0.7% w / v, about 0.01% w / v to about 0.6% w / v, about 0.01% w / v to about 0.5% w / v, about 0.01% w / v to about 0.4% w / v, about 0.01% w / v to about 0.3% w / v, about 0.01% w / v to about 0.2% w / v, about 0.01% w / v to about 0.1% w / v, about 0.01% w / v to about 0.09% w / v, about 0.01% w / v to about 0.08% w / v, about 0.01% w / v to about 0.07% w / v, about 0.01% w / v to about 0.06% w / v, about 0.01% w / v to about 0.05% w / v, about 0.02% w / v to about 0.1% w / v, about 0.02% w / v to about 0.09% w / v, about 0.02% w / v to about 0.08% w / v, about 0.02% w / v to about 0.07% w / v, about 0.02% w / v to about 0.06% w / v, about 0.02% w / v to about 0.05% w / v, about 0.03% w / v to about 0.1% w / v, about 0.03% w / v to about 0.09% w / v, about 0.03% w / v to about 0.08% w / v, about 0.03% w / v to about 0.07% w / v, about 0.03% w / v to about 0.06% w / v, about 0.03% w / v to about 0.05% w / v, about 0.04% w / v to about 0.1% w / v, about 0.04% w / v to about 0.09% w / v, about 0.04% w / v to about 0.08% w / v, about 0.04% w / v to about 0.07% w / v, about 0.04% w / v to about 0.06% w / v, about 0.04% w / v to about 0.05%, about 0.05% w / v to about 0.1% w / v, about 0.05% w / v to about 0.09% w / v, about 0.05% w / v to about 0.08% w / v, about 0.05% w / v to about 0.07% w / v, or about 0.05% w / v to about 0.06% w / v of polysorbate 80. In some aspects, the pharmaceutical composition comprises about 0.001% w / v, about 0.002% w / v, about 0.003% w / v, about 0.004% w / v, about 0.005% w / v, about 0.006% w / v, about 0.007% w / v, about 0.008% w / v, about 0.009% w / v, about 0.01% w / v, about 0.02% w / v, about 0.03% w / v, about 0.04% w / v, about 0.05% w / v, about 0.06% w / v, about 0.07% w / v, about 0.08% w / v, about 0.09% w / v, about 0.1% w / v, about 0.2% w / v, about 0.3% w / v, about 0.4% w / v, about 0.5% w / v, about 0.6% w / v, about 0.7% w / v, about 0.8% w / v,about 0.9% w / v, or about 1% w / v of polysorbate 80. In some aspects, the pharmaceutical composition comprises about 0.05% of w / v polysorbate 80.
[0093] In some aspects, the pharmaceutical composition further comprises comprising an endoglycosidase hydrolase enzyme. In some aspects, the endoglycosidase hydrolase enzyme cleaves hyaluronic acid at a hexosaminidic P (1-4) or (1-3) linkage. In some aspects, the endoglycosidase hydrolase enzyme comprises a catalytic domain of hyaluronidase PH-20 (HuPH20), HYAL1, HYAL2, HYAL3, HYAL4, or HYALPS1. In some aspects, the endoglycosidase hydrolase enzyme comprises a hyaluronidase. In some aspects, the hyaluronidase comprises HuPH20, HYAL1, HYAL2, HYAL3, HYAL4, or a variant or isoform thereof. In some aspects, the endoglycosidase hydrolase enzyme comprises rHuPH20 or a fragment thereof. In some aspects, the endoglycosidase hydrolase enzyme comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity to amino acids 36-490 of SEQ ID NO:87. In some aspects, the endoglycosidase hydrolase enzyme comprises a modified hyaluronidase comprising one or more amino acid substitutions relative to a wild-type hyaluronidase that is HuPH20, HYAL1, HYAL2, HYAL3, HYAL4, HYALPS1, or a fragment thereof. In some aspects, the endoglycosidase hydrolase enzyme comprises a modified hyaluronidase comprising (i) one or more amino acid substitution in an alpha-helix region, (ii) one or more amino acid substitution in a linker region, (iii) deletion of one or more N-terminal and / or C-terminal amino acids, or (iv) any combination of (i)-(iii), relative to a wild-type hyaluronidase that is HuPH20, HYAL1, HYAL2, HYAL3, HYAL4, HYALPS1, or a fragment thereof. In some aspects, the endoglycosidase hydrolase enzyme comprises a modified rHuPH20, wherein the modified rHuPH20 comprises: (a) one or more amino acid substitution in an alpha-helix region, a linker region, or both an alpha-helix region and a linker region relative to wild-type rHuPH20; (b) deletion of one or more N-terminal amino acid, one or more C-terminal amino acid, or one or more N-terminal amino acid and one or more C-terminal amino acid relative to wild-type rHuPH20; or (c) both (a) and (b). In some aspects, the pharmaceutical composition comprises at least about 50 IU / mL, at least about 100 IU / mL, at least about 150 IU / mL, at least about 200 IU / mL, at least about 250 IU / mL, at least about 300 IU / mL, at least about 350 IU / mL, at least about 400 IU / mL, at least about 450 IU / mL, at least about 500 IU / mL, at least about 550 IU / mL, at least about 600 IU / mL, at least about 650 IU / mL, at least about 700 IU / mL, at least about 750 IU / mL, at least about 800 IU / mL, at least about 850 IU / mL, at least about 900 IU / mL, at least about 950 IU / mL, at least about 1000 IU / mL, at least about 1100IU / mL, at least about 1200 IU / mL, at least about 1300 IU / mL, at least about 1400 IU / mL, at least about 1500 IU / mL, at least about 1600 IU / mL, at least about 1700 IU / mL, at least about 1800 IU / mL, at least about 1900 IU / mL, at least about 2000 IU / mL, at least about 2100 IU / mL, at least about 2200 IU / mL, at least about 2300 IU / mL, at least about 2400 IU / mL, at least about 2500 IU / mL, at least about 3000 IU / mL, at least about 3500 IU / mL, at least about 4000 IU / mL, at least about 4500 IU / mL, or at least about 5000 IU / mL of the endoglycosidase hydrolase enzyme. In some aspects, the pharmaceutical composition comprises about 50 IU / mL to about 10,000 IU / mL, about 100 IU / mL to about 9500 IU / mL, about 150 IU / mL to about 9000 IU / mL, about 200 IU / mL to about 8500 IU / mL, about 250 IU / mL to about 8000 IU / mL, about 300 IU / mL to about 7500 IU / mL, about 350 IU / mL to about 7000 IU / mL, about 400 IU / mL to about 6500 IU / mL, about 450 IU / mL to about 6000 IU / mL, about 500 IU / mL to about 5500 IU / mL, about 550 IU / mL to about 5000 IU / mL, about 600 IU / mL to about 4500 IU / mL, about 650 IU / mL to about 4000 IU / mL, about 700 IU / mL to about 3500 IU / mL, about 750 IU / mL to about 3000 IU / mL, about 800 IU / mL to about 2500 IU / mL, about 900 IU / mL to about 2500 IU / mL, about 1000 IU / mL to about 2500 IU / mL, about 1500 IU / mL to about 2500 IU / mL, about 1600 IU / mL to about 2500 IU / mL, about 1700 IU / mL to about 2500 IU / mL, about 1800 IU / mL to about 2500 IU / mL, about 1900 IU / mL to about 2500 IU / mL, about 2000 IU / mL to about 2500 IU / mL, about 2100 IU / mL to about 2500 IU / mL, about 2200 IU / mL to about 2500 IU / mL, about 2300 IU / mL to about 2500 IU / mL, about 1500 IU / mL to about 2500 IU / mL, about 1600 IU / mL to about 2400 IU / mL, about 1700 IU / mL to about 2300 IU / mL, about 1800 IU / mL to about 2200 IU / mL, or about 1900 IU / mL to about 2100 IU / mL of the endoglycosidase hydrolase enzyme. In some aspects, the pharmaceutical composition comprises about 50 IU / mL, about 100 IU / mL, about 150 IU / mL, about 200 IU / mL, about 250 IU / mL, about 300 IU / mL, about 350 IU / mL, about 400 IU / mL, about 450 IU / mL, about 500 IU / mL, about 550 IU / mL, about 600 IU / mL, about 650 IU / mL, about 700 IU / mL, about 750 IU / mL, about 800 IU / mL, about 850 IU / mL, about 900 IU / mL, about 950 IU / mL, about 1000 IU / mL, about 1100 IU / mL, about 1200 IU / mL, about 1300 IU / mL, about 1400 IU / mL, about 1500 IU / mL, about 1600 IU / mL, about 1700 IU / mL, about 1800 IU / mL, about 1900 IU / mL, about 2000 IU / mL, about 2100 IU / mL, about 2200 IU / mL, about 2300 IU / mL, about 2400 IU / mL, about 2500 IU / mL, about 3000 IU / mL, about 3500 IU / mL, about 4000 IU / mL, about 4500 IU / mL, about 5000 IU / mL, about 5500 IU / mL, about 6000 IU / mL, about 6500 IU / mL, about 7000 IU / mL, about 7500 IU / mL, about 8000 IU / mL, about 8500 IU / mL, about 9000 IU / mL, about 9500 IU / mL, or about 10,000 IU / mL of the endoglycosidase hydrolase enzyme. In some aspects, the pharmaceutical composition comprises about 2000 IU / mL of the endoglycosidase hydrolase enzyme.
[0094] In some aspects, the pharmaceutical composition is capable of being injected within about 10 minutes or less. In some aspects, the pharmaceutical composition is capable of being injected within about 5 minutes to about 7 minutes. In some aspects, the pharmaceutical composition is capable of being injected within about 3 minutes to about 5 minutes.
[0095] The present invention is directed to a pharmaceutical composition comprising: (a) about 100 mg / mL or more of a protein, (b) means for producing a lower viscosity of the pharmaceutical composition as compared to a corresponding composition comprising the same concentration of the protein, and (c) means for producing an osmolality of about 200 mOsmol / kg to about 600 mOsmol / kg of the pharmaceutical composition.
[0096] In some aspects, the osmolality is about 210 mOsmol / kg to about 600 mOsmol / kg, about 220 mOsmol / kg to about 600 mOsmol / kg, about 230 mOsmol / kg to about 600 mOsmol / kg, about 240 mOsmol / kg to about 600 mOsmol / kg, 260 mOsmol / kg to about 600 mOsmol / kg, about 270 mOsmol / kg to about 600 mOsmol / kg, about 280 mOsmol / kg to about 600 mOsmol / kg, about 290 mOsmol / kg to about 600 mOsmol / kg, about 300 mOsmol / kg to about 600 mOsmol / kg, about 350 mOsmol / kg to about 600 mOsmol / kg, about 400 mOsmol / kg to about 600 mOsmol / kg, about 450 mOsmol / kg to about 600 mOsmol / kg, about 500 mOsmol / kg to about 600 mOsmol / kg, about 550 mOsmol / kg to about 600 mOsmol / kg, about 500 mOsmol / kg to about 550 mOsmol / kg, about 450 mOsmol / kg to about 550 mOsmol / kg, about 400 mOsmol / kg to about 550 mOsmol / kg, about 350 mOsmol / kg to about 550 mOsmol / kg, about 300 mOsmol / kg to about 550 mOsmol / kg, about 250 mOsmol / kg to about 550 mOsmol / kg, about 200 mOsmol / kg to about 550 mOsmol / kg, about 200 mOsmol / kg to about 500 mOsmol / kg, about 250 mOsmol / kg to about 500 mOsmol / kg, about 300 mOsmol / kg to about 500 mOsmol / kg, about 350 mOsmol / kg to about 500 mOsmol / kg, about 400 mOsmol / kg to about 500 mOsmol / kg, about 450 mOsmol / kg to about 500 mOsmol / kg, about 400 mOsmol / kg to about 450 mOsmol / kg, about 350 mOsmol / kg to about 450 mOsmol / kg, about 300 mOsmol / kg to about 450 mOsmol / kg, about 250 mOsmol / kg to about 450 mOsmol / kg, about 200 mOsmol / kg to about 450 mOsmol / kg, about 200 mOsmol / kg to about 400 mOsmol / kg, about 250 mOsmol / kg to about 400 mOsmol / kg, about 300 mOsmol / kg to about 400 mOsmol / kg, about 350 mOsmol / kg to about 400 mOsmol / kg, about 300 mOsmol / kg to about 350 mOsmol / kg, about 250 mOsmol / kg to about 350 mOsmol / kg, about 200 mOsmol / kg to about 350 mOsmol / kg, about 200 mOsmol / kg to about 300 mOsmol / kg, or about 250 mOsmol / kg to about 300 mOsmol / kg.
[0097] In some aspects, the osmolality is about 280 mOsmol / kg to about 600 mOsmol / kg.
[0098] In some aspects, the osmolality is about 200 mOsmol / kg, about 205 mOsmol / kg, about 210 mOsmol / kg, about 215 mOsmol / kg, about 220 mOsmol / kg, about 225 mOsmol / kg,about 230 mOsmol / kg, about 235 mOsmol / kg, about 240 mOsmol / kg, about 245 mOsmol / kg, about 250 mOsmol / kg, about 255 mOsmol / kg, about 260 mOsmol / kg, about 265 mOsmol / kg, about 270 mOsmol / kg, about 275 mOsmol / kg, about 280 mOsmol / kg, about 285 mOsmol / kg, about 290 mOsmol / kg, about 295 mOsmol / kg, about 300 mOsmol / kg, about 305 mOsmol / kg, about 310 mOsmol / kg, about 315 mOsmol / kg, about 320 mOsmol / kg, about 325 mOsmol / kg, about 330 mOsmol / kg, about 335 mOsmol / kg, about 340 mOsmol / kg, about 345 mOsmol / kg, about 350 mOsmol / kg, about 355 mOsmol / kg, about 360 mOsmol / kg, about 365 mOsmol / kg, about 370 mOsmol / kg, about 375 mOsmol / kg, about 380 mOsmol / kg, about 385 mOsmol / kg, about 390 mOsmol / kg, about 395 mOsmol / kg, about 400 mOsmol / kg, about 405 mOsmol / kg, about 410 mOsmol / kg, about 415 mOsmol / kg, about 420 mOsmol / kg, about 425 mOsmol / kg, about 430 mOsmol / kg, about 435 mOsmol / kg, about 440 mOsmol / kg, about 445 mOsmol / kg, about 450 mOsmol / kg, about 455 mOsmol / kg, about 460 mOsmol / kg, about 465 mOsmol / kg, about 470 mOsmol / kg, about 475 mOsmol / kg, about 480 mOsmol / kg, about 485 mOsmol / kg, about 490 mOsmol / kg, about 495 mOsmol / kg, about 500 mOsmol / kg, about 505 mOsmol / kg, about 510 mOsmol / kg, about 515 mOsmol / kg, about 520 mOsmol / kg, about 525 mOsmol / kg, about 530 mOsmol / kg, about 535 mOsmol / kg, about 540 mOsmol / kg, about 545 mOsmol / kg, about 550 mOsmol / kg, about 555 mOsmol / kg, about 560 mOsmol / kg, about 565 mOsmol / kg, about 570 mOsmol / kg, about 575 mOsmol / kg, about 580 mOsmol / kg, about 585 mOsmol / kg, about 590 mOsmol / kg, or about 595 mOsmol / kg.
[0099] In some aspects, the osmolality is determined by vapor-pressure osmometry.
[0100] In some aspects, the osmolality is determined with a vapor pressure osmometer.
[0101] In some aspects, the means for producing a lower viscosity produces a viscosity of about 15 centipoise (cP) or less of the pharmaceutical composition.
[0102] In some aspects, the means for producing a lower viscosity produces a viscosity of about 1 cP to about 15 cP, about 1 cP to about 14 cP, about 1 cP to about 13 cP, about 1 cP to about 12 cP, about 1 cP to about 11 cP, about 1 cP to about 10 cP, about 1 cP to about 9 cP, about 1 cP to about 8 cP, about 1 cP to about 7 cP, about 1 cP to about 6 cP, about 1 cP to about 5 cP, about 1 cP to about 4 cP, about 1 cP to about 3 cP, about 2 cP to about 15 cP, about 2 cP to about 14 cP, about 2 cP to about 13 cP, about 2 cP to about 12 cP, about 2 cP to about 11 cP, about 2 cP to about 10 cP, about 2 cP to about 9 cP, about 2 cP to about 8 cP, about 2 cP to about 7 cP, about 2 cP to about 6 cP, about 2 cP to about 5 cP, about 2 cP to about 4 cP, about 3 cP to about 15 cP, about 3 cP to about 14 cP, about 3 cP to about 13 cP, about 3 cP to about 12 cP, about 3 cP to about 11 cP, about 3 cP to about 10 cP, about 3 cP to about 9 cP, about 3 cP to about 8 cP, about 3 cP to about7 cP, about 3 cP to about 6 cP, about 3 cP to about 5 cP, about 4 cP to about 15 cP, about 4 cP to about 14 cP, about 4 cP to about 13 cP, about 4 cP to about 12 cP, about 4 cP to about 11 cP, about 4 cP to about 10 cP, about 4 cP to about 9 cP, about 4 cP to about 8 cP, about 4 cP to about 7 cP, about 4 cP to about 6 cP, about 5 cP to about 15 cP, about 5 cP to about 14 cP, about 5 cP to about 13 cP, about 5 cP to about 12 cP, about 5 cP to about 11 cP, about 5 cP to about 10 cP, about 5 cP to about 9 cP, about 5 cP to about 8 cP, about 5 cP to about 7 cP, about 6 cP to about 15 cP, about 6 cP to about 14 cP, about 6 cP to about 13 cP, about 6 cP to about 12 cP, about 6 cP to about 11 cP, about 6 cP to about 10 cP, about 6 cP to about 9 cP, about 6 cP to about 8 cP, about 7 cP to about 15 cP, about 7 cP to about 14 cP, about 7 cP to about 13 cP, about 7 cP to about 12 cP, about 7 cP to about 11 cP, about 7 cP to about 10 cP, about 7 cP to about 9 cP, about 8 cP to about 15 cP, about 8 cP to about 14 cP, about 8 cP to about 13 cP, about 8 cP to about 12 cP, about 8 cP to about 11 cP, about 8 cP to about 10 cP, about 9 cP to about 15 cP, about 9 cP to about 14 cP, about 9 cP to about 13 cP, about 9 cP to about 12 cP, about 9 cP to about 11 cP, about 10 cP to about 15 cP, about 10 cP to about 14 cP, about 10 cP to about 13 cP, about 10 cP to about 12 cP, about 11 cP to about 15 cP, about 11 cP to about 14 cP, about 11 cP to about 13 cP, about 12 cP to about 15 cP, about 12 cP to about 14 cP, or about 13 cP to about 15 cP.
[0103] In some aspects, the viscosity is determined with a microfluidic viscometer.
[0104] In some aspects, the viscosity is determined at 20 °C. In some aspects, the pharmaceutical composition comprises a volume of about 0.001 mL to about 20 mL.
[0105] In some aspects, the pharmaceutical composition comprises a volume of about 0.001 mL, about 0.005 mL, about 0.010 mL, about 0.015 mL, about 0.020 mL, about 0.025 mL, about 0.030 mL, about 0.035 mL, about 0.040 mL, about 0.045 mL, about 0.050 mL, about 0.055 mL, about 0.060 mL, about 0.065 mL, about 0.070 mL, about 0.075 mL, about 0.080 mL, about 0.085 mL, about 0.090 mL, about 0.095 mL, about 0.100 mL, about 0.150 mL, about 0.200 mL, about 0.250 mL, about 0.300 mL, about 0.350 mL, about 0.400 mL, about 0.450 mL, about 0.500 mL, about 0.550 mL, about 0.600 mL, about 0.650 mL, about 0.700 mL, about 0.750 mL, about 0.800 mL, about 0.850 mL, about 0.900 mL, about 0.950 mL, about 1 mL, about 1.1 mL, about 1.2 mL, about 1.3 mL, about 1.4 mL, about 1.5 mL, about 1.6 mL, about 1.7 mL, about 1.8 mL, about 1.9 mL, about 2 mL, about 2.1 mL, about 2.2 mL, about 2.3 mL, about 2.4 mL, about 2.5 mL, about 2.6 mL, about 2.7 mL, about 2.8 mL, about 2.9 mL, about 3 mL, about 3.1 mL, about 3.2 mL, about 3.3 mL, about 3.4 mL, about 3.5 mL, about 3.6 mL, about 3.7 mL, about 3.8 mL, about 3.9 mL, about 4 mL, about 4.1 mL, about 4.2 mL, about 4.3 mL, about 4.4 mL, about 4.5 mL, about 4.6 mL, about 4.7 mL, about 4.8 mL, about 4.9 mL, about 5 mL, about 5.1 mL, about5.2 mL, about 5.3 mL, about 5.4 mL, about 5.5 mL, about 5.6 mL, about 5.7 mL, about 5.8 mL, about 5.9 mL, about 6 mL, about 6.1 mL, about 6.2 mL, about 6.3 mL, about 6.4 mL, about 6.5 mL, about 6.6 mL, about 6.7 mL, about 6.8 mL, about 6.9 mL, about 7 mL, about 7.1 mL, about 7.2 mL, about 7.3 mL, about 7.4 mL, about 7.5 mL, about 7.6 mL, about 7.7 mL, about 7.8 mL, about 7.9 mL, about 8 mL, about 8.1 mL, about 8.2 mL, about 8.3 mL, about 8.4 mL, about 8.5 mL, about 8.6 mL, about 8.7 mL, about 8.8 mL, about 8.9 mL, about 9 mL, about 9.1 mL, about 9.2 mL, about 9.3 mL, about 9.4 mL, about 9.5 mL, about 9.6 mL, about 9.7 mL, about 9.8 mL, about 9.9 mL, about 10 mL, about 10.1 mL, about 10.2 mL, about 10.3 mL, about 10.4 mL, about 10.5 mL, about 10.6 mL, about 10.7 mL, about 10.8 mL, about 10.9 mL, about 11 mL, about 11.1 mL, about 11.2 mL, about 11.3 mL, about 11.4 mL, about 11.5 mL, about 11.6 mL, about 11.7 mL, about 11.8 mL, about 11.9 mL, about 12 mL, about 12.1 mL, about 12.2 mL, about 12.3 mL, about 12.4 mL, about 12.5 mL, about 12.6 mL, about 12.7 mL, about 12.8 mL, about 12.9 mL, about 13 mL, about 13.1 mL, about 13.2 mL, about 13.3 mL, about 13.4 mL, about 13.5 mL, about 13.6 mL, about 13.7 mL, about 13.8 mL, about 13.9 mL, about 14 mL, about 14.1 mL, about 14.2 mL, about 14.3 mL, about 14.4 mL, about 14.5 mL, about 14.6 mL, about 14.7 mL, about 14.8 mL, about 14.9 mL, about 15 mL, about 15.1 mL, about 15.2 mL, about 15.3 mL, about 15.4 mL, about 15.5 mL, about 15.6 mL, about 15.7 mL, about 15.8 mL, about 15.9 mL, about 16 mL, about 16.1 mL, about 16.2 mL, about 16.3 mL, about 16.4 mL, about 16.5 mL, about 16.6 mL, about 16.7 mL, about 16.8 mL, about 16.9 mL, about 17 mL, about 17.1 mL, about 17.2 mL, about 17.3 mL, about 17.4 mL, about 17.5 mL, about 17.6 mL, about 17.7 mL, about 17.8 mL, about 17.9 mL, about 18 mL, about 18.1 mL, about 18.2 mL, about 18.3 mL, about 18.4 mL, about 18.5 mL, about 18.6 mL, about 18.7 mL, about 18.8 mL, about 18.9 mL, about 19 mL, about 19.1 mL, about 19.2 mL, about 19.3 mL, about 19.4 mL, about 19.5 mL, about 19.6 mL, about 19.7 mL, about 19.8 mL, about 19.9 mL, or about 20 mL.
[0106] In some aspects, the pharmaceutical composition comprises a volume of about 8.4 mL, about 9 mL, about 9.6 mL, about 10 mL, about 12 mL, about 12.8 mL, about 15 mL, or about 16 mL.
[0107] In some aspects, the pharmaceutical composition comprises about 100 mg / mL to about 500 mg / mL, about 100 mg / mL to about 450 mg / mL, about 100 mg / mL to about 400 mg / mL, about 100 mg / mL to about 350 mg / mL, about 100 mg / mL to about 300 mg / mL, about 100 mg / mL to about 250 mg / mL, about 100 mg / mL to about 200 mg / mL, about 100 mg / mL to about 150 mg / mL, about 100 mg / mL to about 140 mg / mL, about 100 mg / mL to about 130 mg / mL, about 100 mg / mL to about 120 mg / mL, about 100 mg / mL to about 115 mg / mL, about 100 mg / mL to about110 mg / mL, about 100 mg / mL to about 105 mg / mL, about 110 mg / mL to about 500 mg / mL, about 110 mg / mL to about 450 mg / mL, about 110 mg / mL to about 400 mg / mL, about 110 mg / mL to about 350 mg / mL, about 110 mg / mL to about 300 mg / mL, about 110 mg / mL to about 250 mg / mL, about 110 mg / mL to about 200 mg / mL, about 110 mg / mL to about 150 mg / mL, about 110 mg / mL to about 140 mg / mL, about 110 mg / mL to about 130 mg / mL, about 110 mg / mL to about 120 mg / mL, about 110 mg / mL to about 115 mg / mL, about 115 mg / mL to about 500 mg / mL, about 115 mg / mL to about 450 mg / mL, about 115 mg / mL to about 400 mg / mL, about 115 mg / mL to about 350 mg / mL, about 115 mg / mL to about 300 mg / mL, about 115 mg / mL to about 250 mg / mL, about 115 mg / mL to about 200 mg / mL, about 115 mg / mL to about 150 mg / mL, about 115 mg / mL to about 140 mg / mL, about 115 mg / mL to about 130 mg / mL, about 115 mg / mL to about 120 mg / mL, about 120 mg / mL to about 450 mg / mL, about 120 mg / mL to about 400 mg / mL, about 120 mg / mL to about 350 mg / mL, about 120 mg / mL to about 300 mg / mL, about 120 mg / mL to about 250 mg / mL, about 120 mg / mL to about 200 mg / mL, about 120 mg / mL to about 150 mg / mL, about 120 mg / mL to about 140 mg / mL, about 120 mg / mL to about 130 mg / mL, about 150 mg / mL to about 500 mg / mL, about 150 mg / mL to about 450 mg / mL, about 150 mg / mL to about 400 mg / mL, about 150 mg / mL to about 350 mg / mL, about 150 mg / mL to about 300 mg / mL, about 150 mg / mL to about 250 mg / mL, or about 150 mg / mL to about 200 mg / mL of the protein.
[0108] In some aspects, the pharmaceutical composition comprises about 100 mg / mL, about 101 mg / mL, about 102 mg / mL, about 103 mg / mL, about 104 mg / mL, about 105 mg / mL, about 106 mg / mL, about 107 mg / mL, about 108 mg / mL, about 109 mg / mL, about 110 mg / mL, about 111 mg / mL, about 112 mg / mL, about 113 mg / mL, about 114 mg / mL, about 115 mg / mL, about 116 mg / mL, about 117 mg / mL, about 118 mg / mL, about 119 mg / mL, about 120 mg / mL, about 121 mg / mL, about 122 mg / mL, about 123 mg / mL, about 124 mg / mL, about 125 mg / mL, about 126 mg / mL, about 127 mg / mL, about 128 mg / mL, about 129 mg / mL, about 130 mg / mL, about 131 mg / mL, about 132 mg / mL, about 133 mg / mL, about 134 mg / mL, about 135 mg / mL, about 136 mg / mL, about 137 mg / mL, about 138 mg / mL, about 139 mg / mL, about 140 mg / mL, about 141 mg / mL, about 142 mg / mL, about 143 mg / mL, about 144 mg / mL, about 145 mg / mL, about 146 mg / mL, about 147 mg / mL, about 148 mg / mL, about 149 mg / mL, about 150 mg / mL, about 155 mg / mL, about 160 mg / mL, about 165 mg / mL, about 170 mg / mL, about 175 mg / mL, about 180 mg / mL, about 185 mg / mL, about 190 mg / mL, about 195 mg / mL, about 200 mg / mL, about 205 mg / mL, about 210 mg / mL, about 215 mg / mL, about 220 mg / mL, about 225 mg / mL, about 230 mg / mL, about 235 mg / mL, about 240 mg / mL, about 245 mg / mL, about 250 mg / mL, about 255 mg / mL, about 260 mg / mL, about 265 mg / mL, about 270 mg / mL, about 275 mg / mL,about 280 mg / mL, about 285 mg / mL, about 290 mg / mL, about 295 mg / mL, about 300 mg / mL, about 305 mg / mL, about 310 mg / mL, about 315 mg / mL, about 320 mg / mL, about 325 mg / mL, about 330 mg / mL, about 335 mg / mL, about 340 mg / mL, about 345 mg / mL, about 350 mg / mL, about 355 mg / mL, about 360 mg / mL, about 365 mg / mL, about 370 mg / mL, about 375 mg / mL, about 380 mg / mL, about 385 mg / mL, about 390 mg / mL, about 395 mg / mL, about 400 mg / mL, about 405 mg / mL, about 410 mg / mL, about 415 mg / mL, about 420 mg / mL, about 425 mg / mL, about 430 mg / mL, about 435 mg / mL, about 440 mg / mL, about 445 mg / mL, about 450 mg / mL, about 455 mg / mL, about 460 mg / mL, about 465 mg / mL, about 470 mg / mL, about 475 mg / mL, about 480 mg / mL, about 485 mg / mL, about 490 mg / mL, about 495 mg / mL, or about 500 mg / mL of the protein.
[0109] In some aspects, the pharmaceutical composition comprises about 105 mg / mL, about 120 mg / mL, about 126 mg / mL, about 128 mg / mL, about 140 mg / mL, about 144 mg / mL, about 150 mg / mL, or about 160 mg / mL of the protein.
[0110] In some aspects, the pharmaceutical composition comprises about 0.25 mg to about 4000 mg, about 0.25 mg to about 3600 mg, about 0.25 mg to about 3200 mg, about 0.25 mg to about 3000 mg, about 0.25 mg to about 2600 mg, about 0.25 mg to about 2200 mg, about 0.25 mg to about 2000 mg, about 0.25 mg to about 1600 mg, about 0.25 mg to about 1200 mg, about 0.25 mg to about 1000 mg, about 0.25 mg to about 800 mg, about 0.25 mg to about 600 mg, about 0.25 mg to about 400 mg, about 0.25 mg to about 200 mg, about 0.25 mg to about 100 mg, about 0.25 mg to about 50 mg, about 0.25 mg to about 40 mg, about 0.25 mg to about 30 mg, about 0.25 mg to about 20 mg, about 20 mg to about 4000 mg, about 20 mg to about 3600 mg, about 20 mg to about 3200 mg, about 20 mg to about 3000 mg, about 20 mg to about 2600 mg, about 20 mg to about 2200 mg, about 20 mg to about 2000 mg, about 20 mg to about 1600 mg, about 20 mg to about 1200 mg, about 20 mg to about 1000 mg, about 20 mg to about 800 mg, about 20 mg to about 600 mg, about 20 mg to about 400 mg, about 20 mg to about 200 mg, about 20 mg to about 100 mg, about 100 mg to about 4000 mg, about 100 mg to about 3600 mg, about 100 mg to about 3200 mg, about 100 mg to about 3000 mg, about 100 mg to about 2600 mg, about 100 mg to about 2200 mg, about 100 mg to about 2000 mg, about 100 mg to about 1800 mg, about 100 mg to about 1600 mg, about 100 mg to about 1400 mg, about 100 mg to about 1200 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, about 400 mg to about 4000 mg, about 400 mg to about 3600 mg, about 400 mg to about 3200 mg, about 400 mg to about 3000 mg, about 400 mg to about 2600 mg, about 400 mg to about 2200 mg, about 400 mg to about 2000 mg, about 400 mg to about 1800 mg, about 400 mg to about1600 mg, about 400 mg to about 1400 mg, about 400 mg to about 1200 mg, or about 400 mg to about 1000 mg of the protein.
[0111] In some aspects, the pharmaceutical composition comprises about 0.25 mg, about 0.5 mg, about 0.75 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3 mg, about 3.25 mg, about 3.5 mg, about 3.75 mg, about 4 mg, about 4.25 mg, about 4.5 mg, about 4.75 mg, about 5 mg, about 5.25 mg, about 5.5 mg, about 5.75 mg, about 6 mg, about 6.25 mg, about 6.5 mg, about 6.75 mg, about 7 mg, about 7.25 mg, about 7.5 mg, about 7.75 mg, about 8 mg, about 8.25 mg, about 8.5 mg, about 8.75 mg, about 9 mg, about 9.25 mg, about 9.5 mg, about 9.75 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, about 710 mg, about 720 mg, about 730 mg, about 740 mg, about 750 mg, about 760 mg, about 770 mg, about 780 mg, about 790 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 980 mg, about 990 mg, about 1000 mg, about 1020 mg, about 1040 mg, about 1060 mg, about 1080 mg, about 1100 mg, about 1120 mg, about 1140 mg, about 1160 mg, about 1180 mg, about 1200 mg, about 1220 mg, about 1240 mg, about 1260 mg, about 1280 mg, about 1300 mg, about 1320 mg, about 1340 mg, about 1360 mg, about 1380 mg, about 1400 mg, about 1420 mg, about 1440 mg, about 1460 mg, about 1480 mg, about 1500 mg, about 1520 mg, about 1540 mg, about 1560 mg, about 1580 mg, about 1600 mg, about 1620 mg, about 1640 mg, about 1660 mg, about 1680 mg, about 1700 mg, about 1720 mg, about 1740 mg, about 1760 mg, about 1780 mg, about 1800 mg, about 1820 mg, about 1840 mg, about 1860 mg, about 1880 mg, about 1900 mg, about 1920 mg, about 1940 mg, about 1960 mg, about 1980 mg, about 2000 mg, about 2020 mg,about 2040 mg, about 2060 mg, about 2080 mg, about 2100 mg, about 2120 mg, about 2140 mg, about 2160 mg, about 2180 mg, about 2200 mg, about 2220 mg, about 2240 mg, about 2260 mg, about 2280 mg, about 2300 mg, about 2320 mg, about 2340 mg, about 2360 mg, about 2380 mg, about 2400 mg, about 2420 mg, about 2440 mg, about 2460 mg, about 2480 mg, about 2500 mg, about 2520 mg, about 2540 mg, about 2560 mg, about 2580 mg, about 2600 mg, about 2620 mg, about 2640 mg, about 2660 mg, about 2680 mg, about 2700 mg, about 2720 mg, about 2740 mg, about 2760 mg, about 2780 mg, about 2800 mg, about 2820 mg, about 2840 mg, about 2860 mg, about 2880 mg, about 2900 mg, about 2920 mg, about 2940 mg, about 2960 mg, about 2980 mg, about 3000 mg, about 3020 mg, about 3040 mg, about 3060 mg, about 3080 mg, about 3100 mg, about 3120 mg, about 3140 mg, about 3160 mg, about 3180 mg, about 3200 mg, about 3220 mg, about 3240 mg, about 3260 mg, about 3280 mg, about 3300 mg, about 3320 mg, about 3340 mg, about 3360 mg, about 3380 mg, about 3400 mg, about 3420 mg, about 3440 mg, about 3460 mg, about 3480 mg, about 3500 mg, about 3520 mg, about 3540 mg, about 3560 mg, about 3580 mg, about 3600 mg, about 3620 mg, about 3640 mg, about 3660 mg, about 3680 mg, about 3700 mg, about 3720 mg, about 3740 mg, about 3760 mg, about 3780 mg, about 3800 mg, about 3820 mg, about 3840 mg, about 3860 mg, about 3880 mg, about 3900 mg, about 3920 mg, about 3940 mg, about 3960 mg, about 3980 mg, or about 4000 mg of the protein.
[0112] In some aspects, the pharmaceutical composition comprises about 1260 mg, about 1440 mg, or about 1920 mg of the protein.
[0113] In some aspects, the protein comprises an antibody, a checkpoint inhibitor, a fusion protein, a growth factor, a hormone, an enzyme, a cytokine, a coagulation factor, a plasma protein, or a combination thereof. In some aspects, the protein comprises an antibody. In some aspects, the antibody comprises a full-length antibody. In some aspects, the antibody comprises a monoclonal, human, humanized, chimeric, or multispecific antibody. In some aspects, the multispecific antibody comprises a dual-affinity re-targeting antibody, a dual variable domain immunoglobulin, or a bispecific antibody. In some aspects, the antibody comprises a F(ab')2 fragment, a Fab' fragment, a Fab fragment, a Fv fragment, a scFv fragment, a dsFv fragment, a dAb fragment, or a single chain binding polypeptide. In some aspects, the antibody comprises an anti-LAG-3 antibody, an anti-PD-1 antibody, an anti-PD-Ll antibody, an anti-CTLA-4 antibody, an anti-TIM-3 antibody, an anti-TIGIT antibody, an anti-NKG2a antibody, an anti-OX40 antibody, an anti-ICOS antibody, an anti-MICA antibody, an anti-CD137 antibody, an anti-KIR antibody, an anti-TGFp antibody, an anti-IL-10 antibody, an anti-IL-8 antibody, an anti-B7-H4 antibody, an anti-Fas ligand antibody, an anti-CXCR4 antibody, an anti-mesothelin antibody, an anti-CD27 antibody, an anti-GITRantibody, an anti-CCR8 antibody, an anti-ILT4 antibody, or a combination thereof. In some aspects, the anti-LAG-3 antibody comprises BMS-986016 (relatlimab), IMP731 (H5L7BW), MK4280 (28G-10, favezelimab), REGN3767 (fianlimab), GSK2831781, humanized BAP050, IMP-701 (LAG525, ieramilimab), aLAG3(0414), aLAG3(0416), Sym022, TSR-033, TSR-075, XmAb841 (XmAb22841), MGD013 (tebotelimab), BI754111, FS118, P 13B02-30, AVA-017, 25F7, AGEN1746, RO7247669, INCAGN02385, IBI-110, EMB-02, IBI-323, LBL-007, ABL501, or an antigen-binding portion thereof. In some aspects, the anti-LAG-3 antibody comprises relatlimab, or an antigen-binding portion thereof. In some aspects, the anti-LAG-3 antibody comprises: (a) CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:3, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO:4; (b) a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10, respectively; (c) heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:3 and 4, respectively; (d) heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:l and 2, respectively; or (e) heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:21 and 2, respectively. In some aspects, the anti-PD-1 antibody comprises nivolumab, pembrolizumab, PDR001 (spartalizumab), MEDI-0680, TSR-042, cemiplimab, JS001, PF-06801591, BGB-A317, BI 754091, INCSHR1210, GLS-010, AM-001, STI-1110, AGEN2034, MGA012, BCD-100, IBI308, SSI-361, or an antigen-binding portion thereof. In some aspects, the anti-PD-1 antibody comprises nivolumab, or an antigen-binding portion thereof. In some aspects, the anti-PD-1 antibody comprises: (a) CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 13, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO: 14; (b) a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO:20, respectively; (c) heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:13 and 14, respectively; or (d) heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:11 and 12, respectively. In some aspects, the anti-PD-Ll antibody comprises BMS-936559, atezolizumab, durvalumab, avelumab,STI-1014, CX-072, KN035, LY3300054, BGB-A333, ICO 36, FAZ053, CK-301, or an antigenbinding portion thereof. In some aspects, the anti-CTLA-4 antibody comprises ipilimumab, tremelimumab, MK-1308, AGEN-1884, or an antigen-binding portion thereof. In some aspects, the antibody comprises two antibodies. In some aspects, the antibody comprises an anti-PD-1 or anti-PD-Ll antibody and an anti -LAG-3 antibody. In some aspects, the mg:mg or mg / mL:mg / mL ratio of the anti-PD-1 or anti-PD-Ll antibody to the anti-LAG-3 antibody is about 1:1, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, about 1:15, about 1:20, about 1:30, about 1:40, about 1:50, about 1:60, about 1:70, about 1:80, about 1:90, about 1:100, about 1:120, about 1:140, about 1:160, about 1:180, about 1:200, about 200:1, about 180:1, about 160:1, about 140:1, about 120:1, about 100:1, about 90:1, about 80:1, about 70:1, about 60:1, about 50:1, about 40:1, about30:l, about 20:1, about 15:1, about 10:1, about9:l, about 8:1, about 7:1, about 6:1, about 5:1, about 4:1, about 3:1, about 2:1, about 3:4, about 3:2, about 2:3, or about 4:3. In some aspects, the mg:mg or mg / mL:mg / mL ratio of the anti-PD-1 or anti-PD-Ll antibody to the anti-LAG-3 antibody is about 1:1, about 2:1, or about 3:4. In some aspects, the concentration of the anti-PD-1 or anti-PD-Ll antibody is about 10 mg / mL, about 15 mg / mL, about 20 mg / mL, about 25 mg / mL, about 30 mg / mL, about 35 mg / mL, about 40 mg / mL, about 45 mg / mL, about 50 mg / mL, about 52.5 mg / mL, about 55 mg / mL, about 60 mg / mL, about 64 mg / mL, about 65 mg / mL, about 70 mg / mL, about 72 mg / mL, about 75 mg / mL, about 78.8 mg / mL, about 80 mg / mL, about 85 mg / mL, about 90 mg / mL, about 94.5 mg / mL, about 95 mg / mL, about 100 mg / mL, about 105 mg / mL, about 108 mg / mL, about 110 mg / mL, about 120 mg / mL, about 130 mg / mL, about 132 mg / mL, about 135 mg / mL, about 137.5 mg / mL, about 140 mg / mL, about 150 mg / mL, about 160 mg / mL, about 170 mg / mL, about 175 mg / mL, about 180 mg / mL, about 190 mg / mL, about 200 mg / mL, about 210 mg / mL, about 220 mg / mL, about 230 mg / mL, about 240 mg / mL, about 250 mg / mL, about 260 mg / mL, about 270 mg / mL, about 280 mg / mL, about 290 mg / mL, about 300 mg / mL, about 310 mg / mL, about 320 mg / mL, about 330 mg / mL, about 340 mg / mL, about 350 mg / mL, about 360 mg / mL, about 370 mg / mL, about 380 mg / mL, about 390 mg / mL, about 400 mg / mL, about 410 mg / mL, about 420 mg / mL, about 430 mg / mL, about 440 mg / mL, about 450 mg / mL, about 460 mg / mL, about 470 mg / mL, about 480 mg / mL, about 490 mg / mL, or about 500 mg / mL. In some aspects, the pharmaceutical composition comprises about 0.25 mg to about 2000 mg, about 0.25 mg to about 1600 mg, about 0.25 mg to about 1200 mg, about 0.25 mg to about 800 mg, about 0.25 mg to about 400 mg, about 0.25 mg to about 100 mg, about 0.25 mg to about 50 mg, about 0.25 mg to about 40 mg, about 0.25 mg to about 30 mg, about 0.25 mg to about 20 mg, about 20 mg to about 2000 mg, about 20 mg to about 1600 mg, about 20mg to about 1200 mg, about 20 mg to about 800 mg, about 20 mg to about 400 mg, about 20 mg to about 100 mg, about 100 mg to about 2000 mg, about 100 mg to about 1800 mg, about 100 mg to about 1600 mg, about 100 mg to about 1400 mg, about 100 mg to about 1200 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, about 400 mg to about 2000 mg, about 400 mg to about 1800 mg, about 400 mg to about 1600 mg, about 400 mg to about 1400 mg, about 400 mg to about 1200 mg, or about 400 mg to about 1000 mg of the anti-PD-1 or anti-PD-Ll antibody. In some aspects, the pharmaceutical composition comprises about 0.25 mg, about 0.5 mg, about 0.75 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3 mg, about 3.25 mg, about 3.5 mg, about 3.75 mg, about 4 mg, about 4.25 mg, about 4.5 mg, about 4.75 mg, about 5 mg, about 5.25 mg, about 5.5 mg, about 5.75 mg, about 6 mg, about 6.25 mg, about 6.5 mg, about 6.75 mg, about 7 mg, about 7.25 mg, about 7.5 mg, about 7.75 mg, about 8 mg, about 8.25 mg, about 8.5 mg, about 8.75 mg, about 9 mg, about 9.25 mg, about 9.5 mg, about 9.75 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, about 710 mg, about 720 mg, about 730 mg, about 740 mg, about 750 mg, about 760 mg, about 770 mg, about 780 mg, about 790 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 980 mg, about 990 mg, about 1000 mg, about 1040 mg, about 1080 mg, about 1100 mg, about 1140 mg, about 1180 mg, about 1200 mg, about 1240 mg, about 1280 mg, about 1300 mg, about 1340 mg, about 1380 mg, about 1400 mg, about 1440 mg, about 1480 mg, about 1500 mg, about 1540 mg, about 1580 mg, about 1600 mg, about 1640 mg, about 1680 mg, about 1700 mg, about 1740 mg, about 1780 mg, about 1800 mg, about1840 mg, about 1880 mg, about 1900 mg, about 1940 mg, about 1980 mg, or about 2000 mg of the anti-PD-1 or anti-PD-Ll antibody. In some aspects, the concentration of the anti -LAG-3 antibody is about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 3.3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 6 mg / mL, about 7 mg / mL, about 8 mg / mL, about 9 mg / mL, about 10 mg / mL, about 13 mg / mL, about 13.35 mg / mL, about 15 mg / mL, about 18 mg / mL, about 20 mg / mL, about 23 mg / mL, about 25 mg / mL, about 26 mg / mL, about 26.2 mg / mL, about 26.7 mg / mL, about 27 mg / mL, about 28 mg / mL, about 29 mg / mL, about 30 mg / mL, about 31.5 mg / mL, about 35 mg / mL, about 37.5 mg / mL, about 40 mg / mL, about 45 mg / mL, about 50 mg / mL, about 52.5 mg / mL, about 55 mg / mL, about 60 mg / mL, about 64 mg / mL, about 65 mg / mL, about 70 mg / mL, about 72 mg / mL, about 75 mg / mL, about 80 mg / mL, about 85 mg / mL, about 90 mg / mL, about 95 mg / mL, about 100 mg / mL, about 108 mg / mL, about 110 mg / mL, about 120 mg / mL, about 130 mg / mL, about 132 mg / mL, about 135 mg / mL, about 140 mg / mL, about 150 mg / mL, about 160 mg / mL, about 170 mg / mL, about 175 mg / mL, about 180 mg / mL, about 190 mg / mL, about 200 mg / mL, about 210 mg / mL, about 220 mg / mL, about 230 mg / mL, about 240 mg / mL, about 250 mg / mL, about 260 mg / mL, about 270 mg / mL, about 280 mg / mL, about 290 mg / mL, about 300 mg / mL, about 310 mg / mL, about 320 mg / mL, about 330 mg / mL, about 340 mg / mL, about 350 mg / mL, about 360 mg / mL, about 370 mg / mL, about 380 mg / mL, about 390 mg / mL, about 400 mg / mL, about 410 mg / mL, about 420 mg / mL, about 430 mg / mL, about 440 mg / mL, about 450 mg / mL, about 460 mg / mL, about 470 mg / mL, about 480 mg / mL, about 490 mg / mL, or about 500 mg / mL. In some aspects, the pharmaceutical composition comprises about 0.25 mg to about 2000 mg, about 0.25 mg to about 1600 mg, about 0.25 mg to about 1200 mg, about 0.25 mg to about 800 mg, about 0.25 mg to about 400 mg, about 0.25 mg to about 100 mg, about 0.25 mg to about 50 mg, about 0.25 mg to about 40 mg, about 0.25 mg to about 30 mg, about 0.25 mg to about 20 mg, about 20 mg to about 2000 mg, about 20 mg to about 1600 mg, about 20 mg to about 1200 mg, about 20 mg to about 800 mg, about 20 mg to about 400 mg, about 20 mg to about 100 mg, about 100 mg to about 2000 mg, about 100 mg to about 1800 mg, about 100 mg to about 1600 mg, about 100 mg to about 1400 mg, about 100 mg to about 1200 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, about 400 mg to about 2000 mg, about 400 mg to about 1800 mg, about 400 mg to about 1600 mg, about 400 mg to about 1400 mg, about 400 mg to about 1200 mg, or about 400 mg to about 1000 mg of the anti -LAG-3 antibody. In some aspects, the pharmaceutical composition comprises about 0.25 mg, about 0.5 mg, about 0.75 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3 mg, about 3.25 mg, about3.5 mg, about 3.75 mg, about 4 mg, about 4.25 mg, about 4.5 mg, about 4.75 mg, about 5 mg, about 5.25 mg, about 5.5 mg, about 5.75 mg, about 6 mg, about 6.25 mg, about 6.5 mg, about 6.75 mg, about 7 mg, about 7.25 mg, about 7.5 mg, about 7.75 mg, about 8 mg, about 8.25 mg, about 8.5 mg, about 8.75 mg, about 9 mg, about 9.25 mg, about 9.5 mg, about 9.75 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, about 710 mg, about 720 mg, about 730 mg, about 740 mg, about 750 mg, about 760 mg, about 770 mg, about 780 mg, about 790 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 980 mg, about 990 mg, about 1000 mg, about 1040 mg, about 1080 mg, about 1100 mg, about 1140 mg, about 1180 mg, about 1200 mg, about 1240 mg, about 1280 mg, about 1300 mg, about 1340 mg, about 1380 mg, about 1400 mg, about 1440 mg, about 1480 mg, about 1500 mg, about 1540 mg, about 1580 mg, about 1600 mg, about 1640 mg, about 1680 mg, about 1700 mg, about 1740 mg, about 1780 mg, about 1800 mg, about 1840 mg, about 1880 mg, about 1900 mg, about 1940 mg, about 1980 mg, or about 2000 mg of the anti -LAG-3 antibody. In some aspects, the pharmaceutical composition comprises about 80 mg / mL of the anti-PD-1 antibody and about 80 mg / mL of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises a volume of about 12 mL. In some aspects, the pharmaceutical composition comprises a volume of about 9 mL. In some aspects, the pharmaceutical composition comprises about 75 mg / mL of the anti-PD-1 antibody and about 75 mg / mL of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises a volume of about 12.8 mL. In some aspects, the pharmaceutical composition comprises a volume of about 9.6 mL. In some aspects, the pharmaceutical composition comprises about 72 mg / mL of the anti-PD-1 antibody and about72 mg / mL of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises a volume of about 10 mL. In some aspects, the pharmaceutical composition comprises about 64 mg / mL of the anti-PD-1 antibody and about 64 mg / mL of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises a volume of about 15 mL. In some aspects, the pharmaceutical composition comprises about 60 mg / mL of the anti-PD-1 antibody and about 60 mg / mL of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises a volume of about 16 mL. In some aspects, the pharmaceutical composition comprises a volume of about 12 mL. In some aspects, the pharmaceutical composition comprises about 52.5 mg / mL of the anti-PD-1 antibody and about 52.5 mg / mL of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises a volume of about 18.3 mL. In some aspects, the pharmaceutical composition comprises about 64.3 mg / mL of the anti-PD-1 antibody and about 85.7 mg / mL of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises a volume of about 8.4 mL. In some aspects, the pharmaceutical composition comprises about 60 mg / mL of the anti-PD-1 antibody and about 80 mg / mL of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises a volume of about 9 mL. In some aspects, the pharmaceutical composition comprises about 54 mg / mL of the anti-PD-1 antibody and about 72 mg / mL of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises a volume of about 10 mL. In some aspects, the pharmaceutical composition comprises about 45 mg / mL of the anti-PD-1 antibody and about 60 mg / mL of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises a volume of about 12 mL. In some aspects, the pharmaceutical composition comprises about 960 mg of the anti-PD-1 antibody and about 960 mg of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises about 720 mg of the anti-PD-1 antibody and about 720 mg of the anti-LAG-3 antibody. In some aspects, the pharmaceutical composition comprises about 540 mg of the anti-PD-1 antibody and about 720 mg of the anti-LAG-3 antibody. In some aspects, the anti-PD-1 antibody comprises nivolumab, or an antigen-binding portion thereof, and the anti-LAG-3 antibody comprises relatlimab, or an antigen-binding portion thereof. In some aspects, (a) the anti-LAG-3 antibody comprises CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:3, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO:4, and the anti-PD-1 antibody comprises CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 13, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO: 14; (b)the anti -LAG-3 antibody comprises a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO: 10, respectively, and the anti-PD-1 antibody comprises a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO:20, respectively; (c) the anti-LAG-3 antibody comprises heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:3 and 4, respectively, and the anti-PD-1 antibody comprises heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:13 and 14, respectively; (d) the anti-LAG-3 antibody comprises heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:1 and 2, respectively, and the anti-PD-1 antibody comprises heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs: 11 and 12, respectively; or (e) the anti-LAG-3 antibody comprises heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:21 and 2, respectively, and the anti-PD-1 antibody comprises heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs: 11 and 12, respectively. In some aspects, percent high molecular weight (% HMW) species in the pharmaceutical composition as measured by size exclusion chromatography are less than about 1.5% following: agitation at 250 rpm for 1 week at 30 °C, agitation at 250 rpm for 2 weeks at 30 °C, storage at room temperature and room light conditions for 2 weeks, storage at 40 °C for 2 weeks, and / or storage at 50 °C for 2 weeks. In some aspects, the % HMW species are about 1 % or less. In some aspects, the %HMW species are less than about 1%. In some aspects, percent monomer (% monomer) in the pharmaceutical composition as measured by size exclusion chromatography is greater than about 97% following: agitation at 250 rpm for 1 week at 30 °C, agitation at 250 rpm for 2 weeks at 30 °C, storage at room temperature and room light conditions for 2 weeks, storage at 40 °C for 2 weeks, and / or storage at 50 °C for 2 weeks. In some aspects, the % monomer in the pharmaceutical composition as measured by size exclusion chromatography is about 98% or more following: agitation at 250 rpm for 1 week at 30 °C, agitation at 250 rpm for 2 weeks at 30 °C, storage at room temperature and room light conditions for 2 weeks, and / or storage at 40 °C for 2 weeks.
[0114] In some aspects, the pharmaceutical composition is suitable for intravitreal, intravenous, intramuscular, and / or subcutaneous administration.
[0115] In some aspects, the pharmaceutical composition is suitable for subcutaneous administration.
[0116] In some aspects, the pharmaceutical composition is capable of being injected within about 10 minutes or less. In some aspects, the pharmaceutical composition is capable of being injected within about 5 minutes to about 7 minutes. In some aspects, the pharmaceutical composition is capable of being injected within about 3 minutes to about 5 minutes.BRIEF DESCRIPTION OF THE DRAWINGS
[0117] FIGs. 1A-1B show graphs of viscosity and osmolality profiles, respectively, for exemplary formulations comprising a 1:1 ratio of nivolumab and relatlimab at a total antibody concentration of 150 mg / mL ( / .<., 75 mg / mL of each antibody), varying concentrations of NaCl, and either 250 mM or 209 mM sucrose. “cP” in FIG. 1A and subsequent figures = centiPoise; “mOsmol / kg” in FIG. IB and subsequent figures = milliOsmoles per kilogram.
[0118] FIGs. 2A-2B show graphs of viscosity and osmolality profiles, respectively, for exemplary formulations comprising a 1:1 ratio of nivolumab and relatlimab at a total antibody concentration of 150 mg / mL, varying concentrations of arginine hydrochloride (“Arginine”), and either 250 mM or 209 mM sucrose.
[0119] FIGs. 3A-3B show graphs of viscosity and osmolality profiles, respectively, for exemplary formulations comprising a 1:1 ratio of nivolumab and relatlimab at a total antibody concentration of 150 mg / mL, varying concentrations of NaCl, 100 mM arginine hydrochloride (“Arg”), and 209 mM sucrose. FIG. 3B also includes the osmolality profile from FIG. IB for the exemplary formulation containing varying concentrations of NaCl and 209 mM sucrose without arginine hydrochloride as a comparison.
[0120] FIG. 4 shows a graph of viscosity profiles for exemplary formulations comprising a 1:1 ratio of nivolumab and relatlimab at a total antibody concentration of 120 mg / mL ( / .<., 60 mg / mL of each antibody) and varying concentrations of NaCl with either 250 mM or 167 mM sucrose.
[0121] FIG. 5 shows a graph of viscosity profiles for exemplary formulations comprising a 1: 1 ratio of nivolumab and relatlimab at a total antibody concentration of 120 mg / mL and varying concentration of sucrose either with or without 40 mM NaCl.
[0122] FIG. 6 shows a graph of viscosity profiles for exemplary formulations comprising a 1:1 ratio of nivolumab and relatlimab at a total antibody concentration of 105 mg / mL (z.e., 52.5 mg / mL of each antibody), varying concentrations of NaCl, and 146 mM sucrose.
[0123] FIG. 7 shows the effect of temperature on the viscosity of an exemplary formulation comprising a 1: 1 ratio of nivolumab and relatlimab at a total antibody concentration of 120 mg / mL (z.e., 60 mg / mL of each antibody).
[0124] FIGs. 8A-8J show bar graphs of the percentages of high molecular weight (HMW) species (FIGs. 8A, 8C, 8E, 8G, 81) and monomeric species (FIGs. 8B, 8D, 8F, 8H, 8J) as measured by size exclusion chromatography (SEC) for the 13 formulations (Fl -Fl 3) described in Table 9 of Example 2 following: agitation at 250 rpm for 1 week at 30 °C (FIGs.8A-8B), agitation at 250 rpm for 2 weeks at 30 °C (FIGs. 8C-8D), storage at room temperature and room light conditions for 14 days (FIGs. 8E-8F), storage at 40 °C for 14 days (FIGs. 8G-8H), storage at 50 °C for 14 days (FIGs. 8I-8J).
[0125] FIGs. 9A-9C show bar graphs of the nivolumab (Nivo) heavy chain (HC) charge variant profiles as measured by imaged capillary isoelectric focusing (iCIEF) for the 13 formulations (F1-F13) described in Table 9 of Example 2: at time zero (TO), following storage at room temperature and room light conditions for 14 days (RTRL T14D), following agitation at 250 rpm for 14 days at 30 °C (30C Shaking T14D), following storage at 40 °C for 14 days (40C T14D), and following storage at 50 °C for 14 days (50C T14D). FIG. 9A shows the percentages of the main species of the Nivo HC (% Main Peak), FIG. 9B shows the percentages of the acidic species of the Nivo HC (% Acidic Groups), and FIG. 9C shows the percentages of the basic species of the Nivo HC (% Basic Groups).
[0126] FIGs. 10A-10C show bar graphs of the relatlimab (Rela) HC charge variant profiles as measured by iCIEF for the 13 formulations (F1-F13) described in Table 9 of Example 2. TO, RTRL T14D, 30C Shaking T14D, 40C T14D, and 50C T14D are as defined in the brief description of FIGs. 9A-9C. FIG. 10A shows the percentages of the main species of the Rela HC (% Main Peak), FIG. 10B shows the percentages of the acidic species of the Rela HC (% Acidic Groups), and FIG. 10C shows the percentages of the basic species of the Rela HC (% Basic Groups).
[0127] FIGs. 11A-11C show bar graphs of sub-visible particle counts at 10-25 pm equivalent sphere diameter (ESD) and greater than 25 pm for the 13 formulations (Fl -Fl 3) described in Table 9 of Example 2 following: storage at room temperature and room light conditions for 14 days (FIG. HA), agitation at 250 rpm for 14 days at 30 °C (FIG. 11B), and storage at 50 °C for 14 days (FIG. HC).
[0128] FIGs. 12A-12B show bar graphs of sub-visible particle counts (# / mL) at particle sizes of > 10 pm or > 25 pm for the exemplary 120 mg / mL formulation of Example 3 stored in either OMPI or SCHOTT vials for 10 days, 2 weeks, 3 weeks, or 1 month at room temperature and room light conditions (FIG. 12A) or after 3 freeze / thaw cycles or storage at 1 month at 5 °C, 25 °C, or 40 °C (FIG. 12B).
[0129] FIGs. 13A-13C show bar graphs of the nivolumab HC charge variant profiles for the exemplary 120 mg / mL formulation of Example 3: at time zero (TO), following 3 freeze / thaw cycles (FT-3x), following storage at room temperature and room light conditions for 7 days (RTRL T-7Day), 10 days (RTRL 10 Day), 2 weeks (RTRL-T2Wk), 3 weeks (RTRL-T3Wk), and 1 month (RTRL TIM). FIG. 13A shows the percentages of the main species of the nivolumab HC (% Main Peak of Nivo), FIG. 13B shows the percentages of the acidic species of the nivolumab HC (% Acidic Group of Nivo), and FIG. 13C shows the percentages of the basic species of the nivolumab HC (% Basic Group of Nivo).
[0130] FIGs. 14A-14C show bar graphs of the nivolumab HC charge variant profiles for the exemplary 120 mg / mL formulation of Example 3: at time zero (TO), following storage at room temperature and room light conditions for 7 days (RTRL T-7Day), following storage at 40 °C for 2 weeks (40C-T2Wk) or 1 month (40C TIM), following storage at 25 °C for 1 month (25C TIM), and following storage at 5 °C for 1 month (5C TIM). FIG. 14A shows the percentages of the main species of the nivolumab HC (% Main Peak of Nivo), FIG. 14B shows the percentages of the acidic species of the nivolumab HC (% Acidic Group of Nivo), and FIG. 14C shows the percentages of the basic species of the nivolumab HC (% Basic Group of Nivo).
[0131] FIGs. 15A-15C show bar graphs of the relatlimab HC charge variant profiles for the exemplary 120 mg / mL formulation of Example 3. TO, FT-3x, RTRL T-7Day, RTRL 10 Day, RTRL-T2Wk, RTRL-T3Wk, and RTRL TIM are as defined in the brief description of FIGs. 13A-13C. FIG. 15A shows the percentages of the main species of the relatlimab HC (% Main Peak of Rela), FIG. 15B shows the percentages of the acidic species of the relatlimab HC (% Acidic Group of Rela), and FIG. 15C shows the percentages of the basic species of the relatlimab HC (% Basic Group of Rela).
[0132] FIGs. 16A-16C show bar graphs of the relatlimab HC charge variant profiles for the exemplary 120 mg / mL formulation of Example 3. TO, 40C-T2Wk, 40C TIM, 25C TIM, and 5C TIM are as defined in the brief description of FIGs. 14A-14C. FIG. 16A shows the percentages of the main species of the relatlimab HC (% Main Peak of Rela), FIG. 16B shows the percentagesof the acidic species of the relatlimab HC (% Acidic Group of Rela), and FIG. 16C shows the percentages of the basic species of the relatlimab HC (% Basic Group of Rela).
[0133] FIG. 17 shows a simulated nivolumab concentration-time profile for doses of 480 mg administered intravenously every 4 weeks (“IV 480 mg Q4W”), 720 mg administered subcutaneously every 4 weeks (“SC 720 mg Q4W”), 800 mg administered subcutaneously every 4 weeks (“SC 800 mg Q4W”), and 960 mg administered subcutaneously every 4 weeks (“SC 960 mg Q4W”) in a 79% bioavailability scenario. Nivo Geo Mean = nivolumab geometric mean.
[0134] FIG. 18 shows observed relatlimab concentration-time curves following a single subcutaneous dose of either 480 mg or 720 mg to subjects in a Phase I clinical study.
[0135] FIG. 19 shows a simulated relatlimab concentration-time profile for a dose of 480 mg administered intravenously every 4 weeks (“480 mg Q4W IV”) as compared to a dose of 960 mg administered subcutaneously every 4 weeks (“960 mg Q4W SC”) in a 58% bioavailability scenario.
[0136] FIGs. 20A-20C show predicted relatlimab exposures in a 58% BA scenario for a dose of 480 mg administered intravenously every 4 weeks (“480 mg Q4W IV”) as compared to 720 mg administered subcutaneously every 4 weeks (“720 mg Q4W SC”), 840 mg administered subcutaneously every 4 weeks (“840 mg Q4W SC”), and 960 mg administered subcutaneously every 4 weeks (“960 mg Q4W SC”). FIG. 20A shows the relatlimab geometric mean average concentrations for the dose groups at day 28 (“CavgD28”). FIG. 20B shows the relatlimab geometric mean minimum concentrations for the dose groups at day 28 (“CminD28”). FIG. 20C shows the relatlimab geometric mean maximum concentrations for the dose groups following the first dose (“Cmaxl”).DETAILED DESCRIPTION OF THE INVENTION
[0137] The present disclosure provides a pharmaceutical composition comprising about 100 mg / mL or more of a protein, a salt, and a sugar, wherein the pharmaceutical composition comprises an osmolality of less than about 600 mOsmol / kg, and wherein the pharmaceutical composition comprises a lower viscosity than a corresponding composition that lacks the salt and / or that comprises a higher concentration of the sugar. The present disclosure provides a pharmaceutical composition comprising about 100 mg / mL or more of a protein, a salt, and a sugar, wherein the pharmaceutical composition comprises a lower viscosity than a corresponding composition that lacks the salt and that comprises a higher concentration of the sugar. In someaspects, the protein is an antibody (e.g., and anti -LAG-3 antibody and / or an anti-PD-1 antibody). The present disclosure also provides a method of treating a disease or disorder in a subject in need thereof comprising administering to the subject a pharmaceutically effective amount of the pharmaceutical composition. The present disclosure also provides a method of reducing the viscosity of a pharmaceutical composition, comprising: (a) preparing a pharmaceutical composition comprising about 100 mg / mL or more of a protein and a lower concentration of a sugar as compared to a corresponding composition that comprises the sugar and the same concentration of the protein, and (b) adding a salt to the pharmaceutical composition, wherein the viscosity of the pharmaceutical composition is reduced as compared to the corresponding composition. The present disclosure also provides a pharmaceutical composition comprising: (a) about 100 mg / mL or more of a protein, (b) means for producing a lower viscosity of the pharmaceutical composition as compared to a corresponding composition comprising the same concentration of the protein, and (c) means for producing an osmolality of about 200 mOsmol / kg to about 600 mOsmol / kg of the pharmaceutical composition.I. Terms
[0138] In order that the present disclosure can be more readily understood, certain terms are first defined. As used in this application, except as otherwise expressly provided herein, each of the following terms shall have the meaning set forth below. Additional definitions are set forth throughout the application. It is to be noted that the term "a" or "an" entity refers to one or more of that entity; for example, "a protein," is understood to represent one or more proteins. As such, the terms "a" (or "an"), "one or more," and "at least one" can be used interchangeably herein.
[0139] The term "and / or" where used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. Thus, the term "and / or" as used in a phrase such as " A and / or B" herein is intended to include " A and B," " A or B," " A" (alone), and " B" (alone). Likewise, the term "and / or" as used in a phrase such as " A, B, and / or C" is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
[0140] It is understood that wherever aspects are described herein with the language "comprising," otherwise analogous aspects described in terms of "consisting of' and / or "consisting essentially of' are also provided.
[0141] The terms "about" or "comprising essentially of' refer to a value or composition that is within an acceptable error range for the particular value or composition as determined byone of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined, z.e., the limitations of the measurement system. For example, "about" or "comprising essentially of can mean within 1 or more than 1 standard deviation per the practice in the art. Alternatively, "about" or "comprising essentially of' can mean a range of up to 10% or 20% (z.e., ±10% or ±20%). In some aspects, "about" comprises a range of up to 10% (z.e., ±10%). In some aspects, "about" comprises a range of up to 20% (z.e., ±20%). For example, about 3 mg can include any number between 2.7 mg and 3.3 mg (for 10%) or between 2.4 mg and 3.6 mg (for 20%). Furthermore, particularly with respect to biological systems or processes, the terms can mean up to an order of magnitude or up to 5-fold of a value. When particular values or compositions are provided in the application and claims, unless otherwise stated, the meaning of "about" or "comprising essentially of' should be assumed to be within an acceptable error range for that particular value or composition.
[0142] As described herein, any concentration range, percentage range, ratio range or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one-tenth and one-hundredth of an integer), unless otherwise indicated.
[0143] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure is related. For example, the Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 5th ed., 2013, Academic Press; and the Oxford Dictionary Of Biochemistry And Molecular Biology, 2006, Oxford University Press, provide one of skill with a general dictionary of many of the terms used in this disclosure.
[0144] Units, prefixes, and symbols are denoted in their Systeme International de Unites (SI) accepted form. Numeric ranges are inclusive of the numbers defining the range.
[0145] The headings provided herein are not limitations of the various aspects of the disclosure, which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the specification in its entirety.
[0146] An "antagonist" shall include, without limitation, any molecule capable of blocking, reducing, or otherwise limiting an interaction or activity of a target molecule (e.g., LAG-3). In some aspects, the antagonist is an antibody. In some aspects, the antagonist comprises a small molecule. The terms "antagonist" and "inhibitor" are used interchangeably herein.
[0147] An "antibody" (Ab) shall include, without limitation, a glycoprotein immunoglobulin which binds specifically to an antigen and comprises at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. Each H chain comprises a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region (abbreviated herein as CH. The heavy chain constant region comprises three constant domains, CHI, CHI and Cm. Each light chain comprises a light chain variable region (abbreviated herein as VL) and a light chain constant region (abbreviated herein as CL). The light chain constant region comprises one constant domain, CL. The NH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FR). Each NH and VL comprises three CDRs and four FRs, arranged from amino-terminus to carboxy -terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant regions of the antibodies can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system. A heavy chain can have the C-terminal lysine or not. Unless specified otherwise herein, the amino acids in the variable regions are numbered using the Kabat numbering system and those in the constant regions are numbered using the EU system.
[0148] An immunoglobulin can derive from any of the commonly known isotypes, including but not limited to IgA, secretory IgA, IgG and IgM. IgG subclasses are also well known to those in the art and include but are not limited to human IgGl, IgG2, IgG3 and IgG4. " Isotype" refers to the antibody class or subclass (e.g., IgM or IgGl) that is encoded by the heavy chain constant region genes. The term "antibody" includes, by way of example, both naturally occurring and non-naturally occurring antibodies; monoclonal and polyclonal antibodies; chimeric and humanized antibodies; human or nonhuman antibodies; wholly synthetic antibodies; single chain antibodies; monospecific antibodies; bispecific antibodies; and multi-specific antibodies. A nonhuman antibody can be humanized by recombinant methods to reduce its immunogenicity in humans. Where not expressly stated, and unless the context indicates otherwise, the term "antibody" also includes an antigen-binding fragment or an antigen-binding portion of any of the aforementioned immunoglobulins, and includes a monovalent and a divalent fragment or portion, that retains the ability to bind specifically to the antigen bound by the whole immunoglobulin. Examples of an "antigen-binding portion" or "antigen-binding fragment" include: (1) a Fab fragment (fragment from papain cleavage) or a similar monovalent fragment consisting of the VL,NH, LC and CHI domains; (2) a F(ab')2 fragment (fragment from pepsin cleavage) or a similar bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (3) a Fd fragment consisting of the VH and CHI domains; (4) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody; (5) a single domain antibody (dAb) fragment (Ward et aL, (1989) Nature 341:544-46), which consists of a NH domain; (6) a bi-single domain antibody which consists of two NH domains linked by a hinge (dual-affinity re-targeting antibodies (DARTs)); or (7) a dual variable domain immunoglobulin. Furthermore, although the two domains of the Fv fragment, VL and NH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and NH regions pair to form monovalent molecules (known as single chain Fv (scFv); see, e.g., Bird etal. (1988) Science 242:423-426; and Huston etal. N )Proc. Natl. Acad. Sci. USA 85:5879-5883).
[0149] An "isolated antibody" refers to an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that binds specifically to LAG-3 is substantially free of antibodies that do not bind specifically to LAG-3). An isolated antibody that binds specifically to LAG-3 can, however, have cross-reactivity to other antigens, such as LAG-3 molecules from different species. Moreover, an isolated antibody can be substantially free of other cellular material and / or chemicals.
[0150] The term "monoclonal antibody" ("mAb") refers to a non-naturally occurring preparation of antibody molecules of single molecular composition, i.e., antibody molecules whose primary sequences are essentially identical, and which exhibits a single binding specificity and affinity for a particular epitope. A mAb is an example of an isolated antibody. MAbs can be produced by hybridoma, recombinant, transgenic or other techniques known to those skilled in the art.
[0151] A "human" antibody (HuMAb) refers to an antibody having variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences. Furthermore, if the antibody contains a constant region, the constant region is also derived from human germline immunoglobulin sequences. The human antibodies of the invention can include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). However, the term "human antibody," as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as amouse, have been grafted onto human framework sequences. The terms "human" antibodies and "fully human" antibodies and are used synonymously.
[0152] A "humanized antibody" refers to an antibody in which some, most or all of the amino acids outside the CDR domains of a non-human antibody are replaced with corresponding amino acids derived from human immunoglobulins. In some aspects of a humanized form of an antibody, some, most or all of the amino acids outside the CDR domains have been replaced with amino acids from human immunoglobulins, whereas some, most or all amino acids within one or more CDR regions are unchanged. Small additions, deletions, insertions, substitutions or modifications of amino acids are permissible as long as they do not abrogate the ability of the antibody to bind to a particular antigen. A "humanized" antibody retains an antigenic specificity similar to that of the original antibody.
[0153] A "chimeric antibody" refers to an antibody in which the variable regions are derived from one species and the constant regions are derived from another species, such as an antibody in which the variable regions are derived from a mouse antibody and the constant regions are derived from a human antibody.
[0154] An "anti-antigen" antibody refers to an antibody that binds specifically to the antigen. For example, an anti-LAG-3 antibody binds specifically to LAG-3.
[0155] " LAG-3" refers to Lymphocyte Activation Gene-3. The term " LAG-3" includes variants, isoforms, homologs, orthologs and paralogs. For example, antibodies specific for a human LAG-3 protein can, in certain cases, cross-react with a LAG-3 protein from a species other than human. In some aspects, the antibodies specific for a human LAG-3 protein can be completely specific for the human LAG-3 protein and not exhibit species or other types of cross-reactivity, or can cross-react with LAG-3 from certain other species, but not all other species (e.g., cross-react with monkey LAG-3 but not mouse LAG-3). The term "human LAG-3" refers to human sequence LAG-3, such as the complete amino acid sequence of human LAG-3 having GenBank Accession No. NP_002277. The term "mouse LAG-3" refers to mouse sequence LAG-3, such as the complete amino acid sequence of mouse LAG-3 having GenBank Accession No. NP 032505. LAG-3 is also known in the art as, for example, CD223. The human LAG-3 sequence can differ from human LAG-3 of GenBank Accession No. NP_002277 by having, e.g., conserved mutations or mutations in non-conserved regions, and the LAG-3 has substantially the same biological function as the human LAG-3 of GenBank Accession No. NP 002277. For example, a biological function of human LAG-3 is having an epitope in the extracellular domain of LAG-3 that is specifically boundby an antibody of the instant disclosure or a biological function of human LAG-3 is binding to MHC Class II molecules.
[0156] A particular human LAG-3 sequence will generally be at least about 90% identical in amino acid sequence to human LAG-3 of GenBank Accession No. NP 002277 and contains amino acid residues that identify the amino acid sequence as being human when compared to LAG-3 amino acid sequences of other species (e.g., murine). In certain cases, a human LAG-3 can be at least about 95%, or even at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical in amino acid sequence to LAG-3 of GenBank Accession No. NP 002277. In some aspects, a human LAG-3 sequence will display no more than 10 amino acid differences from the LAG-3 sequence of GenBank Accession No. NP_002277. In some aspects, the human LAG-3 can display no more than 5, or even no more than 4, 3, 2, or 1 amino acid difference from the LAG-3 sequence of GenBank Accession No. NP_002277.
[0157] " Programmed Death-1 (PD-1)" refers to an immunoinhibitory receptor belonging to the CD28 family. PD-1 is expressed predominantly on previously activated T cells in vivo, and binds to two ligands, PD-L1 and PD-L2. The term " PD-1" as used herein includes human PD-1 (hPD-1), variants, isoforms, and species homologs of hPD-1, and analogs having at least one common epitope with hPD-1. The complete hPD-1 sequence can be found under GenBank Accession No. U64863. " PD-1" and " PD-1 receptor" are used interchangeably herein.
[0158] " Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4)" refers to an immunoinhibitory receptor belonging to the CD28 family. CTLA-4 is expressed exclusively on T cells in vivo, and binds to two ligands, CD80 and CD86 (also called B7-1 and B7-2, respectively). The term " CTLA-4" as used herein includes human CTLA-4 (hCTLA-4), variants, isoforms, and species homologs of hCTLA-4, and analogs having at least one common epitope with hCTLA-4. The complete hCTLA-4 sequence can be found under GenBank Accession No. AAB59385.
[0159] " Programmed Death Ligand- 1 (PD-L1)" is one of two cell surface glycoprotein ligands for PD- 1 (the other being PD-L2) that downregulate T cell activation and cytokine secretion upon binding to PD-1. The term " PD-L1" as used herein includes human PD-L1 (hPD-Ll), variants, isoforms, and species homologs of hPD-Ll, and analogs having at least one common epitope with hPD-Ll. The complete hPD-Ll sequence can be found under GenBank Accession No. Q9NZQ7.
[0160] " Programmed Death Ligand-2 (PD-L2)" as used herein includes human PD-L2 (hPD-L2), variants, isoforms, and species homologs of hPD-L2, and analogs having at least onecommon epitope with hPD-L2. The complete hPD-L2 sequence can be found under GenBank Accession No. Q9BQ51.
[0161] " Hyaluronidase," as used herein, refers to an enzyme capable of catalyzing the cleavage of hyaluronan. Hyaluronan is a repeating polymer of N-acetyl-glucosamine and glucuronic acid, which is present in the subcutaneous space and contributes to the soluble gel-like component of the extracellular matrix of the skin and is restored by rapid turnover (resynthesis). In some aspects, the hyaluronidase comprises rHuPH20, which is a glycosylated 447-amino acid single chain polypeptide that depolymerizes hyaluronan in the subcutaneous space locally at the site of injection in the skin. Depolymerization of hyaluronan by hyaluronidase is accomplished by hydrolysis of the polysaccharide polymer. Depolymerization of hyaluronan results in a transient reduction in the viscosity of the gel-like phase of the extracellular matrix and increased hydraulic conductance that facilitates the dispersion and absorption of the coadministered therapeutic agent. Thus, a hyaluronidase, e.g., rHuPH20, can improve the speed and ease of subcutaneous delivery of injectable biologies and drugs by acting as a permeation enhancer. In some aspects, the hyaluronidase comprises ENHANZE.
[0162] A "subject" as used herein includes humans and nonhuman animals. In some aspects, the subject is a human. The terms "subject" and "patient" are used interchangeably herein.
[0163] " Administering" refers to the physical introduction of a therapeutic agent to a subject (e.g., a composition or formulation comprising the therapeutic agent, including a single unit dose comprising the composition or formulation), using any of the various methods and delivery systems known to those skilled in the art. Exemplary routes of administration include intravenous, intramuscular, subcutaneous, intraperitoneal, spinal or other parenteral routes of administration, for example by injection or infusion. The phrase "parenteral administration" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion, as well as in vivo electroporation. In some aspects, the formulation is administered via a non-parenteral route, in some aspects, orally. Other non-parenteral routes include a topical, epidermal or mucosal route of administration, for example, intranasally, vaginally, rectally, sublingually or topically. Administering can also be performed, for example, once, a plurality of times, and / or over one or more extended periods.
[0164] " Treatment" or "therapy" of a subject refers to any type of intervention or process performed on, or the administration of an active agent to, the subject with the objective of eliminating, reversing, alleviating, ameliorating, inhibiting, reducing, slowing down progression, development, severity or recurrence of a symptom, complication or condition, or biochemical indicia associated with a disease. Response Evaluation Criteria In Solid Tumors (RECIST) is a measure for treatment efficacy and are established rules that define when tumors respond, stabilize, or progress during treatment. RECIST 1.1 is the current guideline to solid tumor measurement and definitions for objective assessment of change in tumor size for use in adult and pediatric cancer clinical trials.
[0165] As used herein, "maintenance therapy" refers to a therapy that is intended to prevent the occurrence or recurrence of tumors.
[0166] As used herein, "a recovery period" is a duration beginning upon the completion of one therapy and ending upon the start of another therapy. In some aspects, the recovery period is a duration sufficient for a subject to recover from adverse events or serious adverse events associated with a therapy.
[0167] As used herein, "effective treatment" refers to treatment producing a beneficial effect, e.g., amelioration of at least one symptom of a disease or disorder. A beneficial effect can take the form of an improvement over baseline, z.e., an improvement over a measurement or observation made prior to initiation of therapy according to the method. A beneficial effect can also take the form of arresting, slowing, retarding, or stabilizing of a deleterious progression of a marker of solid tumor. Effective treatment can refer to alleviation of at least one symptom of a solid tumor. Such effective treatment can, e.g., reduce patient pain, reduce the size and / or number of lesions, can reduce or prevent metastasis of a tumor, and / or can slow tumor growth.
[0168] The term "effective amount" refers to an amount of an agent that provides the desired biological, therapeutic, and / or prophylactic result. That result can be reduction, amelioration, palliation, lessening, delaying, and / or alleviation of one or more of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. In reference to solid tumors, an effective amount comprises an amount sufficient to cause a tumor to shrink and / or to decrease the growth rate of the tumor (such as to suppress tumor growth) or to delay other unwanted cell proliferation. In some aspects, an effective amount is an amount sufficient to prevent or delay tumor recurrence. An effective amount can be administered in one or more administrations. The effective amount of a drug or composition can: (i) reduce the number of cancer cells; (ii) reduce tumor size; (iii) inhibit, retard, slow to some extent and can stop cancercell infiltration into peripheral organs; (iv) inhibit ( / .<., slow to some extent and can stop tumor metastasis); (v) inhibit tumor growth; (vi) prevent or delay occurrence and / or recurrence of tumor; and / or (vii) relieve to some extent one or more of the symptoms associated with the cancer. In one example, an "effective amount" is the amount of a LAG-3 antagonist (e.g., an anti-LAG-3 antibody) alone or the amount of a LAG-3 antagonist (e.g., an anti-LAG-3 antibody) and the amount an additional therapeutic agent (e.g., a PD-1 pathway inhibitor such as an anti-PD-1 antibody), in combination, clinically proven to affect a significant decrease in cancer or slowing of progression of cancer, such as an advanced solid tumor.
[0169] As used herein, the term "dose" or "dosage" is defined as an amount of a therapeutic agent that can be administered at a given point. The dose or dosage can be an amount sufficient to achieve or at least partially achieve a desired effect, but such a desired effect may not be visible or detectable. A "dose" can comprise a single unit dose or multiple unit doses. In some aspects, the dose comprises a single unit dose. In some aspects, the dose comprises multiple unit doses.
[0170] As used herein, a subcutaneous "unit dose" refers to a single amount of a substance delivered by a subcutaneous administration, e.g, from a single vial, a single auto-injector, a single needle-free injector, a single pen injector, and / or a single syringe. In some aspects, multiple subcutaneous doses are administered to achieve a therapeutically effective dose. When multiple unit doses are administered, individual unit doses can be administered at the same time or sequentially. In some aspects, each unit dose of a therapeutically effective dose is administered on the same day. Each unit dose can be administered at the same bodily location or at different bodily locations. In some aspects, a first unit dose is administered at a first bodily location, and a second unit dose is administered at a second bodily location. Any bodily locations known in the art to be suitable for subcutaneous delivery can be used in the methods disclosed herein. In some aspects, at least one subcutaneous unit dose of the dose is administered to a bodily location selected from the arm (e.g, the side or back of an upper arm), the abdomen, and the front of the thigh.
[0171] As used herein, the terms "fixed dose," "flat dose," and "flat-fixed dose" are used interchangeably and refer to a dose that is administered to a patient without regard for the weight or body surface area (BSA) of the patient. The fixed or flat dose is therefore not provided as a mg / kg dose, but rather as an absolute amount of the agent (e.g., an amount in pg or mg).
[0172] The use of the term "fixed dose combination" with regard to a composition of the invention means that two or more different inhibitors as described herein (e.g., a LAG-3 antagonist such as an anti-LAG-3 antibody and a PD-1 pathway inhibitor such as an anti-PD-1 antibody) in a single composition are present in the composition in particular (fixed) ratios with each other. Insome aspects, the fixed dose is based on the weight (e.g., mg) of the inhibitors (e.g., a mg:mg ratio of the inhibitors). In some aspects, the fixed dose is based on the concentration (e.g., mg / ml) of the inhibitors e.g., a mg / mL:mg / mL ratio of the inhibitors). In some aspects, the ratio is at least about 1:1, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, about 1:15, about 1:20, about 1:30, about 1:40, about 1:50, about 1:60, about 1:70, about 1:80, about 1:90, about 1:100, about 1:120, about 1:140, about 1:160, about 1:180, about 1:200, about 200:1, about 180:1, about 160:1, about 140:1, about 120:1, about 100:1, about 90:1, about 80:1, about 70:1, about 60:1, about 50:1, about 40:1, about 30:1, about 20:1, about 15:1, about 10:1, about 9:1, about 8:1, about 7:1, about 6:1, about 5:1, about 4:1, about 3:1, about 2:1, about 3:4, about 3:2, about 2:3, or about 4:3 mg first inhibitor (e.g., an anti-PD-1 antibody) to mg second inhibitor (e.g., an anti -LAG-3 antibody) or mg / mL first inhibitor (e.g., an anti-PD-1 antibody) to mg / mL second inhibitor (e.g., an anti -LAG-3 antibody). For example, a 3:1 ratio of a first inhibitor and a second inhibitor can mean that a vial can contain about 240 mg of the first inhibitor and about 80 mg of the second inhibitor, about 480 mg of the first inhibitor and about 160 mg of the second inhibitor, about 360 mg of the first inhibitor and about 120 mg of the second inhibitor, about 960 mg of the first inhibitor and about 320 mg of the second inhibitor, or about 12 mg / ml of the first inhibitor and about 4 mg / ml of the second inhibitor. For example, a 1: 1 ratio of a first inhibitor and a second inhibitor can mean that a vial can contain about 960 mg of the first inhibitor and about 960 mg of the second inhibitor, about 720 mg of the first inhibitor and about 720 mg of the second inhibitor, about 480 mg of the first inhibitor and about 480 mg of the second inhibitor, about 360 mg of the first inhibitor and about 360 mg of the second inhibitor, about 80 mg / ml of the first inhibitor and about 80 mg / ml of the second inhibitor, about 75 mg / ml of the first inhibitor and about 75 mg / ml of the second inhibitor, about 72 mg / ml of the first inhibitor and about 72 mg / ml of the second inhibitor, about 64 mg / ml of the first inhibitor and about 64 mg / ml of the second inhibitor, about 60 mg / ml of the first inhibitor and about 60 mg / ml of the second inhibitor, about 52.5 mg / ml of the first inhibitor and about 52.5 mg / ml of the second inhibitor, or about 12 mg / ml of the first inhibitor and about 12 mg / ml of the second inhibitor. For example, a 3:4 ratio of a first inhibitor and a second inhibitor can mean that a vial can contain about 540 mg of the first inhibitor and about 720 mg of the second inhibitor, about 64.3 mg / ml of the first inhibitor and about 85.7 mg / ml of the second inhibitor, about 60 mg / ml of the first inhibitor and about 80 mg / ml of the second inhibitor, about 54 mg / ml of the first inhibitor and about 72 mg / ml of the second inhibitor, or about 45 mg / ml of the first inhibitor and about 60 mg / ml of the second inhibitor.
[0173] The term "weight based dose" as referred to herein means that a dose that is administered to a patient is calculated based on the weight of the patient.
[0174] " Dosing interval," as used herein, means the amount of time that elapses between multiple doses of a formulation disclosed herein being administered to a subject. Dosing interval can thus be indicated as ranges.
[0175] The term "dosing frequency" as used herein refers to the frequency of administering doses of a formulation disclosed herein in a given time. Dosing frequency can be indicated as the number of doses per a given time, e.g., once a week or once in two weeks, etc.
[0176] The terms "about once a week," "once about every week," "once about every two weeks," or any other similar dosing interval terms as used herein means approximate number, and "about once a week" or "once about every week" can include every seven days ± two days, i.e., every five days to every nine days. The dosing frequency of "about once a week" or "once about every week" thus can be every five days, every six days, every seven days, every eight days, or every nine days. " Once about every three weeks" can include every 21 days ± 3 days, i.e., every 25 days to every 31 days. Similar approximations apply, for example, to once about every two weeks, once about every four weeks, once about every five weeks, once about every six weeks, once about every seven weeks, once about every eight weeks, once about every nine weeks, once about every ten weeks, once about every eleven weeks, and once about every twelve weeks. In some aspects, a dosing interval of once about every six weeks or once about every twelve weeks means that the first dose can be administered any day in the first week, and then the next dose can be administered any day in the sixth or twelfth week, respectively. In some aspects, a dosing interval of once about every six weeks or once about every twelve weeks means that the first dose is administered on a particular day of the first week (e.g., Monday) and then the next dose is administered on the same day of the sixth or twelfth weeks (i.e., Monday), respectively.
[0177] An "adverse event" (AE) as used herein is any unfavorable and generally unintended or undesirable sign (including an abnormal laboratory finding), symptom, or disease associated with the use of a medical treatment. For example, an adverse event can be associated with activation of the immune system or expansion of immune system cells (e.g., T cells) in response to a treatment. A medical treatment can have one or more associated AEs and each AE can have the same or different level of severity.
[0178] A "cancer" refers a broad group of various diseases characterized by the uncontrolled growth of abnormal cells in the body. Unregulated cell division and growth divideand grow results in the formation of malignant tumors that invade neighboring tissues and can also metastasize to distant parts of the body through the lymphatic system or bloodstream.
[0179] The term "tumor" as used herein refers to any mass of tissue that results from excessive cell growth or proliferation, either benign (non-cancerous) or malignant (cancerous), including pre-cancerous lesions.
[0180] The term "hematological" as used herein can be used interchangeably with "hematologic," and a hematological cancer can be interchangeably referred to as a hematological malignancy.
[0181] The term "biological sample" as used herein refers to biological material isolated from a subject. The term "biological sample" can be used interchangeably with the term "sample" as referred to herein, such as, for example, in the phrase "a sample of the subject’s tumor." The biological sample can contain any biological material suitable for analysis, for example, by sequencing nucleic acids in the tumor (or circulating tumor cells) and identifying a genomic alteration in the sequenced nucleic acids. The biological sample can be any suitable biological tissue or fluid such as, for example, tumor tissue, blood, blood plasma, and serum. The biological sample can be a test tissue sample (e.g., a tissue sample comprising tumor cells and tumorinfiltrating inflammatory cells). In some aspects, the sample is a tumor tissue biopsy, e.g., a formalin-fixed, paraffin-embedded (FFPE) tumor tissue or a fresh-frozen tumor tissue or the like. In some aspects, the biological sample is a liquid biopsy that, in some aspects, comprises one or more of blood, serum, plasma, circulating tumor cells, exoRNA, ctDNA, and cfDNA.
[0182] By way of example, an "anti-cancer agent" promotes cancer regression in a subject. In some aspects, a therapeutically effective amount of the agent promotes cancer regression to the point of eliminating the cancer. " Promoting cancer regression" means that administering an effective amount of the anti-cancer agent, alone or in combination with another agent, results in a reduction in tumor growth or size, necrosis of the tumor, a decrease in severity of at least one disease symptom, an increase in frequency and duration of disease symptom-free periods, or a prevention of impairment or disability due to the disease affliction. In addition, the terms "effective" and "effectiveness" with regard to a treatment includes both pharmacological effectiveness and physiological safety. Pharmacological effectiveness refers to the ability of the agent to promote cancer regression in the patient. Physiological safety refers to the level of toxicity, or other adverse physiological effects at the cellular, organ and / or organism level (adverse effects) resulting from administration of the agent.
[0183] By way of example for the treatment of tumors, a therapeutically effective amount of an anti-cancer agent can inhibit cell growth or tumor growth by at least about 20%, at least about 40%, at least about 60%, or at least about 80% relative to untreated subjects. In some aspects, tumor regression can be observed and continue for a period of at least about 20 days, at least about 40 days, or at least about 60 days. Notwithstanding these measurements of therapeutic effectiveness, evaluation of immunotherapeutic drugs must also make allowance for immune-related response patterns.
[0184] As used herein, an "immuno-oncology" therapy or an " I-O" or " IO" therapy refers to a therapy that comprises utilizing an immune response to target and treat a tumor in a subject. As such, as used herein, an 1-0 therapy is a type of anti-cancer therapy. In some aspects, an 1-0 therapy comprises administering an antibody to a subject. In some aspects, an 1-0 therapy comprises administering to a subject an immune cell, e.g., a T cell, e.g., a modified T cell, e.g., a T cell modified to express a chimeric antigen receptor or a particular T cell receptor. In some aspects, the 1-0 therapy comprises administering a therapeutic vaccine to a subject. In some aspects, the 1-0 therapy comprises administering a cytokine or a chemokine to a subject. In some aspects, the 1-0 therapy comprises administering an interleukin to a subject. In some aspects, the 1-0 therapy comprises administering an interferon to a subject. In some aspects, the 1-0 therapy comprises administering a colony stimulating factor to a subject.
[0185] An "immune response" refers to the action of a cell of the immune system (for example, T lymphocytes, B lymphocytes, natural killer (NK) cells, macrophages, eosinophils, mast cells, dendritic cells and neutrophils) and soluble macromolecules produced by any of these cells or the liver (including antibodies, cytokines, and complement) that results in selective targeting, binding to, damage to, destruction of, and / or elimination from a vertebrate's body of invading pathogens, cells or tissues infected with pathogens, cancerous or other abnormal cells, or, in cases of autoimmunity or pathological inflammation, normal human cells or tissues.
[0186] A "tumor-infiltrating inflammatory cell" or "tumor-associated inflammatory cell" is any type of cell that typically participates in an inflammatory response in a subject and which infiltrates tumor tissue. Such cells include tumor-infiltrating lymphocytes (TILs), macrophages, monocytes, eosinophils, histiocytes and dendritic cells.
[0187] The term " FGL-1 positive" or " FGL-1 expression positive," relating to FGL-1 expression, refers to tumor tissue (e.g., a test tissue sample) that is scored as expressing FGL-1 based on the proportion (i.e., percentage) of tumor cells expressing FGL-1 (e.g., greater than or equal to 1% expression).
[0188] " FGL-1 negative" or " FGL-1 expression negative," refers to tumor tissue (e.g., a test tissue sample) that is not scored as expressing FGL-1 (e.g., less than 1% FGL-1 expression in tumor cells).
[0189] The term " LAG-3 positive" or " LAG-3 expression positive," relating to LAG-3 expression, refers to tumor tissue (e.g., a test tissue sample) that is scored as expressing LAG-3 based on the proportion (i.e., percentage) of immune cells (e.g., tumor-infiltrating lymphocytes such as CD8+ T cells) expressing LAG-3 (e.g., greater than or equal to 1% expression) or the proportion (i.e., percentage) of nucleated cells expressing LAG-3 (i.e., the immune cells that express LAG-3 as a proportion of total nucleated cells, e.g., greater than or equal to 1% expression).
[0190] " LAG-3 negative" or " LAG-3 expression negative," refers to tumor tissue (e.g., a test tissue sample) that is not scored as expressing LAG-3 (e.g., less than 1% LAG-3 expression in immune cells and / or nucleated cells).
[0191] The term " PD-1 positive" or " PD-1 expression positive," relating to cell surface PD-L1 expression, refers to tumor tissue (e.g., a test tissue sample) that is scored as expressing PD-L1 based on the tumor proportion score (TPS), which is the proportion (i.e., percentage) of tumor cells expressing PD-L1 (e.g., greater than or equal to 1% expression), or based on the combined positive score (CPS), which is the number of tumor and immune cells (e.g., tumor cells, lymphocytes, and macrophages) in the tumor tissue that express PD-L1 as a percentage of the total number of viable tumor cells (i.e., the number of tumor and immune cells expressing PD-L1 divided by the total number of viable tumor cells and multiplied by 100 (i.e., e.g., greater than or equal to 1%)), or based on the proportion (i.e., percentage) of nucleated cells expressing PD-L1 (i.e., the tumor cells that express PD-L1 as a proportion of total nucleated cells, e.g., greater than or equal to 1% expression).
[0192] " PD-1 negative" or " PD-1 expression negative," refers to tumor tissue (e.g., a test tissue sample) that is not scored as expressing PD-1 (e.g., less than 1% PD-1 expression).
[0193] The term " PD-L1 positive" or " PD-L1 expression positive," relating to cell surface PD-L1 expression, refers to tumor tissue (e.g., a test tissue sample) that is scored as expressing PD-L1 based on the proportion (i.e., percentage) of tumor cells expressing PD-L1 (e.g., greater than or equal to 1% expression) or the proportion (i.e., percentage) of nucleated cells expressing PD-L1 (i.e., the tumor cells that express PD-L1 as a proportion of total nucleated cells, e.g., greater than or equal to 1% expression).
[0194] The term " PD-L1 negative" or " PD-L1 expression negative" refers to tumor tissue (e.g., a test tissue sample) that is not scored as expressing PD-L1 (e.g., less than 1% expression).
[0195] Various aspects of the invention are described in further detail in the following subsections.II. Pharmaceutical Compositions
[0196] Provided herein is a pharmaceutical composition comprising about 100 mg / mL or more of a protein, a salt, and a sugar, wherein the pharmaceutical composition comprises an osmolality of less than about 600 mOsmol / kg, and wherein the pharmaceutical composition comprises a lower viscosity than a corresponding composition that lacks the salt and / or that comprises a higher concentration of the sugar. The term "corresponding composition" as used herein can be used interchangeably with the term "reference composition." Other than a lower concentration of the sugar and / or the addition of a salt, the pharmaceutical composition comprises the ingredients of the corresponding composition and contains the same concentrations of those ingredients unless otherwise disclosed herein. In some aspects, the osmolality is about 200 mOsmol / kg to less than about 600 mOsmol / kg, about 210 mOsmol / kg to less than about 600 mOsmol / kg, about 220 mOsmol / kg to less than about 600 mOsmol / kg, about 230 mOsmol / kg to less than about 600 mOsmol / kg, about 240 mOsmol / kg to less than about 600 mOsmol / kg, about 250 mOsmol / kg to less than about 600 mOsmol / kg, about 260 mOsmol / kg to less than about 600 mOsmol / kg, about 270 mOsmol / kg to less than about 600 mOsmol / kg, about 280 mOsmol / kg to less than about 600 mOsmol / kg, about 290 mOsmol / kg to less than about 600 mOsmol / kg, about 300 mOsmol / kg to less than about 600 mOsmol / kg, about 350 mOsmol / kg to less than about 600 mOsmol / kg, about 400 mOsmol / kg to less than about 600 mOsmol / kg, about 450 mOsmol / kg to less than about 600 mOsmol / kg, about 500 mOsmol / kg to less than about 600 mOsmol / kg, about 550 mOsmol / kg to less than about 600 mOsmol / kg, about 500 mOsmol / kg to about 550 mOsmol / kg, about 450 mOsmol / kg to about 550 mOsmol / kg, about 400 mOsmol / kg to about 550 mOsmol / kg, about 350 mOsmol / kg to about 550 mOsmol / kg, about 300 mOsmol / kg to about 550 mOsmol / kg, about 250 mOsmol / kg to about 550 mOsmol / kg, about 200 mOsmol / kg to about 550 mOsmol / kg, about 200 mOsmol / kg to about 500 mOsmol / kg, about 250 mOsmol / kg to about 500 mOsmol / kg, about 300 mOsmol / kg to about 500 mOsmol / kg, about 350 mOsmol / kg to about 500 mOsmol / kg, about 400 mOsmol / kg to about 500 mOsmol / kg, about 450 mOsmol / kg to about 500 mOsmol / kg, about 400 mOsmol / kg to about 450 mOsmol / kg, about 350 mOsmol / kg to about 450 mOsmol / kg, about 300 mOsmol / kg to about 450 mOsmol / kg, about 250 mOsmol / kg to about 450 mOsmol / kg, about 200 mOsmol / kg to about 450 mOsmol / kg, about 200 mOsmol / kg to about 400 mOsmol / kg, about 250 mOsmol / kg to about 400 mOsmol / kg, about 300 mOsmol / kg to about 400mOsmol / kg, about 350 mOsmol / kg to about 400 mOsmol / kg, about 300 mOsmol / kg to about 350 mOsmol / kg, about 250 mOsmol / kg to about 350 mOsmol / kg, about 200 mOsmol / kg to about 350 mOsmol / kg, about 200 mOsmol / kg to about 300 mOsmol / kg, or about 250 mOsmol / kg to about 300 mOsmol / kg. In some aspects, the osmolality is about 280 mOsmol / kg to less than about 600 mOsmol / kg.
[0197] Provided herein is a pharmaceutical composition comprising about 100 mg / mL or more of a protein, a salt, and a sugar, wherein the pharmaceutical composition comprises a lower viscosity than a corresponding composition that lacks the salt and that comprises a higher concentration of the sugar. In some aspects, the osmolality of the pharmaceutical composition is isotonic. In some aspects, the osmolality of the pharmaceutical composition is no greater than about 600 mOsmol / kg. In some aspects, the pharmaceutical composition comprises an osmolality of about 200 mOsmol / kg to about 600 mOsmol / kg, about 210 mOsmol / kg to about 600 mOsmol / kg, about 220 mOsmol / kg to about 600 mOsmol / kg, about 230 mOsmol / kg to about 600 mOsmol / kg, about 240 mOsmol / kg to about 600 mOsmol / kg, about 250 mOsmol / kg to about 600 mOsmol / kg, about 260 mOsmol / kg to about 600 mOsmol / kg, about 270 mOsmol / kg to about 600 mOsmol / kg, about 280 mOsmol / kg to about 600 mOsmol / kg, about 290 mOsmol / kg to about 600 mOsmol / kg, about 300 mOsmol / kg to about 600 mOsmol / kg, about 350 mOsmol / kg to about 600 mOsmol / kg, about 400 mOsmol / kg to about 600 mOsmol / kg, about 450 mOsmol / kg to about 600 mOsmol / kg, about 500 mOsmol / kg to about 600 mOsmol / kg, about 550 mOsmol / kg to about 600 mOsmol / kg, about 500 mOsmol / kg to about 550 mOsmol / kg, about 450 mOsmol / kg to about 550 mOsmol / kg, about 400 mOsmol / kg to about 550 mOsmol / kg, about 350 mOsmol / kg to about 550 mOsmol / kg, about 300 mOsmol / kg to about 550 mOsmol / kg, about 250 mOsmol / kg to about 550 mOsmol / kg, about 200 mOsmol / kg to about 550 mOsmol / kg, about 200 mOsmol / kg to about 500 mOsmol / kg, about 250 mOsmol / kg to about 500 mOsmol / kg, about 300 mOsmol / kg to about 500 mOsmol / kg, about 350 mOsmol / kg to about 500 mOsmol / kg, about 400 mOsmol / kg to about 500 mOsmol / kg, about 450 mOsmol / kg to about 500 mOsmol / kg, about 400 mOsmol / kg to about 450 mOsmol / kg, about 350 mOsmol / kg to about 450 mOsmol / kg, about 300 mOsmol / kg to about 450 mOsmol / kg, about 250 mOsmol / kg to about 450 mOsmol / kg, about 200 mOsmol / kg to about 450 mOsmol / kg, about 200 mOsmol / kg to about 400 mOsmol / kg, about 250 mOsmol / kg to about 400 mOsmol / kg, about 300 mOsmol / kg to about 400 mOsmol / kg, about 350 mOsmol / kg to about 400 mOsmol / kg, about 300 mOsmol / kg to about 350 mOsmol / kg, about 250 mOsmol / kg to about 350 mOsmol / kg, about 200 mOsmol / kg to about 350 mOsmol / kg, about 200 mOsmol / kg to about 300 mOsmol / kg,or about 250 mOsmol / kg to about 300 mOsmol / kg. In some aspects, the osmolality is about 280 mOsmol / kg to about 600 mOsmol / kg.
[0198] Provided herein is a pharmaceutical composition comprising: (a) about 100 mg / mL or more of a protein, (b) means for producing a lower viscosity of the pharmaceutical composition as compared to a corresponding composition comprising the same concentration of the protein, and (c) means for producing an osmolality of about 200 mOsmol / kg to about 600 mOsmol / kg of the pharmaceutical composition. In some aspects, the osmolality is about 210 mOsmol / kg to about 600 mOsmol / kg, about 220 mOsmol / kg to about 600 mOsmol / kg, about 230 mOsmol / kg to about 600 mOsmol / kg, about 240 mOsmol / kg to about 600 mOsmol / kg, about 250 mOsmol / kg to about 600 mOsmol / kg, about 260 mOsmol / kg to about 600 mOsmol / kg, about 270 mOsmol / kg to about 600 mOsmol / kg, about 280 mOsmol / kg to about 600 mOsmol / kg, about 290 mOsmol / kg to about 600 mOsmol / kg, about 300 mOsmol / kg to about 600 mOsmol / kg, about 350 mOsmol / kg to about 600 mOsmol / kg, about 400 mOsmol / kg to about 600 mOsmol / kg, about 450 mOsmol / kg to about 600 mOsmol / kg, about 500 mOsmol / kg to about 600 mOsmol / kg, about 550 mOsmol / kg to about 600 mOsmol / kg, about 500 mOsmol / kg to about 550 mOsmol / kg, about 450 mOsmol / kg to about 550 mOsmol / kg, about 400 mOsmol / kg to about 550 mOsmol / kg, about 350 mOsmol / kg to about 550 mOsmol / kg, about 300 mOsmol / kg to about 550 mOsmol / kg, about 250 mOsmol / kg to about 550 mOsmol / kg, about 200 mOsmol / kg to about 550 mOsmol / kg, about 200 mOsmol / kg to about 500 mOsmol / kg, about 250 mOsmol / kg to about 500 mOsmol / kg, about 300 mOsmol / kg to about 500 mOsmol / kg, about 350 mOsmol / kg to about 500 mOsmol / kg, about 400 mOsmol / kg to about 500 mOsmol / kg, about 450 mOsmol / kg to about 500 mOsmol / kg, about 400 mOsmol / kg to about 450 mOsmol / kg, about 350 mOsmol / kg to about 450 mOsmol / kg, about 300 mOsmol / kg to about 450 mOsmol / kg, about 250 mOsmol / kg to about 450 mOsmol / kg, about 200 mOsmol / kg to about 450 mOsmol / kg, about 200 mOsmol / kg to about 400 mOsmol / kg, about 250 mOsmol / kg to about 400 mOsmol / kg, about 300 mOsmol / kg to about 400 mOsmol / kg, about 350 mOsmol / kg to about 400 mOsmol / kg, about 300 mOsmol / kg to about 350 mOsmol / kg, about 250 mOsmol / kg to about 350 mOsmol / kg, about 200 mOsmol / kg to about 350 mOsmol / kg, about 200 mOsmol / kg to about 300 mOsmol / kg, or about 250 mOsmol / kg to about 300 mOsmol / kg. In some aspects, the osmolality is about 280 mOsmol / kg to about 600 mOsmol / kg.
[0199] In some aspects, the osmolality of a pharmaceutical composition as disclosed herein is about 200 mOsmol / kg, about 205 mOsmol / kg, about 210 mOsmol / kg, about 215 mOsmol / kg, about 220 mOsmol / kg, about 225 mOsmol / kg, about 230 mOsmol / kg, about 235 mOsmol / kg, about 240 mOsmol / kg, about 245 mOsmol / kg, about 250 mOsmol / kg, about 255 mOsmol / kg,about 260 mOsmol / kg, about 265 mOsmol / kg, about 270 mOsmol / kg, about 275 mOsmol / kg, about 280 mOsmol / kg, about 285 mOsmol / kg, about 290 mOsmol / kg, about 295 mOsmol / kg, about 300 mOsmol / kg, about 305 mOsmol / kg, about 310 mOsmol / kg, about 315 mOsmol / kg, about 320 mOsmol / kg, about 325 mOsmol / kg, about 330 mOsmol / kg, about 335 mOsmol / kg, about 340 mOsmol / kg, about 345 mOsmol / kg, about 350 mOsmol / kg, about 355 mOsmol / kg, about 360 mOsmol / kg, about 365 mOsmol / kg, about 370 mOsmol / kg, about 375 mOsmol / kg, about 380 mOsmol / kg, about 385 mOsmol / kg, about 390 mOsmol / kg, about 395 mOsmol / kg, about 400 mOsmol / kg, about 405 mOsmol / kg, about 410 mOsmol / kg, about 415 mOsmol / kg, about 420 mOsmol / kg, about 425 mOsmol / kg, about 430 mOsmol / kg, about 435 mOsmol / kg, about 440 mOsmol / kg, about 445 mOsmol / kg, about 450 mOsmol / kg, about 455 mOsmol / kg, about 460 mOsmol / kg, about 465 mOsmol / kg, about 470 mOsmol / kg, about 475 mOsmol / kg, about 480 mOsmol / kg, about 485 mOsmol / kg, about 490 mOsmol / kg, about 495 mOsmol / kg, about 500 mOsmol / kg, about 505 mOsmol / kg, about 510 mOsmol / kg, about 515 mOsmol / kg, about 520 mOsmol / kg, about 525 mOsmol / kg, about 530 mOsmol / kg, about 535 mOsmol / kg, about 540 mOsmol / kg, about 545 mOsmol / kg, about 550 mOsmol / kg, about 555 mOsmol / kg, about 560 mOsmol / kg, about 565 mOsmol / kg, about 570 mOsmol / kg, about 575 mOsmol / kg, about 580 mOsmol / kg, about 585 mOsmol / kg, about 590 mOsmol / kg, or about 595 mOsmol / kg.
[0200] In some aspects, the osmolality of a pharmaceutical composition as disclosed herein is determined by vapor-pressure osmometry (VPO, also known as vapor phase osmometry), freezing point osmometry (FPO, also known as cryoscopic osmometry), or direct membrane osmometry (DM0).
[0201] In some aspects, the osmolality of a pharmaceutical composition as disclosed herein is determined with a vapor pressure osmometer, a freezing point osmometer (also known as a cryoscopic osmometer), or a membrane osmometer.
[0202] In some aspects, the osmolality of a pharmaceutical composition as disclosed herein is determined by vapor-pressure osmometry.
[0203] In some aspects, the osmolality of a pharmaceutical composition as disclosed herein is determined with a vapor pressure osmometer.
[0204] In some aspects, the osmolality of a pharmaceutical composition as disclosed herein is determined at room temperature (e.g., the osmolality is determined by vapor-pressure osmometry with a vapor pressure osmometer at room temperature).
[0205] In some aspects, the viscosity of a pharmaceutical composition as disclosed herein is about 15 centipoise (cP) or less.
[0206] In some aspects, the viscosity of a pharmaceutical composition as disclosed herein is about 1 cP to about 15 cP, about 1 cP to about 14 cP, about 1 cP to about 13 cP, about 1 cP to about 12 cP, about 1 cP to about 11 cP, about 1 cP to about 10 cP, about 1 cP to about 9 cP, about 1 cP to about 8 cP, about 1 cP to about 7 cP, about 1 cP to about 6 cP, about 1 cP to about 5 cP, about 1 cP to about 4 cP, about 1 cP to about 3 cP, about 2 cP to about 15 cP, about 2 cP to about 14 cP, about 2 cP to about 13 cP, about 2 cP to about 12 cP, about 2 cP to about 11 cP, about 2 cP to about 10 cP, about 2 cP to about 9 cP, about 2 cP to about 8 cP, about 2 cP to about 7 cP, about 2 cP to about 6 cP, about 2 cP to about 5 cP, about 2 cP to about 4 cP, about 3 cP to about 15 cP, about 3 cP to about 14 cP, about 3 cP to about 13 cP, about 3 cP to about 12 cP, about 3 cP to about 11 cP, about 3 cP to about 10 cP, about 3 cP to about 9 cP, about 3 cP to about 8 cP, about 3 cP to about 7 cP, about 3 cP to about 6 cP, about 3 cP to about 5 cP, about 4 cP to about 15 cP, about 4 cP to about 14 cP, about 4 cP to about 13 cP, about 4 cP to about 12 cP, about 4 cP to about 11 cP, about 4 cP to about 10 cP, about 4 cP to about 9 cP, about 4 cP to about 8 cP, about 4 cP to about 7 cP, about 4 cP to about 6 cP, about 5 cP to about 15 cP, about 5 cP to about 14 cP, about 5 cP to about 13 cP, about 5 cP to about 12 cP, about 5 cP to about 11 cP, about 5 cP to about 10 cP, about 5 cP to about 9 cP, about 5 cP to about 8 cP, about 5 cP to about 7 cP, about 6 cP to about 15 cP, about 6 cP to about 14 cP, about 6 cP to about 13 cP, about 6 cP to about 12 cP, about 6 cP to about 11 cP, about 6 cP to about 10 cP, about 6 cP to about 9 cP, about 6 cP to about 8 cP, about 7 cP to about 15 cP, about 7 cP to about 14 cP, about 7 cP to about 13 cP, about 7 cP to about 12 cP, about 7 cP to about 11 cP, about 7 cP to about 10 cP, about 7 cP to about 9 cP, about 8 cP to about 15 cP, about 8 cP to about 14 cP, about 8 cP to about 13 cP, about 8 cP to about 12 cP, about 8 cP to about 11 cP, about 8 cP to about 10 cP, about 9 cP to about 15 cP, about 9 cP to about 14 cP, about 9 cP to about 13 cP, about 9 cP to about 12 cP, about 9 cP to about 11 cP, about 10 cP to about 15 cP, about 10 cP to about 14 cP, about 10 cP to about 13 cP, about 10 cP to about 12 cP, about 11 cP to about 15 cP, about 11 cP to about 14 cP, about 11 cP to about 13 cP, about 12 cP to about 15 cP, about 12 cP to about 14 cP, or about 13 cP to about 15 cP.
[0207] In some aspects, the viscosity of a pharmaceutical composition as disclosed herein is determined with a microfluidic viscometer.
[0208] In some aspects, the viscosity of a pharmaceutical composition as disclosed herein is determined at 20 °C (e.g., the viscosity is determined with a microfluidic viscometer at 20 °C).
[0209] In some aspects, a pharmaceutical composition as disclosed herein comprises a volume of about 0.001 mL to about 20 mL.
[0210] In some aspects, a pharmaceutical composition as disclosed herein comprises a volume of about 0.001 mL, about 0.005 mL, about 0.010 mL, about 0.015 mL, about 0.020 mL, about 0.025 mL, about 0.030 mL, about 0.035 mL, about 0.040 mL, about 0.045 mL, about 0.050 mL, about 0.055 mL, about 0.060 mL, about 0.065 mL, about 0.070 mL, about 0.075 mL, about 0.080 mL, about 0.085 mL, about 0.090 mL, about 0.095 mL, about 0.100 mL, about 0.150 mL, about 0.200 mL, about 0.250 mL, about 0.300 mL, about 0.350 mL, about 0.400 mL, about 0.450 mL, about 0.500 mL, about 0.550 mL, about 0.600 mL, about 0.650 mL, about 0.700 mL, about 0.750 mL, about 0.800 mL, about 0.850 mL, about 0.900 mL, about 0.950 mL, about 1 mL, about 1.1 mL, about 1.2 mL, about 1.3 mL, about 1.4 mL, about 1.5 mL, about 1.6 mL, about 1.7 mL, about 1.8 mL, about 1.9 mL, about 2 mL, about 2.1 mL, about 2.2 mL, about 2.3 mL, about 2.4 mL, about 2.5 mL, about 2.6 mL, about 2.7 mL, about 2.8 mL, about 2.9 mL, about 3 mL, about 3.1 mL, about 3.2 mL, about 3.3 mL, about 3.4 mL, about 3.5 mL, about 3.6 mL, about 3.7 mL, about 3.8 mL, about 3.9 mL, about 4 mL, about 4.1 mL, about 4.2 mL, about 4.3 mL, about 4.4 mL, about 4.5 mL, about 4.6 mL, about 4.7 mL, about 4.8 mL, about 4.9 mL, about 5 mL, about 5.1 mL, about 5.2 mL, about 5.3 mL, about 5.4 mL, about 5.5 mL, about 5.6 mL, about 5.7 mL, about 5.8 mL, about 5.9 mL, about 6 mL, about 6.1 mL, about 6.2 mL, about 6.3 mL, about 6.4 mL, about 6.5 mL, about 6.6 mL, about 6.7 mL, about 6.8 mL, about 6.9 mL, about 7 mL, about 7.1 mL, about 7.2 mL, about 7.3 mL, about 7.4 mL, about 7.5 mL, about 7.6 mL, about 7.7 mL, about 7.8 mL, about 7.9 mL, about 8 mL, about 8.1 mL, about 8.2 mL, about 8.3 mL, about 8.4 mL, about 8.5 mL, about 8.6 mL, about 8.7 mL, about 8.8 mL, about 8.9 mL, about 9 mL, about 9.1 mL, about 9.2 mL, about 9.3 mL, about 9.4 mL, about 9.5 mL, about 9.6 mL, about 9.7 mL, about 9.8 mL, about 9.9 mL, about 10 mL, about 10.1 mL, about 10.2 mL, about 10.3 mL, about 10.4 mL, about 10.5 mL, about 10.6 mL, about 10.7 mL, about 10.8 mL, about 10.9 mL, about 11 mL, about 11.1 mL, about 11.2 mL, about 11.3 mL, about 11.4 mL, about 11.5 mL, about 11.6 mL, about 11.7 mL, about 11.8 mL, about 11.9 mL, about 12 mL, about 12.1 mL, about 12.2 mL, about 12.3 mL, about 12.4 mL, about 12.5 mL, about 12.6 mL, about 12.7 mL, about 12.8 mL, about 12.9 mL, about 13 mL, about 13.1 mL, about 13.2 mL, about 13.3 mL, about 13.4 mL, about 13.5 mL, about 13.6 mL, about 13.7 mL, about 13.8 mL, about 13.9 mL, about 14 mL, about 14.1 mL, about 14.2 mL, about 14.3 mL, about 14.4 mL, about 14.5 mL, about 14.6 mL, about 14.7 mL, about 14.8 mL, about 14.9 mL, about 15 mL, about 15.1 mL, about 15.2 mL, about 15.3 mL, about 15.4 mL, about 15.5 mL, about 15.6 mL, about 15.7 mL, about 15.8 mL, about 15.9 mL, about 16 mL, about 16.1 mL, about 16.2 mL, about 16.3 mL, about 16.4 mL, about 16.5 mL, about 16.6 mL, about 16.7 mL, about 16.8 mL, about 16.9 mL, about 17 mL, about 17.1 mL, about 17.2mL, about 17.3 mL, about 17.4 mL, about 17.5 mL, about 17.6 mL, about 17.7 mL, about 17.8 mL, about 17.9 mL, about 18 mL, about 18.1 mL, about 18.2 mL, about 18.3 mL, about 18.4 mL, about 18.5 mL, about 18.6 mL, about 18.7 mL, about 18.8 mL, about 18.9 mL, about 19 mL, about 19.1 mL, about 19.2 mL, about 19.3 mL, about 19.4 mL, about 19.5 mL, about 19.6 mL, about 19.7 mL, about 19.8 mL, about 19.9 mL, or about 20 mL.
[0211] In some aspects, a pharmaceutical composition as disclosed herein comprises a volume of about 8.4 mL, about 9 mL, about 9.6 mL, about 10 mL, about 12 mL, about 12.8 mL, about 15 mL, or about 16 mL.
[0212] In some aspects, a pharmaceutical composition as disclosed herein is suitable for intravitreal, intravenous, intramuscular, and / or subcutaneous administration.
[0213] In some aspects, a pharmaceutical composition as disclosed herein is suitable for subcutaneous administration.
[0214] In some aspects, a pharmaceutical composition as disclosed herein is capable of being injected within about 10 minutes or less.
[0215] In some aspects, a pharmaceutical composition as disclosed herein is capable of being injected within about 5 minutes to about 7 minutes.
[0216] In some aspects, pharmaceutical composition as disclosed herein is capable of being injected within about 3 minutes to about 5 minutes.ILA. Salts
[0217] In some aspects, a pharmaceutical composition as disclosed herein comprises about 10 mM to about 400 mM, about 10 mM to about 350 mM, about 10 mM to about 300 mM, about 10 mM to about 250 mM, about 10 mM to about 200 mM, about 10 mM to about 150 mM, about 10 mM to about 100 mM, about 10 mM to about 90 mM, about 10 mM to about 80 mM, about 10 mM to about 70 mM, about 10 mM to about 60 mM, about 10 mM to about 50 mM, about 30 mM to about 400 mM, about 30 mM to about 350 mM, about 30 mM to about 300 mM, about 30 mM to about 250 mM, about 30 mM to about 200 mM, about 30 mM to about 150 mM, about 30 mM to about 100 mM, about 30 mM to about 90 mM, about 30 mM to about 80 mM, about 30 mM to about 70 mM, about 30 mM to about 60 mM, about 30 mM to about 50 mM, about 50 mM to about 400 mM, about 50 mM to about 350 mM, about 50 mM to about 300 mM, about 50 mM to about 250 mM, about 50 mM to about 200 mM, about 50 mM to about 150 mM, about 50 mM to about 100 mM, about 100 mM to about 400 mM, about 100 mM to about 350 mM, about 100 mM toabout 300 mM, about 100 mM to about 250 mM, about 100 mM to about 200 mM, or about 100 mM to about 150 mM of the salt.
[0218] In some aspects, a pharmaceutical composition as disclosed herein comprises about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 21 mM, about 22 mM, about 23 mM, about 24 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM, about 60 mM, about 70 mM, about 80 mM, about 90 mM, about 100 mM, about 110 mM, about 120 mM, about 130 mM, about 140 mM, about 150 mM, about 160 mM, about 170 mM, about 180 mM, about 190 mM, about 200 mM, about 210 mM, about 220 mM, about 230 mM, about 240 mM, about 250 mM, about 260 mM, about 270 mM, about 280 mM, about 290 mM, about 300 mM, about 310 mM, about 320 mM, about 330 mM, about 340 mM, about 350 mM, about 360 mM, about 370 mM, about 380 mM, about 390 mM, or about 400 mM of the salt.
[0219] In some aspects, a pharmaceutical composition as disclosed herein comprises sodium chloride, arginine hydrochloride, histidine hydrochloride, lysine hydrochloride, magnesium chloride, potassium chloride, ammonium chloride, calcium chloride, sodium acetate, zinc chloride, ammonium thiocyanate, sodium thiocyanate, sodium sulfate, ammonium sulfate, sodium phosphate, sodium biphosphate, potassium phosphate, dipotassium hydrogen phosphate, monobasic potassium phosphate, calcium phosphate, tris(hydroxymethyl)aminomethane, or a combination thereof.
[0220] In some aspects, the salt in a pharmaceutical composition as disclosed herein comprises sodium chloride.
[0221] In some aspects, the salt in a pharmaceutical composition as disclosed herein comprises arginine hydrochloride.
[0222] In some aspects, the salt in a pharmaceutical composition as disclosed herein comprises sodium chloride and arginine hydrochloride.II. B. Sugars
[0223] In some aspects, a pharmaceutical composition as disclosed herein comprises about 500 mM or less, about 475 mM or less, about 450 mM or less, about 425 mM or less, about 400 mM or less, about 375 mM or less, about 350 mM or less, about 325 mM or less, about 300 mM or less, about 275 mM or less, about 250 mM or less, about 225 mM or less, about 200 mM or less, about 175 mM or less, about 150 mM or less, about 125 mM or less, about 100 mM or less, or about 75 mM or less of the sugar.
[0224] In some aspects, a pharmaceutical composition as disclosed herein comprises about 1 mM to about 500 mM, about 1 mM to about 475 mM, about 1 mM to about 450 mM, about 1 mM to about 425 mM, about 1 mM to about 400 mM, about 1 mM to about 375 mM, about 1 mM to about 350 mM, about 1 mM to about 325 mM, about 1 mM to about 300 mM, about 1 mM to about 275 mM, about 1 mM to about 250 mM, about 1 mM to about 225 mM, about 1 mM to about 200 mM, about 1 mM to about 175 mM, about 1 mM to about 150 mM, about 1 mM to about 125 mM, about 1 mM to about 100 mM, or about 1 mM to about 75 mM of the sugar.
[0225] In some aspects, a pharmaceutical composition as disclosed herein comprises about 1 mM, about 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 21 mM, about 22 mM, about 23 mM, about 24 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM, about 60 mM, about 70 mM, about 80 mM, about 90 mM, about 100 mM, about 110 mM, about 120 mM, about 130 mM, about 140 mM, about 150 mM, about 160 mM, about 170 mM, about 180 mM, about 190 mM, about 200 mM, about 210 mM, about 220 mM, about 230 mM, about 240 mM, about 250 mM, about 260 mM, about 270 mM, about 280 mM, about 290 mM, about 300 mM, about 310 mM, about 320 mM, about 330 mM, about 340 mM, about 350 mM, about 360 mM, about 370 mM, about 380 mM, about 390 mM, about 400 mM, about 410 mM, about 420 mM, about 430 mM, about 440 mM, about 450 mM, about 460 mM, about 470 mM, about 480 mM, about 490 mM, or about 500 mM of the sugar.
[0226] In some aspects, the sugar in a pharmaceutical composition as disclosed herein comprises a monosaccharide, a disaccharide, a polysaccharide, a polyol, or a combination thereof.
[0227] In some aspects, the sugar in a pharmaceutical composition as disclosed herein comprises glucose, xylose, erythritol, sucrose, trehalose, maltose, galactose, dextrose, raffinose, stachyose, lactose, mannitol, sorbitol, xylitol, lactitol, maltitol, glycerol, or a combination thereof.
[0228] In some aspects, the sugar in a pharmaceutical composition as disclosed herein comprises sucrose.
[0229] In some aspects, the sugar in a pharmaceutical composition as disclosed herein comprises trehalose.II. C. Proteins
[0230] In some aspects, a pharmaceutical composition as disclosed herein comprises about 100 mg / mL to about 500 mg / mL, about 100 mg / mL to about 450 mg / mL, about 100 mg / mL toabout 400 mg / mL, about 100 mg / mL to about 350 mg / mL, about 100 mg / mL to about 300 mg / mL, about 100 mg / mL to about 250 mg / mL, about 100 mg / mL to about 200 mg / mL, about 100 mg / mL to about 150 mg / mL, about 100 mg / mL to about 140 mg / mL, about 100 mg / mL to about 130 mg / mL, about 100 mg / mL to about 120 mg / mL, about 100 mg / mL to about 115 mg / mL, about 100 mg / mL to about 110 mg / mL, about 100 mg / mL to about 105 mg / mL, about 110 mg / mL to about 500 mg / mL, about 110 mg / mL to about 450 mg / mL, about 110 mg / mL to about 400 mg / mL, about 110 mg / mL to about 350 mg / mL, about 110 mg / mL to about 300 mg / mL, about 110 mg / mL to about 250 mg / mL, about 110 mg / mL to about 200 mg / mL, about 110 mg / mL to about 150 mg / mL, about 110 mg / mL to about 140 mg / mL, about 110 mg / mL to about 130 mg / mL, about 110 mg / mL to about 120 mg / mL, about 110 mg / mL to about 115 mg / mL, about 115 mg / mL to about 500 mg / mL, about 115 mg / mL to about 450 mg / mL, about 115 mg / mL to about 400 mg / mL, about 115 mg / mL to about 350 mg / mL, about 115 mg / mL to about 300 mg / mL, about 115 mg / mL to about 250 mg / mL, about 115 mg / mL to about 200 mg / mL, about 115 mg / mL to about 150 mg / mL, about 115 mg / mL to about 140 mg / mL, about 115 mg / mL to about 130 mg / mL, about 115 mg / mL to about 120 mg / mL, about 120 mg / mL to about 450 mg / mL, about 120 mg / mL to about 400 mg / mL, about 120 mg / mL to about 350 mg / mL, about 120 mg / mL to about 300 mg / mL, about 120 mg / mL to about 250 mg / mL, about 120 mg / mL to about 200 mg / mL, about 120 mg / mL to about 150 mg / mL, about 120 mg / mL to about 140 mg / mL, about 120 mg / mL to about 130 mg / mL, about 150 mg / mL to about 500 mg / mL, about 150 mg / mL to about 450 mg / mL, about 150 mg / mL to about 400 mg / mL, about 150 mg / mL to about 350 mg / mL, about 150 mg / mL to about 300 mg / mL, about 150 mg / mL to about 250 mg / mL, or about 150 mg / mL to about 200 mg / mL of the protein.
[0231] In some aspects, a pharmaceutical composition as disclosed herein comprises about 100 mg / mL, about 101 mg / mL, about 102 mg / mL, about 103 mg / mL, about 104 mg / mL, about 105 mg / mL, about 106 mg / mL, about 107 mg / mL, about 108 mg / mL, about 109 mg / mL, about 110 mg / mL, about 111 mg / mL, about 112 mg / mL, about 113 mg / mL, about 114 mg / mL, about 115 mg / mL, about 116 mg / mL, about 117 mg / mL, about 118 mg / mL, about 119 mg / mL, about 120 mg / mL, about 121 mg / mL, about 122 mg / mL, about 123 mg / mL, about 124 mg / mL, about 125 mg / mL, about 126 mg / mL, about 127 mg / mL, about 128 mg / mL, about 129 mg / mL, about 130 mg / mL, about 131 mg / mL, about 132 mg / mL, about 133 mg / mL, about 134 mg / mL, about 135 mg / mL, about 136 mg / mL, about 137 mg / mL, about 138 mg / mL, about 139 mg / mL, about 140 mg / mL, about 141 mg / mL, about 142 mg / mL, about 143 mg / mL, about 144 mg / mL, about 145 mg / mL, about 146 mg / mL, about 147 mg / mL, about 148 mg / mL, about 149 mg / mL, about 150 mg / mL, about 155 mg / mL, about 160 mg / mL, about 165 mg / mL, about 170 mg / mL, about175 mg / mL, about 180 mg / mL, about 185 mg / mL, about 190 mg / mL, about 195 mg / mL, about 200 mg / mL, about 205 mg / mL, about 210 mg / mL, about 215 mg / mL, about 220 mg / mL, about 225 mg / mL, about 230 mg / mL, about 235 mg / mL, about 240 mg / mL, about 245 mg / mL, about 250 mg / mL, about 255 mg / mL, about 260 mg / mL, about 265 mg / mL, about 270 mg / mL, about 275 mg / mL, about 280 mg / mL, about 285 mg / mL, about 290 mg / mL, about 295 mg / mL, about 300 mg / mL, about 305 mg / mL, about 310 mg / mL, about 315 mg / mL, about 320 mg / mL, about 325 mg / mL, about 330 mg / mL, about 335 mg / mL, about 340 mg / mL, about 345 mg / mL, about 350 mg / mL, about 355 mg / mL, about 360 mg / mL, about 365 mg / mL, about 370 mg / mL, about 375 mg / mL, about 380 mg / mL, about 385 mg / mL, about 390 mg / mL, about 395 mg / mL, about 400 mg / mL, about 405 mg / mL, about 410 mg / mL, about 415 mg / mL, about 420 mg / mL, about 425 mg / mL, about 430 mg / mL, about 435 mg / mL, about 440 mg / mL, about 445 mg / mL, about 450 mg / mL, about 455 mg / mL, about 460 mg / mL, about 465 mg / mL, about 470 mg / mL, about 475 mg / mL, about 480 mg / mL, about 485 mg / mL, about 490 mg / mL, about 495 mg / mL, or about 500 mg / mL of the protein.
[0232] In some aspects, a pharmaceutical composition as disclosed herein comprises about 105 mg / mL, about 120 mg / mL, about 126 mg / mL, about 128 mg / mL, about 140 mg / mL, about 144 mg / mL, about 150 mg / mL, or about 160 mg / mL of the protein.
[0233] In some aspects, a pharmaceutical composition as disclosed herein comprises about 0.25 mg to about 4000 mg, about 0.25 mg to about 3600 mg, about 0.25 mg to about 3200 mg, about 0.25 mg to about 3000 mg, about 0.25 mg to about 2600 mg, about 0.25 mg to about 2200 mg, about 0.25 mg to about 2000 mg, about 0.25 mg to about 1600 mg, about 0.25 mg to about 1200 mg, about 0.25 mg to about 1000 mg, about 0.25 mg to about 800 mg, about 0.25 mg to about 600 mg, about 0.25 mg to about 400 mg, about 0.25 mg to about 200 mg, about 0.25 mg to about 100 mg, about 0.25 mg to about 50 mg, about 0.25 mg to about 40 mg, about 0.25 mg to about 30 mg, about 0.25 mg to about 20 mg, about 20 mg to about 4000 mg, about 20 mg to about 3600 mg, about 20 mg to about 3200 mg, about 20 mg to about 3000 mg, about 20 mg to about 2600 mg, about 20 mg to about 2200 mg, about 20 mg to about 2000 mg, about 20 mg to about 1600 mg, about 20 mg to about 1200 mg, about 20 mg to about 1000 mg, about 20 mg to about 800 mg, about 20 mg to about 600 mg, about 20 mg to about 400 mg, about 20 mg to about 200 mg, about 20 mg to about 100 mg, about 100 mg to about 4000 mg, about 100 mg to about 3600 mg, about 100 mg to about 3200 mg, about 100 mg to about 3000 mg, about 100 mg to about 2600 mg, about 100 mg to about 2200 mg, about 100 mg to about 2000 mg, about 100 mg to about 1800 mg, about 100 mg to about 1600 mg, about 100 mg to about 1400 mg, about 100 mg to about 1200 mg, about100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, about 400 mg to about 4000 mg, about 400 mg to about 3600 mg, about 400 mg to about 3200 mg, about 400 mg to about 3000 mg, about 400 mg to about 2600 mg, about 400 mg to about 2200 mg, about 400 mg to about 2000 mg, about 400 mg to about 1800 mg, about 400 mg to about 1600 mg, about 400 mg to about 1400 mg, about 400 mg to about 1200 mg, or about 400 mg to about 1000 mg of the protein.
[0234] In some aspects, a pharmaceutical composition as disclosed herein comprises about 0.25 mg, about 0.5 mg, about 0.75 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3 mg, about 3.25 mg, about 3.5 mg, about 3.75 mg, about 4 mg, about 4.25 mg, about 4.5 mg, about 4.75 mg, about 5 mg, about 5.25 mg, about 5.5 mg, about 5.75 mg, about 6 mg, about 6.25 mg, about 6.5 mg, about 6.75 mg, about 7 mg, about 7.25 mg, about 7.5 mg, about 7.75 mg, about 8 mg, about 8.25 mg, about 8.5 mg, about 8.75 mg, about 9 mg, about 9.25 mg, about 9.5 mg, about 9.75 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, about 710 mg, about 720 mg, about 730 mg, about 740 mg, about 750 mg, about 760 mg, about 770 mg, about 780 mg, about 790 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 980 mg, about 990 mg, about 1000 mg, about 1020 mg, about 1040 mg, about 1060 mg, about 1080 mg, about 1100 mg, about 1120 mg, about 1140 mg, about 1160 mg, about 1180 mg, about 1200 mg, about 1220 mg, about 1240 mg, about 1260 mg, about 1280 mg, about 1300 mg, about 1320 mg, about 1340 mg, about 1360 mg, about 1380 mg, about 1400 mg, about 1420 mg, about 1440 mg, about 1460 mg, about 1480 mg, about 1500 mg, about 1520 mg, about1540 mg, about 1560 mg, about 1580 mg, about 1600 mg, about 1620 mg, about 1640 mg, about 1660 mg, about 1680 mg, about 1700 mg, about 1720 mg, about 1740 mg, about 1760 mg, about 1780 mg, about 1800 mg, about 1820 mg, about 1840 mg, about 1860 mg, about 1880 mg, about 1900 mg, about 1920 mg, about 1940 mg, about 1960 mg, about 1980 mg, about 2000 mg, about 2020 mg, about 2040 mg, about 2060 mg, about 2080 mg, about 2100 mg, about 2120 mg, about 2140 mg, about 2160 mg, about 2180 mg, about 2200 mg, about 2220 mg, about 2240 mg, about 2260 mg, about 2280 mg, about 2300 mg, about 2320 mg, about 2340 mg, about 2360 mg, about 2380 mg, about 2400 mg, about 2420 mg, about 2440 mg, about 2460 mg, about 2480 mg, about 2500 mg, about 2520 mg, about 2540 mg, about 2560 mg, about 2580 mg, about 2600 mg, about 2620 mg, about 2640 mg, about 2660 mg, about 2680 mg, about 2700 mg, about 2720 mg, about 2740 mg, about 2760 mg, about 2780 mg, about 2800 mg, about 2820 mg, about 2840 mg, about 2860 mg, about 2880 mg, about 2900 mg, about 2920 mg, about 2940 mg, about 2960 mg, about 2980 mg, about 3000 mg, about 3020 mg, about 3040 mg, about 3060 mg, about 3080 mg, about 3100 mg, about 3120 mg, about 3140 mg, about 3160 mg, about 3180 mg, about 3200 mg, about 3220 mg, about 3240 mg, about 3260 mg, about 3280 mg, about 3300 mg, about 3320 mg, about 3340 mg, about 3360 mg, about 3380 mg, about 3400 mg, about 3420 mg, about 3440 mg, about 3460 mg, about 3480 mg, about 3500 mg, about 3520 mg, about 3540 mg, about 3560 mg, about 3580 mg, about 3600 mg, about 3620 mg, about 3640 mg, about 3660 mg, about 3680 mg, about 3700 mg, about 3720 mg, about 3740 mg, about 3760 mg, about 3780 mg, about 3800 mg, about 3820 mg, about 3840 mg, about 3860 mg, about 3880 mg, about 3900 mg, about 3920 mg, about 3940 mg, about 3960 mg, about 3980 mg, or about 4000 mg of the protein.
[0235] In some aspects, a pharmaceutical composition as disclosed herein comprises about 1260 mg, about 1440 mg, or about 1920 mg of the protein.
[0236] In some aspects, a pharmaceutical composition as disclosed herein comprises about 100 mg / mL to about 150 mg / mL of the protein, about 200 mM or less of the salt, and about 250 mM or less of the sugar. In some aspects, the sugar is sucrose and the salt is sodium chloride.
[0237] In some aspects, the protein in a pharmaceutical composition as disclosed herein comprises an antibody, a checkpoint inhibitor, a fusion protein, a growth factor, a hormone, an enzyme, a cytokine, a coagulation factor, a plasma protein, or a combination thereof.
[0238] In some aspects, the protein in a pharmaceutical composition as disclosed herein comprises an antibody. In some aspects, the antibody comprises a full-length antibody. In some aspects, the antibody comprises a monoclonal, human, humanized, chimeric, or multispecific antibody. In some aspects, the multispecific antibody comprises a dual-affinity re-targetingantibody, a dual variable domain immunoglobulin, or a bispecific antibody. In some aspects, the antibody comprises a F(ab')2 fragment, a Fab' fragment, a Fab fragment, a Fv fragment, a scFv fragment, a dsFv fragment, a dAb fragment, or a single chain binding polypeptide. In some aspects, the antibody comprises an anti -lymphocyte activation gene-3 (LAG-3) antibody, an antiprogrammed death- 1 (PD-1) antibody, an anti-programmed death-ligand 1 (PD-L1) antibody, an anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, an anti-T cell immunoglobulin and mucin-domain containing-3 (TIM-3) antibody, an anti-TIM-1 antibody, an anti-TIM-4 antibody, an anti-T cell immunoglobulin and ITIM domain (TIGIT) antibody, an antinatural killer G2a (NKG2a) antibody, an anti-OX40 antibody, an anti-inducible T-cell costimulator (ICOS) antibody, an anti-MHC class I polypeptide-related sequence A (MICA) antibody, an anti-CD137 antibody, an anti-killer-cell immunoglobulin-like receptor (KIR) antibody, an anti-transforming growth factor beta (TGFP) antibody, an anti-interleukin 10 (IL-10) antibody, an anti-IL-8 antibody, an anti-B7 homolog 4 (B7-H4) antibody, an anti-Fas ligand antibody, an anti-C-X-C chemokine receptor type 4 (CXCR4) antibody, an anti-mesothelin antibody, an anti-CD27 antibody, an anti-glucocorticoid-induced TNFR-related protein (GITR) antibody, an anti-chemokine (C-C motif) receptor 8 (CCR8) antibody, an anti-immunoglobulin-like transcript 4 (ILT4) antibody, an anti-CD73 antibody, an anti-glypican-3 (GPC3) antibody, an anti-CD38 antibody, an anti-CD47 antibody, an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) antibody, an anti-human epidermal growth factor receptor 2 (HER2) antibody, an antigasdermin (GSDM) antibody, an anti-GSDMA antibody, an anti-GSDMB antibody, an antistimulator of interferon genes (STING) antibody, an anti-cell division cycle protein 20 (CDC20) antibody, an anti-trophoblast cell-surface antigen 2 (TROP2) antibody, an anti-proprotein convertase subtilisin / kexin type 9 (PCSK9) antibody, an anti -leucocyte immunoglobulin like receptor Bl (LILRB1) antibody, an anti-cyclin-dependent kinases (CDK1) antibody, an anti-CDK4 / 6 antibody, an anti-nectin-4 antibody, an anti-a-enolase 1 (ENO1) antibody, an anti-hematopoietic progenitor kinase (HPK) antibody, an anti-TANK -binding kinase 1 (TBK1) antibody, an anti -j anus kinase (JAK) antibody, an anti-pyruvate kinase M2 (PKM2) antibody, an anti-KRAS antibody, an anti-toll-like receptor (TLR) antibody, an anti-mammalian target of rapamycin (mTOR) antibody, an anti-cyclooxygenase-2 (COX-2) antibody, an anti-adenosine A2a receptor (A2aR) antibody, an anti-B7 homolog 3 (B7-H3) antibody, an anti-B and T cell lymphocyte attenuator (BTLA) antibody, an anti-V-domain Ig suppressor of T cell activation (VISTA) antibody, an anti-indoleamine 2, 3 -dioxygenase (IDO) antibody, an IDO-1 antibody, an anti -tryptophan 2,3 -dioxygenase (TDO) antibody, an anti -nicotinamide adenine dinucleotidephosphate oxidase isoform 2 (NOX-2) antibody, an anti-phosphoinositide 3-kinase (PI3K) antibody, an anti-CD48 antibody, an anti-CD113 antibody, an anti-sialic acid-binding immunoglobulin-like lectin-7 (SIGLEC-7) antibody, an anti-SIGLEC-9 antibody, an anti-SIGLEC-15 antibody, an anti-galectin-1 antibody, an anti-galectin-9 antibody, an anti-carcinoembryonic antigen-related cell adhesion molecule- 1 (CEACAM-1) antibody, an anti-G protein-coupled receptor 56 (GPR56) antibody, an anti-glycoprotein A repetitions predominant (GARP) antibody, an anti-2B4 antibody, an anti-programmed death-1 homolog (PD1H) antibody, an anti-leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) antibody, or a combination thereof.
[0239] In some aspects, the protein in a pharmaceutical composition as disclosed herein comprises a checkpoint inhibitor. In some aspects, the checkpoint inhibitor comprises a LAG-3 antagonist, a PD-1 pathway inhibitor, a CTLA-4 inhibitor, a TIGIT inhibitor, a TIM-3 inhibitor, a TIM-1 inhibitor, a TIM-4 inhibitor, a B7-H3 inhibitor, a B7-H4 inhibitor, a BTLA inhibitor, a VISTA inhibitor, an IDO inhibitor (e.g., an IDO1 inhibitor, epacadostat (INCB24360), navoximod (GDC-0919), or linrodostat (BMS-986205), including a linrodostat salt such as, for example, linrodostat mesylate), a N0X2 inhibitor, a KIR inhibitor, an A2aR inhibitor, a TGF-P inhibitor, PI3K inhibitor, a CD47 inhibitor, a CD48 inhibitor, a CD73 inhibitor, a CD113 inhibitor, a SIGLEC-7 inhibitor, a SIGLEC-9 inhibitor, a SIGLEC-15 inhibitor, a GITR inhibitor, a galectin-1 inhibitor, a galectin-9 inhibitor, a CEACAM-1 inhibitor, a GPR56 inhibitor, a GARP inhibitor, a 2B4 inhibitor, a PD1H inhibitor, a LAIR1 inhibitor, or any combination thereof.
[0240] In some aspects, the antibody comprises two antibodies (e.g., an anti -LAG-3 antibody and an anti-PD-1 or anti-PD-Ll antibody).II. C.l. Anti-LAG-3 Antibodies and Other LAG-3 Antagonists
[0241] A LAG-3 antagonist for use in the compositions and methods as disclosed herein includes, but is not limited to, LAG-3 binding agents and soluble LAG-3 polypeptides. LAG-3 binding agents include antibodies that specifically bind to LAG-3 (z.e., an "anti-LAG-3 antibody"). The term " LAG-3 antagonist" as used herein is interchangeable with the term " LAG-3 inhibitor."
[0242] An exemplary LAG-3 antibody useful in the present disclosure is 25F7 (described in U. S. Publ. No. 2011 / 0150892). An additional exemplary LAG-3 antibody useful in the present disclosure is BMS-986016 (relatlimab). In some aspects, an anti-LAG-3 antibody useful in the present disclosure cross-competes with 25F7 or BMS-986016. In some aspects, an anti-LAG-3antibody useful in the present disclosure binds to the same epitope as 25F7 or BMS-986016. In some aspects, an anti-LAG-3 antibody comprises six CDRs of 25F7 or BMS-986016.
[0243] Other art-recognized anti-LAG-3 antibodies that can be used in the compositions and / or methods of the disclosure include IMP731 (H5L7BW) described in US 2011 / 007023, MK-4280 (28G-10, favezelimab) described in WO2016028672 and U. S. Publication No.2020 / 0055938, REGN3767 (fianlimab) described in Burova E, et al., J. Immunother. Cancer (2016); 4(Supp. 1): P195 and U. S. Patent No. 10,358,495, humanized BAP050 described in WO2017 / 019894, GSK2831781, IMP-701 (LAG525; ieramilimab) described in U. S. Patent No.10,711,060 and U. S. Publ. No. 2020 / 0172617, aLAG3(0414), aLAG3(0416), Sym022, TSR-033, TSR-075, XmAb841 (previously XmAb22841), MGD013 (tebotelimab), BI754111, FS118, P 13B02-30, AVA-017, AGEN1746, RO7247669, INCAGN02385, IBL110, EMB-02, IBI-323, LBL-007, and ABL501. These and other anti-LAG-3 antibodies useful in the claimed invention can be found in, for example: US 10,188,730, WO 2016 / 028672, WO 2017 / 106129, WO2017 / 062888, W02009 / 044273, WO2018 / 069500, WO2016 / 126858, WO2014 / 179664, WO2016 / 200782, WO2015 / 200119, WO2017 / 019846, WO2017 / 198741, WO2017 / 220555, WO2017 / 220569, WO2018 / 071500, W02017 / 015560, WO2017 / 025498, WO2017 / 087589, WO2017 / 087901, W02018 / 083087, WO2017 / 149143, WO2017 / 219995, US2017 / 0260271, WO2017 / 086367, WO2017 / 086419, WO2018 / 034227, WO2018 / 185046, WO2018 / 185043, WO2018 / 217940, W019 / 011306, WO2018 / 208868, W02014 / 140180, WO2018 / 201096, WO2018 / 204374, and W02019 / 018730. The contents of each of these references are incorporated by reference in their entirety.
[0244] Anti-LAG-3 antibodies that can be used in the compositions and / or methods of the disclosure also include isolated antibodies that bind specifically to human LAG-3 and crosscompete for binding to human LAG-3 with any anti-LAG-3 antibody disclosed herein, e.g., relatlimab. In some aspects, the anti-LAG-3 antibody binds the same epitope as any of the anti-LAG-3 antibodies described herein, e.g., relatlimab.
[0245] In some aspects, the antibodies that cross-compete for binding to human LAG-3 with, or bind to the same epitope region as, any anti-LAG-3 antibody disclosed herein, e.g., relatlimab, are monoclonal antibodies. For administration to human subjects, these crosscompeting antibodies are chimeric antibodies, engineered antibodies, or humanized or human antibodies. Such chimeric, engineered, humanized or human monoclonal antibodies can be prepared and isolated by methods well known in the art.
[0246] The ability of antibodies to cross-compete for binding to an antigen indicates that the antibodies bind to the same epitope region of the antigen and sterically hinder the binding of other cross-competing antibodies to that particular epitope region. These cross-competing antibodies are expected to have functional properties very similar those of the reference antibody, e.g., relatlimab, by virtue of their binding to the same epitope region. Cross-competing antibodies can be readily identified based on their ability to cross-compete in standard binding assays such as BIACORE analysis, ELISA assays or flow cytometry (see, e.g., WO 2013 / 173223).
[0247] Anti-LAG-3 antibodies that can be used in the compositions and / or methods of the disclosure also include antigen-binding portions of any of the above full-length antibodies. It has been amply demonstrated that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody.
[0248] In some aspects, the anti-LAG-3 antibody comprises a full-length antibody.
[0249] In some aspects, the anti-LAG-3 antibody comprises a monoclonal, human, humanized, chimeric, or multispecific antibody. In some aspects, the multispecific antibody is a dual-affinity re-targeting antibody (DART), a DVD-Ig, or bispecific antibody.
[0250] In some aspects, the anti-LAG-3 antibody comprises a multispecific antibody, e.g., a bispecific antibody, that specifically binds (i) LAG-3 and (ii) a second antigen. In some aspects, the antibody comprises a multispecific antibody, e.g., a bispecific antibody, that specifically binds two different antigens (e.g., LAG-3 and PD-1).
[0251] In some aspects, the anti-LAG-3 antibody comprises a trispecific antibody. In some aspects, the antibody specifically binds (i) LAG-3, (ii) a second antigen, and (iii) a third antigen. In some aspects, the second antigen and third antigen are the same. In some aspects, the second antigen and third antigen are different (e.g., PD-1 and CD3, respectively).
[0252] In some aspects, the antigen binding moieties in a bispecific or a trispecific antibody are scFVs, e.g., the scFv of relatlimab for a bispecific or trispecific antibody that specifically binds LAG-3.
[0253] The second or third antigen that is specifically bound by a bispecific or trispecific antibody herein can be any antigen disclosed herein.
[0254] In some aspects, the anti-LAG-3 antibody comprises a F(ab')2 fragment, a Fab' fragment, a Fab fragment, a Fv fragment, a scFv fragment, a dsFv fragment, a dAb fragment, or a single chain binding polypeptide.
[0255] In some aspects, the anti-LAG-3 antibody comprises BMS-986016 (relatlimab), IMP731 (H5L7BW), MK4280 (28G-10, favezelimab), REGN3767 (fianlimab), GSK2831781,humanized BAP050, IMP-701 (LAG525, ieramilimab), aLAG3(0414), aLAG3(0416), Sym022, TSR-033, TSR-075, XmAb841 (XmAb22841), MGD013 (tebotelimab), BI754111, FS118, P 13B02-30, AVA-017, 25F7, AGEN1746, RO7247669, INCAGN02385, IBL110, EMB-02, IBI-323, LBL-007, ABL501, or an antigen-binding portion thereof.
[0256] In some aspects, the anti-LAG-3 antibody comprises relatlimab or an antigenbinding portion thereof.
[0257] In some aspects, the anti-LAG-3 antibody comprises the heavy and light chain variable region CDRs, the heavy and light chain variable regions, and / or the heavy and light chains of relatlimab.
[0258] In some aspects, the anti-LAG-3 antibody comprises: (a) CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:3, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO:4; (b) a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO: 10, respectively; (c) heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:3 and 4, respectively; (d) heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:l and 2, respectively; or (e) heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:21 and 2, respectively.
[0259] In some aspects, the anti-LAG-3 antibody comprises MGD013 (tebotelimab), which is a bispecific PD-1 x LAG-3 DART, or an antigen-binding portion thereof.
[0260] In some aspects, the anti-LAG-3 antibody comprises the heavy and light chain variable region CDRs and / or the heavy and light chain variable regions of tebotelimab.
[0261] In some aspects, the anti-LAG-3 antibody comprises REGN3767 (fianlimab), or an antigen-binding portion thereof.
[0262] In some aspects, the anti-LAG-3 antibody comprises the heavy and light chain variable region CDRs, the heavy and light chain variable regions, and / or the heavy and light chains of fianlimab.
[0263] In some aspects, the anti-LAG-3 antibody comprises CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:25, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO:26. In some aspects, the anti-LAG-3 antibody comprises (a)a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:27; (b) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:28; (c) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:29; (d) a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:30; (e) a light chain variable region CDR2 comprising the amino acid sequence DAS; and (f) a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:32. In some aspects, the anti-LAG-3 antibody comprises heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:25 and 26, respectively. In some aspects, the anti-LAG-3 antibody comprises heavy and light chains comprising the amino acid sequences as set forth in SEQ ID NOs:23 and 24, respectively.
[0264] In some aspects, the anti-LAG-3 antibody comprises LAG525 (ieramilimab), or an antigen-binding portion thereof.
[0265] In some aspects, the anti-LAG-3 antibody comprises the heavy and light chain variable region CDRs, the heavy and light chain variable regions, and / or the heavy and light chains of ieramilimab.
[0266] In some aspects, the anti-LAG-3 antibody comprises CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:47, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO:49. In some aspects, the anti-LAG-3 antibody comprises CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:48, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO:50. In some aspects, the anti-LAG-3 antibody comprises (a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:51; (b) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 52; (c) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:53; (d) a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:54; (e) a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:55; and (f) a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:56. In some aspects, the anti-LAG-3 antibody comprises heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:47 and 49, respectively. In some aspects, the anti-LAG-3 antibody comprises heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:48 and 50, respectively. In some aspects, the anti-LAG-3antibody comprises heavy and light chains comprising the amino acid sequences as set forth in SEQ ID NOs:43 and 45, respectively. In some aspects, the anti-LAG-3 antibody comprises heavy and light chains comprising the amino acid sequences as set forth in SEQ ID NOs:44 and 46, respectively.
[0267] In some aspects, the anti-LAG-3 antibody comprises MK4280 (favezelimab), or an antigen-binding portion thereof.
[0268] In some aspects, the anti-LAG-3 antibody comprises the heavy and light chain variable region CDRs, the heavy and light chain variable regions, and / or the heavy and light chains of favezelimab.
[0269] In some aspects, the anti-LAG-3 antibody comprises CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 69, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO:70. In some aspects, the anti-LAG-3 antibody comprises (a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:71; (b) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:72; (c) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:73; (d) a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:74; (e) a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:75; and (f) a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:76. In some aspects, the anti-LAG-3 antibody comprises heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:69 and 70, respectively.
[0270] In some aspects, the LAG-3 antagonist comprises a soluble LAG-3 polypeptide. In some aspects, the soluble LAG-3 polypeptide comprises a fusion polypeptide, e.g., a fusion protein comprising the extracellular portion of LAG-3. In some aspects, the soluble LAG-3 polypeptide comprises a LAG-3-Fc fusion polypeptide capable of binding to MHC Class II. In some aspects, the soluble LAG-3 polypeptide comprises a ligand binding fragment of the LAG-3 extracellular domain. In some aspects, the ligand binding fragment of the LAG-3 extracellular domain comprises an amino acid sequence with at least about 90%, at least about 95%, at least about 98%, at least about 99%, or about 100% sequence identity to SEQ ID NO:22. In some aspects, the soluble LAG-3 polypeptide further comprises a half-life extending moiety. In some aspects, the half-life extending moiety comprises an immunoglobulin constant region or a portion thereof, an immunoglobulin-binding polypeptide, an immunoglobulin G (IgG), albumin-binding polypeptide(ABP), a PASylation moiety, a HESylation moiety, XTEN, a PEGylation moiety, an Fc region, or any combination thereof. In some aspects, the soluble LAG-3 polypeptide comprises IMP321 (eftilagimod alpha). See, e.g., Brignone C, et al., J. Immunol. (2007); 179:4202-4211 and W02009 / 044273.II. C.2. Anti-PD-1 and Anti-PD-Ll Antibodies, and Other PD-1 Pathway Inhibitors
[0271] A PD-1 pathway inhibitor for use in the compositions and methods as disclosed herein includes, but is not limited to, anti-PD-1 and PD-L1 antibodies and soluble PD-L2 polypeptides.
[0272] In some aspects, the PD-1 pathway inhibitor comprises a soluble PD-L2 polypeptide. In some aspects, the soluble PD-L2 polypeptide comprises a fusion polypeptide. In some aspects, the soluble PD-L2 polypeptide comprises a ligand binding fragment of the PD-L2 extracellular domain. In some aspects, the soluble PD-L2 polypeptide further comprises a half-life extending moiety. In some aspects, the half-life extending moiety comprises an immunoglobulin constant region or a portion thereof, an immunoglobulin-binding polypeptide, an immunoglobulin G (IgG), albumin-binding polypeptide (ABP), a PASylation moiety, a HESylation moiety, XTEN, a PEGylation moiety, an Fc region, or any combination thereof. In some aspects, the soluble PD-L2 polypeptide comprises AMP -224 (see, e.g., US 2013 / 0017199).II. C.2.a. Anti-PD-1 Antibodies
[0273] In some aspects, compositions and / or methods of the disclosure comprise an antibody or an antigen-binding portion thereof that specifically binds PD-1 ("an anti-PD-1 antibody"). Various human monoclonal antibodies that bind specifically to PD-1 with high affinity have been disclosed in U. S. Patent No. 8,008,449. Anti-PD-1 human antibodies disclosed in U. S. Patent No. 8,008,449 have been demonstrated to exhibit one or more of the following characteristics: (a) bind to human PD-1 with a KD of 1 x 10-7M or less, as determined by surface plasmon resonance using a BIACORE biosensor system; (b) do not substantially bind to human CD28, CTLA-4 or ICOS; (c) increase T-cell proliferation in a Mixed Lymphocyte Reaction (MLR) assay; (d) increase interferon-y production in an MLR assay; (e) increase IL-2 secretion in an MLR assay; (f) bind to human PD-1 and cynomolgus monkey PD-1; (g) inhibit the binding of PD-L1 and / or PD-L2 to PD-1; (h) stimulate antigen-specific memory responses; (i) stimulate antibody responses; and (j) inhibit tumor cell growth in vivo. Anti-PD-1 antibodies usable in the presentdisclosure include monoclonal antibodies that bind specifically to human PD-1 and exhibit at least one, in some aspects, at least five, of the preceding characteristics.
[0274] Other anti-PD-1 monoclonal antibodies have been described in, for example, U. S.Patent Nos. 6,808,710, 7,488,802, 8,168,757 and 8,354,509, US Publication No. 2016 / 0272708, and PCT Publication Nos. WO 2012 / 145493, WO 2008 / 156712, WO 2015 / 112900, WO 2012 / 145493, WO 2015 / 112800, WO 2014 / 206107, WO 2015 / 35606, WO 2015 / 085847, WO 2014 / 179664, WO 2017 / 020291, WO 2017 / 020858, WO 2016 / 197367, WO 2017 / 024515, WO 2017 / 025051, WO 2017 / 123557, WO 2016 / 106159, WO 2014 / 194302, WO 2017 / 040790, WO 2017 / 133540, WO 2017 / 132827, WO 2017 / 024465, WO 2017 / 025016, WO 2017 / 106061, WO 2017 / 19846, WO 2017 / 024465, WO 2017 / 025016, WO 2017 / 132825, and WO 2017 / 133540 each of which is incorporated by reference in its entirety.
[0275] In some aspects, the anti-PD-1 antibody comprises a full-length antibody.
[0276] In some aspects, the anti-PD-1 antibody comprises a monoclonal, human, humanized, chimeric, or multispecific antibody. In some aspects, the multispecific antibody comprises a dual-affinity re-targeting antibody (DART), a dual variable domain immunoglobulin (DVD-Ig), or a bispecific antibody.
[0277] In some aspects, the anti-PD-1 antibody comprises a multispecific antibody, e.g., a bispecific antibody, that specifically binds (i) PD-1 and (ii) a second antigen (e.g., LAG-3, CD3, or TIGIT).
[0278] In some aspects, the pharmaceutical composition comprises a bispecific antibody or a multispecific antibody comprising a first antigen binding moiety and a second antigen binding moiety, wherein the first antigen binding moiety comprises an anti-PD-1 antigen-binding portion (e.g., scFv of nivolumab). In some aspects, the second antigen binding moiety is an antigen-binding portion of any one of the antibodies disclosed herein. In some aspects, the second antigen binding moiety is an antigen-binding portion of an anti-LAG-3 antibody, e.g., relatlimab. In some aspects, the second antigen-binding portion is an antigen-binding portion of an anti-TIGIT antibody.
[0279] In some aspects, the anti-PD-1 antibody comprises a trispecific antibody. In some aspects, the trispecific antibody specifically binds (i) PD-1, (ii) a second antigen, and (iii) a third antigen. In some aspects, the second antigen and third antigen are the same. In some aspects, the second antigen and third antigen are different.
[0280] In some aspects, the pharmaceutical composition comprises a multispecific antibody comprising a first antigen binding moiety, a second antigen binding moiety, and at leasta third antigen binding moiety, wherein the first antigen binding moiety comprises an anti-PD-1 antigen-binding portion (e.g., scFv of nivolumab).
[0281] In some aspects, the antigen binding moieties in a bispecific or a trispecific antibody are scFVs, e.g., the scFv of nivolumab for a bispecific or trispecific antibody that specifically binds PD-1.
[0282] The second or third antigen that is specifically bound by a bispecific or trispecific antibody herein can be any antigen disclosed herein.
[0283] In some aspects, the anti-PD-1 antibody comprises a F(ab')2 fragment, a Fab' fragment, a Fab fragment, a Fv fragment, a scFv fragment, a dsFv fragment, a dAb fragment, or a single chain binding polypeptide.
[0284] In some aspects, the anti-PD-1 antibody comprises nivolumab (also known as OPDIVO, 5C4, BMS-936558, MDX-1106, and ONO-4538), pembrolizumab (Merck; also known as KEYTRUDA, lambrolizumab, and MK-3475; see WO2008 / 156712), PDR001 (Novartis; also known as spartalizumab; see WO 2015 / 112900 and U. S. Patent No. 9,683,048), MEDI-0680 (AstraZeneca; also known as AMP-514; see WO 2012 / 145493), TSR-042 (Tesaro Biopharmaceutical; also known as ANB011 or dostarlimab; see WO2014 / 179664), cemiplimab (Regeneron; also known as LIBTAYO or REGN-2810; see WO 2015 / 112800 and U. S. Patent No.9,987,500), JS001 (TAIZHOU JUNSHI PHARMA; also known as toripalimab; see Si-Yang Liu et al., J. Hematol. Oncol. 70:136 (2017)), PF-06801591 (Pfizer; also known as sasanlimab), BGB-A317 (Beigene; also known as tislelizumab; see WO 2015 / 35606 and US 2015 / 0079109), BI 754091 (Boehringer Ingelheim; see Zettl M et al., Cancer. Res. (2018);78(13 Suppl): Abstract 4558), INCSHR1210 (Jiangsu Hengrui Medicine; also known as SHR-1210 or camrelizumab; see WO 2015 / 085847; Si-Yang Liu et al., J. Hematol. Oncol. 70:136 (2017)), GLS-010 (Wuxi / Harbin Gloria Pharmaceuticals; also known as WBP3055; see Si-Yang Liu et al., J. Hematol. Oncol.70:136 (2017)), AM-0001 (Anno), STI-1110 (Sorrento Therapeutics; see WO 2014 / 194302), AGEN2034 (Agenus; see WO 2017 / 040790), MGA012 (Macrogenics, see WO 2017 / 19846), BCD-100 (Biocad; Kaplon et al., mAbs 10(2):183-203 (2018), IBI308 (Innovent; also known as sintilimab; see WO 2017 / 024465, WO 2017 / 025016, WO 2017 / 132825, and WO 2017 / 133540);; US 2016 / 0159905); SSI-361 (Lyvgen Biopharma Holdings Limited, US 2018 / 0346569), or an antigen-binding portion thereof.
[0285] In some aspects, the anti-PD-1 antibody comprises nivolumab, or an antigenbinding portion thereof. Nivolumab is a fully human IgG4 (S228P) PD-1 immune checkpoint inhibitor antibody that selectively prevents interaction with PD-1 ligands (PD-L1 and PD-L2),thereby blocking the down-regulation of antitumor T-cell functions (U. S. Patent No. 8,008,449; Wang et al., 2014 Cancer Immunol Res. 2(9):846-56.
[0286] In some aspects, the anti-PD-1 antibody comprises the heavy and light chain variable region CDRs, the heavy and light chain variable regions, and / or the heavy and light chains of nivolumab.
[0287] In some aspects, the anti-PD-1 antibody comprises: (a) CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 13, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO: 14; (b) a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO:18, SEQ ID NO:19, and SEQ ID NO:20, respectively; (c) heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs: 13 and 14, respectively; or (d) heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs: 11 and 12, respectively.
[0288] In some aspects, the anti-PD-1 antibody comprises pembrolizumab, or an antigenbinding portion thereof. Pembrolizumab is a humanized monoclonal IgG4 (S228P) antibody directed against human cell surface receptor PD-1 (programmed death- 1 or programmed cell death-1). Pembrolizumab is described, for example, in U. S. Patent Nos. 8,354,509 and 8,900,587.
[0289] In some aspects, the anti-PD-1 antibody comprises the heavy and light chain variable region CDRs, the heavy and light chain variable regions, and / or the heavy and light chains of pembrolizumab.
[0290] In some aspects, the anti-PD-1 antibody comprises CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:79, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO:80. In some aspects, the anti-PD-1 antibody comprises (a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:81; (b) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:82; (c) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:83; (d) a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:84; (e) a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:85; and (f) a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:86. In some aspects, the anti-PD-1 antibodycomprises heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:79 and 80, respectively. In some aspects, the anti-PD-1 antibody comprises heavy and light chains comprising the amino acid sequences as set forth in SEQ ID NOs:77 and 78, respectively.
[0291] In some aspects, the anti-PD-1 antibody comprises cemiplimab (REGN2810), or an antigen-binding portion thereof. Cemiplimab is described, for example, in WO 2015 / 112800 and U. S. Patent No. 9,987,500.
[0292] In some aspects, the anti-PD-1 antibody comprises the heavy and light chain variable region CDRs, the heavy and light chain variable regions, and / or the heavy and light chains of cemiplimab.
[0293] In some aspects, the anti-PD-1 antibody comprises CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:35, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO:36. In some aspects, the anti-PD-1 antibody comprises (a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:37; (b) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:38; (c) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:39; (d) a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:40; (e) a light chain va...
Claims
WHAT IS CLAIMED IS:
1. A pharmaceutical composition comprising about 100 mg / mL or more of a protein, a salt, and a sugar, wherein the pharmaceutical composition comprises an osmolality of less than about 600 mOsmol / kg, and wherein the pharmaceutical composition comprises a lower viscosity than a corresponding composition that lacks the salt and / or that comprises a higher concentration of the sugar.
2. The pharmaceutical composition of claim 1, wherein the osmolality is about 200 mOsmol / kg to less than about 600 mOsmol / kg, about 210 mOsmol / kg to less than about 600 mOsmol / kg, about 220 mOsmol / kg to less than about 600 mOsmol / kg, about 230 mOsmol / kg to less than about 600 mOsmol / kg, about 240 mOsmol / kg to less than about 600 mOsmol / kg, about 250 mOsmol / kg to less than about 600 mOsmol / kg, about 260 mOsmol / kg to less than about 600 mOsmol / kg, about 270 mOsmol / kg to less than about 600 mOsmol / kg, about 280 mOsmol / kg to less than about 600 mOsmol / kg, about 290 mOsmol / kg to less than about 600 mOsmol / kg, about 300 mOsmol / kg to less than about 600 mOsmol / kg, about 350 mOsmol / kg to less than about 600 mOsmol / kg, about 400 mOsmol / kg to less than about 600 mOsmol / kg, about 450 mOsmol / kg to less than about 600 mOsmol / kg, about 500 mOsmol / kg to less than about 600 mOsmol / kg, about 550 mOsmol / kg to less than about 600 mOsmol / kg, about 500 mOsmol / kg to about 550 mOsmol / kg, about 450 mOsmol / kg to about 550 mOsmol / kg, about 400 mOsmol / kg to about 550 mOsmol / kg, about 350 mOsmol / kg to about 550 mOsmol / kg, about 300 mOsmol / kg to about 550 mOsmol / kg, about 250 mOsmol / kg to about 550 mOsmol / kg, about 200 mOsmol / kg to about 550 mOsmol / kg, about 200 mOsmol / kg to about 500 mOsmol / kg, about 250 mOsmol / kg to about 500 mOsmol / kg, about 300 mOsmol / kg to about 500 mOsmol / kg, about 350 mOsmol / kg to about 500 mOsmol / kg, about 400 mOsmol / kg to about 500 mOsmol / kg, about 450 mOsmol / kg to about 500 mOsmol / kg, about 400 mOsmol / kg to about 450 mOsmol / kg, about 350 mOsmol / kg to about 450 mOsmol / kg, about 300 mOsmol / kg to about 450 mOsmol / kg, about 250 mOsmol / kg to about 450 mOsmol / kg, about 200 mOsmol / kg to about 450 mOsmol / kg, about 200 mOsmol / kg to about 400 mOsmol / kg, about 250 mOsmol / kg to about 400 mOsmol / kg, about 300 mOsmol / kg to about 400 mOsmol / kg, about 350 mOsmol / kg to about 400 mOsmol / kg, about 300 mOsmol / kg to about 350 mOsmol / kg, about 250 mOsmol / kg toabout 350 mOsmol / kg, about 200 mOsmol / kg to about 350 mOsmol / kg, about 200 mOsmol / kg to about 300 mOsmol / kg, or about 250 mOsmol / kg to about 300 mOsmol / kg.
3. The pharmaceutical composition of claim 1 or 2, wherein the osmolality is about 280 mOsmol / kg to less than about 600 mOsmol / kg.
4. A pharmaceutical composition comprising about 100 mg / mL or more of a protein, a salt, and a sugar, wherein the pharmaceutical composition comprises a lower viscosity than a corresponding composition that lacks the salt and that comprises a higher concentration of the sugar.
5. The pharmaceutical composition of claim 4, wherein the pharmaceutical composition comprises an osmolality of about 200 mOsmol / kg to about 600 mOsmol / kg, about 210 mOsmol / kg to about 600 mOsmol / kg, about 220 mOsmol / kg to about 600 mOsmol / kg, about 230 mOsmol / kg to about 600 mOsmol / kg, about 240 mOsmol / kg to about 600 mOsmol / kg, about 250 mOsmol / kg to about 600 mOsmol / kg, about 260 mOsmol / kg to about 600 mOsmol / kg, about 270 mOsmol / kg to about 600 mOsmol / kg, about 280 mOsmol / kg to about 600 mOsmol / kg, about 290 mOsmol / kg to about 600 mOsmol / kg, about 300 mOsmol / kg to about 600 mOsmol / kg, about 350 mOsmol / kg to about 600 mOsmol / kg, about 400 mOsmol / kg to about 600 mOsmol / kg, about 450 mOsmol / kg to about 600 mOsmol / kg, about 500 mOsmol / kg to about 600 mOsmol / kg, about 550 mOsmol / kg to about 600 mOsmol / kg, about 500 mOsmol / kg to about 550 mOsmol / kg, about 450 mOsmol / kg to about 550 mOsmol / kg, about 400 mOsmol / kg to about 550 mOsmol / kg, about 350 mOsmol / kg to about 550 mOsmol / kg, about 300 mOsmol / kg to about 550 mOsmol / kg, about 250 mOsmol / kg to about 550 mOsmol / kg, about 200 mOsmol / kg to about 550 mOsmol / kg, about 200 mOsmol / kg to about 500 mOsmol / kg, about 250 mOsmol / kg to about 500 mOsmol / kg, about 300 mOsmol / kg to about 500 mOsmol / kg, about 350 mOsmol / kg to about 500 mOsmol / kg, about 400 mOsmol / kg to about 500 mOsmol / kg, about 450 mOsmol / kg to about 500 mOsmol / kg, about 400 mOsmol / kg to about 450 mOsmol / kg, about 350 mOsmol / kg to about 450 mOsmol / kg, about 300 mOsmol / kg to about 450 mOsmol / kg, about 250 mOsmol / kg to about 450 mOsmol / kg, about 200 mOsmol / kg to about 450 mOsmol / kg, about 200 mOsmol / kg to about 400 mOsmol / kg, about 250 mOsmol / kg to about 400 mOsmol / kg, about 300 mOsmol / kg to about 400 mOsmol / kg, about 350 mOsmol / kg to about 400 mOsmol / kg,about 300 mOsmol / kg to about 350 mOsmol / kg, about 250 mOsmol / kg to about 350 mOsmol / kg, about 200 mOsmol / kg to about 350 mOsmol / kg, about 200 mOsmol / kg to about 300 mOsmol / kg, or about 250 mOsmol / kg to about 300 mOsmol / kg.
6. The pharmaceutical composition of claim 5, wherein the osmolality is about 280 mOsmol / kg to about 600 mOsmol / kg.
7. The pharmaceutical composition of any one of claims 1-3, 5, or 6, wherein the osmolality is about 200 mOsmol / kg, about 205 mOsmol / kg, about 210 mOsmol / kg, about 215 mOsmol / kg, about 220 mOsmol / kg, about 225 mOsmol / kg, about 230 mOsmol / kg, about 235 mOsmol / kg, about 240 mOsmol / kg, about 245 mOsmol / kg, about 250 mOsmol / kg, about 255 mOsmol / kg, about 260 mOsmol / kg, about 265 mOsmol / kg, about 270 mOsmol / kg, about 275 mOsmol / kg, about 280 mOsmol / kg, about 285 mOsmol / kg, about 290 mOsmol / kg, about 295 mOsmol / kg, about 300 mOsmol / kg, about 305 mOsmol / kg, about 310 mOsmol / kg, about 315 mOsmol / kg, about 320 mOsmol / kg, about 325 mOsmol / kg, about 330 mOsmol / kg, about 335 mOsmol / kg, about 340 mOsmol / kg, about 345 mOsmol / kg, about 350 mOsmol / kg, about 355 mOsmol / kg, about 360 mOsmol / kg, about 365 mOsmol / kg, about 370 mOsmol / kg, about 375 mOsmol / kg, about 380 mOsmol / kg, about 385 mOsmol / kg, about 390 mOsmol / kg, about 395 mOsmol / kg, about 400 mOsmol / kg, about 405 mOsmol / kg, about 410 mOsmol / kg, about 415 mOsmol / kg, about 420 mOsmol / kg, about 425 mOsmol / kg, about 430 mOsmol / kg, about 435 mOsmol / kg, about 440 mOsmol / kg, about 445 mOsmol / kg, about 450 mOsmol / kg, about 455 mOsmol / kg, about 460 mOsmol / kg, about 465 mOsmol / kg, about 470 mOsmol / kg, about 475 mOsmol / kg, about 480 mOsmol / kg, about 485 mOsmol / kg, about 490 mOsmol / kg, about 495 mOsmol / kg, about 500 mOsmol / kg, about 505 mOsmol / kg, about 510 mOsmol / kg, about 515 mOsmol / kg, about 520 mOsmol / kg, about 525 mOsmol / kg, about 530 mOsmol / kg, about 535 mOsmol / kg, about 540 mOsmol / kg, about 545 mOsmol / kg, about 550 mOsmol / kg, about 555 mOsmol / kg, about 560 mOsmol / kg, about 565 mOsmol / kg, about 570 mOsmol / kg, about 575 mOsmol / kg, about 580 mOsmol / kg, about 585 mOsmol / kg, about 590 mOsmol / kg, or about 595 mOsmol / kg.
8. The pharmaceutical composition of any one of claims 1-7, wherein the osmolality is determined by vapor-pressure osmometry.
9. The pharmaceutical composition of any one of claims 1-8, wherein the osmolality is determined with a vapor pressure osmometer.
10. The pharmaceutical composition of any one of claims 1-9, wherein the viscosity is about 15 centipoise (cP) or less.
11. The pharmaceutical composition of any one of claim 1-10, wherein the viscosity is about 1 cP to about 15 cP, about 1 cP to about 14 cP, about 1 cP to about 13 cP, about 1 cP to about 12 cP, about 1 cP to about 11 cP, about 1 cP to about 10 cP, about 1 cP to about 9 cP, about 1 cP to about 8 cP, about 1 cP to about 7 cP, about 1 cP to about 6 cP, about 1 cP to about 5 cP, about 1 cP to about 4 cP, about 1 cP to about 3 cP, about 2 cP to about 15 cP, about 2 cP to about 14 cP, about 2 cP to about 13 cP, about 2 cP to about 12 cP, about 2 cP to about 11 cP, about 2 cP to about 10 cP, about 2 cP to about 9 cP, about 2 cP to about 8 cP, about 2 cP to about 7 cP, about 2 cP to about 6 cP, about 2 cP to about 5 cP, about 2 cP to about 4 cP, about 3 cP to about 15 cP, about 3 cP to about 14 cP, about 3 cP to about 13 cP, about 3 cP to about 12 cP, about 3 cP to about 11 cP, about 3 cP to about 10 cP, about 3 cP to about 9 cP, about 3 cP to about 8 cP, about 3 cP to about 7 cP, about 3 cP to about 6 cP, about 3 cP to about 5 cP, about 4 cP to about 15 cP, about 4 cP to about 14 cP, about 4 cP to about 13 cP, about 4 cP to about 12 cP, about 4 cP to about 11 cP, about 4 cP to about 10 cP, about 4 cP to about 9 cP, about 4 cP to about 8 cP, about 4 cP to about 7 cP, about 4 cP to about 6 cP, about 5 cP to about 15 cP, about 5 cP to about 14 cP, about 5 cP to about 13 cP, about 5 cP to about 12 cP, about 5 cP to about 11 cP, about 5 cP to about 10 cP, about 5 cP to about 9 cP, about 5 cP to about 8 cP, about 5 cP to about 7 cP, about 6 cP to about 15 cP, about 6 cP to about 14 cP, about 6 cP to about 13 cP, about 6 cP to about 12 cP, about 6 cP to about 11 cP, about 6 cP to about 10 cP, about 6 cP to about 9 cP, about 6 cP to about 8 cP, about 7 cP to about 15 cP, about 7 cP to about 14 cP, about 7 cP to about 13 cP, about 7 cP to about 12 cP, about 7 cP to about 11 cP, about 7 cP to about 10 cP, about 7 cP to about 9 cP, about 8 cP to about 15 cP, about 8 cP to about 14 cP, about 8 cP to about 13 cP, about 8 cP to about 12 cP, about 8 cP to about 11 cP, about 8 cP to about 10 cP, about 9 cP to about 15 cP, about 9 cP to about 14 cP, about 9 cP to about 13 cP, about 9 cP to about 12 cP, about 9 cP to about 11 cP, about 10 cP to about 15 cP, about 10 cP to about 14 cP, about 10 cP to about 13 cP, about 10 cP to about 12 cP, about 11 cP to about 15 cP, about 11 cP to about 14 cP, about 11 cP to about 13 cP, about 12 cP to about 15 cP, about 12 cP to about 14 cP, or about 13 cP to about 15 cP.
12. The pharmaceutical composition of any one of claims 1-11, wherein the viscosity is determined with a microfluidic viscometer.
13. The pharmaceutical composition of any one of claims 1-12, wherein the viscosity is determined at 20 °C.
14. The pharmaceutical composition of any one of claims 1-13, comprising about 10 mM to about 400 mM, about 10 mM to about 350 mM, about 10 mM to about 300 mM, about 10 mM to about 250 mM, about 10 mM to about 200 mM, about 10 mM to about 150 mM, about 10 mM to about 100 mM, about 10 mM to about 90 mM, about 10 mM to about 80 mM, about 10 mM to about 70 mM, about 10 mM to about 60 mM, about 10 mM to about 50 mM, about 30 mM to about 400 mM, about 30 mM to about 350 mM, about 30 mM to about 300 mM, about 30 mM to about 250 mM, about 30 mM to about 200 mM, about 30 mM to about 150 mM, about 30 mM to about 100 mM, about 30 mM to about 90 mM, about 30 mM to about 80 mM, about 30 mM to about 70 mM, about 30 mM to about 60 mM, about 30 mM to about 50 mM, about 50 mM to about 400 mM, about 50 mM to about 350 mM, about 50 mM to about 300 mM, about 50 mM to about 250 mM, about 50 mM to about 200 mM, about 50 mM to about 150 mM, about 50 mM to about 100 mM, about 100 mM to about 400 mM, about 100 mM to about 350 mM, about 100 mM to about 300 mM, about 100 mM to about 250 mM, about 100 mM to about 200 mM, or about 100 mM to about 150 mM of the salt.
15. The pharmaceutical composition of any one of claims 1-14, comprising about 10 mM, about 15 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM, about 55 mM, about 60 mM, about 65 mM, about 70 mM, about 75 mM, about 80 mM, about 85 mM, about 90 mM, about 95 mM, about 100 mM, about 110 mM, about 120 mM, about 130 mM, about 140 mM, about 150 mM, about 160 mM, about 170 mM, about 180 mM, about 190 mM, about 200 mM, about 210 mM, about 220 mM, about 230 mM, about 240 mM, about 250 mM, about 260 mM, about 270 mM, about 280 mM, about 290 mM, about 300 mM, about 310 mM, about 320 mM, about 330 mM, about 340 mM, about 350 mM, about 360 mM, about 370 mM, about 380 mM, about 390 mM, or about 400 mM of the salt.
16. The pharmaceutical composition of any one of claims 1-15, wherein the salt comprises sodium chloride, arginine hydrochloride, histidine hydrochloride, lysine hydrochloride,magnesium chloride, potassium chloride, ammonium chloride, calcium chloride, sodium acetate, zinc chloride, ammonium thiocyanate, sodium thiocyanate, sodium sulfate, ammonium sulfate, sodium phosphate, sodium biphosphate, potassium phosphate, dipotassium hydrogen phosphate, monobasic potassium phosphate, calcium phosphate, tris(hydroxymethyl)aminomethane, or a combination thereof.
17. The pharmaceutical composition of claim 16, wherein the salt comprises sodium chloride.
18. The pharmaceutical composition of claim 16, wherein the salt comprises arginine hydrochloride.
19. The pharmaceutical composition of claim 16, wherein the salt comprises sodium chloride and arginine hydrochloride.
20. The pharmaceutical composition of any one of claims 1-19, comprising about 500 mM or less, about 475 mM or less, about 450 mM or less, about 425 mM or less, about 400 mM or less, about 375 mM or less, about 350 mM or less, about 325 mM or less, about 300 mM or less, about 275 mM or less, about 250 mM or less, about 225 mM or less, about 200 mM or less, about 175 mM or less, about 150 mM or less, about 125 mM or less, about 100 mM or less, or about 75 mM or less of the sugar.
21. The pharmaceutical composition of any one of claims 1-20, comprising about 1 mM to about 500 mM, about 1 mM to about 475 mM, about 1 mM to about 450 mM, about 1 mM to about 425 mM, about 1 mM to about 400 mM, about 1 mM to about 375 mM, about 1 mM to about 350 mM, about 1 mM to about 325 mM, about 1 mM to about 300 mM, about 1 mM to about 275 mM, about 1 mM to about 250 mM, about 1 mM to about 225 mM, about 1 mM to about 200 mM, about 1 mM to about 175 mM, about 1 mM to about 150 mM, about 1 mM to about 125 mM, about 1 mM to about 100 mM, or about 1 mM to about 75 mM of the sugar.
22. The pharmaceutical composition of any one of claims 1-21, wherein the sugar comprises a monosaccharide, a disaccharide, a polysaccharide, a polyol, or a combination thereof.
23. The pharmaceutical composition of any one of claims 1-22, wherein the sugar comprises glucose, xylose, erythritol, sucrose, trehalose, maltose, galactose, dextrose, raffinose,stachyose, lactose, mannitol, sorbitol, xylitol, lactitol, maltitol, glycerol, or a combination thereof.
24. The pharmaceutical composition of claim 23, wherein the sugar comprises sucrose.
25. The pharmaceutical composition of claim 23, wherein the sugar comprises trehalose.
26. The pharmaceutical composition of any one of claims 1-25, comprising a volume of about 0.001 mL to about 20 mL.
27. The pharmaceutical composition of any one of claims 1-26, comprising a volume of about 0.001 mL, about 0.005 mL, about 0.010 mL, about 0.015 mL, about 0.020 mL, about 0.025 mL, about 0.030 mL, about 0.035 mL, about 0.040 mL, about 0.045 mL, about 0.050 mL, about 0.055 mL, about 0.060 mL, about 0.065 mL, about 0.070 mL, about 0.075 mL, about 0.080 mL, about 0.085 mL, about 0.090 mL, about 0.095 mL, about 0.100 mL, about 0.150 mL, about 0.200 mL, about 0.250 mL, about 0.300 mL, about 0.350 mL, about 0.400 mL, about 0.450 mL, about 0.500 mL, about 0.550 mL, about 0.600 mL, about 0.650 mL, about 0.700 mL, about 0.750 mL, about 0.800 mL, about 0.850 mL, about 0.900 mL, about 0.950 mL, about 1 mL, about 1.1 mL, about 1.2 mL, about 1.3 mL, about 1.4 mL, about 1.5 mL, about 1.6 mL, about 1.7 mL, about 1.8 mL, about 1.9 mL, about 2 mL, about 2.1 mL, about 2.2 mL, about 2.3 mL, about 2.4 mL, about 2.5 mL, about 2.6 mL, about 2.7 mL, about 2.8 mL, about 2.9 mL, about 3 mL, about 3.1 mL, about 3.2 mL, about 3.3 mL, about 3.4 mL, about 3.5 mL, about 3.6 mL, about 3.7 mL, about 3.8 mL, about 3.9 mL, about 4 mL, about 4.1 mL, about 4.2 mL, about 4.3 mL, about 4.4 mL, about 4.5 mL, about 4.6 mL, about 4.7 mL, about 4.8 mL, about 4.9 mL, about 5 mL, about 5.1 mL, about 5.2 mL, about 5.3 mL, about 5.4 mL, about 5.5 mL, about 5.6 mL, about 5.7 mL, about 5.8 mL, about 5.9 mL, about 6 mL, about 6.1 mL, about 6.2 mL, about 6.3 mL, about 6.4 mL, about 6.5 mL, about 6.6 mL, about 6.7 mL, about 6.8 mL, about 6.9 mL, about 7 mL, about 7.1 mL, about 7.2 mL, about 7.3 mL, about 7.4 mL, about 7.5 mL, about 7.6 mL, about 7.7 mL, about 7.8 mL, about 7.9 mL, about 8 mL, about 8.1 mL, about 8.2 mL, about 8.3 mL, about 8.4 mL, about 8.5 mL, about 8.6 mL, about 8.7 mL, about 8.8 mL, about 8.9 mL, about 9 mL, about 9.1 mL, about 9.2 mL, about 9.3 mL, about 9.4 mL, about 9.5 mL, about 9.6 mL, about 9.7 mL, about 9.8 mL, about 9.9 mL, about 10 mL, about 10.1 mL, about 10.2 mL, about 10.3 mL, about 10.4 mL, about 10.5 mL, about 10.6 mL, about 10.7 mL, about 10.8 mL, about 10.9 mL, about 11 mL, about 11.1 mL, about 11.2 mL, about 11.3 mL, about 11.4 mL,about 11.5 mL, about 11.6 mL, about 11.7 mL, about 11.8 mL, about 11.9 mL, about 12 mL, about 12.1 mL, about 12.2 mL, about 12.3 mL, about 12.4 mL, about 12.5 mL, about 12.6 mL, about 12.7 mL, about 12.8 mL, about 12.9 mL, about 13 mL, about 13.1 mL, about 13.2 mL, about 13.3 mL, about 13.4 mL, about 13.5 mL, about 13.6 mL, about 13.7 mL, about 13.8 mL, about 13.9 mL, about 14 mL, about 14.1 mL, about 14.2 mL, about 14.3 mL, about 14.4 mL, about 14.5 mL, about 14.6 mL, about 14.7 mL, about 14.8 mL, about 14.9 mL, about 15 mL, about 15.1 mL, about 15.2 mL, about 15.3 mL, about 15.4 mL, about 15.5 mL, about 15.6 mL, about 15.7 mL, about 15.8 mL, about 15.9 mL, about 16 mL, about 16.1 mL, about 16.2 mL, about 16.3 mL, about 16.4 mL, about 16.5 mL, about 16.6 mL, about 16.7 mL, about 16.8 mL, about 16.9 mL, about 17 mL, about 17.1 mL, about 17.2 mL, about 17.3 mL, about 17.4 mL, about 17.5 mL, about 17.6 mL, about 17.7 mL, about 17.8 mL, about 17.9 mL, about 18 mL, about 18.1 mL, about 18.2 mL, about 18.3 mL, about 18.4 mL, about 18.5 mL, about 18.6 mL, about 18.7 mL, about 18.8 mL, about 18.9 mL, about 19 mL, about 19.1 mL, about 19.2 mL, about 19.3 mL, about 19.4 mL, about 19.5 mL, about 19.6 mL, about 19.7 mL, about 19.8 mL, about 19.9 mL, or about 20 mL.
28. The pharmaceutical composition of any one of claims 1-27, comprising a volume of about 8.4 mL, about 9 mL, about 9.6 mL, about 10 mL, about 12 mL, about 12.8 mL, about 15 mL, or about 16 mL.
29. The pharmaceutical composition of any one of claims 1-28, comprising about 100 mg / mL to about 500 mg / mL, about 100 mg / mL to about 450 mg / mL, about 100 mg / mL to about 400 mg / mL, about 100 mg / mL to about 350 mg / mL, about 100 mg / mL to about 300 mg / mL, about 100 mg / mL to about 250 mg / mL, about 100 mg / mL to about 200 mg / mL, about 100 mg / mL to about 150 mg / mL, about 100 mg / mL to about 140 mg / mL, about 100 mg / mL to about 130 mg / mL, about 100 mg / mL to about 120 mg / mL, about 100 mg / mL to about 115 mg / mL, about 100 mg / mL to about 110 mg / mL, about 100 mg / mL to about 105 mg / mL, about 110 mg / mL to about 500 mg / mL, about 110 mg / mL to about 450 mg / mL, about 110 mg / mL to about 400 mg / mL, about 110 mg / mL to about 350 mg / mL, about 110 mg / mL to about 300 mg / mL, about 110 mg / mL to about 250 mg / mL, about 110 mg / mL to about 200 mg / mL, about 110 mg / mL to about 150 mg / mL, about 110 mg / mL to about 140 mg / mL, about 110 mg / mL to about 130 mg / mL, about 110 mg / mL to about 120 mg / mL, about 110 mg / mL to about 115 mg / mL, about 115 mg / mL to about 500 mg / mL, about 115mg / mL to about 450 mg / mL, about 115 mg / mL to about 400 mg / mL, about 115 mg / mL to about 350 mg / mL, about 115 mg / mL to about 300 mg / mL, about 115 mg / mL to about 250 mg / mL, about 115 mg / mL to about 200 mg / mL, about 115 mg / mL to about 150 mg / mL, about 115 mg / mL to about 140 mg / mL, about 115 mg / mL to about 130 mg / mL, about 115 mg / mL to about 120 mg / mL, about 120 mg / mL to about 450 mg / mL, about 120 mg / mL to about 400 mg / mL, about 120 mg / mL to about 350 mg / mL, about 120 mg / mL to about 300 mg / mL, about 120 mg / mL to about 250 mg / mL, about 120 mg / mL to about 200 mg / mL, about 120 mg / mL to about 150 mg / mL, about 120 mg / mL to about 140 mg / mL, about 120 mg / mL to about 130 mg / mL, about 150 mg / mL to about 500 mg / mL, about 150 mg / mL to about 450 mg / mL, about 150 mg / mL to about 400 mg / mL, about 150 mg / mL to about 350 mg / mL, about 150 mg / mL to about 300 mg / mL, about 150 mg / mL to about 250 mg / mL, or about 150 mg / mL to about 200 mg / mL of the protein.
30. The pharmaceutical composition of any one of claims 1-29, comprising about 100 mg / mL, about 101 mg / mL, about 102 mg / mL, about 103 mg / mL, about 104 mg / mL, about 105 mg / mL, about 106 mg / mL, about 107 mg / mL, about 108 mg / mL, about 109 mg / mL, about 110 mg / mL, about 111 mg / mL, about 112 mg / mL, about 113 mg / mL, about 114 mg / mL, about 115 mg / mL, about 116 mg / mL, about 117 mg / mL, about 118 mg / mL, about 119 mg / mL, about 120 mg / mL, about 121 mg / mL, about 122 mg / mL, about 123 mg / mL, about 124 mg / mL, about 125 mg / mL, about 126 mg / mL, about 127 mg / mL, about 128 mg / mL, about 129 mg / mL, about 130 mg / mL, about 131 mg / mL, about 132 mg / mL, about 133 mg / mL, about 134 mg / mL, about 135 mg / mL, about 136 mg / mL, about 137 mg / mL, about 138 mg / mL, about 139 mg / mL, about 140 mg / mL, about 141 mg / mL, about 142 mg / mL, about 143 mg / mL, about 144 mg / mL, about 145 mg / mL, about 146 mg / mL, about 147 mg / mL, about 148 mg / mL, about 149 mg / mL, about 150 mg / mL, about 155 mg / mL, about 160 mg / mL, about 165 mg / mL, about 170 mg / mL, about 175 mg / mL, about 180 mg / mL, about 185 mg / mL, about 190 mg / mL, about 195 mg / mL, about 200 mg / mL, about 205 mg / mL, about 210 mg / mL, about 215 mg / mL, about 220 mg / mL, about 225 mg / mL, about 230 mg / mL, about 235 mg / mL, about 240 mg / mL, about 245 mg / mL, about 250 mg / mL, about 255 mg / mL, about 260 mg / mL, about 265 mg / mL, about 270 mg / mL, about 275 mg / mL, about 280 mg / mL, about 285 mg / mL, about 290 mg / mL, about 295 mg / mL, about 300 mg / mL, about 305 mg / mL, about 310 mg / mL, about 315 mg / mL, about 320 mg / mL, about 325 mg / mL, about 330 mg / mL, about 335 mg / mL, about 340 mg / mL, about 345mg / mL, about 350 mg / mL, about 355 mg / mL, about 360 mg / mL, about 365 mg / mL, about 370 mg / mL, about 375 mg / mL, about 380 mg / mL, about 385 mg / mL, about 390 mg / mL, about 395 mg / mL, about 400 mg / mL, about 405 mg / mL, about 410 mg / mL, about 415 mg / mL, about 420 mg / mL, about 425 mg / mL, about 430 mg / mL, about 435 mg / mL, about 440 mg / mL, about 445 mg / mL, about 450 mg / mL, about 455 mg / mL, about 460 mg / mL, about 465 mg / mL, about 470 mg / mL, about 475 mg / mL, about 480 mg / mL, about 485 mg / mL, about 490 mg / mL, about 495 mg / mL, or about 500 mg / mL of the protein.
31. The pharmaceutical composition of any one of claims 1-30, comprising about 105 mg / mL, about 120 mg / mL, about 126 mg / mL, about 128 mg / mL, about 140 mg / mL, about 144 mg / mL, about 150 mg / mL, or about 160 mg / mL of the protein.
32. The pharmaceutical composition of any one of claims 1-31, comprising about 0.25 mg to about 4000 mg, about 0.25 mg to about 3600 mg, about 0.25 mg to about 3200 mg, about 0.25 mg to about 3000 mg, about 0.25 mg to about 2600 mg, about 0.25 mg to about 2200 mg, about 0.25 mg to about 2000 mg, about 0.25 mg to about 1600 mg, about 0.25 mg to about 1200 mg, about 0.25 mg to about 1000 mg, about 0.25 mg to about 800 mg, about 0.25 mg to about 600 mg, about 0.25 mg to about 400 mg, about 0.25 mg to about 200 mg, about 0.25 mg to about 100 mg, about 0.25 mg to about 50 mg, about 0.25 mg to about 40 mg, about 0.25 mg to about 30 mg, about 0.25 mg to about 20 mg, about 20 mg to about 4000 mg, about 20 mg to about 3600 mg, about 20 mg to about 3200 mg, about 20 mg to about 3000 mg, about 20 mg to about 2600 mg, about 20 mg to about 2200 mg, about 20 mg to about 2000 mg, about 20 mg to about 1600 mg, about 20 mg to about 1200 mg, about 20 mg to about 1000 mg, about 20 mg to about 800 mg, about 20 mg to about 600 mg, about 20 mg to about 400 mg, about 20 mg to about 200 mg, about 20 mg to about 100 mg, about 100 mg to about 4000 mg, about 100 mg to about 3600 mg, about 100 mg to about 3200 mg, about 100 mg to about 3000 mg, about 100 mg to about 2600 mg, about 100 mg to about 2200 mg, about 100 mg to about 2000 mg, about 100 mg to about 1800 mg, about 100 mg to about 1600 mg, about 100 mg to about 1400 mg, about 100 mg to about 1200 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, about 400 mg to about 4000 mg, about 400 mg to about 3600 mg, about 400 mg to about 3200 mg, about 400 mg to about 3000 mg, about 400 mg to about 2600 mg, about 400 mg to about 2200 mg, about 400 mg to about 2000 mg, about 400 mg to about 1800 mg, about 400 mg to about 1600 mg, about 400 mg toabout 1400 mg, about 400 mg to about 1200 mg, or about 400 mg to about 1000 mg of the protein.
33. The pharmaceutical composition of any one of claims 1-32, comprising about 0.25 mg, about 0.5 mg, about 0.75 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3 mg, about 3.25 mg, about 3.5 mg, about 3.75 mg, about 4 mg, about 4.25 mg, about 4.5 mg, about 4.75 mg, about 5 mg, about 5.25 mg, about 5.5 mg, about 5.75 mg, about 6 mg, about 6.25 mg, about 6.5 mg, about 6.75 mg, about 7 mg, about 7.25 mg, about 7.5 mg, about 7.75 mg, about 8 mg, about 8.25 mg, about 8.5 mg, about 8.75 mg, about 9 mg, about 9.25 mg, about 9.5 mg, about 9.75 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, about 710 mg, about 720 mg, about 730 mg, about 740 mg, about 750 mg, about 760 mg, about 770 mg, about 780 mg, about 790 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 980 mg, about 990 mg, about 1000 mg, about 1020 mg, about 1040 mg, about 1060 mg, about 1080 mg, about 1100 mg, about 1120 mg, about 1140 mg, about 1160 mg, about 1180 mg, about 1200 mg, about 1220 mg, about 1240 mg, about 1260 mg, about 1280 mg, about 1300 mg, about 1320 mg, about 1340 mg, about 1360 mg, about 1380 mg, about 1400 mg, about 1420 mg, about 1440 mg, about 1460 mg, about 1480 mg, about 1500 mg, about 1520 mg, about 1540 mg, about 1560 mg, about 1580 mg, about 1600 mg, about 1620 mg, about1640 mg, about 1660 mg, about 1680 mg, about 1700 mg, about 1720 mg, about 1740 mg, about 1760 mg, about 1780 mg, about 1800 mg, about 1820 mg, about 1840 mg, about 1860 mg, about 1880 mg, about 1900 mg, about 1920 mg, about 1940 mg, about 1960 mg, about 1980 mg, about 2000 mg, about 2020 mg, about 2040 mg, about 2060 mg, about 2080 mg, about 2100 mg, about 2120 mg, about 2140 mg, about 2160 mg, about 2180 mg, about 2200 mg, about 2220 mg, about 2240 mg, about 2260 mg, about 2280 mg, about 2300 mg, about 2320 mg, about 2340 mg, about 2360 mg, about 2380 mg, about 2400 mg, about 2420 mg, about 2440 mg, about 2460 mg, about 2480 mg, about 2500 mg, about 2520 mg, about 2540 mg, about 2560 mg, about 2580 mg, about 2600 mg, about 2620 mg, about 2640 mg, about 2660 mg, about 2680 mg, about 2700 mg, about 2720 mg, about 2740 mg, about 2760 mg, about 2780 mg, about 2800 mg, about 2820 mg, about 2840 mg, about 2860 mg, about 2880 mg, about 2900 mg, about 2920 mg, about 2940 mg, about 2960 mg, about 2980 mg, about 3000 mg, about 3020 mg, about 3040 mg, about 3060 mg, about 3080 mg, about 3100 mg, about 3120 mg, about 3140 mg, about 3160 mg, about 3180 mg, about 3200 mg, about 3220 mg, about 3240 mg, about 3260 mg, about 3280 mg, about 3300 mg, about 3320 mg, about 3340 mg, about 3360 mg, about 3380 mg, about 3400 mg, about 3420 mg, about 3440 mg, about 3460 mg, about 3480 mg, about 3500 mg, about 3520 mg, about 3540 mg, about 3560 mg, about 3580 mg, about 3600 mg, about 3620 mg, about 3640 mg, about 3660 mg, about 3680 mg, about 3700 mg, about 3720 mg, about 3740 mg, about 3760 mg, about 3780 mg, about 3800 mg, about 3820 mg, about 3840 mg, about 3860 mg, about 3880 mg, about 3900 mg, about 3920 mg, about 3940 mg, about 3960 mg, about 3980 mg, or about 4000 mg of the protein.
34. The pharmaceutical composition of any one of claims 1-33, comprising about 1260 mg, about 1440 mg, or about 1920 mg of the protein.
35. The pharmaceutical composition of any one of claims 1-34, comprising about 100 mg / mL to about 150 mg / mL of the protein, about 200 mM or less of the salt, and about 250 mM or less of the sugar.
36. The pharmaceutical composition of any one of claims 1-35, wherein the sugar is sucrose and the salt is sodium chloride.
37. The pharmaceutical composition of any one of claims 1-36, wherein the protein comprises an antibody, a checkpoint inhibitor, a fusion protein, a growth factor, a hormone, an enzyme, a cytokine, a coagulation factor, a plasma protein, or a combination thereof.
38. The pharmaceutical composition of claim 37, wherein the protein comprises an antibody.
39. The pharmaceutical composition of claim 37 or 38, wherein the antibody comprises a full- length antibody.
40. The pharmaceutical composition of any one of claims 37-39, wherein the antibody comprises a monoclonal, human, humanized, chimeric, or multispecific antibody.
41. The pharmaceutical composition of claim 40, wherein the multispecific antibody comprises a dual-affinity re-targeting antibody, a dual variable domain immunoglobulin, or a bispecific antibody.
42. The pharmaceutical composition of claim 37 or 38, wherein the antibody comprises a F(ab')2 fragment, a Fab' fragment, a Fab fragment, a Fv fragment, a scFv fragment, a dsFv fragment, a dAb fragment, or a single chain binding polypeptide.
43. The pharmaceutical composition of any one of claims 37-42, wherein the antibody comprises an anti-LAG-3 antibody, an anti-PD-1 antibody, an anti-PD-Ll antibody, an anti-CTLA-4 antibody, an anti-TIM-3 antibody, an anti-TIGIT antibody, an anti-NKG2a antibody, an anti-OX40 antibody, an anti-ICOS antibody, an anti-MICA antibody, an antiCD 137 antibody, an anti -KIR antibody, an anti-TGFp antibody, an anti -IL- 10 antibody, an anti-IL-8 antibody, an anti-B7-H4 antibody, an anti-Fas ligand antibody, an anti-CXCR4 antibody, an anti-mesothelin antibody, an anti-CD27 antibody, an anti-GITR antibody, an anti-CCR8 antibody, an anti-ILT4 antibody, or a combination thereof.
44. The pharmaceutical composition of claim 43, wherein the anti-LAG-3 antibody comprises BMS-986016 (relatlimab), IMP731 (H5L7BW), MK4280 (28G-10, favezelimab), REGN3767 (fianlimab), GSK2831781, humanized BAP050, IMP-701 (LAG525, ieramilimab), aLAG3(0414), aLAG3(0416), Sym022, TSR-033, TSR-075, XmAb841 (XmAb22841), MGD013 (tebotelimab), BI754111, FS118, P 13B02-30, AVA-017, 25F7, AGEN1746, RO7247669, INCAGN02385, IBI-110, EMB-02, IBI-323, LBL-007, ABL501, or an antigen-binding portion thereof.
45. The pharmaceutical composition of claim 43 or 44, wherein the anti -LAG-3 antibody comprises relatlimab, or an antigen-binding portion thereof.
46. The pharmaceutical composition of any one of claims 43-45, wherein the anti-LAG-3 antibody comprises:(a) CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:3, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO:4;(b) a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO:10, respectively;(c) heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:3 and 4, respectively;(d) heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:l and 2, respectively; or(e) heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:21 and 2, respectively.
47. The pharmaceutical composition of any one of claims 43-46, wherein the anti-PD-1 antibody comprises nivolumab, pembrolizumab, PDR001 (spartalizumab), MEDL0680, TSR-042, cemiplimab, JSOO1, PF-06801591, BGB-A317, BI 754091, INCSHR1210, GLS- 010, AM-001, STI-1110, AGEN2034, MGA012, BCD-100, IBI308, SSI-361, or an antigen-binding portion thereof.
48. The pharmaceutical composition of any one of claims 43-47, wherein the anti-PD-1 antibody comprises nivolumab, or an antigen-binding portion thereof.
49. The pharmaceutical composition of any one of claims 43-48, wherein the anti-PD-1 antibody comprises:(a) CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 13, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO: 14;(b) a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO:20, respectively;(c) heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:13 and 14, respectively; or(d) heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:11 and 12, respectively.
50. The pharmaceutical composition of any one of claims 43-49, wherein the anti-PD-Ll antibody comprises BMS-936559, atezolizumab, durvalumab, avelumab, STI-1014, CX- 072, KN035, LY3300054, BGB-A333, ICO 36, FAZ053, CK-301, or an antigen-binding portion thereof.
51. The pharmaceutical composition of any one of claims 43-50, wherein the anti-CTLA-4 antibody comprises ipilimumab, tremelimumab, MK-1308, AGEN-1884, or an antigenbinding portion thereof.
52. The pharmaceutical composition of any one of claims 43-51, wherein the antibody comprises two antibodies.
53. The pharmaceutical composition of claim 52, wherein the antibody comprises an anti-PD- 1 or anti-PD-Ll antibody and an anti-LAG-3 antibody.
54. The pharmaceutical composition of claim 53, wherein the mg:mg or mg / mL:mg / mL ratio of the anti-PD-1 or anti-PD-Ll antibody to the anti-LAG-3 antibody is about 1:1, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, about 1:15, about 1:20, about 1:30, about 1:40, about 1:50, about 1:60, about 1:70, about 1:80, about 1:90, about 1:100, about 1:120, about 1:140, about 1:160, about 1:180, about 1:200, about 200:1, about 180:1, about 160:1, about 140:1, about 120:1, about 100:1, about 90:1, about 80:1, about 70:1, about 60:1, about 50:1, about 40:1, about 30:1, about 20:1, about 15:1, about 10:1, about 9:1, about 8:1, about 7:1, about 6:1, about 5:1, about 4:1, about 3:1, about 2:1, about 3:4, about 3:2, about 2:3, or about 4:3.
55. The pharmaceutical composition of claim 53 or 54, wherein the mg:mg or mg / mL:mg / mL ratio of the anti-PD-1 or anti-PD-Ll antibody to the anti -LAG-3 antibody is about 1:1, about 2:1, or about 3:4.
56. The pharmaceutical composition of any one of claims 53-55, wherein the concentration of the anti-PD-1 or anti-PD-Ll antibody is about 10 mg / mL, about 15 mg / mL, about 20 mg / mL, about 25 mg / mL, about 30 mg / mL, about 35 mg / mL, about 40 mg / mL, about 45 mg / mL, about 50 mg / mL, about 52.5 mg / mL, about 55 mg / mL, about 60 mg / mL, about 64 mg / mL, about 65 mg / mL, about 70 mg / mL, about 72 mg / mL, about 75 mg / mL, about 78.8 mg / mL, about 80 mg / mL, about 85 mg / mL, about 90 mg / mL, about 94.5 mg / mL, about 95 mg / mL, about 100 mg / mL, about 105 mg / mL, about 108 mg / mL, about 110 mg / mL, about 120 mg / mL, about 130 mg / mL, about 132 mg / mL, about 135 mg / mL, about 137.5 mg / mL, about 140 mg / mL, about 150 mg / mL, about 160 mg / mL, about 170 mg / mL, about 175 mg / mL, about 180 mg / mL, about 190 mg / mL, about 200 mg / mL, about 210 mg / mL, about 220 mg / mL, about 230 mg / mL, about 240 mg / mL, about 250 mg / mL, about 260 mg / mL, about 270 mg / mL, about 280 mg / mL, about 290 mg / mL, about 300 mg / mL, about 310 mg / mL, about 320 mg / mL, about 330 mg / mL, about 340 mg / mL, about 350 mg / mL, about 360 mg / mL, about 370 mg / mL, about 380 mg / mL, about 390 mg / mL, about 400 mg / mL, about 410 mg / mL, about 420 mg / mL, about 430 mg / mL, about 440 mg / mL, about 450 mg / mL, about 460 mg / mL, about 470 mg / mL, about 480 mg / mL, about 490 mg / mL, or about 500 mg / mL.
57. The pharmaceutical composition of any one of claims 53-56, comprising about 0.25 mg to about 2000 mg, about 0.25 mg to about 1600 mg, about 0.25 mg to about 1200 mg, about 0.25 mg to about 800 mg, about 0.25 mg to about 400 mg, about 0.25 mg to about 100 mg, about 0.25 mg to about 50 mg, about 0.25 mg to about 40 mg, about 0.25 mg to about 30 mg, about 0.25 mg to about 20 mg, about 20 mg to about 2000 mg, about 20 mg to about 1600 mg, about 20 mg to about 1200 mg, about 20 mg to about 800 mg, about 20 mg to about 400 mg, about 20 mg to about 100 mg, about 100 mg to about 2000 mg, about 100 mg to about 1800 mg, about 100 mg to about 1600 mg, about 100 mg to about 1400 mg, about 100 mg to about 1200 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, about 400 mg to about 2000 mg, about 400 mg to about 1800 mg, about 400 mg to about 1600 mg, about400 mg to about 1400 mg, about 400 mg to about 1200 mg, or about 400 mg to about 1000 mg of the anti-PD-1 or anti-PD-Ll antibody.
58. The pharmaceutical composition of any one of claims 53-57, comprising about 0.25 mg, about 0.5 mg, about 0.75 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3 mg, about 3.25 mg, about 3.5 mg, about 3.75 mg, about 4 mg, about 4.25 mg, about 4.5 mg, about 4.75 mg, about 5 mg, about 5.25 mg, about 5.5 mg, about 5.75 mg, about 6 mg, about 6.25 mg, about 6.5 mg, about 6.75 mg, about 7 mg, about 7.25 mg, about 7.5 mg, about 7.75 mg, about 8 mg, about 8.25 mg, about 8.5 mg, about 8.75 mg, about 9 mg, about 9.25 mg, about 9.5 mg, about 9.75 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, about 710 mg, about 720 mg, about 730 mg, about 740 mg, about 750 mg, about 760 mg, about 770 mg, about 780 mg, about 790 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 980 mg, about 990 mg, about 1000 mg, about 1040 mg, about 1080 mg, about 1100 mg, about 1140 mg, about 1180 mg, about 1200 mg, about 1240 mg, about 1280 mg, about 1300 mg, about 1340 mg, about 1380 mg, about 1400 mg, about 1440 mg, about 1480 mg, about 1500 mg, about 1540 mg, about 1580 mg, about 1600 mg, about 1640 mg, about 1680 mg, about 1700 mg, about 1740 mg, about 1780 mg, about 1800 mg, about 1840 mg, about 1880 mg,about 1900 mg, about 1940 mg, about 1980 mg, or about 2000 mg of the anti-PD-1 or anti- PD-L1 antibody.
59. The pharmaceutical composition of any one of claims 53-58, wherein the concentration of the anti -LAG-3 antibody is about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 3.3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 6 mg / mL, about 7 mg / mL, about 8 mg / mL, about 9 mg / mL, about 10 mg / mL, about 13 mg / mL, about 13.35 mg / mL, about 15 mg / mL, about 18 mg / mL, about 20 mg / mL, about 23 mg / mL, about 25 mg / mL, about 26 mg / mL, about 26.2 mg / mL, about 26.7 mg / mL, about 27 mg / mL, about 28 mg / mL, about 29 mg / mL, about 30 mg / mL, about 31.5 mg / mL, about 35 mg / mL, about 37.5 mg / mL, about 40 mg / mL, about 45 mg / mL, about 50 mg / mL, about 52.5 mg / mL, about 55 mg / mL, about 60 mg / mL, about 64 mg / mL, about 65 mg / mL, about 70 mg / mL, about 72 mg / mL, about 75 mg / mL, about 80 mg / mL, about 85 mg / mL, about 90 mg / mL, about 95 mg / mL, about 100 mg / mL, about 108 mg / mL, about 110 mg / mL, about 120 mg / mL, about 130 mg / mL, about 132 mg / mL, about 135 mg / mL, about 140 mg / mL, about 150 mg / mL, about 160 mg / mL, about 170 mg / mL, about 175 mg / mL, about 180 mg / mL, about 190 mg / mL, about 200 mg / mL, about 210 mg / mL, about 220 mg / mL, about 230 mg / mL, about 240 mg / mL, about 250 mg / mL, about 260 mg / mL, about 270 mg / mL, about 280 mg / mL, about 290 mg / mL, about 300 mg / mL, about 310 mg / mL, about 320 mg / mL, about 330 mg / mL, about 340 mg / mL, about 350 mg / mL, about 360 mg / mL, about 370 mg / mL, about 380 mg / mL, about 390 mg / mL, about 400 mg / mL, about 410 mg / mL, about 420 mg / mL, about 430 mg / mL, about 440 mg / mL, about 450 mg / mL, about 460 mg / mL, about 470 mg / mL, about 480 mg / mL, about 490 mg / mL, or about 500 mg / mL.
60. The pharmaceutical composition of any one of claims 53-59, comprising about 0.25 mg to about 2000 mg, about 0.25 mg to about 1600 mg, about 0.25 mg to about 1200 mg, about 0.25 mg to about 800 mg, about 0.25 mg to about 400 mg, about 0.25 mg to about 100 mg, about 0.25 mg to about 50 mg, about 0.25 mg to about 40 mg, about 0.25 mg to about 30 mg, about 0.25 mg to about 20 mg, about 20 mg to about 2000 mg, about 20 mg to about 1600 mg, about 20 mg to about 1200 mg, about 20 mg to about 800 mg, about 20 mg to about 400 mg, about 20 mg to about 100 mg, about 100 mg to about 2000 mg, about 100 mg to about 1800 mg, about 100 mg to about 1600 mg, about 100 mg to about 1400 mg, about 100 mg to about 1200 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, about 400 mg toabout 2000 mg, about 400 mg to about 1800 mg, about 400 mg to about 1600 mg, about 400 mg to about 1400 mg, about 400 mg to about 1200 mg, or about 400 mg to about 1000 mg of the anti -LAG-3 antibody.
61. The pharmaceutical composition of any one of claims 53-60, comprising about 0.25 mg, about 0.5 mg, about 0.75 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3 mg, about 3.25 mg, about 3.5 mg, about 3.75 mg, about 4 mg, about 4.25 mg, about 4.5 mg, about 4.75 mg, about 5 mg, about 5.25 mg, about 5.5 mg, about 5.75 mg, about 6 mg, about 6.25 mg, about 6.5 mg, about 6.75 mg, about 7 mg, about 7.25 mg, about 7.5 mg, about 7.75 mg, about 8 mg, about 8.25 mg, about 8.5 mg, about 8.75 mg, about 9 mg, about 9.25 mg, about 9.5 mg, about 9.75 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, about 710 mg, about 720 mg, about 730 mg, about 740 mg, about 750 mg, about 760 mg, about 770 mg, about 780 mg, about 790 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 980 mg, about 990 mg, about 1000 mg, about 1040 mg, about 1080 mg, about 1100 mg, about 1140 mg, about 1180 mg, about 1200 mg, about 1240 mg, about 1280 mg, about 1300 mg, about 1340 mg, about 1380 mg, about 1400 mg, about 1440 mg, about 1480 mg, about 1500 mg, about 1540 mg, about 1580 mg, about 1600 mg, about 1640 mg, about 1680 mg, about 1700 mg, about 1740 mg, about 1780 mg, about 1800 mg, about 1840 mg, about 1880 mg,about 1900 mg, about 1940 mg, about 1980 mg, or about 2000 mg of the anti -LAG-3 antibody.
62. The pharmaceutical composition of any one of claims 53-61, comprising about 80 mg / mL of the anti-PD-1 antibody and about 80 mg / mL of the anti -LAG-3 antibody.
63. The pharmaceutical composition of claim 62, comprising a volume of about 12 mL.
64. The pharmaceutical composition of claim 62, comprising a volume of about 9 mL.
65. The pharmaceutical composition of any one of claims 53-61, comprising about 75 mg / mL of the anti-PD-1 antibody and about 75 mg / mL of the anti-LAG-3 antibody.
66. The pharmaceutical composition of claim 65, comprising a volume of about 12.8 mL.
67. The pharmaceutical composition of claim 65, comprising a volume of about 9.6 mL.
68. The pharmaceutical composition of any one of claims 53-61, comprising about 72 mg / mL of the anti-PD-1 antibody and about 72 mg / mL of the anti-LAG-3 antibody.
69. The pharmaceutical composition of claim 68, comprising a volume of about 10 mL.
70. The pharmaceutical composition of any one of claims 53-61, comprising about 64 mg / mL of the anti-PD-1 antibody and about 64 mg / mL of the anti-LAG-3 antibody.
71. The pharmaceutical composition of claim 70, comprising a volume of about 15 mL.
72. The pharmaceutical composition of any one of claims 53-61, comprising about 60 mg / mL of the anti-PD-1 antibody and about 60 mg / mL of the anti-LAG-3 antibody.
73. The pharmaceutical composition of claim 72, comprising a volume of about 16 mL.
74. The pharmaceutical composition of claim 72, comprising a volume of about 12 mL.
75. The pharmaceutical composition of any one of claims 53-61, comprising about 52.5 mg / mL of the anti-PD-1 antibody and about 52.5 mg / mL of the anti-LAG-3 antibody.
76. The pharmaceutical composition of claim 75, comprising a volume of about 18.3 mL.
77. The pharmaceutical composition of any one of claims 53-61, comprising about 64.3 mg / mL of the anti-PD-1 antibody and about 85.7 mg / mL of the anti-LAG-3 antibody.
78. The pharmaceutical composition of claim 77, comprising a volume of about 8.4 mL.
79. The pharmaceutical composition of any one of claims 53-61, comprising about 60 mg / mL of the anti-PD-1 antibody and about 80 mg / mL of the anti-LAG-3 antibody.
80. The pharmaceutical composition of claim 79, comprising a volume of about 9 mL.
81. The pharmaceutical composition of any one of claims 53-61, comprising about 54 mg / mL of the anti-PD-1 antibody and about 72 mg / mL of the anti-LAG-3 antibody.
82. The pharmaceutical composition of claim 81, comprising a volume of about 10 mL.
83. The pharmaceutical composition of any one of claims 53-61, comprising about 45 mg / mL of the anti-PD-1 antibody and about 60 mg / mL of the anti-LAG-3 antibody.
84. The pharmaceutical composition of claim 83, comprising a volume of about 12 mL.
85. The pharmaceutical composition of any one of claims 53-61, comprising about 960 mg of the anti-PD-1 antibody and about 960 mg of the anti-LAG-3 antibody.
86. The pharmaceutical composition of any one of claims 53-61, comprising about 720 mg of the anti-PD-1 antibody and about 720 mg of the anti-LAG-3 antibody.
87. The pharmaceutical composition of any one of claims 53-61, comprising about 540 mg of the anti-PD-1 antibody and about 720 mg of the anti-LAG-3 antibody.
88. The pharmaceutical composition of any one of claims 53-61, comprising about 75 mg / mL of the anti-PD-1 antibody and about 75 mg / mL of an anti-LAG-3 antibody, wherein the salt comprises about 100 mM of sodium chloride, and the sugar comprises about 210 mM of sucrose.
89. The pharmaceutical composition of any one of claims 53-61, comprising about 60 mg / mL of the anti-PD-1 antibody and about 60 mg / mL of the anti-LAG-3 antibody, wherein the salt comprises about 40 mM of sodium chloride, and the sugar comprises about 170 mM of sucrose.
90. The pharmaceutical composition of any one of claims 53-61, comprising about 52.5 mg / mL of the anti-PD-1 antibody and about 52.5 mg / mL of the anti-LAG-3 antibody, wherein the salt comprises about 50 mM of sodium chloride, and the sugar comprises about 150 mM of sucrose.
91. The pharmaceutical composition of any one of claims 53-90, wherein the anti-PD-1 antibody comprises nivolumab and the anti-LAG-3 antibody comprises relatlimab, or an antigen-binding portion thereof.
92. The pharmaceutical composition of any one of claims 53-91, wherein:(a) the anti-LAG-3 antibody comprises CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:3, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO:4, and the anti-PD-1 antibody comprises CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 13, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO: 14;(b) the anti-LAG-3 antibody comprises a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO: 6, and SEQ ID NO: 7, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO: 10, respectively, and the anti-PD-1 antibody comprises a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO:20, respectively;(c) the anti-LAG-3 antibody comprises heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:3 and 4, respectively, and the anti-PD-1 antibody comprises heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:13 and 14, respectively;(d) the anti-LAG-3 antibody comprises heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:1 and 2, respectively, and the anti-PD-1 antibody comprises heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs: 11 and 12, respectively; or(e) the anti-LAG-3 antibody comprises heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:21 and 2, respectively, and the anti-PD-1 antibody comprises heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs: 11 and 12, respectively.
93. The pharmaceutical composition of any one of claims 1-92, further comprising an antioxidant.
94. The pharmaceutical composition of claim 93, wherein the antioxidant comprises a sacrificial antioxidant, a metal ion chelator, or both.
95. The pharmaceutical composition of claim 93 or 94, wherein the antioxidant comprises methionine, tryptophan, histidine, cysteine, ascorbic acid, glycine, pentetic acid (" DTP A"), ethylenediaminetetraacetic acid (" EDTA"), or a combination thereof.
96. The pharmaceutical composition of any one of claims 93-95, comprising at least two antioxidants.
97. The pharmaceutical composition of claim 96, wherein the at least two antioxidants are (i) methionine and DTPA or (ii) methionine and EDTA.
98. The pharmaceutical composition of any one of claims 95-97, comprising at least about 1 mM, at least about 1.5 mM, at least about 2 mM, at least about 2.5 mM, at least about 3 mM, at least about 3.5 mM, at least about 4 mM, at least about 4.5 mM, at least about 5 mM, at least about 5.5 mM, at least about 6 mM, at least about 6.5 mM, at least about 7 mM, at least about 7.5 mM, at least about 8 mM, at least about 8.5 mM, at least about 9 mM, at least about 9.5 mM, at least about 10 mM, at least about 11 mM, at least about 12 mM, at least about 13 mM, at least about 14 mM, at least about 15 mM, at least about 16 mM, at least about 17 mM, at least about 18 mM, at least about 19 mM, or at least about 20 mM of methionine.
99. The pharmaceutical composition of any one of claims 95-98, comprising about 0.1 mM to about 100 mM, about 0.1 mM to about 90 mM, about 0.1 mM to about 80 mM, about 0.1 mM to about 70 mM, about 0.1 mM to about 60 mM, about 0.1 mM to about 50 mM, about 0.1 mM to about 40 mM, about 0.1 mM to about 30 mM, about 0.1 mM to about 20 mM, about 0.1 mM to about 10 mM, about 1 mM to about 20 mM, about 1 mM to about 15 mM, about 1 mM to about 10 mM, about 1 mM to about 9 mM, about 1 mM to about 8 mM, about 1 mM to about 7 mM, about 1 mM to about 6 mM, about 1 mM to about 5 mM, about 2 mM to about 9 mM, about 3 mM to about 8 mM, about 4 mM to about 7 mM, about 4 mM to about 6 mM, about 4 mM to about 5 mM, about 5 mM to about 20 mM, about 5 mM to about 15 mM, about 5 mM to about 10 mM, about 5 mM to about 9 mM, about 5 mM to about 8 mM, about 5 mM to about 7 mM, or about 5 mM to about 6 mM of methionine.
100. The pharmaceutical composition of any one of claims 95-99, comprising about 1 mM, about 1.5 mM, about 2 mM, about 2.5 mM, about 3 mM, about 3.5 mM, about 4 mM, about 4.5 mM, about 5 mM, about 5.5 mM, about 6 mM, about 6.5 mM, about 7 mM, about 7.5 mM, about 8 mM, about 8.5 mM, about 9 mM, about 9.5 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM, about 55 mM, about 60 mM, about 65 mM, about 70 mM, about 75 mM, about 80 mM, about 85 mM, about 90 mM, about 95 mM, or about 100 mM of methionine.
101. The pharmaceutical composition of any one of claims 95-100, comprising about 5 mM of methionine.
102. The pharmaceutical composition of any one of claims 95-101, comprising about 1 pM to about 250 pM, about 10 pM to about 200 pM, about 10 pM to about 175 pM, about 10 pM to about 150 pM, about 10 pM to about 125 pM, about 10 pM to about 100 pM, about 10 pM to about 75 pM, about 10 pM to about 70 pM, about 10 pM to about 60 pM, about 10 pM to about 50 pM, about 20 pM to about 100 pM, about 20 pM to about 75 pM, about 20 pM to about 70 pM, about 20 pM to about 60 pM, about 20 pM to about 50 pM, about 25 pM to about 100 pM, about 25 pM to about 75 pM, about 25 pM to about 50 pM, about 30 pM to about 100 pM, about 30 pM to about 75 pM, about 30 pM to about 70 pM, about30 pM to about 60 pM, about 30 pM to about 50 pM, about 40 pM to about 100 pM, about 40 pM to about 75 pM, about 40 pM to about 70 pM, about 40 pM to about 60 pM, about 40 pM to about 50 pM, about 41 pM to about 59 pM, about 42 pM to about 58 pM, about 43 pM to about 57 pM, about 44 pM to about 56 pM, about 45 pM to about 55 pM, about 46 pM to about 54 pM, about 47 pM to about 53 pM, about 48 pM to about 52 pM, about 49 pM to about 51 pM, about 50 pM to about 100 pM, about 50 pM to about 75 pM, about 50 pM to about 70 pM, about 50 pM to about 60 pM of DTPA.
103. The pharmaceutical composition of any one of claims 95-102, comprising about 1 pM, about 5 pM, about 10 pM, about 15 pM, about 20 pM, about 25 pM, about 30 pM, about 35 pM, about 40 pM, about 45 pM, about 50 pM, about 55 pM, about 60 pM, about 65 pM, about 70 pM, about 75 pM, about 80 pM, about 85 pM, about 90 pM, about 95 pM, about 100 pM, about 110 pM, about 120 pM, about 130 pM, about 140 pM, about 150 pM, about 160 pM, about 170 pM, about 180 pM, about 190 pM, about 200 pM, about 210 pM, about 220 pM, about 230 pM, about 240 pM, or about 250 pM of DTPA.
104. The pharmaceutical composition of any one of claims 95-103, comprising about 50 pM of DTPA.
105. The pharmaceutical composition of any one of claims 1-104, further comprising a buffering agent.
106. The pharmaceutical composition of claim 105, wherein the pharmaceutical composition comprises a higher concentration of the buffering agent as compared to the corresponding composition.
107. The pharmaceutical composition of claim 105 or 106, wherein the buffering agent comprises histidine, succinate, Tris, sodium phosphate, sodium acetate, sodium citrate, or a combination thereof.
108. The pharmaceutical composition of any one of claims 105-107, wherein the buffering agent comprises histidine.
109. The pharmaceutical composition of claim 107 or 108, wherein the buffering agent comprises at least about 5 mM, at least about 10 mM, at least about 15 mM, at least about 20 mM, at least about 25 mM, at least about 30 mM, at least about 35 mM, at least about40 mM, at least about 45 mM, at least about 50 mM, at least about 60 mM, at least about 70 mM, at least about 80 mM, at least about 90 mM, or at least about 100 mM of histidine.
110. The pharmaceutical composition of any one of claims 107-109, wherein the buffering agent comprises about 1 mM to about 100 mM, about 1 mM to about 90 mM, about 1 mM to about 80 mM, about 1 mM to about 75 mM, about 1 mM to about 70 mM, about 1 mM to about 65 mM, about 1 mM to about 60 mM, about 1 mM to about 55 mM, about 1 mM to about 50 mM, about 1 mM to about 45 mM, about 1 mM to about 40 mM, about 1 mM to about 35 mM, about 1 mM to about 30 mM, about 1 mM to about 25 mM, about 1 mM to about 20 mM, about 1 mM to about 15 mM, about 1 mM to about 10 mM, about 1 mM to about 5 mM, about 5 mM to about 100 mM, about 5 mM to about 90 mM, about 5 mM to about 80 mM, about 5 mM to about 75 mM, about 5 mM to about 70 mM, about 5 mM to about 65 mM, about 5 mM to about 60 mM, about 5 mM to about 55 mM, about 5 mM to about 50 mM, about 5 mM to about 45 mM, about 5 mM to about 40 mM, about 5 mM to about 35 mM, about 5 mM to about 30 mM, about 5 mM to about 25 mM, about 5 mM to about 20 mM, about 5 mM to about 15 mM, about 5 mM to about 10 mM, about 10 mM to about 100 mM, about 10 mM to about 90 mM, about 10 mM to about 80 mM, about 10 mM to about 75 mM, about 10 mM to about 70 mM, about 10 mM to about 65 mM, about 10 mM to about 60 mM, about 10 mM to about 55 mM, about 10 mM to about 50 mM, about 10 mM to about 45 mM, about 10 mM to about 40 mM, about 10 mM to about 35 mM, about 10 mM to about 30 mM, about 10 mM to about 25 mM, about 10 mM to about 20 mM, about 10 mM to about 15 mM, about 15 mM to about 100 mM, about 15 mM to about 90 mM, about 15 mM to about 80 mM, about 15 mM to about 75 mM, about 15 mM to about 70 mM, about 15 mM to about 65 mM, about 15 mM to about 60 mM, about 15 mM to about 55 mM, about 15 mM to about 50 mM, about 15 mM to about 45 mM, about 15 mM to about 40 mM, about 15 mM to about 35 mM, about 15 mM to about 30 mM, about 15 mM to about 25 mM, about 15 mM to about 20 mM, about 16 mM to about 24 mM, about 17 mM to about 23 mM, about 18 mM to about 22 mM, about 19 mM to about 21 mM, about 20 mM to about 100 mM, about 20 mM to about 90 mM, about 20 mM to about 80 mM, about 20 mM to about 75 mM, about 20 mM to about 70 mM, about 20 mM to about 65 mM, about 20 mM to about 60 mM, about 20 mM to about 55 mM, about 20 mM to about 50 mM, about 20 mM to about 45 mM, about 20 mM to about 40 mM, about 20 mM to about 35 mM, about 20 mM to about 30 mM, about 20 mM to about 25 mM,about 25 mM to about 100 mM, about 30 mM to about 100 mM, about 35 mM to about 100 mM, about 40 mM to about 100 mM, about 45 mM to about 100 mM, or about 50 mM to about 100 mM of histidine.
111. The pharmaceutical composition of any one of claims 107-110, wherein the buffering agent comprises about 1 mM, about 5 mM, about 10 mM, about 15 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM, about 55 mM, about 60 mM, about 65 mM, about 70 mM, about 75 mM, about 80 mM, about 90 mM, or about 100 mM of histidine.
112. The pharmaceutical composition of any one of claims 107-111, wherein the buffering agent comprises about 20 mM of histidine.
113. The pharmaceutical composition of any one of claims 1-112, further comprising a surfactant.
114. The pharmaceutical composition of claim 113, wherein the surfactant comprises polysorbate 20, polysorbate 80, or poloxamer 188.
115. The pharmaceutical composition of claim 113 or 114, wherein the surfactant comprises polysorbate 80.
116. The pharmaceutical composition of claim 114 or 115, comprising at least about 0.01% w / v, at least about 0.02% w / v, at least about 0.03% w / v, at least about 0.04% w / v, at least about 0.05% w / v, at least about 0.06% w / v, at least about 0.07% w / v, at least about 0.08% w / v, at least about 0.09% w / v, or at least about 0.1% w / v of polysorbate 80.
117. The pharmaceutical composition of any one of claims 114-116, comprising about 0.001% to about 1% w / v, about 0.001% w / v to about 0.9% w / v, about 0.001% w / v to about 0.8% w / v, about 0.001% w / v to about 0.7% w / v, about 0.001% w / v to about 0.6% w / v, about 0.001% w / v to about 0.5% w / v, about 0.001% w / v to about 0.4% w / v, about 0.001% w / v to about 0.3% w / v, about 0.001% w / v to about 0.2% w / v, about 0.001% w / v to about 0.1% w / v, about 0.001% w / v to about 0.09% w / v, about 0.001% w / v to about 0.08% w / v, about 0.001% w / v to about 0.07% w / v, about 0.001% w / v to about 0.06% w / v, about 0.001% w / v to about 0.05% w / v, about 0.01% w / v to about 0.9% w / v, about 0.01% w / v to about 0.8% w / v, about 0.01% w / v to about 0.7% w / v, about 0.01% w / v to about 0.6% w / v, about 0.01%w / v to about 0.5% w / v, about 0.01% w / v to about 0.4% w / v, about 0.01% w / v to about 0.3% w / v, about 0.01% w / v to about 0.2% w / v, about 0.01% w / v to about 0.1% w / v, about 0.01% w / v to about 0.09% w / v, about 0.01% w / v to about 0.08% w / v, about 0.01% w / v to about 0.07% w / v, about 0.01% w / v to about 0.06% w / v, about 0.01% w / v to about 0.05% w / v, about 0.02% w / v to about 0.1% w / v, about 0.02% w / v to about 0.09% w / v, about 0.02% w / v to about 0.08% w / v, about 0.02% w / v to about 0.07% w / v, about 0.02% w / v to about 0.06% w / v, about 0.02% w / v to about 0.05% w / v, about 0.03% w / v to about 0.1% w / v, about 0.03% w / v to about 0.09% w / v, about 0.03% w / v to about 0.08% w / v, about 0.03% w / v to about 0.07% w / v, about 0.03% w / v to about 0.06% w / v, about 0.03% w / v to about 0.05% w / v, about 0.04% w / v to about 0.1% w / v, about 0.04% w / v to about 0.09% w / v, about 0.04% w / v to about 0.08% w / v, about 0.04% w / v to about 0.07% w / v, about 0.04% w / v to about 0.06% w / v, about 0.04% w / v to about 0.05%, about 0.05% w / v to about 0.1% w / v, about 0.05% w / v to about 0.09% w / v, about 0.05% w / v to about 0.08% w / v, about 0.05% w / v to about 0.07% w / v, or about 0.05% w / v to about 0.06% w / v of polysorbate 80.
118. The pharmaceutical composition of any one of claims 114-117, comprising about 0.001% w / v, about 0.002% w / v, about 0.003% w / v, about 0.004% w / v, about 0.005% w / v, about 0.006% w / v, about 0.007% w / v, about 0.008% w / v, about 0.009% w / v, about 0.01% w / v, about 0.02% w / v, about 0.03% w / v, about 0.04% w / v, about 0.05% w / v, about 0.06% w / v, about 0.07% w / v, about 0.08% w / v, about 0.09% w / v, about 0.1% w / v, about 0.2% w / v, about 0.3% w / v, about 0.4% w / v, about 0.5% w / v, about 0.6% w / v, about 0.7% w / v, about 0.8% w / v, about 0.9% w / v, or about 1% w / v of polysorbate 80.
119. The pharmaceutical composition of any one of claims 114-118, comprising about 0.05% w / v of polysorbate 80.
120. The pharmaceutical composition of any one of claims 1-119, further comprising an endoglycosidase hydrolase enzyme.
121. The pharmaceutical composition of claim 120, wherein the endoglycosidase hydrolase enzyme cleaves hyaluronic acid at a hexosaminidic P (1-4) or (1-3) linkage.
122. The pharmaceutical composition of claim 120 or 121, wherein the endoglycosidase hydrolase enzyme comprises a catalytic domain of hyaluronidase PH-20 (HuPH20), HYAL1, HYAL2, HYAL3, HYAL4, orHYALPSl.
123. The pharmaceutical composition of any one of claims 120-122, wherein the endoglycosidase hydrolase enzyme comprises a hyaluronidase.
124. The pharmaceutical composition of claim 123, wherein the hyaluronidase comprises HuPH20, HYAL1, HYAL2, HYAL3, HYAL4, or a variant or isoform thereof.
125. The pharmaceutical composition of any one of claims 120-124, wherein the endoglycosidase hydrolase enzyme comprises rHuPH20 or a fragment thereof.
126. The pharmaceutical composition of any one of claims 120-125, wherein the endoglycosidase hydrolase enzyme comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity to amino acids 36-490 of SEQ ID NO:87.
127. The pharmaceutical composition of any one of claims 120-126, wherein the endoglycosidase hydrolase enzyme comprises a modified hyaluronidase comprising one or more amino acid substitutions relative to a wild-type hyaluronidase that is HuPH20, HYAL1, HYAL2, HYAL3, HYAL4, HYALPS1, or a fragment thereof.
128. The pharmaceutical composition of any one of claims 120-127, wherein the endoglycosidase hydrolase enzyme comprises a modified hyaluronidase comprising (i) one or more amino acid substitution in an alpha-helix region, (ii) one or more amino acid substitution in a linker region, (iii) deletion of one or more N-terminal and / or C-terminal amino acids, or (iv) any combination of (i)-(iii), relative to a wild-type hyaluronidase that is HuPH20, HYAL1, HYAL2, HYAL3, HYAL4, HYALPS1, or a fragment thereof.
129. The pharmaceutical composition of any one of claims 120-128, wherein the endoglycosidase hydrolase enzyme comprises a modified rHuPH20, wherein the modified rHuPH20 comprises:(a) one or more amino acid substitution in an alpha-helix region, a linker region, or both an alpha-helix region and a linker region relative to wild-type rHuPH20;(b) deletion of one or more N-terminal amino acid, one or more C-terminal amino acid, or one or more N-terminal amino acid and one or more C-terminal amino acid relative to wild-type rHuPH20; or(c) both (a) and (b).
130. The pharmaceutical composition of any one of claims 120-129, comprising at least about 50 IU / mL, at least about 100 IU / mL, at least about 150 IU / mL, at least about 200 IU / mL, at least about 250 IU / mL, at least about 300 IU / mL, at least about 350 IU / mL, at least about 400 IU / mL, at least about 450 IU / mL, at least about 500 IU / mL, at least about 550 IU / mL, at least about 600 IU / mL, at least about 650 IU / mL, at least about 700 IU / mL, at least about 750 IU / mL, at least about 800 IU / mL, at least about 850 IU / mL, at least about 900 IU / mL, at least about 950 IU / mL, at least about 1000 IU / mL, at least about 1100 IU / mL, at least about 1200 IU / mL, at least about 1300 IU / mL, at least about 1400 IU / mL, at least about 1500 IU / mL, at least about 1600 IU / mL, at least about 1700 IU / mL, at least about 1800 IU / mL, at least about 1900 IU / mL, at least about 2000 IU / mL, at least about 2100 IU / mL, at least about 2200 IU / mL, at least about 2300 IU / mL, at least about 2400 IU / mL, at least about 2500 IU / mL, at least about 3000 IU / mL, at least about 3500 IU / mL, at least about 4000 IU / mL, at least about 4500 IU / mL, or at least about 5000 IU / mL of the endoglycosidase hydrolase enzyme.
131. The pharmaceutical composition of any one of claims 120-130, comprising about 50 IU / mL to about 10,000 IU / mL, about 100 IU / mL to about 9500 IU / mL, about 150 IU / mL to about 9000 IU / mL, about 200 IU / mL to about 8500 IU / mL, about 250 IU / mL to about 8000 IU / mL, about 300 IU / mL to about 7500 IU / mL, about 350 IU / mL to about 7000 IU / mL, about 400 IU / mL to about 6500 IU / mL, about 450 IU / mL to about 6000 IU / mL, about 500 IU / mL to about 5500 IU / mL, about 550 IU / mL to about 5000 IU / mL, about 600 IU / mL to about 4500 IU / mL, about 650 IU / mL to about 4000 IU / mL, about 700 IU / mL to about 3500 IU / mL, about 750 IU / mL to about 3000 IU / mL, about 800 IU / mL to about 2500 IU / mL, about 900 IU / mL to about 2500 IU / mL, about 1000 IU / mL to about 2500 IU / mL, about 1500 IU / mL to about 2500 IU / mL, about 1600 IU / mL to about 2500 IU / mL, about 1700 IU / mL to about 2500 IU / mL, about 1800 IU / mL to about 2500 IU / mL, about 1900 IU / mL to about 2500 IU / mL, about 2000 IU / mL to about 2500 IU / mL, about 2100 IU / mL to about 2500 IU / mL, about 2200 IU / mL to about 2500 IU / mL, about 2300 IU / mL to about 2500 IU / mL, about 1500 IU / mL to about 2500 IU / mL, about 1600 IU / mL to about 2400 IU / mL,about 1700 IU / mL to about 2300 IU / mL, about 1800 IU / mL to about 2200 IU / mL, or about 1900 IU / mL to about 2100 IU / mL of the endoglycosidase hydrolase enzyme.
132. The pharmaceutical composition of any one of claims 120-131, comprising about 50 IU / mL, about 100 IU / mL, about 150 IU / mL, about 200 IU / mL, about 250 IU / mL, about 300 IU / mL, about 350 IU / mL, about 400 IU / mL, about 450 IU / mL, about 500 IU / mL, about 550 IU / mL, about 600 IU / mL, about 650 IU / mL, about 700 IU / mL, about 750 IU / mL, about 800 IU / mL, about 850 IU / mL, about 900 IU / mL, about 950 IU / mL, about 1000 IU / mL, about 1100 IU / mL, about 1200 IU / mL, about 1300 IU / mL, about 1400 IU / mL, about 1500 IU / mL, about 1600 IU / mL, about 1700 IU / mL, about 1800 IU / mL, about 1900 IU / mL, about 2000 IU / mL, about 2100 IU / mL, about 2200 IU / mL, about 2300 IU / mL, about 2400 IU / mL, about 2500 IU / mL, about 3000 IU / mL, about 3500 IU / mL, about 4000 IU / mL, about 4500 IU / mL, about 5000 IU / mL, about 5500 IU / mL, about 6000 IU / mL, about 6500 IU / mL, about 7000 IU / mL, about 7500 IU / mL, about 8000 IU / mL, about 8500 IU / mL, about 9000 IU / mL, about 9500 IU / mL, or about 10,000 IU / mL of the endoglycosidase hydrolase enzyme.
133. The pharmaceutical composition of any one of claims 120-132, comprising about 2000 IU / mL of the endoglycosidase hydrolase enzyme.
134. The pharmaceutical composition of any one of claims 1-133, comprising a pH of about 4.0 to about 12.0.
135. The pharmaceutical composition of any one of claims 1-134, comprising a pH of about 5.2 to about 6.8.
136. The pharmaceutical composition of any one of claims 1-135, comprising a pH of about 5.2, about 5.3, about 5.4, about 5.5, about 5.6, about 5.7, about 5.8, about 5.9, about 6.0, about 6.1, about 6.2, about 6.3, about 6.4, about 6.5, about 6.6, about 6.7, or about 6.8.
137. The pharmaceutical composition of any one of claims 1-136, comprising a pH of about 5.8.
138. A pharmaceutical composition comprising:(a) about 80 mg / mL of relatlimab;(b) about 80 mg / mL of nivolumab;(c) about 100 mM of sodium chloride;(d) about 222 mM of sucrose;(e) about 20 mM of histidine;(f) about 0.05% w / v of polysorbate 80;(g) about 50 pM of DTPA;(h) about 5 mM of methionine;(i) about 2000 IU / mL of rHuPH20; and(j) a pH of about 5.8.
139. The pharmaceutical composition of claim 138, comprising a volume of about 12 mL.
140. The pharmaceutical composition of claim 138, comprising a volume of about 9 mL.
141. A pharmaceutical composition comprising:(a) about 75 mg / mL of relatlimab;(b) about 75 mg / mL of nivolumab;(c) about 100 mM of sodium chloride;(d) about 209 mM of sucrose;(e) about 20 mM of histidine;(f) about 0.05% w / v of polysorbate 80;(g) about 50 pM of DTPA;(h) about 5 mM of methionine;(i) about 2000 IU / mL of rHuPH20; and(j) a pH of about 5.8.
142. The pharmaceutical composition of claim 141, comprising a volume of about 12.8 mL.
143. The pharmaceutical composition of claim 141, comprising a volume of about 9.6 mL.
144. A pharmaceutical composition comprising:(a) about 60 mg / mL of relatlimab;(b) about 60 mg / mL of nivolumab;(c) about 40 mM of sodium chloride;(d) about 167 mM of sucrose;(e) about 20 mM of histidine;(f) about 0.05% w / v of polysorbate 80;(g) about 50 pM of DTPA;(h) about 5 mM of methionine;(i) about 2000 IU / mL of rHuPH20; and(j) a pH of about 5.8.
145. The pharmaceutical composition of claim 144, comprising a volume of about 16 mL.
146. A pharmaceutical composition comprising:(a) about 52.5 mg / mL of relatlimab;(b) about 52.5 mg / mL of nivolumab;(c) about 50 mM of sodium chloride;(d) about 146 mM of sucrose;(e) about 20 mM of histidine;(f) about 0.05% w / v of polysorbate 80;(g) about 50 pM of DTPA;(h) about 5 mM of methionine;(i) about 2000 IU / mL of rHuPH20; and(j) a pH of about 5.8.
147. The pharmaceutical composition of claim 146, comprising a volume of about 18.3 mL.
148. A pharmaceutical composition comprising:(a) about 960 mg of relatlimab;(b) about 960 mg of nivolumab;(c) about 100 mM of sodium chloride;(d) about 222 mM of sucrose;(e) about 20 mM of histidine;(f) about 0.05% w / v of polysorbate 80;(g) about 50 pM of DTPA;(h) about 5 mM of methionine;(i) about 2000 IU / mL of rHuPH20; and(j) a pH of about 5.8.
149. A pharmaceutical composition comprising:(a) about 720 mg of relatlimab;(b) about 720 mg of nivolumab;(c) about 100 mM of sodium chloride; (d) about 222 mM of sucrose;(e) about 20 mM of histidine;(f) about 0.05% w / v of polysorbate 80; (g) about 50 pM of DTPA;(h) about 5 mM of methionine;(i) about 2000 IU / mL of rHuPH20; and (j) a pH of about 5.8.
150. A pharmaceutical composition comprising:(a) about 960 mg of relatlimab;(b) about 960 mg of nivolumab;(c) about 100 mM of sodium chloride; (d) about 209 mM of sucrose;(e) about 20 mM of histidine;(f) about 0.05% w / v of polysorbate 80; (g) about 50 pM of DTPA;(h) about 5 mM of methionine;(i) about 2000 IU / mL of rHuPH20; and (j) a pH of about 5.8.
151. A pharmaceutical composition comprising:(a) about 720 mg of relatlimab;(b) about 720 mg of nivolumab;(c) about 100 mM of sodium chloride; (d) about 209 mM of sucrose;(e) about 20 mM of histidine;(f) about 0.05% w / v of polysorbate 80; (g) about 50 pM of DTPA;(h) about 5 mM of methionine;(i) about 2000 IU / mL of rHuPH20; and (j) a pH of about 5.8.
152. A pharmaceutical composition comprising: (a) about 960 mg of relatlimab;(b) about 960 mg of nivolumab;(c) about 40 mM of sodium chloride; (d) about 167 mM of sucrose;(e) about 20 mM of histidine;(f) about 0.05% w / v of polysorbate 80; (g) about 50 pM of DTPA;(h) about 5 mM of methionine;(i) about 2000 IU / mL of rHuPH20; and (j) a pH of about 5.8.
153. A pharmaceutical composition comprising:(a) about 720 mg of relatlimab;(b) about 720 mg of nivolumab;(c) about 40 mM of sodium chloride; (d) about 167 mM of sucrose;(e) about 20 mM of histidine;(f) about 0.05% w / v of polysorbate 80; (g) about 50 pM of DTPA;(h) about 5 mM of methionine;(i) about 2000 IU / mL of rHuPH20; and (j) a pH of about 5.8.
154. A pharmaceutical composition comprising:(a) about 960 mg of relatlimab;(b) about 960 mg of nivolumab;(c) about 50 mM of sodium chloride; (d) about 146 mM of sucrose;(e) about 20 mM of histidine;(f) about 0.05% w / v of polysorbate 80; (g) about 50 pM of DTPA;(h) about 5 mM of methionine;(i) about 2000 IU / mL of rHuPH20; and(j) a pH of about 5.8.
155. The pharmaceutical composition of any one of claims 1-154, which is suitable for intravitreal, intravenous, intramuscular, and / or subcutaneous administration.
156. The pharmaceutical composition of any one of claims 1-155, which is suitable for subcutaneous administration.
157. The pharmaceutical composition of any one of claims 1-156, which is capable of being injected within about 10 minutes or less.
158. The pharmaceutical composition of claim 157, which is capable of being injected within about 5 minutes to about 7 minutes.
159. The pharmaceutical composition of claim 157, which is capable of being injected within about 3 minutes to about 5 minutes.
160. The pharmaceutical composition of any one of claims 37-159, wherein percent high molecular weight (% HMW) species in the pharmaceutical composition as measured by size exclusion chromatography are less than about 1.5% following: agitation at 250 rpm for 1 week at 30 °C, agitation at 250 rpm for 2 weeks at 30 °C, storage at room temperature and room light conditions for 2 weeks, storage at 40 °C for 2 weeks, and / or storage at 50 °C for 2 weeks.
161. The pharmaceutical composition of claim 160, wherein the % HMW species are about 1% or less.
162. The pharmaceutical composition of claim 160 or 161, wherein the %HMW species are less than about 1%.
163. The pharmaceutical composition of any one of claims 37-162, wherein percent monomer (% monomer) in the pharmaceutical composition as measured by size exclusion chromatography is greater than about 97% following: agitation at 250 rpm for 1 week at 30 °C, agitation at 250 rpm for 2 weeks at 30 °C, storage at room temperature and room light conditions for 2 weeks, storage at 40 °C for 2 weeks, and / or storage at 50 °C for 2 weeks.
164. The pharmaceutical composition of any one of claims 37-163, wherein the % monomer in the pharmaceutical composition as measured by size exclusion chromatography is about 98% or more following: agitation at 250 rpm for 1 week at 30 °C, agitation at 250 rpm for 2 weeks at 30 °C, storage at room temperature and room light conditions for 2 weeks, and / or storage at 40 °C for 2 weeks.
165. A vial comprising the pharmaceutical composition of any one of claims 1-164.
166. A syringe comprising the pharmaceutical composition of any one of claims 1-164.
167. The syringe of claim 166, wherein the syringe is a pre-filled syringe and / or further comprises a plunger.
168. An auto-injector comprising the pharmaceutical composition of any one of claims 1-164.
169. A wearable pump or a wearable device comprising the pharmaceutical composition of any one of claims 1-164.
170. A pen injector comprising the pharmaceutical composition of any one of claims 1-164.
171. A needle-free injector comprising the pharmaceutical composition of any one of claims 1- 164.
172. A method of treating a disease or disorder in a subject in need thereof comprising administering to the subject a pharmaceutically effective amount of the pharmaceutical composition of any one of claims to 1-164.
173. The method of claim 172, wherein the pharmaceutical composition is administered intravitreally, intravenously, intramuscularly, and / or subcutaneously.
174. The method of claim 172 or 173, wherein the pharmaceutical composition is administered subcutaneously.
175. The method of any one of claims 172-174, wherein the disease or disorder comprises a tumor.
176. The method of claim 175, wherein the tumor comprises a hepatocellular carcinoma, colorectal cancer, gastric cancer, small-cell lung cancer (SCLC), non-small cell lung cancer(NSCLC), squamous NSCLC, nonsquamous NSCLC, solid cancer with liver metastatic disease, cervical cancer, breast cancer, triple-negative breast cancer, pancreatic cancer, urothelial cancer, prostate cancer, hormone refractory prostate adenocarcinoma, hematological cancer, squamous cell carcinoma, glioma, gastrointestinal cancer, renal cancer, clear cell carcinoma, ovarian cancer, liver cancer, endometrial cancer, kidney cancer, renal cell carcinoma (RCC), thyroid cancer, neuroblastoma, glioblastoma, glioblastoma multiforme, stomach cancer, bladder cancer, hepatoma, colon cancer, head and neck cancer, gastroesophageal cancer, germ cell tumor, pediatric sarcoma, sinonasal natural killer T-cell lymphoma, melanoma, bone cancer, skin cancer, uterine cancer, cancer of the anal region, testicular cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, rectal cancer, solid tumor of childhood, cancer of the ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, spinal axis tumor, brain cancer, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, environmentally- induced cancer, virus-related cancer or cancer of viral origin, or a combination thereof.
177. The method of any one of claims 175 or 176, wherein the tumor is recurrent or refractory.
178. The method of any one of claims 175-177, wherein the tumor is unresectable, advanced, and / or metastatic.
179. The method of any one of claims 175-178, wherein the tumor is a malignant tumor.
180. The method of any one of claims 175-179, wherein the method further comprises administering an additional anti-cancer therapy.
181. The method of claim 180, wherein the additional anti-cancer therapy comprises a surgery, a radiation therapy, a chemotherapy, an immunotherapy, or any combination thereof.
182. The method of claim 180 or 181, wherein the additional anti-cancer therapy comprises a chemotherapy.
183. A method of reducing the viscosity of a pharmaceutical composition, comprising:(a) preparing a pharmaceutical composition comprising about 100 mg / mL or more of a protein and a lower concentration of a sugar as compared to a corresponding composition that comprises the sugar and the same concentration of the protein, and (b) adding a salt to the pharmaceutical composition,wherein the viscosity of the pharmaceutical composition is reduced as compared to the corresponding composition.
184. The method of claim 183, wherein the pharmaceutical composition comprises about 100 mg / mL to about 500 mg / mL, about 100 mg / mL to about 450 mg / mL, about 100 mg / mL to about 400 mg / mL, about 100 mg / mL to about 350 mg / mL, about 100 mg / mL to about 300 mg / mL, about 100 mg / mL to about 250 mg / mL, about 100 mg / mL to about 200 mg / mL, about 100 mg / mL to about 150 mg / mL, about 100 mg / mL to about 140 mg / mL, about 100 mg / mL to about 130 mg / mL, about 100 mg / mL to about 120 mg / mL, about 100 mg / mL to about 115 mg / mL, about 100 mg / mL to about 110 mg / mL, about 100 mg / mL to about 105 mg / mL, about 110 mg / mL to about 500 mg / mL, about 110 mg / mL to about 450 mg / mL, about 110 mg / mL to about 400 mg / mL, about 110 mg / mL to about 350 mg / mL, about 110 mg / mL to about 300 mg / mL, about 110 mg / mL to about 250 mg / mL, about 110 mg / mL to about 200 mg / mL, about 110 mg / mL to about 150 mg / mL, about 110 mg / mL to about 140 mg / mL, about 110 mg / mL to about 130 mg / mL, about 110 mg / mL to about 120 mg / mL, about 110 mg / mL to about 115 mg / mL, about 115 mg / mL to about 500 mg / mL, about 115 mg / mL to about 450 mg / mL, about 115 mg / mL to about 400 mg / mL, about 115 mg / mL to about 350 mg / mL, about 115 mg / mL to about 300 mg / mL, about 115 mg / mL to about 250 mg / mL, about 115 mg / mL to about 200 mg / mL, about 115 mg / mL to about 150 mg / mL, about 115 mg / mL to about 140 mg / mL, about 115 mg / mL to about 130 mg / mL, about 115 mg / mL to about 120 mg / mL, about 120 mg / mL to about 450 mg / mL, about 120 mg / mL to about 400 mg / mL, about 120 mg / mL to about 350 mg / mL, about 120 mg / mL to about 300 mg / mL, about 120 mg / mL to about 250 mg / mL, about 120 mg / mL to about 200 mg / mL, about 120 mg / mL to about 150 mg / mL, about 120 mg / mL to about 140 mg / mL, about 120 mg / mL to about 130 mg / mL, about 150 mg / mL to about 500 mg / mL, about 150 mg / mL to about 450 mg / mL, about 150 mg / mL to about 400 mg / mL, about 150 mg / mL to about 350 mg / mL, about 150 mg / mL to about 300 mg / mL, about 150 mg / mL to about 250 mg / mL, or about 150 mg / mL to about 200 mg / mL of the protein.
185. The method of claim 183 or 184, wherein the pharmaceutical composition comprises about 100 mg / mL, about 101 mg / mL, about 102 mg / mL, about 103 mg / mL, about 104 mg / mL, about 105 mg / mL, about 106 mg / mL, about 107 mg / mL, about 108 mg / mL, about 109 mg / mL, about 110 mg / mL, about 111 mg / mL, about 112 mg / mL, about 113 mg / mL, about 114 mg / mL, about 115 mg / mL, about 116 mg / mL, about 117 mg / mL, about 118 mg / mL, about 119 mg / mL, about 120 mg / mL, about 121 mg / mL, about 122 mg / mL, about 123 mg / mL, about 124 mg / mL, about 125 mg / mL, about 126 mg / mL, about 127 mg / mL, about 128 mg / mL, about 129 mg / mL, about 130 mg / mL, about 131 mg / mL, about 132 mg / mL, about 133 mg / mL, about 134 mg / mL, about 135 mg / mL, about 136 mg / mL, about 137 mg / mL, about 138 mg / mL, about 139 mg / mL, about 140 mg / mL, about 141 mg / mL, about 142 mg / mL, about 143 mg / mL, about 144 mg / mL, about 145 mg / mL, about 146 mg / mL, about 147 mg / mL, about 148 mg / mL, about 149 mg / mL, about 150 mg / mL, about 155 mg / mL, about 160 mg / mL, about 165 mg / mL, about 170 mg / mL, about 175 mg / mL, about 180 mg / mL, about 185 mg / mL, about 190 mg / mL, about 195 mg / mL, about 200 mg / mL, about 205 mg / mL, about 210 mg / mL, about 215 mg / mL, about 220 mg / mL, about 225 mg / mL, about 230 mg / mL, about 235 mg / mL, about 240 mg / mL, about 245 mg / mL, about 250 mg / mL, about 255 mg / mL, about 260 mg / mL, about 265 mg / mL, about 270 mg / mL, about 275 mg / mL, about 280 mg / mL, about 285 mg / mL, about 290 mg / mL, about 295 mg / mL, about 300 mg / mL, about 305 mg / mL, about 310 mg / mL, about 315 mg / mL, about 320 mg / mL, about 325 mg / mL, about 330 mg / mL, about 335 mg / mL, about 340 mg / mL, about 345 mg / mL, about 350 mg / mL, about 355 mg / mL, about 360 mg / mL, about 365 mg / mL, about 370 mg / mL, about 375 mg / mL, about 380 mg / mL, about 385 mg / mL, about 390 mg / mL, about 395 mg / mL, about 400 mg / mL, about 405 mg / mL, about 410 mg / mL, about 415 mg / mL, about 420 mg / mL, about 425 mg / mL, about 430 mg / mL, about 435 mg / mL, about 440 mg / mL, about 445 mg / mL, about 450 mg / mL, about 455 mg / mL, about 460 mg / mL, about 465 mg / mL, about 470 mg / mL, about 475 mg / mL, about 480 mg / mL, about 485 mg / mL, about 490 mg / mL, about 495 mg / mL, or about 500 mg / mL of the protein.
186. The method of any one of claims 183-185, wherein the pharmaceutical composition comprises a volume of about 0.001 mL to about 20 mL.
187. The method of any one of claims 183-186, wherein the pharmaceutical composition comprises a volume of about 0.001 mL, about 0.005 mL, about 0.010 mL, about 0.015 mL,about 0.020 mL, about 0.025 mL, about 0.030 mL, about 0.035 mL, about 0.040 mL, about 0.045 mL, about 0.050 mL, about 0.055 mL, about 0.060 mL, about 0.065 mL, about 0.070 mL, about 0.075 mL, about 0.080 mL, about 0.085 mL, about 0.090 mL, about 0.095 mL, about 0.100 mL, about 0.150 mL, about 0.200 mL, about 0.250 mL, about 0.300 mL, about 0.350 mL, about 0.400 mL, about 0.450 mL, about 0.500 mL, about 0.550 mL, about 0.600 mL, about 0.650 mL, about 0.700 mL, about 0.750 mL, about 0.800 mL, about 0.850 mL, about 0.900 mL, about 0.950 mL, about 1 mL, about 1.1 mL, about 1.2 mL, about 1.3 mL, about 1.4 mL, about 1.5 mL, about 1.6 mL, about 1.7 mL, about 1.8 mL, about 1.9 mL, about 2 mL, about 2.1 mL, about 2.2 mL, about 2.3 mL, about 2.4 mL, about 2.5 mL, about 2.6 mL, about 2.7 mL, about 2.8 mL, about 2.9 mL, about 3 mL, about 3.1 mL, about 3.2 mL, about 3.3 mL, about 3.4 mL, about 3.5 mL, about 3.6 mL, about 3.7 mL, about 3.8 mL, about 3.9 mL, about 4 mL, about 4.1 mL, about 4.2 mL, about 4.3 mL, about 4.4 mL, about 4.5 mL, about 4.6 mL, about 4.7 mL, about 4.8 mL, about 4.9 mL, about 5 mL, about 5.1 mL, about 5.2 mL, about 5.3 mL, about 5.4 mL, about 5.5 mL, about 5.6 mL, about 5.7 mL, about 5.8 mL, about 5.9 mL, about 6 mL, about 6.1 mL, about 6.2 mL, about 6.3 mL, about 6.4 mL, about 6.5 mL, about 6.6 mL, about 6.7 mL, about 6.8 mL, about 6.9 mL, about 7 mL, about 7.1 mL, about 7.2 mL, about 7.3 mL, about 7.4 mL, about 7.5 mL, about 7.6 mL, about 7.7 mL, about 7.8 mL, about 7.9 mL, about 8 mL, about 8.1 mL, about 8.2 mL, about 8.3 mL, about 8.4 mL, about 8.5 mL, about 8.6 mL, about 8.7 mL, about 8.8 mL, about 8.9 mL, about 9 mL, about 9.1 mL, about 9.2 mL, about 9.3 mL, about 9.4 mL, about 9.5 mL, about 9.6 mL, about 9.7 mL, about 9.8 mL, about 9.9 mL, about 10 mL, about 10.1 mL, about 10.2 mL, about 10.3 mL, about 10.4 mL, about 10.5 mL, about 10.6 mL, about 10.7 mL, about 10.8 mL, about 10.9 mL, about 11 mL, about 11.1 mL, about 11.2 mL, about 11.3 mL, about 11.4 mL, about 11.5 mL, about 11.6 mL, about 11.7 mL, about 11.8 mL, about 11.9 mL, about 12 mL, about 12.1 mL, about 12.2 mL, about 12.3 mL, about 12.4 mL, about 12.5 mL, about 12.6 mL, about 12.7 mL, about 12.8 mL, about 12.9 mL, about 13 mL, about 13.1 mL, about 13.2 mL, about 13.3 mL, about 13.4 mL, about 13.5 mL, about 13.6 mL, about 13.7 mL, about 13.8 mL, about 13.9 mL, about 14 mL, about 14.1 mL, about 14.2 mL, about 14.3 mL, about 14.4 mL, about 14.5 mL, about 14.6 mL, about 14.7 mL, about 14.8 mL, about 14.9 mL, about 15 mL, about 15.1 mL, about 15.2 mL, about 15.3 mL, about 15.4 mL, about 15.5 mL, about 15.6 mL, about 15.7 mL, about 15.8 mL, about 15.9 mL, about 16 mL, about 16.1 mL, about 16.2 mL, about 16.3 mL, about 16.4 mL, about 16.5 mL, about 16.6 mL, about 16.7 mL, about 16.8 mL,about 16.9 mL, about 17 mL, about 17.1 mL, about 17.2 mL, about 17.3 mL, about 17.4 mL, about 17.5 mL, about 17.6 mL, about 17.7 mL, about 17.8 mL, about 17.9 mL, about 18 mL, about 18.1 mL, about 18.2 mL, about 18.3 mL, about 18.4 mL, about 18.5 mL, about 18.6 mL, about 18.7 mL, about 18.8 mL, about 18.9 mL, about 19 mL, about 19.1 mL, about 19.2 mL, about 19.3 mL, about 19.4 mL, about 19.5 mL, about 19.6 mL, about 19.7 mL, about 19.8 mL, about 19.9 mL, or about 20 mL.
188. The method of any one of claims 183-187, wherein the pharmaceutical composition comprises about 0.25 mg to about 4000 mg, about 0.25 mg to about 3600 mg, about 0.25 mg to about 3200 mg, about 0.25 mg to about 3000 mg, about 0.25 mg to about 2600 mg, about 0.25 mg to about 2200 mg, about 0.25 mg to about 2000 mg, about 0.25 mg to about 1600 mg, about 0.25 mg to about 1200 mg, about 0.25 mg to about 1000 mg, about 0.25 mg to about 800 mg, about 0.25 mg to about 600 mg, about 0.25 mg to about 400 mg, about 0.25 mg to about 200 mg, about 0.25 mg to about 100 mg, about 0.25 mg to about 50 mg, about 0.25 mg to about 40 mg, about 0.25 mg to about 30 mg, about 0.25 mg to about 20 mg, about 20 mg to about 4000 mg, about 20 mg to about 3600 mg, about 20 mg to about 3200 mg, about 20 mg to about 3000 mg, about 20 mg to about 2600 mg, about 20 mg to about 2200 mg, about 20 mg to about 2000 mg, about 20 mg to about 1600 mg, about 20 mg to about 1200 mg, about 20 mg to about 1000 mg, about 20 mg to about 800 mg, about 20 mg to about 600 mg, about 20 mg to about 400 mg, about 20 mg to about 200 mg, about 20 mg to about 100 mg, about 100 mg to about 4000 mg, about 100 mg to about 3600 mg, about 100 mg to about 3200 mg, about 100 mg to about 3000 mg, about 100 mg to about 2600 mg, about 100 mg to about 2200 mg, about 100 mg to about 2000 mg, about 100 mg to about 1800 mg, about 100 mg to about 1600 mg, about 100 mg to about 1400 mg, about 100 mg to about 1200 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, about 400 mg to about 4000 mg, about 400 mg to about 3600 mg, about 400 mg to about 3200 mg, about 400 mg to about 3000 mg, about 400 mg to about 2600 mg, about 400 mg to about 2200 mg, about 400 mg to about 2000 mg, about 400 mg to about 1800 mg, about 400 mg to about 1600 mg, about 400 mg to about 1400 mg, about 400 mg to about 1200 mg, or about 400 mg to about 1000 mg of the protein.
189. The method of any one of claims 183-188, wherein the pharmaceutical composition comprises about 0.25 mg, about 0.5 mg, about 0.75 mg, about 1 mg, about 1.25 mg, about1.5 mg, about 1.75 mg, about 2 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3 mg, about 3.25 mg, about 3.5 mg, about 3.75 mg, about 4 mg, about 4.25 mg, about 4.5 mg, about 4.75 mg, about 5 mg, about 5.25 mg, about 5.5 mg, about 5.75 mg, about 6 mg, about 6.25 mg, about 6.5 mg, about 6.75 mg, about 7 mg, about 7.25 mg, about 7.5 mg, about 7.75 mg, about 8 mg, about 8.25 mg, about 8.5 mg, about 8.75 mg, about 9 mg, about 9.25 mg, about 9.5 mg, about 9.75 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, about 710 mg, about 720 mg, about 730 mg, about 740 mg, about 750 mg, about 760 mg, about 770 mg, about 780 mg, about 790 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 980 mg, about 990 mg, about 1000 mg, about 1020 mg, about 1040 mg, about 1060 mg, about 1080 mg, about 1100 mg, about 1120 mg, about 1140 mg, about 1160 mg, about 1180 mg, about 1200 mg, about 1220 mg, about 1240 mg, about 1260 mg, about 1280 mg, about 1300 mg, about 1320 mg, about 1340 mg, about 1360 mg, about 1380 mg, about 1400 mg, about 1420 mg, about 1440 mg, about 1460 mg, about 1480 mg, about 1500 mg, about 1520 mg, about 1540 mg, about 1560 mg, about 1580 mg, about 1600 mg, about 1620 mg, about 1640 mg, about 1660 mg, about 1680 mg, about 1700 mg, about 1720 mg, about 1740 mg, about 1760 mg, about 1780 mg, about 1800 mg, about 1820 mg, about 1840 mg, about 1860 mg, about 1880 mg, about 1900 mg, about 1920 mg, about 1940 mg, about 1960 mg, about 1980 mg, about 2000 mg, about 2020 mg, about 2040 mg, about 2060 mg, about 2080 mg, about 2100 mg, about 2120 mg, about 2140 mg,about 2160 mg, about 2180 mg, about 2200 mg, about 2220 mg, about 2240 mg, about 2260 mg, about 2280 mg, about 2300 mg, about 2320 mg, about 2340 mg, about 2360 mg, about 2380 mg, about 2400 mg, about 2420 mg, about 2440 mg, about 2460 mg, about 2480 mg, about 2500 mg, about 2520 mg, about 2540 mg, about 2560 mg, about 2580 mg, about 2600 mg, about 2620 mg, about 2640 mg, about 2660 mg, about 2680 mg, about 2700 mg, about 2720 mg, about 2740 mg, about 2760 mg, about 2780 mg, about 2800 mg, about 2820 mg, about 2840 mg, about 2860 mg, about 2880 mg, about 2900 mg, about 2920 mg, about 2940 mg, about 2960 mg, about 2980 mg, about 3000 mg, about 3020 mg, about 3040 mg, about 3060 mg, about 3080 mg, about 3100 mg, about 3120 mg, about 3140 mg, about 3160 mg, about 3180 mg, about 3200 mg, about 3220 mg, about 3240 mg, about 3260 mg, about 3280 mg, about 3300 mg, about 3320 mg, about 3340 mg, about 3360 mg, about 3380 mg, about 3400 mg, about 3420 mg, about 3440 mg, about 3460 mg, about 3480 mg, about 3500 mg, about 3520 mg, about 3540 mg, about 3560 mg, about 3580 mg, about 3600 mg, about 3620 mg, about 3640 mg, about 3660 mg, about 3680 mg, about 3700 mg, about 3720 mg, about 3740 mg, about 3760 mg, about 3780 mg, about 3800 mg, about 3820 mg, about 3840 mg, about 3860 mg, about 3880 mg, about 3900 mg, about 3920 mg, about 3940 mg, about 3960 mg, about 3980 mg, or about 4000 mg of the protein.
190. The method of any one of claims 183-189, wherein the concentration of the sugar in the pharmaceutical composition is less than about 500 mM, less than about 475 mM, less than about 450 mM, less than about 425 mM, less than about 400 mM, less than about 375 mM, less than about 350 mM, less than about 325 mM, less than about 300 mM, less than about 275 mM, less than about 250 mM, less than about 225 mM, less than about 200 mM, less than about 175 mM, less than about 150 mM, less than about 125 mM, less than about 100 mM, or less than about 75 mM.
191. The method of any one of claims 183-190, wherein the sugar comprises a monosaccharide, a disaccharide, a polysaccharide, a polyol, or a combination thereof.
192. The method of any one of claims 183-191, wherein the sugar comprises glucose, xylose, erythritol, sucrose, trehalose, maltose, galactose, dextrose, raffinose, stachyose, lactose, mannitol, sorbitol, xylitol, lactitol, maltitol, glycerol or a combination thereof.
193. The method of claim 192, wherein the sugar comprises sucrose.
194. The method of claim 192, wherein the sugar comprises trehalose.
195. The method of any one of claims 183-194, wherein about 10 mM to about 400 mM, about 10 mM to about 350 mM, about 10 mM to about 300 mM, about 10 mM to about 250 mM, about 10 mM to about 200 mM, about 10 mM to about 150 mM, about 10 mM to about 100 mM, about 10 mM to about 90 mM, about 10 mM to about 80 mM, about 10 mM to about 70 mM, about 10 mM to about 60 mM, about 10 mM to about 50 mM, about 30 mM to about 400 mM, about 30 mM to about 350 mM, about 30 mM to about 300 mM, about 30 mM to about 250 mM, about 30 mM to about 200 mM, about 30 mM to about 150 mM, about 30 mM to about 100 mM, about 30 mM to about 90 mM, about 30 mM to about 80 mM, about 30 mM to about 70 mM, about 30 mM to about 60 mM, about 30 mM to about 50 mM, about 50 mM to about 400 mM, about 50 mM to about 350 mM, about 50 mM to about 300 mM, about 50 mM to about 250 mM, about 50 mM to about 200 mM, about 50 mM to about 150 mM, about 50 mM to about 100 mM, about 100 mM to about 400 mM, about 100 mM to about 350 mM, about 100 mM to about 300 mM, about 100 mM to about 250 mM, about 100 mM to about 200 mM, or about 100 mM to about 150 mM of the salt is added.
196. The method of any one of claims 183-195, wherein about 10 mM, about 15 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM, about 55 mM, about 60 mM, about 65 mM, about 70 mM, about 75 mM, about 80 mM, about 85 mM, about 90 mM, about 95 mM, about 100 mM, about 110 mM, about 120 mM, about 130 mM, about 140 mM, about 150 mM, about 160 mM, about 170 mM, about 180 mM, about 190 mM, about 200 mM, about 210 mM, about 220 mM, about 230 mM, about 240 mM, about 250 mM, about 260 mM, about 270 mM, about 280 mM, about 290 mM, about 300 mM, about 310 mM, about 320 mM, about 330 mM, about 340 mM, about 350 mM, about 360 mM, about 370 mM, about 380 mM, about 390 mM, or about 400 mM of the salt is added.
197. The method of any one of claims 183-196, wherein the salt comprises sodium chloride, arginine hydrochloride, histidine hydrochloride, lysine hydrochloride, magnesium chloride, potassium chloride, ammonium chloride, calcium chloride, sodium acetate, zinc chloride, ammonium thiocyanate, sodium thiocyanate, sodium sulfate, ammonium sulfate, sodium phosphate, sodium biphosphate, potassium phosphate, dipotassium hydrogenphosphate, monobasic potassium phosphate, calcium phosphate, tris(hydroxymethyl)aminomethane, or a combination thereof.
198. The method of claim 197, wherein the salt comprises sodium chloride.
199. The method of claim 197, wherein the salt comprises arginine hydrochloride.
200. The method of claim 197, wherein the salt comprises sodium chloride and arginine hydrochloride.
201. The method of any one of claims 183-200, wherein the pharmaceutical composition comprises an osmolality of about 600 mOsmol / kg or less.
202. The method of any one of claims 183-201, wherein the pharmaceutical composition comprises an osmolality of about 200 mOsmol / kg to about 600 mOsmol / kg, about 210 mOsmol / kg to about 600 mOsmol / kg, about 220 mOsmol / kg to about 600 mOsmol / kg, about 230 mOsmol / kg to about 600 mOsmol / kg, about 240 mOsmol / kg to about 600 mOsmol / kg, about 250 mOsmol / kg to about 600 mOsmol / kg, about 260 mOsmol / kg to about 600 mOsmol / kg, about 270 mOsmol / kg to about 600 mOsmol / kg, about 280 mOsmol / kg to about 600 mOsmol / kg, about 290 mOsmol / kg to about 600 mOsmol / kg, about 300 mOsmol / kg to about 600 mOsmol / kg, about 350 mOsmol / kg to about 600 mOsmol / kg, about 400 mOsmol / kg to about 600 mOsmol / kg, about 450 mOsmol / kg to about 600 mOsmol / kg, about 500 mOsmol / kg to about 600 mOsmol / kg, about 550 mOsmol / kg to about 600 mOsmol / kg, about 500 mOsmol / kg to about 550 mOsmol / kg, about 450 mOsmol / kg to about 550 mOsmol / kg, about 400 mOsmol / kg to about 550 mOsmol / kg, about 350 mOsmol / kg to about 550 mOsmol / kg, about 300 mOsmol / kg to about 550 mOsmol / kg, about 250 mOsmol / kg to about 550 mOsmol / kg, about 200 mOsmol / kg to about 550 mOsmol / kg, about 200 mOsmol / kg to about 500 mOsmol / kg, about 250 mOsmol / kg to about 500 mOsmol / kg, about 300 mOsmol / kg to about 500 mOsmol / kg, about 350 mOsmol / kg to about 500 mOsmol / kg, about 400 mOsmol / kg to about 500 mOsmol / kg, about 450 mOsmol / kg to about 500 mOsmol / kg, about 400 mOsmol / kg to about 450 mOsmol / kg, about 350 mOsmol / kg to about 450 mOsmol / kg, about 300 mOsmol / kg to about 450 mOsmol / kg, about 250 mOsmol / kg to about 450 mOsmol / kg, about 200 mOsmol / kg to about 450 mOsmol / kg, about 200 mOsmol / kg to about 400 mOsmol / kg, about 250 mOsmol / kg to about 400 mOsmol / kg, about 300mOsmol / kg to about 400 mOsmol / kg, about 350 mOsmol / kg to about 400 mOsmol / kg, about 300 mOsmol / kg to about 350 mOsmol / kg, about 250 mOsmol / kg to about 350 mOsmol / kg, about 200 mOsmol / kg to about 350 mOsmol / kg, about 200 mOsmol / kg to about 300 mOsmol / kg, or about 250 mOsmol / kg to about 300 mOsmol / kg.
203. The method of any one of claims 183-202, wherein the pharmaceutical composition comprises an osmolality of about 280 mOsmol / kg to about 600 mOsmol / kg.
204. The method of any one of claims 202-203, wherein the osmolality is determined by vaporpressure osmometry.
205. The method of any one of claims 202-204, wherein the osmolality is determined with a vapor pressure osmometer.
206. The method of any one of claims 183-205, wherein the viscosity is determined with a microfluidic viscometer.
207. The method of any one of claims 183-206, wherein the viscosity is determined at 20 °C.
208. The method of any one of claims 183-207, wherein the sugar is sucrose and the salt is sodium chloride.
209. The method of any one of claims 183-208, wherein the pharmaceutical composition comprises about 100 mg / mL to about 150 mg / mL of the protein, wherein the concentration of the sugar is less than about 250 mM, and wherein about 200 mM or less of the salt is added.
210. The method of any one of claims 183-209, wherein the protein comprises an antibody, a checkpoint inhibitor, a fusion protein, a growth factor, a hormone, an enzyme, a cytokine, a coagulation factor, a plasma protein, or a combination thereof.
211. The method of claim 210, wherein the protein comprises an antibody.
212. The method of claim 210 or 211, wherein the antibody comprises a full-length antibody.
213. The method of any one of claims 210-212, wherein the antibody comprises a monoclonal, human, humanized, chimeric, or multispecific antibody.
214. The method of claim 213, wherein the multispecific antibody comprises a dual-affinity retargeting antibody, a dual variable domain immunoglobulin, or a bispecific antibody.
215. The method of claim 210 or 211, wherein the antibody comprises a F(ab')2 fragment, a Fab' fragment, a Fab fragment, a Fv fragment, a scFv fragment, a dsFv fragment, a dAb fragment, or a single chain binding polypeptide.
216. The method of any one of claims 210-215, wherein the antibody comprises an anti -LAG-3 antibody, an anti-PD-1 antibody, an anti-PD-Ll antibody, an anti-CTLA-4 antibody, an anti-TIM-3 antibody, an anti-TIGIT antibody, an anti-NKG2a antibody, an anti-OX40 antibody, an anti-ICOS antibody, an anti-MICA antibody, an anti-CD137 antibody, an anti- KIR antibody, an anti-TGFp antibody, an anti-IL-10 antibody, an anti-IL-8 antibody, an anti-B7-H4 antibody, an anti-Fas ligand antibody, an anti-CXCR4 antibody, an anti- mesothelin antibody, an anti-CD27 antibody, an anti-GITR antibody, an anti-CCR8 antibody, an anti-ILT4 antibody, or a combination thereof.
217. The method of claim 216, wherein the anti -LAG-3 antibody comprises BMS-986016 (relatlimab), IMP731 (H5L7BW), MK4280 (28G-10, favezelimab), REGN3767 (fianlimab), GSK2831781, humanized BAP050, IMP-701 (LAG525, ieramilimab), aLAG3(0414), aLAG3(0416), Sym022, TSR-033, TSR-075, XmAb841 (XmAb22841), MGD013 (tebotelimab), BI754111, FS118, P 13B02-30, AVA-017, 25F7, AGEN1746, RO7247669, INCAGN02385, IBL110, EMB-02, IBL323, LBL-007, ABL501, or an antigen-binding portion thereof.
218. The method of claim 216 or 217, wherein the anti -LAG-3 antibody comprises relatlimab, or an antigen-binding portion thereof.
219. The method of any one of claims 216-218, wherein the anti-LAG-3 antibody comprises:(a) CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:3, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO:4;(b) a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, respectively,and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10, respectively;(c) heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:3 and 4, respectively;(d) heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:l and 2, respectively; or(e) heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:21 and 2, respectively.
220. The method of any one of claims 216-219, wherein the anti-PD-1 antibody comprises nivolumab, pembrolizumab, PDR001 (spartalizumab), MEDI-0680, TSR-042, cemiplimab, JS001, PF-06801591, BGB-A317, BI 754091, INCSHR1210, GLS-010, AM- 001, STI-1110, AGEN2034, MGA012, BCD-100, IBI308, SSI-361, or an antigen-binding portion thereof.
221. The method of any one of claims 216-220, wherein the anti-PD-1 antibody comprises nivolumab, or an antigen-binding portion thereof.
222. The method of any one of claims 216-221, wherein the anti-PD-1 antibody comprises:(a) CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 13, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO: 14;(b) a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO:20, respectively;(c) heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:13 and 14, respectively; or(d) heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:11 and 12, respectively.
223. The method of any one of claims 216-222, wherein the anti-PD-Ll antibody comprises BMS-936559, atezolizumab, durvalumab, avelumab, STI-1014, CX-072, KN035, LY3300054, BGB-A333, ICO 36, FAZ053, CK-301, or an antigen-binding portion thereof.
224. The method of any one of claims 216-223, wherein the anti-CTLA-4 antibody comprises ipilimumab, tremelimumab, MK-1308, AGEN-1884, or an antigen-binding portion thereof.
225. The method of any one of claims 216-224, wherein the antibody comprises two antibodies.
226. The method of claim 225, wherein the antibody comprises an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-Ll antibody.
227. The method of claim 226, wherein the mg:mg or mg / mL:mg / mL ratio of the anti-PD-1 or anti-PD-Ll antibody to the anti-LAG-3 antibody is about 1:1, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, about 1:15, about 1:20, about 1:30, about 1:40, about 1:50, about 1:60, about 1:70, about 1:80, about 1:90, about 1:100, about 1:120, about 1:140, about 1:160, about 1:180, about 1:200, about 200:1, about 180:1, about 160:1, about 140:1, about 120:1, about 100:1, about 90:1, about 80:1, about 70:1, about 60:1, about 50:1, about 40:1, about 30:1, about 20:1, about 15:1, about 10:1, about 9:1, about 8:1, about 7:1, about 6:1, about 5:1, about 4:1, about 3:1, about 2:1, or about 3:4.
228. The method of claim 226 or 227, wherein the mg:mg or mg / mL:mg / mL ratio of the anti- PD-1 or anti-PD-Ll antibody to the anti-LAG-3 antibody is about 1:1, about 2:1, or about 3:4.
229. The method of any one of claims 226-228, wherein the concentration of the anti-PD-1 or anti-PD-Ll antibody is about 10 mg / mL, about 15 mg / mL, about 20 mg / mL, about 25 mg / mL, about 30 mg / mL, about 35 mg / mL, about 40 mg / mL, about 45 mg / mL, about 50 mg / mL, about 52.5 mg / mL, about 55 mg / mL, about 60 mg / mL, about 64 mg / mL, about 65 mg / mL, about 70 mg / mL, about 72 mg / mL, about 75 mg / mL, about 78.8 mg / mL, about 80 mg / mL, about 85 mg / mL, about 90 mg / mL, about 94.5 mg / mL, about 95 mg / mL, about 100 mg / mL, about 105 mg / mL, about 108 mg / mL, about 110 mg / mL, about 120 mg / mL, about 130 mg / mL, about 132 mg / mL, about 135 mg / mL, about 137.5 mg / mL, about 140 mg / mL, about 150 mg / mL, about 160 mg / mL, about 170 mg / mL, about 175 mg / mL, about180 mg / mL, about 190 mg / mL, about 200 mg / mL, about 210 mg / mL, about 220 mg / mL, about 230 mg / mL, about 240 mg / mL, about 250 mg / mL, about 260 mg / mL, about 270 mg / mL, about 280 mg / mL, about 290 mg / mL, about 300 mg / mL, about 310 mg / mL, about 320 mg / mL, about 330 mg / mL, about 340 mg / mL, about 350 mg / mL, about 360 mg / mL, about 370 mg / mL, about 380 mg / mL, about 390 mg / mL, about 400 mg / mL, about 410 mg / mL, about 420 mg / mL, about 430 mg / mL, about 440 mg / mL, about 450 mg / mL, about 460 mg / mL, about 470 mg / mL, about 480 mg / mL, about 490 mg / mL, or about 500 mg / mL.
230. The method of any one of claims 226-229, wherein the pharmaceutical composition comprises about 0.25 mg to about 2000 mg, about 0.25 mg to about 1600 mg, about 0.25 mg to about 1200 mg, about 0.25 mg to about 800 mg, about 0.25 mg to about 400 mg, about 0.25 mg to about 100 mg, about 0.25 mg to about 50 mg, about 0.25 mg to about 40 mg, about 0.25 mg to about 30 mg, about 0.25 mg to about 20 mg, about 20 mg to about 2000 mg, about 20 mg to about 1600 mg, about 20 mg to about 1200 mg, about 20 mg to about 800 mg, about 20 mg to about 400 mg, about 20 mg to about 100 mg, about 100 mg to about 2000 mg, about 100 mg to about 1800 mg, about 100 mg to about 1600 mg, about 100 mg to about 1400 mg, about 100 mg to about 1200 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, about 400 mg to about 2000 mg, about 400 mg to about 1800 mg, about 400 mg to about 1600 mg, about 400 mg to about 1400 mg, about 400 mg to about 1200 mg, or about 400 mg to about 1000 mg of the anti-PD-1 or anti-PD-Ll antibody.
231. The method of any one of claims 226-230, wherein the pharmaceutical composition comprises about 0.25 mg, about 0.5 mg, about 0.75 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3 mg, about 3.25 mg, about 3.5 mg, about 3.75 mg, about 4 mg, about 4.25 mg, about 4.5 mg, about 4.75 mg, about 5 mg, about 5.25 mg, about 5.5 mg, about 5.75 mg, about 6 mg, about 6.25 mg, about 6.5 mg, about 6.75 mg, about 7 mg, about 7.25 mg, about 7.5 mg, about 7.75 mg, about 8 mg, about 8.25 mg, about 8.5 mg, about 8.75 mg, about 9 mg, about 9.25 mg, about 9.5 mg, about 9.75 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, about 710 mg, about 720 mg, about 730 mg, about 740 mg, about 750 mg, about 760 mg, about 770 mg, about 780 mg, about 790 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 980 mg, about 990 mg, about 1000 mg, about 1040 mg, about 1080 mg, about 1100 mg, about 1140 mg, about 1180 mg, about 1200 mg, about 1240 mg, about 1280 mg, about 1300 mg, about 1340 mg, about 1380 mg, about 1400 mg, about 1440 mg, about 1480 mg, about 1500 mg, about 1540 mg, about 1580 mg, about 1600 mg, about 1640 mg, about 1680 mg, about 1700 mg, about 1740 mg, about 1780 mg, about 1800 mg, about 1840 mg, about 1880 mg, about 1900 mg, about 1940 mg, about 1980 mg, or about 2000 mg of the anti-PD-1 or anti-PD-Ll antibody.
232. The method of any one of claims 226-231, wherein the concentration of the anti -LAG-3 antibody is about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 3.3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 6 mg / mL, about 7 mg / mL, about 8 mg / mL, about 9 mg / mL, about 10 mg / mL, about 13 mg / mL, about 13.35 mg / mL, about 15 mg / mL, about 18 mg / mL, about 20 mg / mL, about 23 mg / mL, about 25 mg / mL, about 26 mg / mL, about 26.2 mg / mL, about 26.7 mg / mL, about 27 mg / mL, about 28 mg / mL, about 29 mg / mL, about 30 mg / mL, about 31.5 mg / mL, about 35 mg / mL, about 37.5 mg / mL, about 40 mg / mL, about 45 mg / mL, about 50 mg / mL, about 52.5 mg / mL, about 55 mg / mL, about 60 mg / mL, about 64 mg / mL, about 65 mg / mL, about 70 mg / mL, about 72 mg / mL, about 75 mg / mL, about 80 mg / mL, about 85 mg / mL, about 90 mg / mL, about 95 mg / mL, about 100 mg / mL, about 108 mg / mL, about 110 mg / mL, about 120 mg / mL, about 130 mg / mL, about 132 mg / mL, about 135 mg / mL, about 140 mg / mL, about 150 mg / mL, about 160 mg / mL, about 170 mg / mL, about 175 mg / mL, about 180 mg / mL, about 190 mg / mL, about 200 mg / mL, about 210mg / mL, about 220 mg / mL, about 230 mg / mL, about 240 mg / mL, about 250 mg / mL, about 260 mg / mL, about 270 mg / mL, about 280 mg / mL, about 290 mg / mL, about 300 mg / mL, about 310 mg / mL, about 320 mg / mL, about 330 mg / mL, about 340 mg / mL, about 350 mg / mL, about 360 mg / mL, about 370 mg / mL, about 380 mg / mL, about 390 mg / mL, about 400 mg / mL, about 410 mg / mL, about 420 mg / mL, about 430 mg / mL, about 440 mg / mL, about 450 mg / mL, about 460 mg / mL, about 470 mg / mL, about 480 mg / mL, about 490 mg / mL, or about 500 mg / mL.
233. The method of any one of claims 226-232, wherein the pharmaceutical composition comprises about 0.25 mg to about 2000 mg, about 0.25 mg to about 1600 mg, about 0.25 mg to about 1200 mg, about 0.25 mg to about 800 mg, about 0.25 mg to about 400 mg, about 0.25 mg to about 100 mg, about 0.25 mg to about 50 mg, about 0.25 mg to about 40 mg, about 0.25 mg to about 30 mg, about 0.25 mg to about 20 mg, about 20 mg to about 2000 mg, about 20 mg to about 1600 mg, about 20 mg to about 1200 mg, about 20 mg to about 800 mg, about 20 mg to about 400 mg, about 20 mg to about 100 mg, about 100 mg to about 2000 mg, about 100 mg to about 1800 mg, about 100 mg to about 1600 mg, about 100 mg to about 1400 mg, about 100 mg to about 1200 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, about 400 mg to about 2000 mg, about 400 mg to about 1800 mg, about 400 mg to about 1600 mg, about 400 mg to about 1400 mg, about 400 mg to about 1200 mg, or about 400 mg to about 1000 mg of the anti -LAG-3 antibody.
234. The method of any one of claims 226-233, wherein the pharmaceutical composition comprises about 0.25 mg, about 0.5 mg, about 0.75 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3 mg, about 3.25 mg, about 3.5 mg, about 3.75 mg, about 4 mg, about 4.25 mg, about 4.5 mg, about 4.75 mg, about 5 mg, about 5.25 mg, about 5.5 mg, about 5.75 mg, about 6 mg, about 6.25 mg, about 6.5 mg, about 6.75 mg, about 7 mg, about 7.25 mg, about 7.5 mg, about 7.75 mg, about 8 mg, about 8.25 mg, about 8.5 mg, about 8.75 mg, about 9 mg, about 9.25 mg, about 9.5 mg, about 9.75 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, about 710 mg, about 720 mg, about 730 mg, about 740 mg, about 750 mg, about 760 mg, about 770 mg, about 780 mg, about 790 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 980 mg, about 990 mg, about 1000 mg, about 1040 mg, about 1080 mg, about 1100 mg, about 1140 mg, about 1180 mg, about 1200 mg, about 1240 mg, about 1280 mg, about 1300 mg, about 1340 mg, about 1380 mg, about 1400 mg, about 1440 mg, about 1480 mg, about 1500 mg, about 1540 mg, about 1580 mg, about 1600 mg, about 1640 mg, about 1680 mg, about 1700 mg, about 1740 mg, about 1780 mg, about 1800 mg, about 1840 mg, about 1880 mg, about 1900 mg, about 1940 mg, about 1980 mg, or about 2000 mg of the anti-LAG-3 antibody.
235. The method of any one of claims 226-234, wherein the pharmaceutical composition comprises about 80 mg / mL of the anti-PD-1 antibody and about 80 mg / mL of the anti- LAG-3 antibody.
236. The method of claim 235, wherein the pharmaceutical composition comprises a volume of about 12 mL.
237. The method of claim 235, wherein the pharmaceutical composition comprises a volume of about 9 mL.
238. The method of any one of claims 226-234, wherein the pharmaceutical composition comprises about 75 mg / mL of the anti-PD-1 antibody and about 75 mg / mL of the anti- LAG-3 antibody.
239. The method of claim 238, wherein the pharmaceutical composition comprises a volume of about 12.8 mL.
240. The method of claim 238, wherein the pharmaceutical composition comprises a volume of about 9.6 mL.
241. The method of any one of claims 226-234, wherein the pharmaceutical composition comprises about 72 mg / mL of the anti-PD-1 antibody and about 72 mg / mL of the anti- LAG-3 antibody.
242. The method of claim 241, wherein the pharmaceutical composition comprises a volume of about 10 mL.
243. The method of any one of claims 226-234, wherein the pharmaceutical composition comprises about 64 mg / mL of the anti-PD-1 antibody and about 64 mg / mL of the anti- LAG-3 antibody.
244. The method of claim 243, wherein the pharmaceutical composition comprises a volume of about 15 mL.
245. The method of any one of claims 226-234, wherein the pharmaceutical composition comprises about 60 mg / mL of the anti-PD-1 antibody and about 60 mg / mL of the anti- LAG-3 antibody.
246. The method of claim 245, wherein the pharmaceutical composition comprises a volume of about 16 mL.
247. The method of claim 245, wherein the pharmaceutical composition comprises a volume of about 12 mL.
249. The method of any one of claims 226-234, wherein the pharmaceutical composition comprises about 52.5 mg / mL of the anti-PD-1 antibody and about 52.5 mg / mL of the anti- LAG-3 antibody.
250. The method of claim 249, wherein the pharmaceutical composition comprises a volume of about 18.3 mL.
251. The method of any one of claims 226-234, wherein the pharmaceutical composition comprises about 64.3 mg / mL of the anti-PD-1 antibody and about 85.7 mg / mL of the anti- LAG-3 antibody.
252. The method of claim 251, wherein the pharmaceutical composition comprises a volume of about 8.4 mL.
253. The method of any one of claims 226-234, wherein the pharmaceutical composition comprises about 60 mg / mL of the anti-PD-1 antibody and about 80 mg / mL of the anti- LAG-3 antibody.
254. The method of claim 253, wherein the pharmaceutical composition comprises a volume of about 9 mL.
255. The method of any one of claims 226-234, wherein the pharmaceutical composition comprises about 54 mg / mL of the anti-PD-1 antibody and about 72 mg / mL of the anti- LAG-3 antibody.
256. The method of claim 255, wherein the pharmaceutical composition comprises a volume of about 10 mL.
257. The method of any one of claims 226-234, wherein the pharmaceutical composition comprises about 45 mg / mL of the anti-PD-1 antibody and about 60 mg / mL of the anti- LAG-3 antibody.
258. The method of claim 257, wherein the pharmaceutical composition comprises a volume of about 12 mL.
259. The method of any one of claims 226-234, wherein the pharmaceutical composition comprises about 960 mg of the anti-PD-1 antibody and about 960 mg of the anti-LAG-3 antibody.
260. The method of any one of claims 226-234, wherein the pharmaceutical composition comprises about 720 mg of the anti-PD-1 antibody and about 720 mg of the anti-LAG-3 antibody.
261. The method of any one of claims 226-234, wherein the pharmaceutical composition comprises about 540 mg of the anti-PD-1 antibody and about 720 mg of the anti-LAG-3 antibody.
262. The method of any one of claims 226-234, wherein the anti-PD-1 antibody comprises nivolumab, or an antigen-binding portion thereof, and the anti-LAG-3 antibody comprises relatlimab, or an antigen-binding portion thereof.
263. The method of any one of claims 226-262, wherein:(a) the anti-LAG-3 antibody comprises CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:3, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO:4, and the anti-PD-1 antibody comprises CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 13, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO: 14;(b) the anti-LAG-3 antibody comprises a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO: 6, and SEQ ID NO: 7, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO: 10, respectively, and the anti-PD-1 antibody comprises a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO:20, respectively;(c) the anti-LAG-3 antibody comprises heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:3 and 4, respectively, and the anti-PD-1 antibody comprises heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:13 and 14, respectively;(d) the anti-LAG-3 antibody comprises heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:l and 2, respectively, and the anti-PD-1antibody comprises heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs: 11 and 12, respectively; or(e) the anti-LAG-3 antibody comprises heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:21 and 2, respectively, and the anti-PD-1 antibody comprises heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs: 11 and 12, respectively.
264. The method of any one of claims 183-263, wherein the pharmaceutical composition further comprises an increased concentration of a buffering agent as compared to the corresponding composition.
265. The method of claim 264, wherein the buffering agent comprises histidine, succinate, Tris, sodium phosphate, sodium acetate, sodium citrate, or a combination thereof.
266. The method of claim 264 or 265, wherein the buffering agent comprises histidine.
267. The method of any one of claims 183-266, wherein the pharmaceutical composition further comprises an antioxidant.
268. The method of claim 267, wherein the antioxidant comprises a sacrificial antioxidant, a metal ion chelator, or both.
269. The method of claim 267 or 268, wherein the antioxidant comprises methionine, tryptophan, histidine, cysteine, ascorbic acid, glycine, pentetic acid (" DTPA"), ethylenediaminetetraacetic acid (" EDTA"), or a combination thereof.
270. The method of any one of claims 267-269, comprising at least two antioxidants.
271. The method of claim 270, wherein the at least two antioxidants are (i) methionine and DTPA or (ii) methionine and EDTA.
272. The method of any one of claims 269-271, comprising at least about 1 mM, at least about 1.5 mM, at least about 2 mM, at least about 2.5 mM, at least about 3 mM, at least about 3.5 mM, at least about 4 mM, at least about 4.5 mM, at least about 5 mM, at least about 5.5 mM, at least about 6 mM, at least about 6.5 mM, at least about 7 mM, at least about 7.5 mM, at least about 8 mM, at least about 8.5 mM, at least about 9 mM, at least about 9.5 mM, at least about 10 mM, at least about 11 mM, at least about 12 mM, at least about 13mM, at least about 14 mM, at least about 15 mM, at least about 16 mM, at least about 17 mM, at least about 18 mM, at least about 19 mM, or at least about 20 mM of methionine.
273. The method of any one of claims 269-272, comprising about 0.1 mM to about 100 mM, about 0.1 mM to about 90 mM, about 0.1 mM to about 80 mM, about 0.1 mM to about 70 mM, about 0.1 mM to about 60 mM, about 0.1 mM to about 50 mM, about 0.1 mM to about 40 mM, about 0.1 mM to about 30 mM, about 0.1 mM to about 20 mM, about 0.1 mM to about 10 mM, about 1 mM to about 20 mM, about 1 mM to about 15 mM, about 1 mM to about 10 mM, about 1 mM to about 9 mM, about 1 mM to about 8 mM, about 1 mM to about 7 mM, about 1 mM to about 6 mM, about 1 mM to about 5 mM, about 2 mM to about 9 mM, about 3 mM to about 8 mM, about 4 mM to about 7 mM, about 4 mM to about 6 mM, about 4 mM to about 5 mM, about 5 mM to about 20 mM, about 5 mM to about 15 mM, about 5 mM to about 10 mM, about 5 mM to about 9 mM, about 5 mM to about 8 mM, about 5 mM to about 7 mM, or about 5 mM to about 6 mM of methionine.
274. The method of any one of claims 269-273 comprising about 1 mM, about 1.5 mM, about 2 mM, about 2.5 mM, about 3 mM, about 3.5 mM, about 4 mM, about 4.5 mM, about 5 mM, about 5.5 mM, about 6 mM, about 6.5 mM, about 7 mM, about 7.5 mM, about 8 mM, about 8.5 mM, about 9 mM, about 9.5 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM, about 55 mM, about 60 mM, about 65 mM, about 70 mM, about 75 mM, about 80 mM, about 85 mM, about 90 mM, about 95 mM, or about 100 mM of methionine.
275. The method of any one of claims 269-274, comprising about 5 mM of methionine.
276. The method of any one of claims 269-275, comprising about 1 pM to about 250 pM, about 10 pM to about 200 pM, about 10 pM to about 175 pM, about 10 pM to about 150 pM, about 10 pM to about 125 pM, about 10 pM to about 100 pM, about 10 pM to about 75 pM, about 10 pM to about 70 pM, about 10 pM to about 60 pM, about 10 pM to about 50 pM, about 20 pM to about 100 pM, about 20 pM to about 75 pM, about 20 pM to about 70 pM, about 20 pM to about 60 pM, about 20 pM to about 50 pM, about 25 pM to about 100 pM, about 25 pM to about 75 pM, about 25 pM to about 50 pM, about 30 pM to about 100 pM, about 30 pM to about 75 pM, about 30 pM to about 70 pM, about 30 pM to about60 pM, about 30 pM to about 50 pM, about 40 pM to about 100 pM, about 40 pM to about 75 pM, about 40 pM to about 70 pM, about 40 pM to about 60 pM, about 40 pM to about 50 pM, about 41 pM to about 59 pM, about 42 pM to about 58 pM, about 43 pM to about 57 pM, about 44 pM to about 56 pM, about 45 pM to about 55 pM, about 46 pM to about 54 pM, about 47 pM to about 53 pM, about 48 pM to about 52 pM, about 49 pM to about 51 pM, about 50 pM to about 100 pM, about 50 pM to about 75 pM, about 50 pM to about 70 pM, about 50 pM to about 60 pM of DTPA.
277. The method of any one of claims 269-276, comprising about 1 pM, about 5 pM, about 10 pM, about 15 pM, about 20 pM, about 25 pM, about 30 pM, about 35 pM, about 40 pM, about 45 pM, about 50 pM, about 55 pM, about 60 pM, about 65 pM, about 70 pM, about 75 pM, about 80 pM, about 85 pM, about 90 pM, about 95 pM, about 100 pM, about 110 pM, about 120 pM, about 130 pM, about 140 pM, about 150 pM, about 160 pM, about 170 pM, about 180 pM, about 190 pM, about 200 pM, about 210 pM, about 220 pM, about 230 pM, about 240 pM, or about 250 pM of DTPA.
278. The method of any one of claims 269-277, comprising about 50 pM of DTPA.
279. The method of any one of claims 183-278, further comprising a surfactant.
280. The method of claim 279, wherein the surfactant comprises polysorbate 20, polysorbate 80, or poloxamer 188.
281. The method of claim 279 or 280, wherein the surfactant comprises polysorbate 80.
282. The method of claim 280 or 281, comprising at least about 0.01% w / v, at least about 0.02% w / v, at least about 0.03% w / v, at least about 0.04% w / v, at least about 0.05% w / v, at least about 0.06% w / v, at least about 0.07% w / v, at least about 0.08% w / v, at least about 0.09% w / v, or at least about 0.1% w / v of polysorbate 80.
283. The method of any one of claims 280-282, comprising about 0.001% to about 1% w / v, about 0.001% w / v to about 0.9% w / v, about 0.001% w / v to about 0.8% w / v, about 0.001% w / v to about 0.7% w / v, about 0.001% w / v to about 0.6% w / v, about 0.001% w / v to about 0.5% w / v, about 0.001% w / v to about 0.4% w / v, about 0.001% w / v to about 0.3% w / v, about 0.001% w / v to about 0.2% w / v, about 0.001% w / v to about 0.1% w / v, about 0.001% w / v to about 0.09% w / v, about 0.001% w / v to about 0.08% w / v, about 0.001% w / v to about0.07% w / v, about 0.001% w / v to about 0.06% w / v, about 0.001% w / v to about 0.05% w / v, about 0.01% w / v to about 0.9% w / v, about 0.01% w / v to about 0.8% w / v, about 0.01% w / v to about 0.7% w / v, about 0.01% w / v to about 0.6% w / v, about 0.01% w / v to about 0.5% w / v, about 0.01% w / v to about 0.4% w / v, about 0.01% w / v to about 0.3% w / v, about 0.01% w / v to about 0.2% w / v, about 0.01% w / v to about 0.1% w / v, about 0.01% w / v to about 0.09% w / v, about 0.01% w / v to about 0.08% w / v, about 0.01% w / v to about 0.07% w / v, about 0.01% w / v to about 0.06% w / v, about 0.01% w / v to about 0.05% w / v, about 0.02% w / v to about 0.1% w / v, about 0.02% w / v to about 0.09% w / v, about 0.02% w / v to about 0.08% w / v, about 0.02% w / v to about 0.07% w / v, about 0.02% w / v to about 0.06% w / v, about 0.02% w / v to about 0.05% w / v, about 0.03% w / v to about 0.1% w / v, about 0.03% w / v to about 0.09% w / v, about 0.03% w / v to about 0.08% w / v, about 0.03% w / v to about 0.07% w / v, about 0.03% w / v to about 0.06% w / v, about 0.03% w / v to about 0.05% w / v, about 0.04% w / v to about 0.1% w / v, about 0.04% w / v to about 0.09% w / v, about 0.04% w / v to about 0.08% w / v, about 0.04% w / v to about 0.07% w / v, about 0.04% w / v to about 0.06% w / v, about 0.04% w / v to about 0.05%, about 0.05% w / v to about 0.1% w / v, about 0.05% w / v to about 0.09% w / v, about 0.05% w / v to about 0.08% w / v, about 0.05% w / v to about 0.07% w / v, or about 0.05% w / v to about 0.06% w / v of polysorbate 80.
284. The method of any one of claims 280-283, comprising about 0.001% w / v, about 0.002% w / v, about 0.003% w / v, about 0.004% w / v, about 0.005% w / v, about 0.006% w / v, about 0.007% w / v, about 0.008% w / v, about 0.009% w / v, about 0.01% w / v, about 0.02% w / v, about 0.03% w / v, about 0.04% w / v, about 0.05% w / v, about 0.06% w / v, about 0.07% w / v, about 0.08% w / v, about 0.09% w / v, about 0.1% w / v, about 0.2% w / v, about 0.3% w / v, about 0.4% w / v, about 0.5% w / v, about 0.6% w / v, about 0.7% w / v, about 0.8% w / v, about 0.9% w / v, or about 1% w / v of polysorbate 80.
285. The method of any one of claims 280-283, comprising about 0.05% of w / v polysorbate 80.
286. The method of any one of claims 183-285, further comprising an endoglycosidase hydrolase enzyme.
287. The method of claim 286, wherein the endoglycosidase hydrolase enzyme cleaves hyaluronic acid at a hexosaminidic P (1-4) or (1-3) linkage.
288. The method of claim 286 or 287, wherein the endoglycosidase hydrolase enzyme comprises a catalytic domain of hyaluronidase PH-20 (HuPH20), HYAL1, HYAL2, HYAL3, HYAL4, orHYALPSl.
289. The method of any one of claims 287-288, wherein the endoglycosidase hydrolase enzyme comprises a hyaluronidase.
290. The method of claim 289, wherein the hyaluronidase comprises HuPH20, HYAL1, HYAL2, HYAL3, HYAL4, or a variant or isoform thereof.
291. The method of any one of claims 289-290, wherein the endoglycosidase hydrolase enzyme comprises rHuPH20 or a fragment thereof.
292. The method of any one of claims 289-291, wherein the endoglycosidase hydrolase enzyme comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity to amino acids 36-490 of SEQ ID NO:87.
293. The method of any one of claims 289-292, wherein the endoglycosidase hydrolase enzyme comprises a modified hyaluronidase comprising one or more amino acid substitutions relative to a wild-type hyaluronidase that is HuPH20, HYAL1, HYAL2, HYAL3, HYAL4, HYALPS1, or a fragment thereof.
294. The method of any one of claims 289-293, wherein the endoglycosidase hydrolase enzyme comprises a modified hyaluronidase comprising (i) one or more amino acid substitution in an alpha-helix region, (ii) one or more amino acid substitution in a linker region, (iii) deletion of one or more N-terminal and / or C-terminal amino acids, or (iv) any combination of (i)-(iii), relative to a wild-type hyaluronidase that is HuPH20, HYAL1, HYAL2, HYAL3, HYAL4, HYALPS1, or a fragment thereof.
295. The method of any one of claims 289-294, wherein the endoglycosidase hydrolase enzyme comprises a modified rHuPH20, wherein the modified rHuPH20 comprises:(a) one or more amino acid substitution in an alpha-helix region, a linker region, or both an alpha-helix region and a linker region relative to wild-type rHuPH20;(b) deletion of one or more N-terminal amino acid, one or more C-terminal amino acid, or one or more N-terminal amino acid and one or more C-terminal amino acid relative to wild-type rHuPH20; or(c) both (a) and (b).
296. The method of any one of claims 289-295, comprising at least about 50 IU / mL, at least about 100 IU / mL, at least about 150 IU / mL, at least about 200 IU / mL, at least about 250 IU / mL, at least about 300 IU / mL, at least about 350 IU / mL, at least about 400 IU / mL, at least about 450 IU / mL, at least about 500 IU / mL, at least about 550 IU / mL, at least about 600 IU / mL, at least about 650 IU / mL, at least about 700 IU / mL, at least about 750 IU / mL, at least about 800 IU / mL, at least about 850 IU / mL, at least about 900 IU / mL, at least about 950 IU / mL, at least about 1000 IU / mL, at least about 1100 IU / mL, at least about 1200 IU / mL, at least about 1300 IU / mL, at least about 1400 IU / mL, at least about 1500 IU / mL, at least about 1600 IU / mL, at least about 1700 IU / mL, at least about 1800 IU / mL, at least about 1900 IU / mL, at least about 2000 IU / mL, at least about 2100 IU / mL, at least about 2200 IU / mL, at least about 2300 IU / mL, at least about 2400 IU / mL, at least about 2500 IU / mL, at least about 3000 IU / mL, at least about 3500 IU / mL, at least about 4000 IU / mL, at least about 4500 IU / mL, or at least about 5000 IU / mL of the endoglycosidase hydrolase enzyme.
297. The method of any one of claims 289-296, comprising about 50 IU / mL to about 10,000 IU / mL, about 100 IU / mL to about 9500 IU / mL, about 150 IU / mL to about 9000 IU / mL, about 200 IU / mL to about 8500 IU / mL, about 250 IU / mL to about 8000 IU / mL, about 300 IU / mL to about 7500 IU / mL, about 350 IU / mL to about 7000 IU / mL, about 400 IU / mL to about 6500 IU / mL, about 450 IU / mL to about 6000 IU / mL, about 500 IU / mL to about 5500 IU / mL, about 550 IU / mL to about 5000 IU / mL, about 600 IU / mL to about 4500 IU / mL, about 650 IU / mL to about 4000 IU / mL, about 700 IU / mL to about 3500 IU / mL, about 750 IU / mL to about 3000 IU / mL, about 800 IU / mL to about 2500 IU / mL, about 900 IU / mL to about 2500 IU / mL, about 1000 IU / mL to about 2500 IU / mL, about 1500 IU / mL to about 2500 IU / mL, about 1600 IU / mL to about 2500 IU / mL, about 1700 IU / mL to about 2500 IU / mL, about 1800 IU / mL to about 2500 IU / mL, about 1900 IU / mL to about 2500 IU / mL, about 2000 IU / mL to about 2500 IU / mL, about 2100 IU / mL to about 2500 IU / mL, about 2200 IU / mL to about 2500 IU / mL, about 2300 IU / mL to about 2500 IU / mL, about 1500 IU / mL to about 2500 IU / mL, about 1600 IU / mL to about 2400 IU / mL, about 1700 IU / mLto about 2300 IU / mL, about 1800 IU / mL to about 2200 IU / mL, or about 1900 IU / mL to about 2100 IU / mL of the endoglycosidase hydrolase enzyme.
298. The method of any one of claims 289-297, comprising about 50 IU / mL, about 100 IU / mL, about 150IU / mL, about 200 IU / mL, about 250 IU / mL, about 300 IU / mL, about 350 IU / mL, about 400 IU / mL, about 450 IU / mL, about 500 IU / mL, about 550 IU / mL, about 600 IU / mL, about 650 IU / mL, about 700 IU / mL, about 750 IU / mL, about 800 IU / mL, about 850 IU / mL, about 900 IU / mL, about 950 IU / mL, about 1000 IU / mL, about 1100 IU / mL, about 1200 IU / mL, about 1300 IU / mL, about 1400 IU / mL, about 1500 IU / mL, about 1600 IU / mL, about 1700 IU / mL, about 1800 IU / mL, about 1900 IU / mL, about 2000 IU / mL, about 2100 IU / mL, about 2200 IU / mL, about 2300 IU / mL, about 2400 IU / mL, about 2500 IU / mL, about 3000 IU / mL, about 3500 IU / mL, about 4000 IU / mL, about 4500 IU / mL, about 5000 IU / mL, about 5500 IU / mL, about 6000 IU / mL, about 6500 IU / mL, about 7000 IU / mL, about 7500 IU / mL, about 8000 IU / mL, about 8500 IU / mL, about 9000 IU / mL, about 9500 IU / mL, or about 10,000 IU / mL of the endoglycosidase hydrolase enzyme.
299. The method of any one of claims 289-298, comprising about 2000 IU / mL of the endoglycosidase hydrolase enzyme.
300. The method of any one of claims 183-299, wherein the pharmaceutical composition is capable of being injected within about 10 minutes or less.
301. The method of claim 300, wherein the pharmaceutical composition is capable of being injected within about 5 minutes to about 7 minutes.
302. The method of claim 300, wherein the pharmaceutical composition is capable of being injected within about 3 minutes to about 5 minutes.
303. The method of any one of claims 183-302, wherein percent high molecular weight (% HMW) species in the pharmaceutical composition are about 1.5% or less as measured by size exclusion chromatography following: agitation at 250 rpm for 1 week at 30 °C, agitation at 250 rpm for 2 weeks at 30 °C, storage at room temperature and room light conditions for 2 weeks, storage at 40 °C for 2 weeks, and / or storage at 50 °C for 2 weeks.
304. The method of claim 303, wherein the % HMW species are about 1% or less.
305. The method of claim 303 or 304, wherein the %HMW species are less than about 1%.
306. The method of any one of claims 183-305, wherein percent monomer (% monomer) in the pharmaceutical composition as measured by size exclusion chromatography is greater than about 97% following: agitation at 250 rpm for 1 week at 30 °C, agitation at 250 rpm for 2 weeks at 30 °C, storage at room temperature and room light conditions for 2 weeks, storage at 40 °C for 2 weeks, and / or storage at 50 °C for 2 weeks.
307. The method of any one of claims 183-306, wherein the % monomer in the pharmaceutical composition as measured by size exclusion chromatography is about 98% or more following: agitation at 250 rpm for 1 week at 30 °C, agitation at 250 rpm for 2 weeks at 30 °C, storage at room temperature and room light conditions for 2 weeks, and / or storage at 40 °C for 2 weeks.
308. A pharmaceutical composition comprising: (a) about 100 mg / mL or more of a protein, (b) means for producing a lower viscosity of the pharmaceutical composition as compared to a corresponding composition comprising the same concentration of the protein, and (c) means for producing an osmolality of about 200 mOsmol / kg to about 600 mOsmol / kg of the pharmaceutical composition.
309. The pharmaceutical composition of claim 308, wherein the osmolality is about 210 mOsmol / kg to about 600 mOsmol / kg, about 220 mOsmol / kg to about 600 mOsmol / kg, about 230 mOsmol / kg to about 600 mOsmol / kg, about 240 mOsmol / kg to about 600 mOsmol / kg, about 250 mOsmol / kg to about 600 mOsmol / kg, about 260 mOsmol / kg to about 600 mOsmol / kg, about 270 mOsmol / kg to about 600 mOsmol / kg, about 280 mOsmol / kg to about 600 mOsmol / kg, about 290 mOsmol / kg to about 600 mOsmol / kg, about 300 mOsmol / kg to about 600 mOsmol / kg, about 350 mOsmol / kg to about 600 mOsmol / kg, about 400 mOsmol / kg to about 600 mOsmol / kg, about 450 mOsmol / kg to about 600 mOsmol / kg, about 500 mOsmol / kg to about 600 mOsmol / kg, about 550 mOsmol / kg to about 600 mOsmol / kg, about 500 mOsmol / kg to about 550 mOsmol / kg, about 450 mOsmol / kg to about 550 mOsmol / kg, about 400 mOsmol / kg to about 550 mOsmol / kg, about 350 mOsmol / kg to about 550 mOsmol / kg, about 300 mOsmol / kg to about 550 mOsmol / kg, about 250 mOsmol / kg to about 550 mOsmol / kg, about 200 mOsmol / kg to about 550 mOsmol / kg, about 200 mOsmol / kg to about 500 mOsmol / kg, about 250 mOsmol / kg to about 500 mOsmol / kg, about 300 mOsmol / kg to about 500mOsmol / kg, about 350 mOsmol / kg to about 500 mOsmol / kg, about 400 mOsmol / kg to about 500 mOsmol / kg, about 450 mOsmol / kg to about 500 mOsmol / kg, about 400 mOsmol / kg to about 450 mOsmol / kg, about 350 mOsmol / kg to about 450 mOsmol / kg, about 300 mOsmol / kg to about 450 mOsmol / kg, about 250 mOsmol / kg to about 450 mOsmol / kg, about 200 mOsmol / kg to about 450 mOsmol / kg, about 200 mOsmol / kg to about 400 mOsmol / kg, about 250 mOsmol / kg to about 400 mOsmol / kg, about 300 mOsmol / kg to about 400 mOsmol / kg, about 350 mOsmol / kg to about 400 mOsmol / kg, about 300 mOsmol / kg to about 350 mOsmol / kg, about 250 mOsmol / kg to about 350 mOsmol / kg, about 200 mOsmol / kg to about 350 mOsmol / kg, about 200 mOsmol / kg to about 300 mOsmol / kg, or about 250 mOsmol / kg to about 300 mOsmol / kg.
310. The pharmaceutical composition of claim 308 or 309, wherein the osmolality is about 280 mOsmol / kg to about 600 mOsmol / kg.
311. The pharmaceutical composition of any one of claims 308-310, wherein the osmolality is about 200 mOsmol / kg, about 205 mOsmol / kg, about 210 mOsmol / kg, about 215 mOsmol / kg, about 220 mOsmol / kg, about 225 mOsmol / kg, about 230 mOsmol / kg, about 235 mOsmol / kg, about 240 mOsmol / kg, about 245 mOsmol / kg, about 250 mOsmol / kg, about 255 mOsmol / kg, about 260 mOsmol / kg, about 265 mOsmol / kg, about 270 mOsmol / kg, about 275 mOsmol / kg, about 280 mOsmol / kg, about 285 mOsmol / kg, about 290 mOsmol / kg, about 295 mOsmol / kg, about 300 mOsmol / kg, about 305 mOsmol / kg, about 310 mOsmol / kg, about 315 mOsmol / kg, about 320 mOsmol / kg, about 325 mOsmol / kg, about 330 mOsmol / kg, about 335 mOsmol / kg, about 340 mOsmol / kg, about 345 mOsmol / kg, about 350 mOsmol / kg, about 355 mOsmol / kg, about 360 mOsmol / kg, about 365 mOsmol / kg, about 370 mOsmol / kg, about 375 mOsmol / kg, about 380 mOsmol / kg, about 385 mOsmol / kg, about 390 mOsmol / kg, about 395 mOsmol / kg, about 400 mOsmol / kg, about 405 mOsmol / kg, about 410 mOsmol / kg, about 415 mOsmol / kg, about 420 mOsmol / kg, about 425 mOsmol / kg, about 430 mOsmol / kg, about 435 mOsmol / kg, about 440 mOsmol / kg, about 445 mOsmol / kg, about 450 mOsmol / kg, about 455 mOsmol / kg, about 460 mOsmol / kg, about 465 mOsmol / kg, about 470 mOsmol / kg, about 475 mOsmol / kg, about 480 mOsmol / kg, about 485 mOsmol / kg, about 490 mOsmol / kg, about 495 mOsmol / kg, about 500 mOsmol / kg, about 505 mOsmol / kg, about 510 mOsmol / kg, about 515 mOsmol / kg, about 520 mOsmol / kg, about 525 mOsmol / kg, about 530 mOsmol / kg, about 535 mOsmol / kg, about 540 mOsmol / kg, about 545mOsmol / kg, about 550 mOsmol / kg, about 555 mOsmol / kg, about 560 mOsmol / kg, about 565 mOsmol / kg, about 570 mOsmol / kg, about 575 mOsmol / kg, about 580 mOsmol / kg, about 585 mOsmol / kg, about 590 mOsmol / kg, or about 595 mOsmol / kg.
312. The pharmaceutical composition of any one of claims 308-311, wherein the osmolality is determined by vapor-pressure osmometry.
313. The pharmaceutical composition of any one of claims 308-312, wherein the osmolality is determined with a vapor pressure osmometer.
314. The pharmaceutical composition of any one of claims 308-313, wherein the means for producing a lower viscosity produces a viscosity of about 15 centipoise (cP) or less of the pharmaceutical composition.
315. The pharmaceutical composition of any one of claim 308-314, wherein the means for producing a lower viscosity produces a viscosity of about 1 cP to about 15 cP, about 1 cP to about 14 cP, about 1 cP to about 13 cP, about 1 cP to about 12 cP, about 1 cP to about 11 cP, about 1 cP to about 10 cP, about 1 cP to about 9 cP, about 1 cP to about 8 cP, about 1 cP to about 7 cP, about 1 cP to about 6 cP, about 1 cP to about 5 cP, about 1 cP to about 4 cP, about 1 cP to about 3 cP, about 2 cP to about 15 cP, about 2 cP to about 14 cP, about 2 cP to about 13 cP, about 2 cP to about 12 cP, about 2 cP to about 11 cP, about 2 cP to about 10 cP, about 2 cP to about 9 cP, about 2 cP to about 8 cP, about 2 cP to about 7 cP, about 2 cP to about 6 cP, about 2 cP to about 5 cP, about 2 cP to about 4 cP, about 3 cP to about 15 cP, about 3 cP to about 14 cP, about 3 cP to about 13 cP, about 3 cP to about 12 cP, about 3 cP to about 11 cP, about 3 cP to about 10 cP, about 3 cP to about 9 cP, about 3 cP to about 8 cP, about 3 cP to about 7 cP, about 3 cP to about 6 cP, about 3 cP to about 5 cP, about 4 cP to about 15 cP, about 4 cP to about 14 cP, about 4 cP to about 13 cP, about 4 cP to about 12 cP, about 4 cP to about 11 cP, about 4 cP to about 10 cP, about 4 cP to about 9 cP, about 4 cP to about 8 cP, about 4 cP to about 7 cP, about 4 cP to about 6 cP, about 5 cP to about 15 cP, about 5 cP to about 14 cP, about 5 cP to about 13 cP, about 5 cP to about 12 cP, about 5 cP to about 11 cP, about 5 cP to about 10 cP, about 5 cP to about 9 cP, about 5 cP to about 8 cP, about 5 cP to about 7 cP, about 6 cP to about 15 cP, about 6 cP to about 14 cP, about 6 cP to about 13 cP, about 6 cP to about 12 cP, about 6 cP to about 11 cP, about 6 cP to about 10 cP, about 6 cP to about 9 cP, about 6 cP to about 8 cP, about 7 cP to about 15 cP, about 7 cP to about 14 cP, about 7 cP to about 13 cP, about 7 cP toabout 12 cP, about 7 cP to about 11 cP, about 7 cP to about 10 cP, about 7 cP to about 9 cP, about 8 cP to about 15 cP, about 8 cP to about 14 cP, about 8 cP to about 13 cP, about 8 cP to about 12 cP, about 8 cP to about 11 cP, about 8 cP to about 10 cP, about 9 cP to about 15 cP, about 9 cP to about 14 cP, about 9 cP to about 13 cP, about 9 cP to about 12 cP, about 9 cP to about 11 cP, about 10 cP to about 15 cP, about 10 cP to about 14 cP, about 10 cP to about 13 cP, about 10 cP to about 12 cP, about 11 cP to about 15 cP, about 11 cP to about 14 cP, about 11 cP to about 13 cP, about 12 cP to about 15 cP, about 12 cP to about 14 cP, or about 13 cP to about 15 cP.
316. The pharmaceutical composition of any one of claims 308-315, wherein the viscosity is determined with a microfluidic viscometer.
317. The pharmaceutical composition of any one of claims 308-316, wherein the viscosity is determined at 20 °C.
318. The pharmaceutical composition of any one of claims 308-317, comprising a volume of about 0.001 mL to about 20 mL.
319. The pharmaceutical composition of any one of claims 308-318, comprising a volume of about 0.001 mL, about 0.005 mL, about 0.010 mL, about 0.015 mL, about 0.020 mL, about 0.025 mL, about 0.030 mL, about 0.035 mL, about 0.040 mL, about 0.045 mL, about 0.050 mL, about 0.055 mL, about 0.060 mL, about 0.065 mL, about 0.070 mL, about 0.075 mL, about 0.080 mL, about 0.085 mL, about 0.090 mL, about 0.095 mL, about 0.100 mL, about 0.150 mL, about 0.200 mL, about 0.250 mL, about 0.300 mL, about 0.350 mL, about 0.400 mL, about 0.450 mL, about 0.500 mL, about 0.550 mL, about 0.600 mL, about 0.650 mL, about 0.700 mL, about 0.750 mL, about 0.800 mL, about 0.850 mL, about 0.900 mL, about 0.950 mL, about 1 mL, about 1.1 mL, about 1.2 mL, about 1.3 mL, about 1.4 mL, about 1.5 mL, about 1.6 mL, about 1.7 mL, about 1.8 mL, about 1.9 mL, about 2 mL, about 2.1 mL, about 2.2 mL, about 2.3 mL, about 2.4 mL, about 2.5 mL, about 2.6 mL, about 2.7 mL, about 2.8 mL, about 2.9 mL, about 3 mL, about 3.1 mL, about 3.2 mL, about 3.3 mL, about 3.4 mL, about 3.5 mL, about 3.6 mL, about 3.7 mL, about 3.8 mL, about 3.9 mL, about 4 mL, about 4.1 mL, about 4.2 mL, about 4.3 mL, about 4.4 mL, about 4.5 mL, about 4.6 mL, about 4.7 mL, about 4.8 mL, about 4.9 mL, about 5 mL, about 5.1 mL, about 5.2 mL, about 5.3 mL, about 5.4 mL, about 5.5 mL, about 5.6 mL, about 5.7 mL, about 5.8 mL, about 5.9 mL, about 6 mL, about 6.1 mL, about 6.2 mL, about 6.3 mL, about 6.4 mL,about 6.5 mL, about 6.6 mL, about 6.7 mL, about 6.8 mL, about 6.9 mL, about 7 mL, about 7.1 mL, about 7.2 mL, about 7.3 mL, about 7.4 mL, about 7.5 mL, about 7.6 mL, about 7.7 mL, about 7.8 mL, about 7.9 mL, about 8 mL, about 8.1 mL, about 8.2 mL, about 8.3 mL, about 8.4 mL, about 8.5 mL, about 8.6 mL, about 8.7 mL, about 8.8 mL, about 8.9 mL, about 9 mL, about 9.1 mL, about 9.2 mL, about 9.3 mL, about 9.4 mL, about 9.5 mL, about 9.6 mL, about 9.7 mL, about 9.8 mL, about 9.9 mL, about 10 mL, about 10.1 mL, about 10.2 mL, about 10.3 mL, about 10.4 mL, about 10.5 mL, about 10.6 mL, about 10.7 mL, about 10.8 mL, about 10.9 mL, about 11 mL, about 11.1 mL, about 11.2 mL, about 11.3 mL, about 11.4 mL, about 11.5 mL, about 11.6 mL, about 11.7 mL, about 11.8 mL, about 11.9 mL, about 12 mL, about 12.1 mL, about 12.2 mL, about 12.3 mL, about 12.4 mL, about 12.5 mL, about 12.6 mL, about 12.7 mL, about 12.8 mL, about 12.9 mL, about 13 mL, about 13.1 mL, about 13.2 mL, about 13.3 mL, about 13.4 mL, about 13.5 mL, about 13.6 mL, about 13.7 mL, about 13.8 mL, about 13.9 mL, about 14 mL, about 14.1 mL, about 14.2 mL, about 14.3 mL, about 14.4 mL, about 14.5 mL, about 14.6 mL, about 14.7 mL, about 14.8 mL, about 14.9 mL, about 15 mL, about 15.1 mL, about 15.2 mL, about 15.3 mL, about 15.4 mL, about 15.5 mL, about 15.6 mL, about 15.7 mL, about 15.8 mL, about 15.9 mL, about 16 mL, about 16.1 mL, about 16.2 mL, about 16.3 mL, about 16.4 mL, about 16.5 mL, about 16.6 mL, about 16.7 mL, about 16.8 mL, about 16.9 mL, about 17 mL, about 17.1 mL, about 17.2 mL, about 17.3 mL, about 17.4 mL, about 17.5 mL, about 17.6 mL, about 17.7 mL, about 17.8 mL, about 17.9 mL, about 18 mL, about 18.1 mL, about 18.2 mL, about 18.3 mL, about 18.4 mL, about 18.5 mL, about 18.6 mL, about 18.7 mL, about 18.8 mL, about 18.9 mL, about 19 mL, about 19.1 mL, about 19.2 mL, about 19.3 mL, about 19.4 mL, about 19.5 mL, about 19.6 mL, about 19.7 mL, about 19.8 mL, about 19.9 mL, or about 20 mL.
320. The pharmaceutical composition of any one of claims 308-319, comprising a volume of about 8.4 mL, about 9 mL, about 9.6 mL, about 10 mL, about 12 mL, about 12.8 mL, about 15 mL, or about 16 mL.
321. The pharmaceutical composition of any one of claims 308-320, comprising about 100 mg / mL to about 500 mg / mL, about 100 mg / mL to about 450 mg / mL, about 100 mg / mL to about 400 mg / mL, about 100 mg / mL to about 350 mg / mL, about 100 mg / mL to about 300 mg / mL, about 100 mg / mL to about 250 mg / mL, about 100 mg / mL to about 200 mg / mL, about 100 mg / mL to about 150 mg / mL, about 100 mg / mL to about 140 mg / mL, about 100mg / mL to about 130 mg / mL, about 100 mg / mL to about 120 mg / mL, about 100 mg / mL to about 115 mg / mL, about 100 mg / mL to about 110 mg / mL, about 100 mg / mL to about 105 mg / mL, about 110 mg / mL to about 500 mg / mL, about 110 mg / mL to about 450 mg / mL, about 110 mg / mL to about 400 mg / mL, about 110 mg / mL to about 350 mg / mL, about 110 mg / mL to about 300 mg / mL, about 110 mg / mL to about 250 mg / mL, about 110 mg / mL to about 200 mg / mL, about 110 mg / mL to about 150 mg / mL, about 110 mg / mL to about 140 mg / mL, about 110 mg / mL to about 130 mg / mL, about 110 mg / mL to about 120 mg / mL, about 110 mg / mL to about 115 mg / mL, about 115 mg / mL to about 500 mg / mL, about 115 mg / mL to about 450 mg / mL, about 115 mg / mL to about 400 mg / mL, about 115 mg / mL to about 350 mg / mL, about 115 mg / mL to about 300 mg / mL, about 115 mg / mL to about 250 mg / mL, about 115 mg / mL to about 200 mg / mL, about 115 mg / mL to about 150 mg / mL, about 115 mg / mL to about 140 mg / mL, about 115 mg / mL to about 130 mg / mL, about 115 mg / mL to about 120 mg / mL, about 120 mg / mL to about 450 mg / mL, about 120 mg / mL to about 400 mg / mL, about 120 mg / mL to about 350 mg / mL, about 120 mg / mL to about 300 mg / mL, about 120 mg / mL to about 250 mg / mL, about 120 mg / mL to about 200 mg / mL, about 120 mg / mL to about 150 mg / mL, about 120 mg / mL to about 140 mg / mL, about 120 mg / mL to about 130 mg / mL, about 150 mg / mL to about 500 mg / mL, about 150 mg / mL to about 450 mg / mL, about 150 mg / mL to about 400 mg / mL, about 150 mg / mL to about 350 mg / mL, about 150 mg / mL to about 300 mg / mL, about 150 mg / mL to about 250 mg / mL, or about 150 mg / mL to about 200 mg / mL of the protein.
322. The pharmaceutical composition of any one of claims 308-321, comprising about 100 mg / mL, about 101 mg / mL, about 102 mg / mL, about 103 mg / mL, about 104 mg / mL, about 105 mg / mL, about 106 mg / mL, about 107 mg / mL, about 108 mg / mL, about 109 mg / mL, about 110 mg / mL, about 111 mg / mL, about 112 mg / mL, about 113 mg / mL, about 114 mg / mL, about 115 mg / mL, about 116 mg / mL, about 117 mg / mL, about 118 mg / mL, about 119 mg / mL, about 120 mg / mL, about 121 mg / mL, about 122 mg / mL, about 123 mg / mL, about 124 mg / mL, about 125 mg / mL, about 126 mg / mL, about 127 mg / mL, about 128 mg / mL, about 129 mg / mL, about 130 mg / mL, about 131 mg / mL, about 132 mg / mL, about 133 mg / mL, about 134 mg / mL, about 135 mg / mL, about 136 mg / mL, about 137 mg / mL, about 138 mg / mL, about 139 mg / mL, about 140 mg / mL, about 141 mg / mL, about 142 mg / mL, about 143 mg / mL, about 144 mg / mL, about 145 mg / mL, about 146 mg / mL, about 147 mg / mL, about 148 mg / mL, about 149 mg / mL, about 150 mg / mL, about 155 mg / mL,about 160 mg / mL, about 165 mg / mL, about 170 mg / mL, about 175 mg / mL, about 180 mg / mL, about 185 mg / mL, about 190 mg / mL, about 195 mg / mL, about 200 mg / mL, about 205 mg / mL, about 210 mg / mL, about 215 mg / mL, about 220 mg / mL, about 225 mg / mL, about 230 mg / mL, about 235 mg / mL, about 240 mg / mL, about 245 mg / mL, about 250 mg / mL, about 255 mg / mL, about 260 mg / mL, about 265 mg / mL, about 270 mg / mL, about 275 mg / mL, about 280 mg / mL, about 285 mg / mL, about 290 mg / mL, about 295 mg / mL, about 300 mg / mL, about 305 mg / mL, about 310 mg / mL, about 315 mg / mL, about 320 mg / mL, about 325 mg / mL, about 330 mg / mL, about 335 mg / mL, about 340 mg / mL, about 345 mg / mL, about 350 mg / mL, about 355 mg / mL, about 360 mg / mL, about 365 mg / mL, about 370 mg / mL, about 375 mg / mL, about 380 mg / mL, about 385 mg / mL, about 390 mg / mL, about 395 mg / mL, about 400 mg / mL, about 405 mg / mL, about 410 mg / mL, about 415 mg / mL, about 420 mg / mL, about 425 mg / mL, about 430 mg / mL, about 435 mg / mL, about 440 mg / mL, about 445 mg / mL, about 450 mg / mL, about 455 mg / mL, about 460 mg / mL, about 465 mg / mL, about 470 mg / mL, about 475 mg / mL, about 480 mg / mL, about 485 mg / mL, about 490 mg / mL, about 495 mg / mL, or about 500 mg / mL of the protein.
323. The pharmaceutical composition of any one of claims 308-322, comprising about 105 mg / mL, about 120 mg / mL, about 126 mg / mL, about 128 mg / mL, about 140 mg / mL, about 144 mg / mL, about 150 mg / mL, or about 160 mg / mL of the protein.
324. The pharmaceutical composition of any one of claims 308-323, comprising about 0.25 mg to about 4000 mg, about 0.25 mg to about 3600 mg, about 0.25 mg to about 3200 mg, about 0.25 mg to about 3000 mg, about 0.25 mg to about 2600 mg, about 0.25 mg to about 2200 mg, about 0.25 mg to about 2000 mg, about 0.25 mg to about 1600 mg, about 0.25 mg to about 1200 mg, about 0.25 mg to about 1000 mg, about 0.25 mg to about 800 mg, about 0.25 mg to about 600 mg, about 0.25 mg to about 400 mg, about 0.25 mg to about 200 mg, about 0.25 mg to about 100 mg, about 0.25 mg to about 50 mg, about 0.25 mg to about 40 mg, about 0.25 mg to about 30 mg, about 0.25 mg to about 20 mg, about 20 mg to about 4000 mg, about 20 mg to about 3600 mg, about 20 mg to about 3200 mg, about 20 mg to about 3000 mg, about 20 mg to about 2600 mg, about 20 mg to about 2200 mg, about 20 mg to about 2000 mg, about 20 mg to about 1600 mg, about 20 mg to about 1200 mg, about 20 mg to about 1000 mg, about 20 mg to about 800 mg, about 20 mg to about 600 mg, about 20 mg to about 400 mg, about 20 mg to about 200 mg, about 20 mg to about 100 mg, about 100 mg to about 4000 mg, about 100 mg to about 3600 mg, about 100 mg to about3200 mg, about 100 mg to about 3000 mg, about 100 mg to about 2600 mg, about 100 mg to about 2200 mg, about 100 mg to about 2000 mg, about 100 mg to about 1800 mg, about 100 mg to about 1600 mg, about 100 mg to about 1400 mg, about 100 mg to about 1200 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, about 400 mg to about 4000 mg, about 400 mg to about 3600 mg, about 400 mg to about 3200 mg, about 400 mg to about 3000 mg, about 400 mg to about 2600 mg, about 400 mg to about 2200 mg, about 400 mg to about 2000 mg, about 400 mg to about 1800 mg, about 400 mg to about 1600 mg, about 400 mg to about 1400 mg, about 400 mg to about 1200 mg, or about 400 mg to about 1000 mg of the protein.
325. The pharmaceutical composition of any one of claims 308-324, comprising about 0.25 mg, about 0.5 mg, about 0.75 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3 mg, about 3.25 mg, about 3.5 mg, about 3.75 mg, about 4 mg, about 4.25 mg, about 4.5 mg, about 4.75 mg, about 5 mg, about 5.25 mg, about 5.5 mg, about 5.75 mg, about 6 mg, about 6.25 mg, about 6.5 mg, about 6.75 mg, about 7 mg, about 7.25 mg, about 7.5 mg, about 7.75 mg, about 8 mg, about 8.25 mg, about 8.5 mg, about 8.75 mg, about 9 mg, about 9.25 mg, about 9.5 mg, about 9.75 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, about 710 mg, about 720 mg, about 730 mg, about 740 mg, about 750 mg, about 760 mg, about 770 mg, about 780 mg, about 790 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg,about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 980 mg, about 990 mg, about 1000 mg, about 1020 mg, about 1040 mg, about 1060 mg, about 1080 mg, about 1100 mg, about 1120 mg, about 1140 mg, about 1160 mg, about 1180 mg, about 1200 mg, about 1220 mg, about 1240 mg, about 1260 mg, about 1280 mg, about 1300 mg, about 1320 mg, about 1340 mg, about 1360 mg, about 1380 mg, about 1400 mg, about 1420 mg, about 1440 mg, about 1460 mg, about 1480 mg, about 1500 mg, about 1520 mg, about 1540 mg, about 1560 mg, about 1580 mg, about 1600 mg, about 1620 mg, about 1640 mg, about 1660 mg, about 1680 mg, about 1700 mg, about 1720 mg, about 1740 mg, about 1760 mg, about 1780 mg, about 1800 mg, about 1820 mg, about 1840 mg, about 1860 mg, about 1880 mg, about 1900 mg, about 1920 mg, about 1940 mg, about 1960 mg, about 1980 mg, about 2000 mg, about 2020 mg, about 2040 mg, about 2060 mg, about 2080 mg, about 2100 mg, about 2120 mg, about 2140 mg, about 2160 mg, about 2180 mg, about 2200 mg, about 2220 mg, about 2240 mg, about 2260 mg, about 2280 mg, about 2300 mg, about 2320 mg, about 2340 mg, about 2360 mg, about 2380 mg, about 2400 mg, about 2420 mg, about 2440 mg, about 2460 mg, about 2480 mg, about 2500 mg, about 2520 mg, about 2540 mg, about 2560 mg, about 2580 mg, about 2600 mg, about 2620 mg, about 2640 mg, about 2660 mg, about 2680 mg, about 2700 mg, about 2720 mg, about 2740 mg, about 2760 mg, about 2780 mg, about 2800 mg, about 2820 mg, about 2840 mg, about 2860 mg, about 2880 mg, about 2900 mg, about 2920 mg, about 2940 mg, about 2960 mg, about 2980 mg, about 3000 mg, about 3020 mg, about 3040 mg, about 3060 mg, about 3080 mg, about 3100 mg, about 3120 mg, about 3140 mg, about 3160 mg, about 3180 mg, about 3200 mg, about 3220 mg, about 3240 mg, about 3260 mg, about 3280 mg, about 3300 mg, about 3320 mg, about 3340 mg, about 3360 mg, about 3380 mg, about 3400 mg, about 3420 mg, about 3440 mg, about 3460 mg, about 3480 mg, about 3500 mg, about 3520 mg, about 3540 mg, about 3560 mg, about 3580 mg, about 3600 mg, about 3620 mg, about 3640 mg, about 3660 mg, about 3680 mg, about 3700 mg, about 3720 mg, about 3740 mg, about 3760 mg, about 3780 mg, about 3800 mg, about 3820 mg, about 3840 mg, about 3860 mg, about 3880 mg, about 3900 mg, about 3920 mg, about 3940 mg, about 3960 mg, about 3980 mg, or about 4000 mg of the protein.
326. The pharmaceutical composition of any one of claims 308-325, comprising about 1260 mg, about 1440 mg, or about 1920 mg of the protein.
327. The pharmaceutical composition of any one of claims 308-326, wherein the protein comprises an antibody, a checkpoint inhibitor, a fusion protein, a growth factor, a hormone, an enzyme, a cytokine, a coagulation factor, a plasma protein, or a combination thereof.
328. The pharmaceutical composition of claim 327, wherein the protein comprises an antibody.
329. The pharmaceutical composition of claim 327 or 328, wherein the antibody comprises a full-length antibody.
330. The pharmaceutical composition of any one of claims 327-329, wherein the antibody comprises a monoclonal, human, humanized, chimeric, or multispecific antibody.
331. The pharmaceutical composition of claim 330, wherein the multispecific antibody comprises a dual-affinity re-targeting antibody, a dual variable domain immunoglobulin, or a bispecific antibody.
332. The pharmaceutical composition of claim 327 or 328, wherein the antibody comprises a F(ab')2 fragment, a Fab' fragment, a Fab fragment, a Fv fragment, a scFv fragment, a dsFv fragment, a dAb fragment, or a single chain binding polypeptide.
333. The pharmaceutical composition of any one of claims 327-332, wherein the antibody comprises an anti-LAG-3 antibody, an anti-PD-1 antibody, an anti-PD-Ll antibody, an anti-CTLA-4 antibody, an anti-TIM-3 antibody, an anti-TIGIT antibody, an anti-NKG2a antibody, an anti-OX40 antibody, an anti-ICOS antibody, an anti-MICA antibody, an antiCD 137 antibody, an anti -KIR antibody, an anti-TGFp antibody, an anti -IL- 10 antibody, an anti-IL-8 antibody, an anti-B7-H4 antibody, an anti-Fas ligand antibody, an anti-CXCR4 antibody, an anti-mesothelin antibody, an anti-CD27 antibody, an anti-GITR antibody, an anti-CCR8 antibody, an anti-ILT4 antibody, or a combination thereof.
334. The pharmaceutical composition of claim 333, wherein the anti-LAG-3 antibody comprises BMS-986016 (relatlimab), IMP731 (H5L7BW), MK4280 (28G-10, favezelimab), REGN3767 (fianlimab), GSK2831781, humanized BAP050, IMP-701 (LAG525, ieramilimab), aLAG3(0414), aLAG3(0416), Sym022, TSR-033, TSR-075, XmAb841 (XmAb22841), MGD013 (tebotelimab), BI754111, FS118, P 13B02-30, AVA-017, 25F7, AGEN1746, RO7247669, INCAGN02385, IBI-110, EMB-02, IBI-323, LBL-007, ABL501, or an antigen-binding portion thereof.
335. The pharmaceutical composition of claim 333 or 334, wherein the anti-LAG-3 antibody comprises relatlimab, or an antigen-binding portion thereof.
336. The pharmaceutical composition of any one of claims 333-335, wherein the anti-LAG-3 antibody comprises:(a) CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:3, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO:4;(b) a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO:10, respectively;(c) heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:3 and 4, respectively;(d) heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:l and 2, respectively; or(e) heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:21 and 2, respectively.
337. The pharmaceutical composition of any one of claims 333-336, wherein the anti-PD-1 antibody comprises nivolumab, pembrolizumab, PDR001 (spartalizumab), MEDL0680, TSR-042, cemiplimab, JSOO1, PF-06801591, BGB-A317, BI 754091, INCSHR1210, GLS- 010, AM-001, STI-1110, AGEN2034, MGA012, BCD-100, IBI308, SSI-361, or an antigen-binding portion thereof.
338. The pharmaceutical composition of any one of claims 333-337, wherein the anti-PD-1 antibody comprises nivolumab, or an antigen-binding portion thereof.
339. The pharmaceutical composition of any one of claims 333-338, wherein the anti-PD-1 antibody comprises:(a) CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 13, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO: 14;(b) a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO:20, respectively;(c) heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:13 and 14, respectively; or(d) heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:11 and 12, respectively.
340. The pharmaceutical composition of any one of claims 333-339, wherein the anti-PD-Ll antibody comprises BMS-936559, atezolizumab, durvalumab, avelumab, STI-1014, CX- 072, KN035, LY3300054, BGB-A333, ICO 36, FAZ053, CK-301, or an antigen-binding portion thereof.
341. The pharmaceutical composition of any one of claims 333-340, wherein the anti-CTLA-4 antibody comprises ipilimumab, tremelimumab, MK-1308, AGEN-1884, or an antigenbinding portion thereof.
342. The pharmaceutical composition of any one of claims 333-341, wherein the antibody comprises two antibodies.
343. The pharmaceutical composition of claim 342, wherein the antibody comprises an anti-PD- 1 or anti-PD-Ll antibody and an anti-LAG-3 antibody.
344. The pharmaceutical composition of claim 343, wherein the mg:mg or mg / mL:mg / mL ratio of the anti-PD-1 or anti-PD-Ll antibody to the anti-LAG-3 antibody is about 1:1, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, about 1:15, about 1:20, about 1:30, about 1:40, about 1:50, about 1:60, about 1:70, about 1:80, about 1:90, about 1:100, about 1:120, about 1:140, about 1:160, about 1:180, about 1:200, about 200:1, about 180:1, about 160:1, about 140:1, about 120:1, about 100:1, about 90:1, about 80:1, about 70:1, about 60:1, about 50:1, about 40:1, about 30:1, about 20:1, about 15:1, about 10:1, about 9:1, about 8:1, about 7:1, about 6:1, about 5:1, about 4:1, about 3:1, about 2:1, about 3:4, about 3:2, about 2:3, or about 4:3.
345. The pharmaceutical composition of claim 343 or 344, wherein the mg:mg or mg / mL:mg / mL ratio of the anti-PD-1 or anti-PD-Ll antibody to the anti-LAG-3 antibody is about 1:1, about 2:1, or about 3:4.
346. The pharmaceutical composition of any one of claims 343-345, wherein the concentration of the anti-PD-1 or anti-PD-Ll antibody is about 10 mg / mL, about 15 mg / mL, about 20 mg / mL, about 25 mg / mL, about 30 mg / mL, about 35 mg / mL, about 40 mg / mL, about 45 mg / mL, about 50 mg / mL, about 52.5 mg / mL, about 55 mg / mL, about 60 mg / mL, about 64 mg / mL, about 65 mg / mL, about 70 mg / mL, about 72 mg / mL, about 75 mg / mL, about 78.8 mg / mL, about 80 mg / mL, about 85 mg / mL, about 90 mg / mL, about 94.5 mg / mL, about 95 mg / mL, about 100 mg / mL, about 105 mg / mL, about 108 mg / mL, about 110 mg / mL, about 120 mg / mL, about 130 mg / mL, about 132 mg / mL, about 135 mg / mL, about 137.5 mg / mL, about 140 mg / mL, about 150 mg / mL, about 160 mg / mL, about 170 mg / mL, about 175 mg / mL, about 180 mg / mL, about 190 mg / mL, about 200 mg / mL, about 210 mg / mL, about 220 mg / mL, about 230 mg / mL, about 240 mg / mL, about 250 mg / mL, about 260 mg / mL, about 270 mg / mL, about 280 mg / mL, about 290 mg / mL, about 300 mg / mL, about 310 mg / mL, about 320 mg / mL, about 330 mg / mL, about 340 mg / mL, about 350 mg / mL, about 360 mg / mL, about 370 mg / mL, about 380 mg / mL, about 390 mg / mL, about 400 mg / mL, about 410 mg / mL, about 420 mg / mL, about 430 mg / mL, about 440 mg / mL, about 450 mg / mL, about 460 mg / mL, about 470 mg / mL, about 480 mg / mL, about 490 mg / mL, or about 500 mg / mL.
347. The pharmaceutical composition of any one of claims 343-346, comprising about 0.25 mg to about 2000 mg, about 0.25 mg to about 1600 mg, about 0.25 mg to about 1200 mg, about 0.25 mg to about 800 mg, about 0.25 mg to about 400 mg, about 0.25 mg to about 100 mg, about 0.25 mg to about 50 mg, about 0.25 mg to about 40 mg, about 0.25 mg to about 30 mg, about 0.25 mg to about 20 mg, about 20 mg to about 2000 mg, about 20 mg to about 1600 mg, about 20 mg to about 1200 mg, about 20 mg to about 800 mg, about 20 mg to about 400 mg, about 20 mg to about 100 mg, about 100 mg to about 2000 mg, about 100 mg to about 1800 mg, about 100 mg to about 1600 mg, about 100 mg to about 1400 mg, about 100 mg to about 1200 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, about 400 mg to about 2000 mg, about 400 mg to about 1800 mg, about 400 mg to about 1600 mg, about400 mg to about 1400 mg, about 400 mg to about 1200 mg, or about 400 mg to about 1000 mg of the anti-PD-1 or anti-PD-Ll antibody.
348. The pharmaceutical composition of any one of claims 343-347, comprising about 0.25 mg, about 0.5 mg, about 0.75 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3 mg, about 3.25 mg, about 3.5 mg, about 3.75 mg, about 4 mg, about 4.25 mg, about 4.5 mg, about 4.75 mg, about 5 mg, about 5.25 mg, about 5.5 mg, about 5.75 mg, about 6 mg, about 6.25 mg, about 6.5 mg, about 6.75 mg, about 7 mg, about 7.25 mg, about 7.5 mg, about 7.75 mg, about 8 mg, about 8.25 mg, about 8.5 mg, about 8.75 mg, about 9 mg, about 9.25 mg, about 9.5 mg, about 9.75 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, about 710 mg, about 720 mg, about 730 mg, about 740 mg, about 750 mg, about 760 mg, about 770 mg, about 780 mg, about 790 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 980 mg, about 990 mg, about 1000 mg, about 1040 mg, about 1080 mg, about 1100 mg, about 1140 mg, about 1180 mg, about 1200 mg, about 1240 mg, about 1280 mg, about 1300 mg, about 1340 mg, about 1380 mg, about 1400 mg, about 1440 mg, about 1480 mg, about 1500 mg, about 1540 mg, about 1580 mg, about 1600 mg, about 1640 mg, about 1680 mg, about 1700 mg, about 1740 mg, about 1780 mg, about 1800 mg, about 1840 mg, about 1880 mg,about 1900 mg, about 1940 mg, about 1980 mg, or about 2000 mg of the anti-PD-1 or anti- PD-L1 antibody.
349. The pharmaceutical composition of any one of claims 343-348, wherein the concentration of the anti-LAG-3 antibody is about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 3.3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 6 mg / mL, about 7 mg / mL, about 8 mg / mL, about 9 mg / mL, about 10 mg / mL, about 13 mg / mL, about 13.35 mg / mL, about 15 mg / mL, about 18 mg / mL, about 20 mg / mL, about 23 mg / mL, about 25 mg / mL, about 26 mg / mL, about 26.2 mg / mL, about 26.7 mg / mL, about 27 mg / mL, about 28 mg / mL, about 29 mg / mL, about 30 mg / mL, about 31.5 mg / mL, about 35 mg / mL, about 37.5 mg / mL, about 40 mg / mL, about 45 mg / mL, about 50 mg / mL, about 52.5 mg / mL, about 55 mg / mL, about 60 mg / mL, about 64 mg / mL, about 65 mg / mL, about 70 mg / mL, about 72 mg / mL, about 75 mg / mL, about 80 mg / mL, about 85 mg / mL, about 90 mg / mL, about 95 mg / mL, about 100 mg / mL, about 108 mg / mL, about 110 mg / mL, about 120 mg / mL, about 130 mg / mL, about 132 mg / mL, about 135 mg / mL, about 140 mg / mL, about 150 mg / mL, about 160 mg / mL, about 170 mg / mL, about 175 mg / mL, about 180 mg / mL, about 190 mg / mL, about 200 mg / mL, about 210 mg / mL, about 220 mg / mL, about 230 mg / mL, about 240 mg / mL, about 250 mg / mL, about 260 mg / mL, about 270 mg / mL, about 280 mg / mL, about 290 mg / mL, about 300 mg / mL, about 310 mg / mL, about 320 mg / mL, about 330 mg / mL, about 340 mg / mL, about 350 mg / mL, about 360 mg / mL, about 370 mg / mL, about 380 mg / mL, about 390 mg / mL, about 400 mg / mL, about 410 mg / mL, about 420 mg / mL, about 430 mg / mL, about 440 mg / mL, about 450 mg / mL, about 460 mg / mL, about 470 mg / mL, about 480 mg / mL, about 490 mg / mL, or about 500 mg / mL.
350. The pharmaceutical composition of any one of claims 343-349, comprising about 0.25 mg to about 2000 mg, about 0.25 mg to about 1600 mg, about 0.25 mg to about 1200 mg, about 0.25 mg to about 800 mg, about 0.25 mg to about 400 mg, about 0.25 mg to about 100 mg, about 0.25 mg to about 50 mg, about 0.25 mg to about 40 mg, about 0.25 mg to about 30 mg, about 0.25 mg to about 20 mg, about 20 mg to about 2000 mg, about 20 mg to about 1600 mg, about 20 mg to about 1200 mg, about 20 mg to about 800 mg, about 20 mg to about 400 mg, about 20 mg to about 100 mg, about 100 mg to about 2000 mg, about 100 mg to about 1800 mg, about 100 mg to about 1600 mg, about 100 mg to about 1400 mg, about 100 mg to about 1200 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, about 400 mg toabout 2000 mg, about 400 mg to about 1800 mg, about 400 mg to about 1600 mg, about 400 mg to about 1400 mg, about 400 mg to about 1200 mg, or about 400 mg to about 1000 mg of the anti -LAG-3 antibody.
351. The pharmaceutical composition of any one of claims 343-350, comprising about 0.25 mg, about 0.5 mg, about 0.75 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3 mg, about 3.25 mg, about 3.5 mg, about 3.75 mg, about 4 mg, about 4.25 mg, about 4.5 mg, about 4.75 mg, about 5 mg, about 5.25 mg, about 5.5 mg, about 5.75 mg, about 6 mg, about 6.25 mg, about 6.5 mg, about 6.75 mg, about 7 mg, about 7.25 mg, about 7.5 mg, about 7.75 mg, about 8 mg, about 8.25 mg, about 8.5 mg, about 8.75 mg, about 9 mg, about 9.25 mg, about 9.5 mg, about 9.75 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, about 710 mg, about 720 mg, about 730 mg, about 740 mg, about 750 mg, about 760 mg, about 770 mg, about 780 mg, about 790 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 980 mg, about 990 mg, about 1000 mg, about 1040 mg, about 1080 mg, about 1100 mg, about 1140 mg, about 1180 mg, about 1200 mg, about 1240 mg, about 1280 mg, about 1300 mg, about 1340 mg, about 1380 mg, about 1400 mg, about 1440 mg, about 1480 mg, about 1500 mg, about 1540 mg, about 1580 mg, about 1600 mg, about 1640 mg, about 1680 mg, about 1700 mg, about 1740 mg, about 1780 mg, about 1800 mg, about 1840 mg, about 1880 mg,about 1900 mg, about 1940 mg, about 1980 mg, or about 2000 mg of the anti -LAG-3 antibody.
352. The pharmaceutical composition of any one of claims 343-351, comprising about 80 mg / mL of the anti-PD-1 antibody and about 80 mg / mL of the anti -LAG-3 antibody.
353. The pharmaceutical composition of claim 352, comprising a volume of about 12 mL.
354. The pharmaceutical composition of claim 352, comprising a volume of about 9 mL.
355. The pharmaceutical composition of any one of claims 343-351, comprising about 75 mg / mL of the anti-PD-1 antibody and about 75 mg / mL of the anti-LAG-3 antibody.
356. The pharmaceutical composition of claim 355, comprising a volume of about 12.8 mL.
357. The pharmaceutical composition of claim 356, comprising a volume of about 9.6 mL.
358. The pharmaceutical composition of any one of claims 343-351, comprising about 72 mg / mL of the anti-PD-1 antibody and about 72 mg / mL of the anti-LAG-3 antibody.
359. The pharmaceutical composition of claim 358, comprising a volume of about 10 mL.
360. The pharmaceutical composition of any one of claims 343-351, comprising about 64 mg / mL of the anti-PD-1 antibody and about 64 mg / mL of the anti-LAG-3 antibody.
361. The pharmaceutical composition of claim 360, comprising a volume of about 15 mL.
362. The pharmaceutical composition of any one of claims 343-351, comprising about 60 mg / mL of the anti-PD-1 antibody and about 60 mg / mL of the anti-LAG-3 antibody.
363. The pharmaceutical composition of claim 362, comprising a volume of about 16 mL.
364. The pharmaceutical composition of claim 362, comprising a volume of about 12 mL.
365. The pharmaceutical composition of any one of claims 343-351, comprising about 52.5 mg / mL of the anti-PD-1 antibody and about 52.5 mg / mL of the anti-LAG-3 antibody.
366. The pharmaceutical composition of claim 365, comprising a volume of about 18.3 mL.
367. The pharmaceutical composition of any one of claims 343-351, comprising about 64.3 mg / mL of the anti-PD-1 antibody and about 85.7 mg / mL of the anti-LAG-3 antibody.
368. The pharmaceutical composition of claim 367, comprising a volume of about 8.4 mL.
369. The pharmaceutical composition of any one of claims 343-351, comprising about 60 mg / mL of the anti-PD-1 antibody and about 80 mg / mL of the anti-LAG-3 antibody.
370. The pharmaceutical composition of claim 369, comprising a volume of about 9 mL.
371. The pharmaceutical composition of any one of claims 343-351, comprising about 54 mg / mL of the anti-PD-1 antibody and about 72 mg / mL of the anti-LAG-3 antibody.
372. The pharmaceutical composition of claim 371, comprising a volume of about 10 mL.
373. The pharmaceutical composition of any one of claims 343-351, comprising about 45 mg / mL of the anti-PD-1 antibody and about 60 mg / mL of the anti-LAG-3 antibody.
374. The pharmaceutical composition of claim 373, comprising a volume of about 12 mL.
375. The pharmaceutical composition of any one of claims 343-351, comprising about 960 mg of the anti-PD-1 antibody and about 960 mg of the anti-LAG-3 antibody.
376. The pharmaceutical composition of any one of claims 343-351, comprising about 720 mg of the anti-PD-1 antibody and about 720 mg of the anti-LAG-3 antibody.
377. The pharmaceutical composition of any one of claims 343-351, comprising about 540 mg of the anti-PD-1 antibody and about 720 mg of the anti-LAG-3 antibody.
378. The pharmaceutical composition of any one of claims 343-377, wherein the anti-PD-1 antibody comprises nivolumab, or an antigen-binding portion thereof, and the anti-LAG-3 antibody comprises relatlimab, or an antigen-binding portion thereof.
379. The pharmaceutical composition of any one of claims 343-378, wherein:(a) the anti-LAG-3 antibody comprises CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:3, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO:4, and the anti-PD-1 antibodycomprises CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 13, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO: 14;(b) the anti -LAG-3 antibody comprises a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO: 6, and SEQ ID NO: 7, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO: 10, respectively, and the anti-PD-1 antibody comprises a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO:20, respectively;(c) the anti-LAG-3 antibody comprises heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:3 and 4, respectively, and the anti-PD-1 antibody comprises heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:13 and 14, respectively;(d) the anti-LAG-3 antibody comprises heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:1 and 2, respectively, and the anti-PD-1 antibody comprises heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs: 11 and 12, respectively; or(e) the anti-LAG-3 antibody comprises heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:21 and 2, respectively, and the anti-PD-1 antibody comprises heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs: 11 and 12, respectively.
380. The pharmaceutical composition of any one of claims 308-379, which is suitable for intravitreal, intravenous, intramuscular, and / or subcutaneous administration.
381. The pharmaceutical composition of any one of claims 308-380, which is suitable for subcutaneous administration.
382. The pharmaceutical composition of any one of claims 308-381, which is capable of being injected within about 10 minutes or less.
383. The pharmaceutical composition of claim 382, which is capable of being injected within about 5 minutes to about 7 minutes.
384. Thee pharmaceutical composition of claim 382, which is capable of being injected within about 3 minutes to about 5 minutes.
385. The pharmaceutical composition of any one of claims 327-384, wherein percent high molecular weight (% HMW) species in the pharmaceutical composition as measured by size exclusion chromatography are less than about 1.5% following: agitation at 250 rpm for 1 week at 30 °C, agitation at 250 rpm for 2 weeks at 30 °C, storage at room temperature and room light conditions for 2 weeks, storage at 40 °C for 2 weeks, and / or storage at 50 °C for 2 weeks.
386. The pharmaceutical composition of claim 385, wherein the % HMW species are about 1 % or less.
387. The pharmaceutical composition of claim 385 or 386, wherein the %HMW species are less than about 1%.
388. The pharmaceutical composition of any one of claims 327-387, wherein percent monomer (% monomer) in the pharmaceutical composition as measured by size exclusion chromatography is greater than about 97% following: agitation at 250 rpm for 1 week at 30 °C, agitation at 250 rpm for 2 weeks at 30 °C, storage at room temperature and room light conditions for 2 weeks, storage at 40 °C for 2 weeks, and / or storage at 50 °C for 2 weeks.
389. The pharmaceutical composition of any one of claims 327-388, wherein the % monomer in the pharmaceutical composition as measured by size exclusion chromatography is about 98% or more following: agitation at 250 rpm for 1 week at 30 °C, agitation at 250 rpm for 2 weeks at 30 °C, storage at room temperature and room light conditions for 2 weeks, and / or storage at 40 °C for 2 weeks.
